,ticker,content
0,AMGN,teva pharmaceutical industry ltd teva free report announce submission biologic license application bla fda seek approval monoclonal antibody candidate fremanezumab preventive treatment migraine bla submission be support positive datum phase iii study halo program evaluate candidate patient episodic migraine chronic migraine cm fremanezumab be subcutaneously administer once month month quarterly dose regimen high mg low dose mg monthly dose regimen study cm patient datum demonstrated statistically significant reduction number monthly headache day treat placebo study also meet secondary endpoint show significant improvement placebo datum study patient show patient be treat monthly well quarterly dose regimen fremanezumab experience clinically statistically significant improvement monthly average number migraine day pre specify analysis give limit treatment option fremanezumab represent significant commercial potential accord teva press release more person suffer migraine world include unite state remind investor bla amgen inc amgn free report partner novartis ag nvs free report approval cgrp receptor erenumab prevention migraine be accept fda july eli lilly company lly free report be also plan file fda approval investigational migraine drug galcanezumab second half year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1,AMGN,swiss pharmaceutical company novartis ag nvs free report be schedule report third quarter result oct novartis stock have rally year date compare industry gain last quarter novartis deliver positive earning surprise company post average positive earning surprise trail quarters let see thing be shape announcement factor playconcurrent second quarter result novartis reiterate guidance net sale be expect be broadly line level include impact continue genericization gleevec glivec unite state europe novartis operate segment innovative medicine pharmaceutical alcon sandoz generic novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu recently approve kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space meanwhile fda have recently approve label expansion zykadia first line treatment patient metastatic small cell lung cancer new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie inc abbv free report humira amgen inc amgn free report enbrel cosentyx achieve blockbuster status record sale entresto be expect record revenue sale cosentyx be project reach additionally novartis generic arm sandoz be make effort strengthen biosimilar portfolio company plan launch biosimilar major oncology immunology biologic key geography company be however face significant pricing pressure be expect impact third quarter result also loss exclusivity key drug novartis portfolio be hurt company top line company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february eu december thereby lead generic competition exforge be also face generic competition unite state eu furthermore oncology drug be face new competition form immuno oncology therapy negative impact generic competition be expect impact sale company ophthalmologic division alcon continue face challenge due lower surgical equipment sale stiff competition face intraocular lens slowdown demand equipment purchase continue act dampener earning whispersour proven model do not conclusively show novartis beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp novartis be be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank novartis currently carry zack rank rank be favorable company negative esp make highly unlikely earning beat quarter be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision novartis ag price ep surprise novartis ag price ep surprise novartis ag quote stock considerhere be stock healthcare sector want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result oct see complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2,AMGN,immunogen inc imgn free report announce be plan move leukemia candidate imgn phase study year end company say fda have complete safety review investigational new drug ind application imgn file mid september treat patient cd positive hematological malignancy include acute myeloid leukemia aml blastic plasmacytoid dendritic cell neoplasm bpdcn notably imgn used company indolino benzodiazepine cancer kill agent know ign immunogen share have significantly outperformed industry year date stock have soar compare industry increase same time ind application imgn be support positive datum preclinical study demonstrated imgn selective activity aml cell spare normal bone marrow cell remind investor immunogen have earlier enter strategic collaboration option agreement jazz pharmaceutical plc jazz free report august development imgn collaboration also include program imgn cd target adc already phase stage treatment aml notably immunogen be focuse develop target cancer therapeutic used proprietary adc technology fact innovative technology company be also used roche rhhby free report market product kadcyla other development stage candidate pipeline additionally adc technology be used development program immunogen partner amgen amgn free report bayer ag biotest cytomx eli lilly novartis sanofi takeda company press release approximately patient be expect be diagnosed aml year unite state patient be anticipate succumb disease hence imgn potential market opportunity be huge country successfully develop immunogen inc price immunogen inc price immunogen inc quotezack rankimmunogen currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3,AMGN,mylan myl free report suffer setback follow fda complete response letter crl company biologic license application bla myl propose biosimilar amgen inc amgn free report neulasta crl relate pending update bla certain cmc datum facility requalification activity post recent plant modification however crl do not raise question biosimilarity pharmacokinetic pharmacodynamic datum clinical datum immunogenicity mylan be explore world biosimilar market have potential grow partnership biocon additional collaboration have help mylan develop wide portfolio biosimilar insulin analog generic product represent total brand market value more worldwide sale earlier fda notified mylan partner biocon target action date biosimilar version roche hold ag rhhby free report herceptin trastuzumab have be extend dec decision fda be expect sep review period be extend due clarificatory information be need be submit agency part process last week fda approve generic version teva pharmaceutical industry limit teva free report multiple sclerosis drug copaxone glatiramer acetate mg ml thrice weekly news boost investor sentiment company share surge same mylan stock have increase last month compare industry decline notably be first generic copaxone have be approve fda also approve generic copaxone mg ml once daily mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity accord quintilesim sale copaxone mg ml dose be approximately mg ml dose month period end july hence generic approval be expect provide significant boost mylan zack rankmylan currently carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
4,AMGN,company amgen amgn free report regeneron regn free report be news amgen provide pipeline regulatory update regeneron partner sanofi get good news appeal court ruling favor pcsk inhibitor lawsuit amgen recap week most important storiesphase ii combination datum amgen imlygic publish positive datum amgen oncolytic viral therapy imlygic used combination bristol myer squibb yervoy be publish journal clinical oncology result mid stage study show objective response rate orr more double imlygic be used combination yervoy compare yervoy alone patient unresectable stage iiib iv melanoma versus moreover complete response rate be almost double combination arm compare yervoy alone versus response be observed inject uninjected lesion include visceral lesion advanced melanoma be highly aggressive most dangerous type skin cancer be need multiple treatment approach course disease datum be encourage open new avenue revenue imlygic eventually gain approval use combination checkpoint inhibitor sale imlygic approve october be yet pick meanwhile amgen say fda have accept regulatory application seek label expansion use prolium glucocorticoid induced osteoporosis most common form secondary osteoporosis response agency be prolium bring sale second quarter be important growth driver amgen company work improve diagnosis treatment rate duration order drive access greater number patient read more amgen label expansion application prolium accept fda amgen be zack rank buy stock share amgen have gain year date significantly outperform industry rally see complete list today zack rank strong buy stock here breather amgen neulasta biosimilar approval delay amgen get bit breather fda issue complete response letter crl mylan biocon biosimilar version amgen blockbuster drug neulasta pegfilgrastim agency do not raise query regard biosimilarity pharmacokinetic pharmacodynamic datum clinical datum immunogenicity myl crl relate pending update regulatory application certain cmc datum facility requalification activity post recent plant modification note mylan biocon be not only company get crl fda biosimilar version neulasta novartis sandoz have receive crl last year coherus be issue crl year june regeneron sanofi score pcsk inhibitor litigation regeneron partner sanofi get major boost court appeal federal circuit order new trial related amgen claim regard patent pcsk inhibitor court also vacated permanent injunction lawsuit mean sanofi regeneron continue selling pcsk inhibitor praluent unite state read more regeneron sanofi get favorable ruling amgen abbvie immuno oncology deal abbvie abbv free report have enter research option license agreement clinical stage immuno oncology company turnstone biologic deal provide abbvie exclusive option license turnstone next generation oncolytic viral immunotherapy turnstone ad mg magea therapy be couple phase ii study different solid tumor indication alone well combination approve pd checkpoint inhibitor promising new datum biogen spinraza new phase iii datum present biogen biib free report spinraza show earlier initiation treatment therapy improve motor function outcome infant child spinal muscular atrophy sma biogen ionis spinraza be first approve medicine treatment sma spinraza be promising start unite state bring sale second quarter clovis seek label expansion parp inhibitor clovis oncology clvs free report have file label expansion parp inhibitor rubraca unite state company be look get drug approve maintenance treatment patient recurrent epithelial ovarian fallopian tube primary peritoneal cancer be complete partial response platinum base chemotherapy company have present impressive late stage datum earlier year june rubraca show treatment significantly improve progression free survival ovarian cancer patient population evaluate ariel study rubraca have gain accelerate fda approval december use advanced ovarian cancer patient have be treat more chemotherapy have deleterious germline somatic brca mutation broader label boost rubraca sale potential read more clovis submit snda ovarian cancer drug rubraca biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen gain celgene celg free report lose last month vertex vrtx free report be see last biotech stock roundup here endocyte shoot deal amgen abbvie settle humira litigation next biotech world sector gear third quarter earning watch usual regulatory pipeline update spark therapeutic voretigene neparvovec be review fda cellular tissue gene therapy advisory committee ctgtac october spark be seek fda approval treatment patient vision loss due confirm biallelic rpe mutation associate retinal dystrophy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
5,AMGN,amgen inc amgn free report announce fda have accept regulatory application unite state seek label expansion prolium treatment patient glucocorticoid induced osteoporosis giop fda be expect give decision next year prolium be presently market unite state treatment postmenopausal woman osteoporosis high risk fracture well increase bone mass man osteoporosis high risk fracture supplemental biologic license application sbla be submit july year sbla be base phase iii study evaluate safety efficacy prolium compare risedronate patient receive glucocorticoid medication giop be most common form secondary osteoporosis serious condition be presently treat glucocorticoid treatment increase fracture risk first month begin treatment prolium approve treatment giop cater expand patient population drive sale higher prolium be key revenue generator amgen be witness market share gain unite state international market first half drug generate sale year year amgen share have rally year so far better industry growth so far year currently amgen hold zack rank buy see complete list today zack rank strong buy stock here key pickssome other top rank biotech stock include vertex pharmaceutical incorporate vrtx free report pdl biopharma inc pdli free report celgene corporation celg free report vertex pdl biopharma sport zack rank strong buy celgene have same zack rank amgen vertex have witness zack consensus estimate current year earning climb past day company share have increase year so far pdl biopharma earning estimate have go share have rise year so far celgene earning estimate inched go past day stock have rally so far year outperform industry today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
6,AMGN,israel base generic drug maker teva pharmaceutical industry limit teva free report see share decline last week company suffering fresh setback form fda approval generic version company top selling brand drug copaxone multiple sclerosis mylan nv myl free report gain fda approval generic version mg thrice weekly dosage well once daily mg formulation copaxone mylan be first applicant challenge mg patent company enjoy day exclusivity mylan have launch product mylan also gain approval mg dose eu fda approval generic copaxone be major blow teva be currently face whole lot challenge teva issue statement say launch mg formulation final resolution pending patent infringement lawsuit mylan be treat risk launch mean mylan have pay significant damage court uphold patent protect drug copaxone bring total sale first half end second quarter copaxone mg account more total copaxone prescription unite state entry mg formulation entry second generic version mg formulation sandoz momenta have be market quite glatopa generic version mg dose be expect cut teva earning least cent share additional detail be company announce third quarter result november entry generic copaxone just add exist list problem be face teva generic pricing erosion remain huge issue generic company teva sharp decline generic drug price blessing patient be prove be major challenge generic drugmaker well drug distributor consolidation industry have increase ability negotiate lower price generic drug lead increase price erosion decrease volume moreover fda be speeding approval generic drug mean more competition increase price cut decrease volume teva say price erosion be second quarter be expect increase high single digit remainder year headwind persist generic unit future result lower revenue profit segment potentially meanwhile company say do not expect earning contribution business venezuela give significant devaluation venezuelan currency teva also cut dividend teva have many challenge ahead pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track company have be work address issue recently announce appointment new ceo read more do teva pharmaceutical stock soar today teva have also make significant progress divestment core business however entry copaxone mg be major setback company well be teva be able get back track teva be zack rank sell stock company have see zack consensus estimate current year earning be revise downward last day zack consensus estimate have be revise downward last day teva have lose value year date versus decline industry teva deal challenge here be look drug company sport strong zack rank look well position celgene corporation celg free report celgene be focuse discovery development innovative therapy treatment cancer inflammatory disease company have several blockbuster product portfolio include revlimid pomalyst otezla celgene have rich promising pipeline well key datum readout line next year celgene zack rank buy stock have gain year date outperform rally industry belong company also have vgm score vgm score be useful tool allow investor gain insight stock strength weakness research show stock vgm score combine zack rank offer best upside potential see complete list today zack rank strong buy stock here pfizer inc pfe free report pfizer be focuse development wide range medicine vaccine well consumer health care product first half year company paid dividend share buyback shareholder include accelerate share repurchase program pfizer expect revenue be affected due loss exclusivity loe be work bring new product market make lose sale company have potential blockbuster line next year half potentially focus also remain grow new product ibrance eliquis xeljanz meanwhile impact loe continue decline come year well less pfizer zack rank stock carry vgm score amgen amgn free report amgen most well know name biotech industry have presence oncology hematology inflammation nephrology bone health cardiovascular disease market key product include enbrel neulasta aranesp prolium xgeva epogen kyproli repatha blincyto other most product be blockbuster have blockbuster potential amgen have deep pipeline company work bring new product market combat impact potential biosimilar competition mature product franchise company have be return value shareholder form share buyback dividend amgen be also zack rank stock vgm score stock have gain year date outperform rally industry belong vertex pharmaceutical vrtx free report vertex be key player cystic fibrosis cf market company hold strong position market market product orkambi kalydeco vertex be work expand cf portfolio be currently seek fda ema approval tezacaftor ivacaftor combination fda grant priority review response be feb vertex zack rank stock have gain year date substantially outperform rally industry belong ligand pharmaceutical incorporate lgnd free report ligand business model be base develop acquire royalty revenue generate asset couple lean corporate cost structure company be focuse development licensing asset ligand captisol formulation technology have allow enter several licensing deal generate royalty company partner include big name amgen novartis other ligand also have licensing deal base omniab technology ligand recent decision acquire crystal bioscience leader avian genetic generation fully human therapeutic antibody be expect boost company revenue least earning least cent share ligand zack rank stock have gain year date substantially outperform rally industry belong look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
7,AMGN,be not much activity cancer space last week notable be immuno oncology partnership deal sign amgen cytomx develop cell base therapy cancer acquisition late stage prostate cancer candidate endocyte also fda grant breakthrough therapy designation seattle genetic adcetric moreover patent trademark office rule favor eli lilly patent litigation alimta let see news detail key newsamgen inc amgn free report cytomx therapeutic inc ctmx free report enter strategic immuno oncology collaboration jointly develop cell engage bispecific probody amgen pay cytomx upfront be invest latter stock deal initial work be do cytomx amgen be responsible late stage study apart upfront payment equity investment cytomx also be eligible receive milestone well opt right profit royalty outside sale product be commercialize addition technology platform expand amgen immuno oncology capability cytomx have strong partner amgen also regular flow fund read more amgen enter immuno oncology partnership cytomx amgen inc price consensus amgen inc price consensus amgen inc quoteendocyte inc ecyt free report acquire late stage prostate cancer candidate abx gmbh lu psma upfront payment pursuant acquisition endocyte now have exclusive worldwide license develop candidate commercialize successful approval candidate be most advanced target radioligand therapeutic development prostate cancer be believe have market opportunity fact lu psma target prostate specific membrane antigen psma present patient metastatic castration resistant prostate cancer mcrpc candidate have also show high response rate late stage prostate cancer patient study present recent european society medical oncology investor be encourage announcement news evident stock price appreciation oct read more endocyte inks deal prostate cancer candidate endocyte inc price consensus endocyte inc price consensus endocyte inc quoteseattle genetic inc sgen free report lymphoma drug adcetris be grant breakthrough therapy designation status frontline treatment advanced classical hodgkin lymphoma recently complete phase iii study evaluate drug indication grant status be expect speed development review process application label expansion drug be expect be file year read more seattle genetic adcetris get breakthrough therapy status seattle genetic inc price consensus seattle genetic inc price consensus seattle genetic inc quoteother newscelsion corporation clsn free report small biotech company announce datum early stage study immunotherapy candidate gen show evident biological activity newly diagnosed stage iii iv ovarian cancer study evaluate drug combination neoadjuvant chemotherapy follow interval debulk surgery candidate have achieve disease control rate patient population meanwhile patent trademark office rule favor eli lilly company lly free report dispute related vitamin regimen patent key cancer drug alimta parte review be initiate neptune generic sandoz drug have generate more company revenue first half approval generic version patent expiration june have strong negative impact lilly top line separate news aveo oncology announce result pre plan futility analysis phase iii study kidney cancer candidate fotivda review result independent statistician suggest continuation study modification look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
8,AMGN,regeneron pharmaceutical inc regn free report partner sanofi inc sny free report receive favorable ruling court appeal federal circuit relate praluent court order new trial vacated permanent injunction dispute concern amgen inc amgn free report assert patent claim antibody target pcsk proprotein convertase subtilisin kexin type result sanofi regeneron continue commercialize praluent unite state note praluent be first pcsk antibody be approve adjunct diet maximally tolerate statin therapy be used treatment adult heterozygous familial clinical atherosclerotic cardiovascular disease require additional lower bad ldl cholesterol unite state amgen repatha be introduce much later market remind investor amgen assert number patent be subsequently narrow patent no patent patent seek permanent injunction prevent regeneron sanofi defendant commercialize praluent be find trial court err multiple ground substantial evidence regard written description enablement jury also claim law require written description invention conclude amgen patent be obvious lack evidence help regeneron sanofi favorable ruling date new trial have not be decide court yet regeneron sanofi do not anticipate new trial proceedings start news relieve regeneron sanofi earlier amgen be grant permanent injunction prohibit sanofi regeneron selling praluent term repatha patent however regeneron sanofi appealed ruling higher court follow news share regeneron have moved fact share company have outperformed industry year date stock have surge compare industry rally period prospect pcsk inhibitor new class cholesterol lower treatment blockbuster potential gain instant popularity even hit market however sale praluent have fail impress drug be face significant payer utilization management restriction unite state limit market access europe be result low volume prescription zack rank key pickregeneron currently sport zack rank hold better rank stock healthcare sector be aduro biotech adro free report carry zack rank buy see complete list today zack strong buy rank stock here aduro loss estimate share have narrow last day company deliver positive earning surprise trail quarters average be trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
9,AMGN,abbvie inc abbv free report share have gain impressive past month compare favorably gain record industry share price surge be support series positive news company past few week last week abbvie announce resolution ongoing patent dispute amgen inc amgn free report have delay launch latter biosimilar version abbvie blockbuster arthritis drug humira settlement abbvie grant exclusive license amgen allow latter sell amjevita unite state jan most country eu oct other market different date license amgen pay abbvie pre specify royalty agreement have remove major overhang abbvie share company be still face patent challenge boehringer ingelheim gain approval biosimilar version humira cyltezo august moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market secondly abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada past couple month mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history abbvie announce positive datum phase iii murano study venclexta rituxan relapse refractory cll last month datum show venclexta roche rhhby free report rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll label expansion indication expand patient population venclexta significantly boost commercial potential abbvie also announce collaboration bristol myer squibb bmy free report evaluate combination investigational antibody drug conjugate abbv bristol myer immunotherapy opdivo meet overexpressing small cell lung cancer nsclc lastly abbvie oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment ra highly statistically significant clinically meaningful result dose mg mg upadacitinib compare placebo upadacitinib also meet primary endpoint phase iib study treatment adult patient atopic dermatitis also know eczema company plan advance candidate phase iii study next year datum upadacitinib study be announce last month fact so far year abbvie share price have increase also compare favorably gain industry abbvie carry zack rank hold see complete list today zack rank strong buy stock here stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
10,AMGN,amgen inc amgn free report announce strategic immuno oncology collaboration cytomx therapeutic inc ctmx free report jointly develop cell engage bispecific probody deal amgen make upfront payment cytomx investing california base biotech company stock markedly company develop cytomx probody cell engage bispecific program target egfr protein thereby offer significant potential treat various type cancer cytomx lead early development amgen take care late stage development however late stage development cost be share company apart upfront payment equity investment cytomx also be eligible receive milestone well opt right profit royalty outside sale product be commercialize deal amgen also receive global right develop commercialize undisclosed cytomx candidate amgen take target cytomx be eligible receive upfront payment milestone well royalty result product addition bispecific technology platform expand amgen immuno oncology capability give cytomx strong partner amgen ensure regular flow fund share cytomx be hour trading tuesday amgen share remain stable nonetheless amgen share have rally better industry growth so far year currently amgen hold zack rank buy seethe complete list today zack rank strong buy stock here key pickssome other top rank biotech stock sporting same bullish rank amgen include biogen inc biib free report celgene corporation celg free report biogen have witness zack consensus estimate current year earning climb past day company share have increase year celgene earning estimate have inched past day stock have rally year outperform industry hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
11,AMGN,company amgen amgn free report endocyte ecyt free report be news amgen signing deal abbvie abbv free report related entry biosimilar version humira endocyte signing licensing deal prove be company recap week most important storiesendocyte soar licensing deal endocyte share have shot whopping follow company announcement have get exclusive worldwide license psma abx gmbh endocyte say quickly move lu psma phase iii development lu psma be radioligand therapeutic rlt target prostate specific membrane antigen psma present patient metastatic castration resistant prostate cancer mcrpc deal provide endocyte most advanced target radioligand therapy development prostate cancer represent market opportunity more company hope start phase iii development first half complete program early term deal include upfront payment well issuance share abx warrant purchase additional share endocyte common stock abx also stand receive milestone payment tiered royalty start mid teen endocyte bear future development expense read more endocyte inks deal prostate cancer candidate share abbvie amgen sign deal delay humira biosimilar entry abbvie have gain breathe space enter settlement agreement amgen related biosimilar competition abbvie multus dollar drug humira amgen gain fda approval amjevita biosimilar version humira have acknowledge validity abbvie extensive intellectual property portfolio humira accord deal exclusive license humira commence jan unite state different date other market include oct most country eu amgen also pay royalty agreement have remove major overhang abbvie share company be still face patent challenge boehringer ingelheim gain approval biosimilar version humira cyltezo august humira generate sale first half include unite state remain key market drug humira continue perform well remain major contributor top line come year moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market expectation be high abbvie boehringer ingelheim announce similar settlement agreement dismiss patent litigation abbvie be zack rank hold stock amgen be zack rank buy stock see complete list today zack rank strong buy stock here ablynx positive phase iii result ablynx share shot positive topline result late stage study caplacizumab company von factor vwf nanobody be be develop treatment acquire thrombotic purpura attp ablynx be currently seek approval caplacizumab eu expect submit regulatory application unite state first half caplacizumab have fast track designation unite state treatment attp timely approval make first therapeutic specifically indicated treatment attp acute life threaten autoimmune blood clot disorder cytomx immuno oncology deal amgen cytomx therapeutic ctmx free report have enter immune oncology focuse strategic collaboration amgen development cytomx probody cell engage bispecific epidermal growth factor receptor egfr early development be lead cytomx amgen lead later development company share global late stage development cost deal see cytomx get upfront payment issue common stock amgen cytomx also earn development regulatory commercial milestone egfr program global commercial activity be lead amgen cytomx have option opt profit share unite state receive tiered double digit royalty net product sale outside unite state agreement also cover additional undisclosed target amgen decide pursue target cytomx get additional upfront milestone payment high single digit mid double digit royalty payment cytomx also receive right undisclosed preclinical cell engage bispecific program amgen make milestone royalty payment result product arrangement expect investor react favorably deal regeneron sanofi eczema drug get eu nod regeneron regn free report partner sanofi gain eu approval eczema treatment dupixent make dupixent first target biologic be approve use adult moderate severe atopic dermatitis ad be candidate systemic therapy dupixent approve unite state earlier year have blockbuster potential be be investigate other indication well include asthma eosinophilic esophagitis nasal polyp share regeneron have gain year date significantly outperform industry rally biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index gain almost last trading session major biotech stock regeneron be gilead gild free report lose last month vertex vrtx free report be see last biotech stock roundup here amgen reiterate outlook intercept hit ocaliva safety issue next biotech world watch usual regulatory pipeline update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
12,AMGN,biotech industry have witness great turnaround year drug pricing issue cripple performance last year decline last year medical biotech genetic industry have rise year so far outpace gain same time frame nasdaq biotechnology index be almost year date slide zack industry rank be zack industry medical biom genetic indicate bright outlook sector go forward biotech sector have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product have play pivotal role bring sector track year factor have contribute sector surge be president trump expect action drug price not be onerous previously fear factor continue drive sector rest year probably next well challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug broader macro front propose tax reform approve leave more cash hand company cash be invest merger acquisition have be relatively fewer year compare last biotech stock tear here have picked biggest biotech company look well poise growth be add portfolioamgen inc amgn free report amgen be lead biotechnology company world several blockbuster drug portfolio amgen newer drug prolium xgeva vectibix nplate sensipar be perform well amgen be also progress pipeline include biosimilar drug last month receive fda approval mvasi biosimilar version roche cancer drug avastin mvasi be first biosimilar approve unite state treatment cancer other recent positive pipeline regulatory development amgen include eu approval pediatric formulation mimpara positive long term datum kyproli endeavor study regulatory filing label expansion prolium kyproli other support positive development amgen share have outperformed industry so far year share have rise compare favorably industry gain amgen carry zack rank buy see complete list today zack rank strong buy stock here earning estimate have rise have go past day celgene corporation celg free report celgene key growth driver multiple myeloma drug revlimid continue drive revenue company meanwhile celgene label expansion effort revlimid bode well further sale growth drug other key product pomalyst imnovid abraxane otezla be also perform well recent positive development celgene be fda approval idhifa treatment adult patient relapse refractory acute myeloid leukemia aml celgene also carry zack rank earning estimate have rise past day stock have go year outperform industry biogen inc biib free report biogen have strong position multiple sclerosis market backed wide range product biogen be try diversify be look strengthen alzheimer disease ad other disorder pipeline newly launch spinraza spinal muscular atrophy be also promising start spinraza have witness faster expect adoption unite state biogen be ramp launch effort internationally recent key positive pipeline regulatory development biogen include promising long term dataon alzheimer disease candidate aducanumab eu approval imraldi biogen biosimilar version abbvie top selling blockbuster drug humira biogen have make several new executive appointment bring management team back track several key executive depart past couple year include ceo george scango cfo paul clancy biogen also rank stock have see earning estimate rise past day share have rise year other biotech company smaller mentioned company be worth mention vertex pharmaceutical incorporate vrtx free report have see share price shoot year so far earning estimate rise stock be ride high success cystic fibrosis cf pipeline particularly triple combination cf regimen have potential treat cf patient regeneron pharmaceutical inc regn free report see launch key pipeline candidate dupixent atopic dermatitis kevzara rheumatoid arthritis unite state year drug be also approve eu meanwhile regeneron key growth driver eylea continue drive revenue market share gain company be expand drug label additional indication regeneron share have rise year earning estimate have go vertex regeneron have be sporting zack rank strong buy quite time soon join league big biotech stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
13,AMGN,radius health inc rdus free report announce first patient have be enroled phase study pipeline candidate rad rad be nonsteroidal selective androgen receptor modulator sarm be be evaluate treatment hormone receptor positive breast cancer phase trial be safety dose range study approximately patient suffering progressive metastatic locally advanced metastatic breast cancer postmenopausal woman metastatic hormone receptor positive breast cancer receive escalate dose rad oral administration period day part study primary safety outcome include rate dose limit toxicity adverse event related treatment tolerability measure dose interruption adjustment addition pharmacokinetic pharmacodynamic tumor response also be evaluate sarm mechanism action be differentiate selective estrogen receptor modulator serm selective estrogen receptor degrader serd consequently rad have significant potential complement future application elacestrant rad target distinct mechanism endocrine resistance note investigational new drug application submit fda rad have be accept radius share price have increase year date compare industry gain april fda approve tymlos abaloparatide sc treatment postmenopausal woman high risk osteoporosis fracture defined history osteoporotic fracture multiple risk factor fracture patient have fail be intolerant other osteoporosis therapy osteoporosis market unite state hold great promise approximately postmenopausal woman suffer osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor company however suffer setback chmp issue second day list outstanding issue meanwhile radius clinical pipeline include investigational abaloparatide transdermal patch potential use osteoporosis investigational drug elacestrant rad potential use hormone drive hormone resistant breast cancer vasomotor symptom postmenopausal woman zack rank key pickradius health currently carry zack rank hold better rank stock healthcare sector be aduro biotech adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
14,AMGN,presidential campaign donald trump have stress tax reform promise bring corporate tax be top priority president unite state keep word trump propose change tax rate individual corporate stimulate economic growth well employment growth tax plan propose lower current corporate tax rate highest world be expect favorably impact post tax earning company territorial tax system tax only domestic income have also be propose american company so create level play field also suggest elimination special tax break company major reform propose be repatriation trillion dollar hold cash reserve overseas company global operation time tax reportedly similar tax move be make bring overseas cash reserve bush administration time tax number company repatriate amount exceed current tax code allow tax repatriation rate however give tax credit amount tax paid overseas country anticipate reform have be propose create new job aid economic growth expand investment more cash available company tax cut repatriation however extent step be successful be uncertain large portion repatriate cash be used fund share buyback dividend payment buyback fuel stock rally be actual economic growth tax reform be expect benefit company have operation globe similar buyback time be also expect help stock grow large cap pharma company base unite sate major operation worldwide include amgen inc amgn free report gilead science other be sit huge pile cash reserve stash overseas country repatriation benefit large drug biotech company more tax saving due rate cutsmoreover repatriation cash hold overseas create surplus domestic cash reserve fuel merger acquisition sector industry have see only major acquisition year actelion johnson johnson jnj free report kite pharma inc gilead science inc gild free report be expect close end let discuss impact tax reform drug biotech giant johnson johnsonjohnson johnson be well know brand world cater wide variety medical need company have paid tax effective rate respectively therefore revision tax rate not bring huge positive change post tax earning june end have cash reserve almost year end company have used major chunk cash reserve hence be expect be least impact reform company have strong presence oncology hematology cardiovascular disease inflammation bone health nephrology market effective tax rate amgen be respectively hence tax rate cut have minimal effect amgen have nearly overseas cash fiscal end bloomberg report total cash reserve company have change minimally first month so repatriation reform initiate buyback moreover tax have more domestic cash reserve total overseas cash be repatriate increase domestic cash also be used acquire new drug technology car therapy gilead sciencesgilead recently announce plan acquire kite pharma nearly add latter car therapy candidate pipeline gilead be plan complete acquisition combination cash debt bloomberg report gilead have cash reserve overseas country end repatriation help company pay debt quickly effective tax rate have be suggest minimal impact due tax rate cut make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
15,AMGN,sep issue update report ligand pharmaceutical incorporate lgnd free report ligand lead captisol formulation technology platform have allow enter partnership several lead drug company novartis ag nvs free report merck co inc mrk free report amgen inc amgn free report thus turn provide fund form milestone royalty payment ligand receive royalty milestone payment several fda approve product use captisol technology ligand major royalty revenue come sale key partner asset novartis kyproli amgen promacta other latest product approval include spectrum evomela lundbeck carnexiv melinta therapeutic baxdela apart several candidate be late stage development expect bring royalty company once commercialize regard company internal pipeline various candidate be observation development indication diabetes such extremely advanced candidate be lgd presently undergo phase ii study treat type ii diabetes month company report positive top line result study further expect lgd bring future licensing opportunity nonetheless ligand entry medical device segment acquisition multiple program own cormatrix be also encourage however ligand obtain captisol single supplier hovione major global supplier active pharmaceutical ingredient drug product intermediate locate portugal interruption captisol supply hit company result make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
16,AMGN,issue update research sanofi inc sny free report sep sanofi perform quite well first half earning rise report basis first half constant currency rate cer year year basis first halfnet sale rise report basis cer january sanofi swap merial animal health business boehringer ingelheim consumer healthcare chc business reflect exchange full consolidation sanofi european vaccine operation sale rise constant structure cer remind investor sanofi terminate sanofi pasteur msd joint venture merck co inc mrk free report europe december last year strong performance genzyme specialty care genzyme vaccine unit be make accelerate decline diabetes franchise support top line fact second quarter conference call sanofi raise previously issue profit outlook backed better expect performance first half cost discipline however tough payer environment hurt sale thediabetesunit continue strong performance genzyme unit especially multiple sclerosis drug aubagio lemtrada rare disease drug myozyme fabrazyme be positive vaccine unit be also expect perform well sale include emerge market rise cer genzyme unit cer vaccine unit first half meanwhile sanofi be quite optimistic sale prospect newly launch drug dupixent treat atopic dermatitis drug be launch unite state march generate sale second quarter backed strong demand management be pleased drug uptake be optimistic sale prospect dupixent prove be important growth driver company other dupixent other new drug kevzara launch june soliqua once daily titratable fix ratio combination lantus lyxumia launch unite state january also bring higher sale back half year however management expect diabetes franchise sale decline faster second half due impact formulary exclusion cvs health corporation cvs free report unitedhealth group difficult comparison last year diabetes sale decline first half sanofi diabetes franchise be significant pressure key product lantus face increase competitive pressure payor level biosimilar competition several european market japan cardiovascular franchise also remain be see sale trend sanofi pcsk therapy praluent improve second half uptake pcsk inhibitor praluent amgen inc amgn free report repatha have be slower expect due significant payer utilization management restriction unite state limit market access europe praluent uptake remain limit guideline support broader use treatment be issue phase iii cardiovascular outcome study datum be also generic competition continue hurt sale many key drug sanofi portfolio include blockbuster drug plavix challenge believe new drug approval solid pipeline aggressive saving pave way growth sanofi more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
17,AMGN,biotech stock amgen amgn free report intercept pharmaceutical icpt free report be news amgen provide update impact hurricane marium intercept continue be impact ocaliva safety concern recap week most important storiesamgen maintain outlook amgen provide update impact hurricane marium impact company manufacturing facility puerto rico maintain outlook company say product process inventory be lose company have enough stock meet patient demand time release second quarter result amgen have guide earning share total revenue ocaliva safety issue continue hit intercept intercept continue be impact safety issue surround sole market product ocaliva company share be initially hit dear doctor letter earlier month see share fall almost drug safety communication issue fda last week communication layer emphasis importance use recommend dosage label liver injury liver decompensation liver failure death be report ocaliva be dose more frequently recommend ocaliva be approve use primary biliary cholangitis pbc patient company be work fda ensure appropriate safe use ocaliva ocaliva approve bring sale second quarter intercept share be year date compare industry rally infinity bristol myer clinical trial collaboration expand infinity pharmaceutical infi free report exist clinical collaboration bristol myer squibb ipi pi gamma inhibitor opdivo pd immune checkpoint inhibitor have be expand include patient triple negative breast cancer tnbc have not be previously expose pd pd therapy ipi be currently phase ib study patient advanced solid tumor abbvie bristol myer clinical trial collaboration abbvie abbv free report be collaborate bristol myer squibb evaluate combination abbvie investigational antibody drug conjugate abbv bristol myer immunotherapy opdivo meet overexpressing small cell lung cancer nsclc phase ib study be ongoing cancer remain challenge medical condition several company be enter clinical trial collaboration evaluate different combination address disease abbvie be zack rank hold stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock gilead gild free report be vertex lose last month vertex vrtx free report be see last biotech stock roundup here fda nod first cancer biosimilar halo deal raise outlook next biotech world watch usual regulatory pipeline update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
18,AMGN,merck co inc mrk free report announce fda have approve pd therapy keytruda monotherapy third line treatment advanced gastric junction adenocarcinoma keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer drug label have now be expand include treatment heavily pre treat patient recurrent locally advanced metastatic gastric junction cancer tumor express pd determine fda approve test however approval tenth new indication keytruda come accelerate basis continue approval dependent further benefit demonstrated clinical study fda approval be base datum keynote study keytruda be key top line driver merck bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer outside keytruda sale be primarily drive melanoma indication meanwhile keytruda development program also significantly advanced year regulatory approval new indication additional indication europe important approval include advanced bladder cancer unite state eu advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer further keytruda datum readout be pending year keytruda be continuously grow expand new indication market globally keytruda be be study more type cancer more study include more combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
19,AMGN,biotech industry witness rebound face odd previous year industry face challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug however have see trend reverse more fda approval new product sale ramp success innovation strong clinical study result continue strong performance legacy product positive factor be expect continue contribute sector growth rest year maybe next nasdaq biotechnology index have gain so far year be sharp contrast last year performance index be major recent event contribute rally be announcement gilead science gild free report acquire immunotherapy focuse company kite pharma second be fda approval first gene therapy unite state novartis ag nvs free report kymriah recently fda also approve first cancer biosimilar amgen amgn free report allergan mvasi biosimilar version roche rhhby free report blockbuster cancer drug avastin momentum biotech sector be likely continue good idea avoid few stock industry not prove be prudent addition portfolio sell rate stock avoidget rid underperform stock right time help maximize portfolio return be tricky avoid stock industry be do well however have take help zack stock screener shortlist stock be dump vast universe biotech sector have picked stock carry zack rank sell strong sell see complete list today zack rank strong buy stock here further narrow list select have vgm score circumstance buy stock zack rank sell strong sell vgm score have also take consideration stock witness negative estimate revision current year well next year last day be likely see further negative estimate revision be dump clearside biomedical inc clsd free report late stage clinical company be develop first class drug therapy treat back eye disease company have be incur loss inception also expect incur loss next few year currently alpharetta ga base company carry zack rank have vgm score further last day zack consensus loss estimate have widen share company have decline year date underperform industry gain abeona therapeutic inc abeo free report clinical stage company focuse develop novel therapy life threaten rare genetic disease company currently carry zack rank have vgm score last day zack consensus loss estimate have widen reata pharmaceutical inc reta free report company currently carry zack rank have vgm score last day zack consensus loss estimate have widen urogen pharma ltd urgn free report be clinical stage company develop treatment address unmet need field urology company currently carry zack rank have vgm score last day zack consensus loss estimate have widen make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
20,AMGN,pfizer inc pfe free report have file lawsuit district court allege johnson johnson jnj free report be resort unfair practice prevent sale inflectra pfizer biosimilar version merck co inc mrk free report blockbuster rheumatoid arthritis drug remicade pfizer biosimilar version be available wholesale acquisition cost wac be lower reference product pfizer share be wednesday share be however pfizer share have underperform industry year so far stock have return period compare unfavorably increase industry pfizer allege complaint file district court eastern district pennsylvania have enter biosimilar exclusion contract insurer contract encourage insurer not cover inflectra thereby make easily accessible patient protect reference product pfizer also claim anticompetitive contract be be offer hospital encourage discount purchase remicade condition do not buy biosimilar version pfizer claim unfair practice benefit sale reference product be key revenue generator latter remind investor second quarter conference call hold august pfizer have say inflectra penetration unite state have be slower expect be experience access challenge national commercial payer other hand have say second quarter conference call hold july rate penetration inflectramay be modest latest lawsuit suggest be responsible slow sale inflectra please note april year samsung bioepis biosimilar version remicade also receive fda approval pfizer have launch inflectra unite state november last year biosimilar be also market ex market inflectra generate sale unite state globally second quarter biosimilar be essentially cheaper version expensive biologic drug be complex make traditional generic drug biosimilar have be available eu quite be regulatory pathway biosimilar unite state long time however change pass biologic price competition innovation act bpci act part affordable care act president obama sign law march several pharma well biotech company be involved development biosimilar first biosimilar gain approval unite state be sandoz zarxio biosimilar version amgen inc amgn free report neupogen zarxio be launch unite state september inflectra be second biosimilar gain approval other approve biosimilar country include sandoz erelzi biosimilar amgen enbrel amgen amjevita biosimilar version abbvie humira however have not be launch yet due ongoing litigation earlier month fda approve first cancer biosimilar amgen allergan mvasi biosimilar version roche blockbuster cancer drug avastin biosimilar be expect reduce health care cost provide large number patient access much need biologic treatment however so far biosimilar have not see much commercial success be yet make significant dent reference product sale unite state fight drug giant be likely aid effort lower drug price increase biosimilar availability pfizer carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
21,AMGN,issue update report novartis ag nvs free report sep novartis have strong portfolio oncology drug afinitor exjade jakavi zykadia tasigna jadenu improve formulation exjade february company receive boost fda approve afinitor advanced progressive nonfunctional neuroendocrine tumor lung origin drug have also be approve eu same indication recent approval kisqali use combination inhibitor first line treatment postmenopausal woman hormone receptor positive human epidermal growth factor receptor negative hr advanced metastatic breast cancer be likely boost oncology portfolio further drug be also approve europe meanwhile fda also approve label expansion zykadia include first line treatment patient metastatic small cell lung cancer major boost fda recently approve breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve approval be major boost novartis give potential car therapy space approval open new frontier treatment cancer advance immunocellular therapy child young adult cell comprise approximately cancer diagnosis child year be most common childhood cancer unite state meanwhile novartis plan make additional filing kymriah unite staes eu year kymriah treatment adult patient diffuse large cell lymphoma april fda grant breakthrough therapy designation kymriah base datum juliet study other hand be pleased progress biosimilar pipeline company plan launch major oncology immunology biosimilar include biosimilar version roche holding ag rhhby free report rituxan rituximab be approve european commission june market rixathon recently fda accept biologic license application propose biosimilar version rituxan august sandoz erelzi biosimilar version amgen inc amgn free report blockbuster drug enbrel gain approval unite state indication erelzi be also approve european commission european medicine agency also accept company marketing authorization application biosimilar version humira adalimumab remicade infliximab review novartis stock have rally year date compare industry gain novartis be currently go transitional stage company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february company also lose patent protection drug eu december lead generic competition loss patent protection top selling drug continue hurt sale hence novartis expect next growth phase begin drive cosentyx psoriasis psoriatic arthritis ankylose spondylitis indication entresto kisqali deep pipeline candidate baf amg rth zack rank stock currently carry zack rank buy top rank stock health care sector worth consider be alexion pharmaceutical inc alxn free report sport zack rank strong buy see complete list today zack rank stock here alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
22,AMGN,key development week be fda approval first cancer biosimilar amgen amgn free report allergan mvasi biosimilar version roche blockbuster cancer drug avastin other update include important datum presentation company nabriva therapeutic nbrv free report abbvie abbv free report recap week most important storiesfirst cancer biosimilar get fda nod fda approve amgen allergan mvasi biosimilar version roche blockbuster cancer drug avastin bevacizumab mvasi be used eligible indication reference product approval be line expectation consider favorable vote biosimilar get fda advisory panel recently approval be quite boost company well effort lower drug price so far biosimilar be yet make significant dent reference product sale unite state mvasi be review eu read more amgen allergan avastin biosimilar secure fda approval nabriva positive antibiotic datum nabriva get major boost company post positive top line result oral lefamulin patient community acquire bacterial pneumonia cabp lead cause infectious death unite state leap study first pivotal late stage study be conduct lefamulin meet fda primary endpoint inferiority compare moxifloxacin adjunctive linezolid early clinical response european medicine agency ema criterium be also meet nabriva be look position lefamulin first line empiric monotherapy second pivotal study be currently enrolling topline result expect next year spring positive result allow company file fda approval second half nabriva have gain year date significantly outperform industry rally read more nabriva lefamulin positive pivotal study stock surge fda advisory panel meeting biomarin drug biomarin pharmaceutical bmrn free report know strong presence market serious life threaten rare disorder say fda be not look hold advisory panel meeting company biologic license application bla pegvaliase biomarin be look get pegvaliase approve reduction blood phenylalanine phe level adult patient pku have uncontrolled blood phe level exist management pegvaliase be currently priority review response fda expect feb however well be push month agency have ask biomarin additional chemistry manufacturing control cmc information read more biomarin say fda not plan adcom pegvaliase bla tesaro zejula step closer eu nod cancer focuse tesaro tsro free report get good news ema committee medicinal product human use chmp issue positive opinion zejula niraparib monotherapy maintenance treatment adult patient platinum sensitive relapse high grade serous epithelial ovarian fallopian tube primary peritoneal cancer be complete partial response platinum base chemotherapy give positive opinion chance gain eu approval look high approval make zejula first oral once daily parp inhibitor europe use patient regardless brca mutation biomarker status zejula be already approve unite state read more tesaro ovarian cancer drug zejula get positive chmp opinion abbvie roche cancer drug positive late stage study abbvie partner roche be look expand label cancer therapy venclexta venclyxto result late stage study murano help effort venclexta rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll murano study independent datum monitoring committee have recommend unblind study base positive result label expansion indication expand patient population venclexta significantly boost commercial potential read more roche announce positive datum leukemia drug halozyme sign deal raise view halozyme therapeutic halo free report share shot company announce deal roche bristol myer squibb enhanze drug delivery technology raise outlook year roche agreement halozyme stand receive upfront achievement specify development regulatory sale base milestone company also receive tiered mid single digit royalty sale commercialize product bristol myer deal see company get upfront future milestone royalty payment base licensing deal halozyme up revenue guidance expect exit year cash balance more previous guidance read more bristol myer collaborate halozyme enhanze halozyme be zack rank buy stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock celgene be biogen lose last month vertex vrtx free report be see last biotech stock roundup here alexion cut job streamline operation kura cancer datum next biotech world watch usual regulatory pipeline update more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
23,AMGN,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put amgen inc amgn free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front amgen have trail month pe ratio see chart level actually compare pretty favorably market large pe ratio compare focus stock long term pe trend current level put amgen current pe ratio midpoint past year number have rise rapidly past few month further stock pe also compare favorably broader industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now amgen have ratio be bit average come right now also see chart be well high stock particular past few year anything amgn be roughly lower end range time period metric suggest level undervalue trading least compare historical norm broad value outlookin aggregate amgen currently have value score putt top stock cover look make amgen solid choice value investor stock overall amgen be good choice value investor be plenty other factor consider investing name particular be worth note company have growth score momentum score give amgn zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be mixed best current quarter have see estimate go higher past day compare lower full year estimate have see same time period have have just small impact consensus estimate current quarter consensus estimate have decrease past month full year estimate have inched upper see consensus estimate trend recent price action stock chart amgen inc price consensus amgen inc price consensus amgen inc somewhat mixed trend be stock have just zack rank hold be look line performance company term bottom lineamgen be inspire choice value investor be hard beat incredible lineup statistic front furthermore solid industry rank top more industry instill investor confidence flipside past year broader industry have clearly underperform broader market see so value investor want estimate analyst sentiment turn name first once happen stock be compelling pick promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
24,AMGN,novartis ag nvs free report announce new datum chronic spontaneous urticarium csu drug xolair european academy dermatology venereology congress geneva switzerland phase iiib study optima optima be phase iiib international multicenter randomize open label comparator study patient csu symptom treatment antagonist be initially randomize xolair mg week first dose period thereafter patient respond well treatment be give break then symptom return be retreat datum csu patient respond well initial treatment xolair regain symptom control week follow treatment interruption base weekly urticarium activity score uas criterium uas datum study re confirm almost third patient treat xolair mg month be well controlled note xolair be approve treatment csu eu unite state chronic idiopathic urticarium xolair be also approve treatment moderate severe severe persistent allergic asthma novartis have collaboration agreement roche holding ag rhhby free report develop co promote xolair unite state note novartis be global leader immunology dermatology drug cosentyx xolair zortress myfortic ilaris novartis stock have rally year so far compare industry gain novartis be currently go transitional stage company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february company also lose patent protection drug eu december lead generic competition loss patent protection top selling drug continue hurt sale hence novartis expect next growth phase begin drive cosentyx psoriasis psoriatic arthritis ankylose spondylitis indication entresto kisqali deep pipeline candidate baf amg rth moreover recent approval kymriah novartis be first company bring car cell therapy cancer treatment go forward expect approval new drug label expansion exist one bode well novartis other hand generic division sandoz be leader biosimilar market market biosimilar omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state company plan launch major oncology immunology biosimilar include biosimilar version rituxan rituximab be approve european commission june market rixathon august sandoz erelzi biosimilar version amgen inc amgn free report blockbuster drug enbrel gain approval unite state indication erelzi be also approve european commission zack rank stock currently carry zack rank hold aduro biotech inc adro free report be better rank biomedical company zack rank buy see complete list today zack rank strong buy stock here aduro loss estimate narrow last day company deliver average earning beat trail quarters new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
25,AMGN,amgen amgn free report partner allergan agn free report announce fda approve biosimilar version roche rhhby free report cancer drug avastin bevacizumab treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi mvasi be first cancer biosimilar approve unite state be also first bevacizumab biosimilar country notably amgen have also submit regulatory application same eu remind investor july fda oncologic drug advisory committee have unanimously vote recommend approval mvasi amgen share have outperformed industry so far year stock have plunge versus broader industry rally approval be support comprehensive datum package demonstrated similarity mvasi bevacizumab datum also include result phase iii comparative efficacy safety immunogenicity study confirm clinically meaningful difference mvasi reference product amgen allergan be also develop biosimilar version roche herceptin abp review unite state eu rituxan abp phase iii amgen biosimilar version abbvie humira amjevita be approve fda september last year however amjevita have not be launch yet due ongoing litigation other development include amgen biosimilar version alexion soliris lilly erbitux johnson johnson jnj free report merck remicade interestingly biosimilar endeavor offer lucrative opportunity annual revenue worth amgen company have also collaborate japan daiichi sankyo biosimilar japan accelerate approval biosimilar number pharmaceutical biotech company be work bring biosimilar market many biosimilar be market eu very few be available unite state last november pfizer have launch inflectra biosimilar version remicade sandoz also market zarxio first biosimilar be approve unite state product be turn biosimilar amgen neupogen july merck have launch reneflexis biosimilar version remicade unite state august last year sandoz have gain fda approval erelzi biosimilar version amgen enbrel however product be hold due ongoing litigation be yet be unveil unite state amgen inc priceamgen inc price amgen inc quotezack rankamgen currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
26,AMGN,biosimilar space remain spotlight number regulatory decision be pending generic drug be follow version chemically synthesize molecule biosimilar contain version active substance already approve original biological drug development biosimilar be technically challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same remain highly lucrative acceleration approval biosimilar market have thus attract lot player be witness rapid growth here be few latest development space lead biosimilar space be novartis ag nvs free report generic arm sandoz be strong player biosimilar market market biosimilar omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state company plan launch major oncology immunology biosimilar include biosimilar version rituxan rituximab be approve european commission june market rixathon recently fda accept biologic license application bla propose biosimilar version rituxan august sandoz erelzi biosimilar version amgen inc amgn free report blockbuster drug enbrel gain approval unite state indication erelzi be also approve european commission european medicine agency also accept company marketing authorization application biosimilar version humira adalimumab remicade infliximab review novartis currently carry zack rank hold see complete list today zack rank strong buy stock here generic leader mylan nv myl free report be also explore world biosimilar market have potential grow fda recently notified mylan partner biocon target action date biosimilar version herceptin trastuzumab have be extend dec decision fda be expect sep fda extend review period due review clarificatory information submit agency part application review process note biocon partnership include biosimilar program such biosimilar version herceptin neulasta humira avastin enbrel neupogen insulin analog lantus humalog novolog mylan have collaboration agreement momenta pharmaceutical inc mnta free report develop manufacture commercialize momenta current biosimilar candidate include momenta biosimilar candidate orencia mylan currently carry zack rank strong sell meanwhile amgen allergan plc agn free report have also submit bla fda abp biosimilar candidate herceptin jul note company be collaborate oncology biosimilar include abp be second be submit fda approval company have also submit marketing authorization application european medicine agency candidate earlier note amgen have total biosimilar pipeline have be approve fda march european commission grant marketing authorization amgevita biosimilar version humira available indication company have important event line fda be expect give decision approval abp biosimilar version avastin shortly amgen currently carry zack rank hold last month biotech major biogen inc biib free report announce european commission grant marketing authorization imraldi biosimilar version humira be third tnf biosimilar biogen receive marketing authorization european union follow approval benepali biosimilar enbrel flixabi infliximab biosimilar version remicade biogen currently carry zack rank hold july merck co inc mrk free report launch reneflexis biosimilar version remicade unite state be approve fda april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold medical sector yr return medical sector yr give fact so much be happen space expect investor focus upcoming approval date trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
27,AMGN,novartis ag nvs free report announce fda accept generic arm sandoz biologic license application bla propose biosimilar version roche hold ag rhhby free report rituxan rituximab application be accept pathway note rituxan be approve treatment blood cancer include hodgkin lymphoma follicular lymphoma diffuse large cell lymphoma chronic lymphocytic leukemia well immunological disease such rheumatoid arthritis remind investor sandoz be leader biosimilar market market biosimilar company plan launch major oncology immunology biosimilar include biosimilar rituximab be approve european commission june market rixathon august sandoz erelzi biosimilar version amgen amgn free report enbrel gain approval unite state indication reference drug european medicine agency have also accept company marketing authorization application biosimilar version humira adalimumab remicade infliximab review believe approval new drug label expansion exist drug boost top line go forward sandoz performance last quarter be disappointing grapple pricing pressure earlier company announce result phase iii study patient stage iii braf mutation positive melanoma complete surgical resection treat combination tafinlar dabrafenib mekinist trametinib year relapse free survival rate patient treat combination be compare placebo novartis be currently go transitional stage company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february company also lose patent protection drug eu december lead generic competition loss patent protection top selling drug continue hurt sale late performance alcon business have be quite disappointing due lower surgical equipment sale due competition face intraocular lens slowdown demand equipment purchase restructure initiative company segment performance remain dismal particular surgical business be take longer turnaround novartis stock have rally year so far compare industry gain last week novartis announce chief executive officer joseph jimenez step position vasant global head drug development chief medical officer replace effective feb zack rank key picknovartis currently carry zack rank hold better rank stock healthcare sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
28,AMGN,abbvie abbv free report share increase almost company announce oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment patient rheumatoid arthritis ra fact abbvie share have rally outperform industry rise so far year phase iii select study be multus center randomize double blind placebo controlled parallel group study be design evaluate efficacy safety dose mg mg upadacitinib compare placebo week patient moderate severe ra be stable dose conventional synthetic dmard have have show inadequate response dosage study meet primary endpoint highly statistically significant clinically meaningful result dose compare placebo trial primary endpoint be acr response low disease activity lda result show patient receive mg patient administer mg dose once daily upadacitinib achieve acr response week treatment comparison patient receive placebo lda be achieve patient mg mg dose arm respectively compare patient receive placebo additionally study meet secondary endpoint too notably select be second ongoing phase iii study select ra clinical trial program conduct upadacitinib other research be also underway upadacitinib treat crohn disease ulcerative colitis atopic dermatitis remind investor last week company announce upadacitinib have meet primary endpoint phase iib study atopic dermatitis company plan advance candidate phase iii study next year give indication note abbvie already have strong presence ra market blockbuster drug humira however several company be work develop biosimilar version humira induce competition market company also ra market be extremely crowd include drug johnson johnson simponi ucb cimzia other significantly eli lilly lly free report jak inhibitor olumiant be recently approve eu pfizer pfe free report xeljanz be market unite state treat ra strong competition upadacitinib approval also amgen amgn free report have already receive approval market humira biosimilar drug have not be launch yet due ongoing litigation upadacitinib be approve reduce potential negative impact humira generic abbvie top line abbvie inc priceabbvie inc price abbvie inc quotezack rankabbvie currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
29,AMGN,amgen inc amgn free report astrazeneca plc azn free report announce pipeline candidate tezepelumab reduce annual asthma exacerbation rate aaer measure deterioration asthma pathway study patient severe uncontrolled asthma tezepelumab thymic stromal lymphopoietin monoclonal antibody be be study phase iib pathway study result study be also publish new england journal medicine be present european respiratory society ers international congress milan amgen share be so far year outperform industry gain period astrazeneca share have underperform industry so far year company rise industry gain period pathway study compare dose candidate mg mg week mg week placebo tezepelumab be administer add therapy patient have experience asthma exacerbation uncontrolled asthma treatment asthma controller corticosteroid datum study demonstrated tezepelumab achieve significant reduction aaer compare placebo fact candidate show reduction mg mg mg dose respectively tezepelumab have also achieve significant clinically meaningful reduction exacerbation rate irrespective baseline blood eosinophil count also improve lung function dose asthma control higher dose press release person be affected asthma globally have severe asthma become uncontrolled receive high dose standard care medicine uncontrolled asthma patient then addition be treat chronic oral corticosteroid tezepelumab help patient control further deterioration disease however asthma market be crowd treatment glaxosmithkline plc gsk free report nucala teva pharmaceutical industry limit teva free report cinqair available moreover astrazeneca be develop benralizumab treat asthma amgen inc price consensus amgen inc price consensus amgen inc quoteamgen astrazeneca currently have zack rank hold see complete list today zack rank stock here astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quoteone simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
30,AMGN,astrazeneca plc azn free report announce positive top line result phase iii amplify study duaklir aclidinium bromide formoterol g g twice daily candidate be be evaluate treatment chronic obstructive pulmonary disease copd study meet primary endpoint show statistically significant improvement lung function patient moderate very severe stable copd compare individual component aclidinium bromide formoterol astrazeneca share have outperformed industry year date stock have rally compare industry gain same time frame full evaluation amplify datum be ongoing further result be present forthcoming medical meeting astrazeneca expect submit new drug application nda duaklir fda first half base amplify datum april company enter strategic collaboration circassia pharmaceutical plc development copd drug tudorza duaklir unite state separate release astrazeneca partner amgen inc amgn free report also announce result pathway phase iib trial tezepelumab show significant reduction annual asthma exacerbation rate compare placebo patient severe uncontrolled asthma tezepelumab be first class tslp monoclonal antibody be develop medimmune astrazeneca plc price astrazeneca plc price astrazeneca plc quotezack rank stock currently carry zack rank hold better rank stock health care sector include alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report sporting zack rank strong buy see complete list today zack rank stock here alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date simple trading idea zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
31,AMGN,merck co inc mrk free report announce pd therapy keytruda have receive approval european commission ec first second line treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer keytruda have be approve first line therapy patient receive standard care chemotherapy contain cisplatin keytruda be also approve second line treatment patient have be previously treat platinum contain approval be expect july committee medicinal product human use chmp european medicine agency ema have grant positive opinion recommend approval keytruda unite state keytruda receive accelerate approval advanced bladder cancer indication year approval be base datum phase ii keynote trial phase iii keynote trial datum study have show clinically meaningful improve overall survival benefit keytruda versus chemotherapy difficult treat population keytruda be presently approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer keytruda bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer outside keytruda sale be primarily drive melanoma indication meanwhile keytruda development program also significantly advanced first half regulatory approval new indication additional indication europe important approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer further keytruda datum readout be pending second half keytruda be continuously grow expand new indication market globally keytruda be be study more type cancer more study include more combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck share have rise year so far increase industry merck carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
32,AMGN,ligand pharmaceutical incorporate lgnd free report announce positive top line result phase ii study evaluate diabetes candidate lgd study achieve statistically significant change hemoglobin hba measure blood glucose baseline week treatment candidate supplement diet exercise be study patient metformin monotherapy inadequately controlled type ii diabetes mellitus dm more detail study be provide future scientific conference publish peer review publication share company rise tuesday trading follow announcement touch new week high fact ligand have outperformed industry so far year gain compare industry rise phase ii study evaluate dose lgd viz mg mg mg versus placebo dm patient datum show candidate achieve reduction hba mg mg mg dose compare placebo candidate be safe well tolerate patient change lipid body weight blood pressure completion treatment diabetes be grow concern worldwide press release be person affected diabetes worldwide approximately person unite state be prediabetic total population unite state be estimate be affected diabetes global drug forecast market analysis estimate diabetes market double ligand top line be drive royalty sale several drug include novartis ag nvs free report promacta spectrum pharmaceutical inc sppi free report evomela amgen inc amgn free report kyproli use former captisol technology manufacturing ligand pharmaceutical incorporate price consensus ligand pharmaceutical incorporate price consensus ligand pharmaceutical incorporate sport zack rank strong buy be part industry rank top see complete list today zack rank stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
33,AMGN,be relatively slow week biotech sector key pipeline update be provide company cellectis cll free report insm insm free report insm sky-rocket positive datum lead pipeline candidate cellectis be hit clinical hold couple phase study recap week most important hit fda clinical hold cellectis share be hit clinical hold place fda couple early stage study be conduct ucart study be acute myeloid leukemia aml other be blastic plasmacytoid dendritic cell neoplasm bpdcn hold come place company report death bpdcn study cellectis be focuse develop immunotherapy base gene edit allogeneic car cell ucart say be work fda investigator resumption study amend protocol include lower dosage share be clinical hold cellectis have gain year date significantly outperform industry rally insm shoot alis datum insm share shot positive top line datum late stage study convert treatment refractory nontuberculous mycobacterial ntm lung disease cause mycobacterium avium complex mac result show addition alis amikacin liposome inhalation suspension guideline base therapy gbt eliminate evidence ntm lung disease cause mac sputum sixth month patient compare patient gbt alone base datum insm intend seek accelerate approval priority review alis subpart alis have breakthrough therapy designation fast track status unite state be also qualify infectious disease product qidp generate antibiotic incentive now gain act provide additional year exclusivity alis be lead candidate insm pipeline accord company patient be diagnosed ntm lung disease be treat ntm lung disease cause mac akcea ionis submit fcs drug fda approval akcea therapeutic akca free report ionis pharmaceutical ion free report announce submission new drug application nda volanesorsen treatment familial chylomicronemia syndrome fcs severe rare disorder characterize extremely high level triglyceride company be look launch volanesorsen globally provide gain timely approval efficacy datum volanesorsen be promising concern remain safety profile candidate give injection site reaction fall platelet count volanesorsen be currently be evaluate late stage study familial partial lipodystrophy fpl topline datum expect ligand diabetes drug fare well mid stage study ligand pharmaceutical lgnd free report announce positive top line result mid stage study investigational type ii diabetes treatment lgd oral small molecule glucagon receptor antagonist gra addition show robust statistically significant dose dependent reduction baseline hemoglobin week treatment lgd be find be safe well tolerate be several diabetes treatment available market remain significant need additional treatment consider diabetes be grow global epidemic affect million world ligand be zack rank strong buy stock see complete list today zack rank stock here amgen mimpara eu label expand amgen amgn free report gain approval eu pediatric formulation mimpara treatment secondary hpt child age year end stage renal disease esrd maintenance dialysis therapy approval be largely expect committee medicinal product human use chmp european medicine agency ema have adopt positive opinion pediatric formulation earlier year june also read amgen get eu nod expand drug label biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock alexion be last month vertex vrtx free report be amgen slip see last biotech stock roundup here car focus gilead kite deal incyte baricitinib update next biotech world watch usual regulatory pipeline update surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
34,AMGN,month have go last earning report amgen inc amgn free report share have lose time frame underperform market recent negative trend continue lead stock next earning release be due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst amgen second quarter earning sale topamgen report second quarter earning share beat zack consensus estimate increase year period better revenue lower operate cost drive bottom line lower tax rate share count also pull profit total revenue rise quarter beating zack consensus estimate unfavorable impact foreign exchange hurt sale quarter revenue rise ex sale grow exclude currency headwind quarter detailtotal product revenue rise year quarter ex strong demand newer product prolium xgeva kyproli repatha blincyto somewhat make lower sale mature brand enbrel epogen neulasta neupogen due competitive pressure revenue amgen erythropoiesis stimulating agent esa aranesp rise year quarter due volume growth however volume quarter benefit favorable timing tender outside market compare year quarter revenue other esa epogen decline due lower selling price owing recently negotiate contract davita inc neulasta revenue decline year period due lower unit demand follow competition pd other new cancer therapy neupogen record decline sale due biosimilar competition zarxio sandoz biosimilar version neupogen be launch sep be hurt sale company expect neulasta neupogen sale be hurt competitive dynamic rest however management do specify call new biosimilar competition be expect year suggest neulasta epogen not start face biosimilar competition year contrary previous expectation company look launch generic version neulasta company look launch generic version epogen have receive complete response letter fda respective application delay launch however neulasta onpro kit body injector continue perform well command market share neulasta sale enbrel deliver revenue year quarter due increase competition offset favorable change inventory price however quarter company say improvement underlie segment performance be witness second quarter compare first market volume growth improve rheumatology dermatology segment second quarter compare first quarter enbrel experience relatively stable unit share market prolium revenue come year quarter due higher demand osteoporosis drug witness market share gain international market meanwhile xgeva deliver revenue year quarter mainly due higher demand company expect multiple myeloma indication be add xgeva label expand eligible patient population boost sale sensipar mimpara revenue increase due higher price increase vectibix revenue come drive higher demand kyproli record sale year year drive higher demand robust uptake outside launch quarter amgen submit regulatory application eu include overall survival datum endeavor study label kyproli study demonstrated combination kyproli dexamethasone reduce risk death improve overall survival month compare velcade overall survival datum approve help drive usage boost sale kyproli amgen also announce final datum phase iii aspire study kyproli jul show triple combination regimen kyproli revlimid lenalidomide dexamethasone krd reduce risk death improve survival month patient relapse multiple myeloma compare revlimid dexamethasone rd blincyto sale surge year period reflect higher demand jul fda approve inclusion overall survival datum tower study label blincyto convert accelerate approval full approval addition datum help boost sale repatha generate revenue higher first quarter drive higher demand repatha hold share pcsk segment europe share trend improve sequentially market second quarter meanwhile new brand share repatha be second quarter management say presentation outcome study datum have positive impact repatha share trend other revenue grow drive higher ibrance royalty revenue offset partially lower nexavar royalty revenue operate margin operate margin rise basis point bps due lower operate cost reflect continue benefit transformation process improvement effort expense decline quarter due lower late stage pipeline related cost sg spend decline due oct expiration enbrel residual royalty payment offset investment support new product launch amgen buy back share worth quarter end second quarter amgen have remain stock repurchase plan guidancewhile amgen slightly cut lower end previously issue sale outlook raise earning guidance account strong first half profit company expect total revenue range compare expect previously adjust earning be now expect range compare share expect previously operate expense be expect be higher second half have estimate be move then follow release investor have witness upward trend fresh estimate have be revision higher current quarter compare lower look back additional day see even more upward momentum have be move higher last month amgen inc price consensus amgen inc price consensus amgen inc quotevgm scoresat time amgen stock have average growth score be lag bit momentum front stock be allocate grade value side putt top investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable value investor growth investor outlookwhile estimate have be broadly trend upward stock magnitude revision indicate downward shift notably stock have zack rank hold expect line return stock next few month
35,AMGN,biogen biib free report third quarter result surpass top bottom line expectation meanwhile gilead gild free report car therapy gain earlier expect fda approval alexion alxn free report also get regulatory boost fda expand label company flagship product soliris recap week most important storiesbiogen beat front biogen third quarter result be better expect company surpass earning revenue expectation share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza spinraza sale be third quarter more less flat second quarter sale company report increase number patient therapy unite state compare end second quarter however second quarter sale include inventory buildup read more biogen top earning sale spinraza sale biogen have gain year date outperform industry rally gilead car therapy yescarta approve gilead yescarta become part company portfolio follow kite pharma acquisition gain fda approval treatment adult patient relapse refractory large cell lymphoma more line systemic therapy make yescarta first chimeric antigen receptor cell car therapy gain approval use patient population yescarta be second gene therapy gain approval unite state first be novartis kymriah treatment come box warning regard risk cytokine release syndrome crs neurologic toxicity yescarta approval be major boost gilead be currently face decline sale hepatitis virus hcv franchise accord information provide company diffuse large cell lymphoma dlbcl be most common aggressive hodgkin lymphoma nhl patient refractory dlbcl be eligible car therapy year yescarta represent new treatment option patient have run treatment option face poor prognosis yescarta be launch list price unite state be currently review eu response be expect first half read more gilead car therapy yescarta clinch fda approval gilead also announce phase ii result investigational treatment nonalcoholic steatohepatitis nash company say higher dose mg gs oral acc inhibitor achieve significant reduction buildup fat liver noninvasive marker fibrosis timp compare placebo however statistical significance be not achieve other parameter liver stiffness fibroscan mre serum alt piii np serum marker fibrogenesis meanwhile difference lower dose mg gs placebo be not statistically significant celgene hit crohn disease study discontinuation celgene celg free report share be news company be discontinue study phase iii revolve study extension study sustain be conduct investigational crohn disease drug ged mongersen decision be base recommendation datum monitoring committee october follow interim futility analysis meaningful safety imbalance be observed analysis celgene also say review full dataset phase ii ulcerative colitis study ged decide path forward company not be initiate phase iii define study crohn disease read more celgene discontinue crohn disease drug study abbvie announce immuno therapy focuse deal abbvie abbv free report announce couple deal week deal be focuse immuno neurology other be focuse immuno oncology immuno neurology deal see abbvie collaborate alector use latter immuno neurology discovery platform innovative new therapy alzheimer disease other neurological disorder immuno neurology rapidly evolve scientific area be focuse harness power immune system attack disorder alzheimer disease development cost well profit be share equally company alector get upfront payment potential future equity investment meanwhile immuno oncology deal see abbvie team harpoon therapeutic use harpoon tri specific cell activate construct tritac platform abbvie research stage immuno oncology target develop cancer therapeutic read more abbvie inks immuno oncology deal harpoon therapeutic label expansion alexion soliris fda grant approval alexion use flagship product soliris eculizumab adult patient generalized myasthenia gravis gmg be achr antibody positive soliris already approve unite state serious ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus bring sale first half year gmg indication represent incremental growth opportunity soliris alexion be zack rank hold stock see complete list today zack strong buy rank stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene lose reflect sell follow crohn disease update biogen be last month vertex vrtx free report be celgene be see last biotech stock roundup here exelixis soar priority review fda panel support spark drug next biotech world week company amgen amgn free report vertex alexion gilead celgene abbvie be report third quarter result zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
36,AMGN,biogen inc biib free report well know name multiple sclerosis ms market surpass expectation earning sale third quarter company revenue be drive continue strong performance newest drug spinraza spinal muscular atrophy better expect result biogen share be almost pre market trading be probably due fact sale multiple sclerosis franchise be expectation increasingly competitive market however note biogen share have gain so far year compare unfavorably industry increase third quarter earning share be comfortably beat zack consensus estimate earning also rally year year sale come year period sale also surpass zack consensus estimate top line exclude hemophilia revenue grow year year company spun hemophilia business february year quarter detail biogen ms revenue be quarter include approximately royalty sale roche ms drug ocrevus tecfidera sale increase year period however drug record sequential drop revenue include sale ex sale unite state tecfidera inventory level third quarter be relatively flat compare year level hurt sale report quarter third quarter tysabri revenue be ex decrease year year sequentially believe ocrevus launch have put pressure tysabri sale quarter combine interferon revenue avonex plegridy third quarter be ex year period avonex revenue decline year period plegridy contribute third quarter revenue year year sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well higher discount allowance zinbryta launch collaboration abbvie inc abbv free report august last year contribute revenue third quarter sequentially newly launch spinraza bring revenue revenue third quarter register growth sequentially drug witness strong demand unite state company be work expand access patient quarter biogen record biosimilar revenue compare second quarter company market benepali biosimilar reference amgen inc amgn free report enbrel europe benepali record revenue register growth rate sequentially biogen also market flixabi biosimilar reference johnson johnson jnj free report blockbuster drug remicade record revenue report quarter compare second quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period third quarter spend decrease report quarter sg spend decline year year collaboration month biogen announce restructure collaboration arrangement eisai neurimmune improve long term value alzheimer candidate aducanumab be presently phase iii study concurrent earning release biogen announce renegotiation agreement neurimmune make time payment exchange reduction neurimmune royalty rate potential sale aducanumab re negotiate deal thus increase aducanumab profit potential oct biogen partner eisai refine exist alzheimer collaboration biogen already have agreement eisai develop phase iii bace inhibitor phase ii amyloid beta antibody ban alzheimer disease however biogen have announce eisai have exercise option jointly develop commercialize aducanumab company now receive aducanumab potential profit unite state europe japan biogen inc price consensus ep surprise biogen inc price consensus ep surprise biogen inc quotezack rankbiogen currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
37,AMGN,radius health inc rdus free report post loss share second quarter wider loss share year quarter wider zack consensus estimate loss year year increase net loss be attributable increase general administrative expense radius share price increase year date industry gain company report sale tymlos abaloparatide first week launch miss zack consensus estimate quarter detailresearch development expense report quarter be year year due decrease regulatory professional fee associate abaloparatide sc regulatory application decrase elacestrant rad project cost decrease development cost associate abaloparatide td general administrative expense report quarter jump increase be attribute growth professional support cost include cost associate increase headcount tymlos higher compensation expense include stock base compensation due increase headcount be also responsible increase cost radius health inc price ep surprise radius health inc price ep surprise radius health inc quotepipeline updateson apr fda approve radius health lead candidate tymlos injection treatment postmenopausal woman high risk osteoporosis fracture defined history osteoporotic fracture multiple risk factor fracture patient have fail be intolerant other available osteoporosis therapy company be develop formulation abaloparatide abaloparatide sc abaloparatide transdermal meanwhile radius health marketing authorisation application maa eladyno abaloparatide sc treatment postmenopausal woman osteoporosis europe be review committee medicinal product human use chmp european medicine agency company however suffer setback chmp issue second day list outstanding issue consequently radius be work chmp address issue company expect response prior end radius health announce positive top line result complete month activextend clinical trial tymlos meet primary secondary endpoint company expect submit snda fda connection activextend result year end company report positive datum ongoing phase dose escalation expansion study elacestrant advanced metastatic breast cancer company discuss datum ongoing phase study fda determine next step elacestrant breast cancer program include design phase ii trial follow discussion fda agree single arm monotherapy phase ii study patient be appropriate agency also provide additional feedback propose clinical protocol include confirmation primary endpoint be objective response rate durability response fda also state study result demonstrate superiority then available therapy single arm phase ii trial be consider pivotal study accelerate approval long company have also commence confirmatory study time new drug application nda submission addition elacestrant be also be evaluate low dose estrogen receptor ligand potential relief frequency severity moderate severe hot flash postmenopausal woman vasomotor symptom company expect report result phase iib clinical study elacestrant potential treatment postmenopausal vasomotor symptom second half company wider expect loss second quarter be disappointing expense continue increase launch tymlos company be move ahead plan contract manage care organization access cover life commercial medicare part plan osteoporosis market have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor company however suffer setback chmp issue second day list outstanding issue zack rank key pickradius health currently have zack rank sell better rank stock healthcare sector be gilead science inc gild free report currently carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
38,AMGN,allergan plc agn free report second quarter earning come share beating zack consensus estimate earning rise year year drive higher revenue operate profitsrevenue come year period beat zack consensus estimate key product botox new product vraylar namzaric viberzi do well quarter sale be once again hurt sale erosion namenda xr loss exclusivity mainly asacol hd minastrin also lower sale key dry eye disease drug restasis hurt top line second quarter revenue however gain addition alloderm lifecell jan coolsculpt body contour system zeltiq apr acquisition adjust operate income increase quarter selling general administrative sg expense rise quarter primarily due higher promotional spend support new product launch expense increase support advance pipeline segment company report revenue segment general medicine specialize therapeutic international specialize therapeutic net revenue increase drive strong growth botox addition lifecell alloderm zeltiq coolsculpt business botox cosmetic rake sale botox therapeutic revenue be addition juvderm collection filler rise ozurdex sale increase contribute upside alloderm add coolsculpt add sale second quarter importantly restasis sale decline quarter due unfavorable trade buy pattern remind investor shire plc shpg free report launch dry eye disease drug xiidra last year have be investor concern xiidra pose strong competition restasis company expect stable restasis revenue year general medicine net revenue decline report quarter sale decline diversify brand woman health franchise infective sale rise central nervous system sale rise establish product linzess loestrin well new product viberzi namzaric vraylar do well quarter linzess sale rise quarter drive strong demand continue otc conversion however lower namenda xr sale hurt performance cns franchise namenda xr sale decline quarter due lower demand lower pricing shift promotional effort namzaric company do not expect generic version namenda xr be launch first quarter delay prior expectation fourth quarter also allergan do not expect generic version estrace cream be launch year namzaric once daily fix dose combination namenda xr record sale compare previous quarter asacol delzicol sale decline due reduction demand ascaol hd follow launch authorize generic aug well lower demand delzicol woman health segment minastrin revenue decline quarter due loss exclusivity mar international segment record net revenue year period drive growth facial aesthetic botox therapeutic addition lifecell coolsculpt outlook company raise previously issue earning sale guidance allergan expect total revenue range compare previously currency headwind be now not expect hurt revenue versus negative impact approximately expect previously adjust earning share be expect range compare previously adjust gross margin be expect expense be expect be approximately maintain sg spend be expect compare previously takeallergan do fairly well beating estimate earning sale second quarter company also raise outlook share be slightly pre market trading however so far year allergan share price be industry decline allergan be reshape portfolio strategic acquisition drugmaker sell generic anda distribution business teva pharmaceutical industry limit teva free report aug oct respectively order focus brand segment allergan also boast strong brand pipeline product launch plan allergan be extend pipeline adjacent category nash parkinson disease gene therapy many promising phase ii iii program development be also encourage allergan focus build biosimilar pipeline allergan have collaboration agreement amgen inc amgn free report worldwide development oncology antibody biosimilar include biosimilar roche cancer drug herceptin avastin however generic competition legacy brand namenda ir xr asacol hd well new competition key growth driver restasis linzess be investor concern allergan carry zack rank hold see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
39,AMGN,major biotech stock gilead gild free report celgene celg free report alexion abbvie abbv free report vertex vrtx free report report second quarter result last few day company gilead amgen amgn free report also provide regulatory update recap week most important storiesa look earning result gilead result be strong company hiv franchise putt strong performance hepatitis virus hcv franchise perform better expect company raise revenue outlook include hcv franchise read more gilead top earning revenue estimate stock celgene also top estimate raise earning guidance year read more celgene beat earning sale estimate up view do alexion read more alexion top earning revenue up view vertex read more vertex earning top solid cystic fibrosis sale abbvie too top expectation read more abbvie top earning revenue outlook intact earlier expect fda approval celgene agio cancer drug celgene partner agio agio free report gain fda approval idhifa enasidenib treatment adult patient relapse refractory acute myeloid leukemia aml idh mutation detected fda approve test approval come ahead fda action date aug make idhifa first only fda approve therapy patient population represent aml patient information provide company more new case aml be detected year majority patient see disease relapse eventually prognosis aml be poor overall survival patient population estimate be less month idhifa come box warning regard differentiation syndrome uptake be strong give significant unmet medical need be third time lucky dynavax heplisav dynavax dvax free report share shot favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult positive vote expectation be high company finally gain approval vaccine have previously receive complete response letter nov other feb decision agency be expect aug approve dynavax plan launch vaccine early next year dynavax share be whopping year date significantly outperform industry rally read more dynavax share jump fda committee approval vertex up cf outlook kalydeco label expansion vertex cystic fibrosis cf drug kalydeco label have be expand now be used more cf patient year older have residual function mutation result splice defect cystic fibrosis transmembrane conductance regulator cftr gene label expansion vertex up sale guidance drug old guidance vertex now expect total cf product revenue old guidance include orkambi sale unchanged regulatory update amgen gilead amgen provide quite few regulatory update last few day company say have submit regulatory application seek label expansion prolium treatment patient glucocorticoid induced osteoporosis giop prolium bring sale first half amgen partner allergan also say have file fda approval abp biosimilar candidate roche herceptin trastuzumab herceptin be approve treatment adjuvant breast cancer metastatic breast cancer metastatic gastric cancer meanwhile amgen pcsk inhibitor repatha get priority review inclusion fourier cardiovascular outcome study datum reduction risk cardiovascular event decision agency be expect dec amgen say second application expansion lipid lower indication include additional patient population study be also accept agency gilead also have update regulatory front company say hcv drug epclusa label be update include use patient co infected hiv epclusa initially gain approval jun be oral pan genotypic once daily single tablet regimen label expansion provide co infected patient convenient pill day regimen work hcv genotype be compatible widely used antiretroviral regimen epclusa sale crossed first half moreover gilead latest hcv offer vosevi gain approval eu treatment genotype marketing authorization harvoni eu be also extend allow use adolescent population vosevi be approve few week back july gilead be zack rank buy stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock alexion gain regeneron lose last month vertex be see last biotech stock roundup here amgen biogen top estimate update incyte ra drug next biotech world watch earning report company biomarin regeneron other more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
40,AMGN,pfizer inc pfe free report report second quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year other hand revenue miss expectation pharma heavyweight deliver revenue fall short zack consensus estimate again revenue decline year period due currency headwind divestiture hospira infusion system business feb pfizer divest hospira infusion system business icu medical sale detailcurrency movement impact pfizer second quarter revenue sale growth be flat operational basis exclude revenue sale rise operational basis lower sale enbrel prevnar prevenar vaccine franchise loss exclusivity product offset strong performance key product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis international revenue decline flat operational basis meanwhile revenue be flat segment second quarter pfizer reorganize report segment pfizer innovative health ih pfizer essential health pfizer ih sale grow operationally year period pfizer ih revenue be drive persistently strong momentum ibrance eliquis globally growth lyrica xeljanz primarily ibrance revenue rise quarter xeljanz rise lyrica sale rise eliquis alliance revenue direct sale rise revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow sep medivation acquisition also propel revenue xtandi record alliance revenue quarter compare first quarter be partially offset continue decline revenue prevnar lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside canada viagra sale decline due lower sale international market due reduce demand global prevnar prevenar revenue decline prevnar revenue tank due high initial capture rate eligible adult patient population follow successful launch result smaller remain catch opportunity second quarter compare year quarter unfavorable timing government purchase pediatric indication also hurt sale eucrisa crisaborole topical ointment treatment atopic dermatitis eczema be buy part jun anacor acquisition be launch first quarter ointment record sale second quarter consumer healthcare revenue rise global oncology revenue surge drive ibrance global vaccine revenue decline internal medicine rise inflammation immunology franchise decline additionally portfolio rare disease decline pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product pristiq generic version launch mar vfend zyvox celebrex lyrica lower revenue legacy hospira product divesture however business biosimilar do well quarter pfizer launch inflectra biosimilar version johnson johnson jnj free report merck co inc mrk free report blockbuster ra drug remicade november last year inflectra record sale globally other biosimilar bring sale outside market adjust selling informational administrative si expense be flat operationally quarter adjust expense rise guidance pfizer raise lower end adjust earning guidance retain revenue expectation year revenue be expect range adjust earning share be expect range compare expect previously higher previously anticipate royalty income certain product lower interest cost lead increase lower end profit outlook mid point revenue be expect be slightly level adjust ep be expect increase previously research development expense be still expect range si spending be project range key drug key pipeline candidate bavencio avelumab receive accelerate fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer candidate be be study different type cancer include several combination therapy other immuno oncology agent pipeline candidate besponsa inotuzumab ozogamicin be approve eu june monotherapy relapse refractory cd positive cell precursor acute lymphoblastic leukemia candidate be review fda decision expect later month takepfizer second quarter result be mixed beat earning estimate miss same sale share decline slightly pre market trading company continue struggle sale performance pfizer share be so far year compare unfavorably increase industry pfizer continue face headwind form genericization key drug lose alliance revenue pricing pressure rise competition be hurt top line product viagra lyrica chantix lose exclusivity couple year nonetheless believe new product ibrance contribution acquisition cost cut effort share buyback help company achieve guidance pfizer also boast strong pipeline expect approximately drug approval next year include product have blockbuster potential bavencio be be consider key long term growth driver pfizer pfizer carry zack rank hold see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
41,AMGN,share advanced micro device inc amd free report increase earning increase year year exceed zack consensus estimate share anthem inc antm free report decline post revenue lower zack consensus estimate share coca cola co ko free report increase beverage company report earning cent share surpass zack consensus estimate share amgen inc amgn free report fall unfavorable impact foreign exchange drag sale second quarter
42,AMGN,second quarter report cycle be full swing quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig eli lilly company lly free report biogen inc biib free report release second quarter result week company beat earning revenue estimate raise sale earning expectation full year moreover vertex pharmaceutical incorporate vrtx free report amgen inc amgn free report report encourage second quarter result jul beating estimate count however glaxosmithkline plc gsk free report report mixed second quarter result same day beating earning miss sale let take look large cap pharma company be set report second quarter result jul abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter abbvie earning performance have be mixed earning beating expectation last quarters meeting same remain result average positive surprise quarter abbvie have earning esp zack rank hold do not conclusively show abbvieis likely beat estimate quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quoteabbvie key drug humira be perform well be expect continue do well second quarter imbruvica have be record strong sale past few quarters expect trend continue however hcv franchise continue be pricing pressure read more abbvie earning disappointment store merck co inc mrk free report merck be also schedule announce result open bell merck have beaten estimate last quarters result average positive surprise last report quarter merck deliver positive surprise merck company inc price ep surprise merck company inc price ep surprise merck company inc company have earning esp zack rank buy thus do not look poise deliver beat time see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection drive top line quarter however company be expect face headwind form genericization increase competition negative impact currency exchange read more merck pull surprise earning season more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
43,AMGN,biotech major amgen inc amgn free report report second quarter earning share beat zack consensus estimate increase year period better revenue lower operate cost drive bottom line lower tax rate share count also pull profit total revenue rise quarter beating zack consensus estimate unfavorable impact foreign exchange hurt sale quarter revenue rise ex sale grow exclude currency headwind quarter detailtotal product revenue rise year quarter ex strong demand newer product prolium xgeva blincyto somewhat make lower sale mature brand enbrel epogen neulasta neupogen due competitive pressure revenue amgen erythropoiesis stimulating agent esa aranesp rise year quarter due higher unit demand revenue other esa epogen decline due lower selling price owing recently negotiate contract davita inc neulasta revenue decline year period due lower unit demand follow competition pd other new cancer therapy neupogen record decline sale due biosimilar competition zarxio sandoz novartis ag nvs free report generic arm biosimilar version neupogen be launch sep be hurt sale company expect neulasta neupogen sale continue be hurt competitive dynamic rest however management do specify call new biosimilar competition be expect year suggest neulasta epogenmay not start face biosimilar competition year contrary previous expectation however neulasta onpro kit body injector continue perform well command market share neulasta sale enbrel deliver revenue year quarter due increase competition offset favorable change inventory price however quarter market volume growth improve rheumatology dermatology segment compare first quarter enbrel experience relatively stable unit share market prolium revenue come year quarter due higher demand osteoporosis drug witness market share gain international market meanwhile xgeva deliver revenue year quarter mainly due higher demand sensipar mimpara revenue increase due higher price increase vectibix revenue come drive higher demand kyproli record sale year year drive higher demand quarter amgen submit regulatory application eu include overall survival datum endeavor study label kyproli study demonstrated combination kyproli dexamethasone lead superior overall survival compare velcade overall survival datum approve help drive usage boost sale kyproli amgen also announce final datum phase iii aspire study kyproli month show triple combination regimen kyproli celgene corporation celg free report revlimid lenalidomide dexamethasone krd significantly improve overall survival os patient relapse multiple myeloma compare revlimidand dexamethasone rd blincyto sale surge year period reflect higher demand earlier month fda approve inclusion overall survival datum tower study label blincyto addition datum help boost sale amgen pcsk inhibitor repatha generate revenue higher first quarter drive higher demand uptake drug gain fda approval aug have not be very encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical also face similar issue pcsk inhibitor praluent remind investor phase iii cardiovascular outcome study fourier repatha have reveal significant reduction myocardial infarction stroke first quarter datum be key commercial success repatha broaden use drug datum study look good be not very clear payer be willing improve access repatha base datum amgen file regulatory application eu include fourier datum repatha label jun operate margin operate margin rise basis point bps due lower operate cost reflect continue benefit transformation process improvement effort expense decline quarter due lower late stage pipeline related cost sg spend decline due oct expiration enbrel residual royalty payment offset investment support new product launch amgen buy back share worth quarter end second quarter amgen have remain stock repurchase plan guidancewhile amgen slightly cut lower end previously issue sale outlook raise earning guidance account strong first half profit company expect total revenue range versus expect previously adjust earning be now expect range compare share expect previously zack consensus estimate earning revenue be peg share respectively operate expense be expect be higher second half takeit be rather strong quarter amgen beat expectation earning sale raise earning guidance share however lose market trading probably due concern related tighten revenue guidance however so far year amgen share be better increase register industry amgen newer product prolium xgeva vectibix nplate sensipar be perform well volume growth not be enough offset decline mature brand enbrel due competitive pressure however amgen restructure plan make leaner more cost efficient amgen be also progress pipeline include biosimilar drug give quite few regulatory datum update schedule second half amgen currently carry zack rank hold see complete list today zack rank strong buy stock here amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
44,AMGN,key biotech stock amgen amgn free report biogen biib free report report second quarter result yesterday company surpass earning sale estimate be several other key update well company incyte incy free report medicine co mdco free report recap week most important storiesamgen biogen earning biogen result be strong company most recent offer spinraza spinal muscular atrophy sma do better expect meanwhile company multiple sclerosis ms franchise continue grow ms be biogen key area expertise biogen expect early be inflection point company key pipeline candidate expect launch period read more biogen top earning sale spinraza sale amgen also top estimate update guidance recently launch product include prolium second fourth quarters be typically strongest product repatha kyproli record strong volume drive growth amgen be work improve repatha patient access world meanwhile mature product enbrel epogen neulasta neupogen decline neupogen be impact short act biosimilar competition continue affect sale amgen stock have gain year date ytd outperform rally industry belong biogen have lag share decline ytd incyte lilly ra drug face least month delay resubmission incyte partner lilly announce be delay least month resubmission regulatory application investigational rheumatoid arthritis ra treatment baricitinib mean resubmission not take place year incyte lilly discuss path forward fda evaluate option resubmission include possibility conduct additional study require fda fda have issue complete response letter crl baricitinib earlier year april time agency have tell company be unable approve baricitinib once daily oral medication treatment moderate severe ra current form fda have ask additional clinical datum determine most appropriate dose well further characterize safety concern treatment arm note baricitinib be approve eu trade name olumiant feb european medicine agency ema committee medicinal product human use chmp recently agree label be update include precaution patient have risk factor deep venous thrombosis dvt pulmonary embolism pe incyte share be baricitinib update nektar lilly deal nektar nktr free report enter deal big pharma company lilly see nektar receive upfront well form milestone payment deal cover co development early stage asset nktr nektar pipeline nktr have potential treat number autoimmune other chronic inflammatory condition work target il receptor complex body activate regulatory cell nktr have potential bring immune system back balance other deal term include sharing phase ii development cost lilly nektar option nektar participate late stage development indication indication basis double digit royalty nektar deal be major nektar consider early stage nature candidate hefty upfront fee lilly make strong partner company nektar share be follow deal announcement ironwood heartburn drug datum ironwood irwd free report share be even company report positive datum iw mid stage study conduct patient uncontrolled reflux disease gerd study meet primary endpoint fail impress investor efficacy result fall short expectation ironwood intend conduct end phase ii meeting fda move candidate phase iii study second half accord company iw represent immense commercial potential annual peak sale opportunity more read more ironwood report positive datum reflux candidate chmp positive regeneron sanofi eczema drug regeneron sanofi be step closer gain eu approval eczema treatment dupixent chmp adopt positive opinion drug company be seek approval use adult moderate severe atopic dermatitis ad be candidate systemic therapy final decision regard approval be come month dupixent gain fda approval earlier year march dupixent have blockbuster potential be be investigate other indication well detailed datum gilead hiv regimen gilead gild free report announce detailed week result couple late stage study fix dose combination bictegravir novel investigational insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone treatment hiv infection treatment nave adult bictegravir contain regimen be find be inferior dolutegravir contain regimen gilead hold strong position hiv market be work strengthen franchise be significant demand simple convenient dose regimen sustain virologic suppression safety profile be appropriate most hiv patient mdco tango stop early superior benefit risk medicine co get good news independent datum safety monitoring board stopping late stage study investigational antibiotic vabomere previously refer carbavance base interim analysis interim result tango study show vabomere improve clinical cure rate infection type reduce rate renal adverse event compare best available therapy vabomere be currently priority fda review response expect third quarter marketing application be file eu well medicine co be zack rank hold stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr returnearning season biotech sector be strong start big player amgen biogen report better expect result nasdaq biotechnology index climb last trading session major biotech stock record gain vertex soar last month vertex be see last biotech stock roundup here vertex boost cf datum fda nod gilead puma drug next biotech world watch earning report company vertex gilead hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
45,AMGN,biogen inc biib free report well know name multiple sclerosis ms market surpass expectation earning sale second quarter drugmaker also raise revenue guidance sale newest drug spinraza spinal muscular atrophy witness faster expect adoption share biogen rise almost pre market trading response strong result however note biogen share have inched so far year compare unfavorably industry increase biogen report second quarter earning share beat zack consensus estimate however earning decrease year year sale come year period sale also surpass zack consensus estimate top line exclude hemophilia revenue grow year year company spun hemophilia business february quarter detail biogen ms revenue grow year year second quarter stable global share tecfidera sale rally year period drug record sequential surge revenue include sale ex sale tecfidera revenue benefit seasonal recovery unit volume discount well allowance second quarter tysabri revenue be flat year year same decrease sequentially ex note tysabri revenue first quarter benefit approximately ex market due agreement price reimbursement committee italian national medicine agency aifa related tysabri sale benefit be miss second quarter lead sequential decline combine interferon revenue avonex plegridy second quarter be ex year period avonex revenue decline year period plegridy contribute second quarter revenue year year sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well higher discount allowance zinbryta launch collaboration abbvie inc abbv free report august last year contribute revenue second quarter compare first quarter newly launch spinraza bring revenue revenue second quarter register massive growth sequentially drug witness strong demand spinraza revenue include approximately related inventory build company be work expand access patient notably jun spinraza be grant marketing authorization eu treatment spinal muscular atrophy sma be also approve japan canada recently quarter biogen record biosimilar revenue compare first quarter company market benepali biosimilar reference amgen inc amgn free report enbrel europe benepali record revenue thus register growth rate sequentially biogen also market flixabi biosimilar reference johnson johnson jnj free report blockbuster drug remicade record revenue report quarter compare first quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period second quarter spend soar report quarter sg spend decrease year year quarter company repurchase share worth share repurchase program outlookbiogen raise earning revenue outlook biogen now expect earning range share old guidance share revenue be now expect range comapr earlier guidance increase prior guidance be primarily attribute faster anticipate adoption spinraza term percentage total revenue company sg expense be expect be respectively biogen inc price consensus ep surprisebiogen inc price consensus ep surprise biogen inc quotezack rankbiogen currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
46,AMGN,hurdle trump plan repeal replace obamacare healthcare be second best perform sector year lag technology optimism come especially encourage industry trend hope favorable policy environment trump administration plan focus ease regulatory hurdle rather lower drug price expedite new drug approval additionally shift investor sentiment defensive sector healthcare generally outperform period low moderate growth rise geopolitical uncertainty have lead rally healthcare stock read top rank healthcare etfs long term investor such popular fund health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far year trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock see earning estimate revision yet be report quarter deliver negative earning surprise past quarters additionally have impressive growth momentum style score respectively value style score be favorable pfizer be schedule report earning august open bell read build winning etf portfolio second half pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result july market open have zack rank earning esp make surprise prediction difficult stock witness positive earning estimate revision penny past day be report quarter deliver positive earning surprise last quarters average beat merck have strong value momentum style score unfavorable growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen have zack rank earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision couple cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning july market close amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp indicate less chance beating estimate quarter company deliver positive earning surprise last quarters average beat see positive earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report july open bell read brighten outlook healthcare etfs focus abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning july market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter have solid value momentum style score respectively growth style score look ugly gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning july open bell have zack rank earning esp make surprise prediction difficult stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision cent be report quarter have unfavorable value growth momentum style score respectively see healthcare etfs here bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum healthcare sector be expect post earning decline second quarter have dismal zack rank bottom surprise well be card suggest upside healthcare etfs particular xlv vht iyh have zack etf rank fhlc have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
47,AMGN,second quarter report cycle seem have get good start abundance positive surprise particularly revenue front meanwhile earning revenue growth also better expectation jul member accounting index total market capitalization report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig only johnson johnson jnj free report swiss company novartis ag nvs free report have report so far report mixed second quarter result beating earning miss sale be third consecutive sale miss due slowdown pharmaceutical product sale however be optimistic sale growth accelerate second half other hand novartis second quarter result be encourage company beat earning sale estimate however sandoz performance be disappointing due pricing pressure here have pharma giant be set report second quarter result jul let see thing be shape quarter eli lilly company lly free report lilly be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning miss expectation last quarters beating other result average negative surprise eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quarter lilly have earning esp zack rank buy zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter new product trulicity cyramza taltz jardiance have support top line past few quarters expect trend continue second quarter well however decline sale alimta cymbalta zyprexa be expect continue due loss exclusivity read more be beat card eli lilly earning previous article show lilly be likely beat earning quarter however estimate change thereafter be not certain beat earning season biogen inc biib free report biogen well know name multiple sclerosis ms market be also schedule announce result open bell biogen earning performance have be pretty impressive so far have deliver back back positive surprise average earning beat last quarters be last quarter company deliver positive earning surprise biogen inc price ep surprise biogen inc price ep surprise biogen inc company have earning esp zack rank hold see complete list today zack rank strong buy stock here biogen expect relatively stable demand key ms drug tecfidera tysabri patient growth ex market offset modest decline due rise competition drug roche ocrevus read more biogen keep earning streak alive amgen inc amgn free report biotech giant be expect report market hour amgen deliver positive earning surprise last quarter amgen performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be amgen inc price ep surprise amgen inc price ep surprise amgen inc company have earning esp zack rank amgen growth drug prolium xgeva continue do well biosimilar competition slowdown sale mature product put pressure sale growth read more amgen report earning card more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
48,AMGN,biotech major amgen inc amgn free report report second quarter result jul market close amgen deliver positive earning surprise last quarter amgen share be so far year compare favorably increase register industry period amgen performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be let see thing be shape company quarter factor playamgen growth product prolium xgeva kyproli vectibix nplate sensipar be likely perform well new patient adoption repeat injection drive prolium sale xgeva be likely benefit superior clinical profile versus competition parsabiv etelcalcetide treatment secondary shpt be approve feb eu nov drug be likely bring revenue second quarter however company have challenge store give presence biosimilar competition slowdown sale mature product epogen neulasta neupogen sale be expect be hurt competition eu note neupogen sale be also be hurt biosimilar competition mainly zarxio sandoz novartis ag nvs free report generic arm biosimilar version neupogen be launch sep neupogen be expect face continue competitive pressure year exist potential biosimilar neulasta epogen start face biosimilar competition year biosimilar be launch second quarter meanwhile blockbuster drug enbrel be face increase competition rheumatology dermatology segment hurt sale volume growth recently launch product not be enough offset decline mature bottom line however benefit company overall cost cut effort share buyback company restructure plan make leaner more cost efficient investor focus remain performance company pcsk inhibitor repatha uptake repatha gain fda approval aug have not be very encourage so far due pricing re imbursement issue payer restriction phase iii cardiovascular outcome study fourier repatha have reveal significant reduction myocardial infarction stroke first quarter datum be key commercial success repatha broaden use drug datum study look good be not very clear payer be willing improve access repatha base datum amgen file regulatory application eu include fourier datum repatha label jun earning whispersour proven model do not conclusively show amgen be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank amgen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision amgen inc price ep surprise amgen inc price ep surprise amgen inc quotestock considersome stock biom genetic sector have positive esp favorable zack rank be celgene corporation celg free report earning esp zack rank company be schedule release result jul schedule release result jul gilead science inc gild free report have earning esp zack rank see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
49,AMGN,key highlight week include impressive datum vertex vrtx free report cystic fibrosis cf pipeline company gilead gild free report puma pbyi free report get fda approval hepatitis virus hcv breast cancer treatment respectively recap week most important storiesvertex cf datum impress vertex get major boost positive datum different triple combination regimen person cystic fibrosis cf have del mutation minimal function mutation del min be first datum show potential treat underlie cause cf patient have severe difficult treat type disease company be look start pivotal program first half vertex share be significantly pre market trading crl amgen ucb osteoporosis drug amgen amgn free report partner ucb get complete response letter crl fda evenity romosozumab investigational treatment postmenopausal woman osteoporosis however crl doesn come surprise consider emergence new safety signal late stage study arch evenity meet primary endpoint key secondary endpoint study company say imbalance positively adjudicate cardiovascular serious adverse event be observed fda have ask company include datum arch study resubmission well datum bridge study man osteoporosis read more amgen get crl osteoporosis drug evenity bla amgen be zack rank hold stock see complete list today zack rank strong buy stock here fda nod gilead hcv drug gilead have add drug hepatitis virus hcv portfolio fda grant approval vosevi single tablet regimen re treatment adult chronic hcv vosevi provide physician new therapeutic option hardest treat patient however vosevi come box warning regard risk hepatitis virus hbv reactivation hcv hbv co infected patient limit uptake gilead hcv franchise be major revenue generator be considerable strain due new competition pricing pressure company have underperform zack categorize medical biomedical genetic industry so far share gain industry be puma fda approval nerlynx puma gain fda approval breast cancer treatment nerlynx neratinib have blockbuster potential nerlynx first approve drug puma portfolio be indicated extend adjuvant treatment early stage breast cancer aggressive type tumor mean nerlynx be take initial treatment so risk cancer come back be reduce further nerlynx approval be line expectation consider favorable advisory panel vote earlier year puma share be news year date ytd puma share be whopping sarepta biomarin settle patent dispute sarepta srpt free report biomarin settle patent dispute regard use sarepta exondys future exon skip product treatment duchenne muscular dystrophy dmd company sign licensing agreement provide sarepta global exclusive right biomarin dmd patent estate exondys future exon skip product biomarin have option convert license co exclusive right decide proceed exon skip therapy dmd term deal include time payment sarepta well certain milestone base payment royalty sarepta share be biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen biib free report be almost last month vertex be alexion alxn free report be see last biotech stock roundup here arena shoot study datum celg inks immuno oncology deal next biotech world watch earning report company biogen sarepta look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
50,AMGN,ligand pharmaceutical incorporate lgnd free report announce have sign commercial license supply agreement amgen inc amgn free report deal amgen be grant exclusive worldwide right use ligand captisol technology development pipeline candidate amg wide variety therapeutic indication captisol be well validate chemically modify cyclodextrin be design improve safety solubility stability bioavailability lessen volatility irritation smell taste drug amgen be develop early stage candidate amg cd cd bite bispecific antibody treatment acute myeloid leukemia share ligand have outperformed zack classify medical biom genetic industry so far year stock have rally compare broader industry increase company already have agreement amgen used captisol develop amg preclinical early clinical study term recent agreement amgen be liable pay undisclosed upfront payment potential milestone payment royalty revenue future sale amg formulate used captisol ligand captisol formulation technology platform have allow enter partnership several lead drug company novartis ag nvs free report merck co inc mrk free report provide fund form milestone royalty payment ligand also derive revenue selling captisol material partner have license company captisol enabled drug have license captisol internal program ligand pharmaceutical incorporate price consensus ligand pharmaceutical incorporate price consensus ligand pharmaceutical incorporate quotezack rankligand currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
51,AMGN,novartis ag nvs free report report second quarter core earning share beating zack consensus estimate record figure be penny lower year figure revenue decline volume growth be offset negative impact generic competition pricing beat zack consensus estimate billiona look novartis share price movement last month show stock outperformed zack classify large cap pharma industry share have rally compare gain record industry growth rate mentioned be year year basis constant exchange rate quarter detailnovartis operate segment innovative medicine pharmaceutical alcon ophthalmology unit sandoz generic innovative medicine division record sale generic competition pricing pressure impact sale segment primarily due entry generic gleevec europe nevertheless growth product cosentyx entresto promacta revolade jakavi tafinlar mekinist gilenya boost sale psoriasis cosentyx sale surge back strong growth approve indication entresto too have solid quarter sale benefit continue access improvement expansion sale force reimbursement europe oncology franchise grow drive mainly promacta revolade jakavi tafinlar mekinist sale sandoz division be volume growth be offset price erosion mainly sale decline due pricing pressure retail generic prior year launch timing sale grow mainly drive zarxio sale alcon division be surgical sale increase drive growth cataract consumable vitreoretinal intraocular lense return growth globally vision care sale be fuelled continue double digit growth daily total outlook expect net sale be broadly line level include impact continue genericization gleevec glivec europe management have earlier estimate impact generic competition sale be approximately pipeline updatenovartis pipeline candidate progress have be encourage oncology portfolio continue gain traction breast cancer drug kisqali receive positive chmp opinion first line option hr advanced metastatic breast cancer combination inhibitor europe drug be already approve company also receive fda approval rydapt treatment newly diagnosed flt mutate acute myeloid leukemia aml type systemic mastocytosis addition zykadia receive fda ema approval first line use alk positive advanced small cell lung cancer nsclc tafinlar mekinist receive fda approval treatment braf mutant metastatic nsclc ctl be unanimously recommend approval fda oncologic drug advisory committee july treatment pediatric young adult patient relapse refractory cell acute lymphoblastic leukemia meanwhile cosentyx be grant approval europe label update include week datum clear study demonstrate long term superiority cosentyx compare johnson johnson jnj free report stelara psoriasis sandoz receive approval launch major biosimilar eu erelzi biosimilar amgen inc amgn free report enbrel rixathon biosimilar version roche holding rhhby free report mabthera treat blood cancer immunological disease ema also accept propose biosimilar adalimumab infliximab sandoz generic version asthma drug advair diskus be accept fda novartis ag price ep surprise novartis ag price ep surprise novartis ag quoteour takenovartis second quarter result be encourage company beat earning sale estimate however sandoz performance be disappointing battle pricing pressure first half novartis announce be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company throw more light plan alcon end positive note growth driver cosentyx entresto more offset impact generic erosion mainly due glivec cosentyx hit blockbuster status recent approval kisqali fda panel recommendation ctl also bode well company portfolio zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
52,AMGN,share radius health rdus free report drop more early morning trading hour monday company announce jesper hiland former top ranking executive nordisk nvo free report have be appoint new president chief executive officer hiland join radius integral moment company recently receive approval once daily injectable osteoporosis treatment tymlos be pleased welcome jesper radius health important time believe be uniquely qualify lead radius successful launch tymlos advancement exciting clinical stage asset include elacestrant say radius chairman kurt grave hiland replace bob serve radius ceo help lead company ipo not long market debut share radius reach peak more summer stock have struggle maintain momentum then be delighted be join radius exciting early stage tymlos say jesper hiland look forward guide continue development strong pipeline new appointment come wake radius health rival amgen amgn free report announcement own osteoporosis drug do not receive fda approval now list approve treatment build bone strength fight degenerative condition remain just eli lilly lly free report forteo remain market leader radius investor today appointment likely lead short term volatility fresh face top company management be much need ignition source zack rank sell stock today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
53,AMGN,mylan myl free report partner biocon ltd announce fda oncologic drug advisory committee odac unanimously recommend approval roche rhhby free report breast cancer drug herceptin trastuzumab fact fda odac vote favor biosimilar candidate have be develop treat positive breast cancer be more aggressive form disease notably share mylan inched follow news release however company have outperformed zack categorize medical generic drug industry year so far stock gain industry decline meanwhile datum present odac include result show propose biosimilar trastuzumab be highly similar herceptin line fda assessment provide pre meeting briefing document odac be clinically meaningful difference mylan biosimilar candidate herceptin term safety purity potency biosimilar trastuzumab be also review regulatory authority australia canada europe several emerge market be good news mylan be blow roche herceptin be key drug last week biosimilar roche be put review odac amgen amgn free report partner allergan plc agn free report announce supplemental biologic license application sbla candidate abp biosimilar roche cancer drug avastin also be review odac herceptin avastin be key drug roche biosimiar version drug once approve hurt sale drug mylan price consensus mylan price consensus mylan quotezack rankmylan currently sport zack rank strong buy see complete list today zack rank stock here today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
54,AMGN,novartis ag nvs free report report encourage result third quarter earning revenue beat estimate drive strong performance cosentyx entresto third quarter core earning share beat zack consensus estimate be record year quarter revenue increase volume growth drive cosentyx entresto be partially offset negative impact generic competition pricing revenue also beat zack consensus estimate novartis stock have rally year date compare industry gain growth rate mentioned be year year basis constant exchange rate quarter detailnovartis operate segment innovative medicine pharmaceutical alcon ophthalmology unit sandoz generic innovative medicine division record sale generic competition impact sale segment primarily due entry generic gleevec unite state europe nevertheless growth product cosentyx entresto promacta revolade jakavi tafinlar mekinist gilenya boost sale psoriasis cosentyx sale surge back strong growth approve indication entresto sale benefit continue access improvement expansion sale force unite state oncology franchise exclude gleevec grow drive mainly promacta revolade jakavi tafinlar mekinist sale sandoz division be volume growth be offset price erosion unite state sale unite state decline due pricing pressure sale grow mainly drive zarxio unite state launch rixathon biosimilar version roche holding inc rhhby free report rituxan rituximab erelzi biosimilar amgen inc amgn free report enbrel eu sale alcon division be surgical sale increase drive broad recovery most market segment include strong growth vitreoretinal product vision care sale be fuel continue double digit growth daily total earlier novartis announce be mull strategic option lag eye care unit alcon include retain business separation capital market transaction such spin initial public offer company update strategic plan announce have potential grow sale market deliver profitability line industry company also make significant progress develop potential capital market solution include financial carve out tax legal entity structuring identify list incorporation location final decision be take depend alcon sale performance be not likely happen first half meanwhile novartis move ophthalmic otc product alcon division effective jan allow innovative medicine division focus pharmaceutical pipeline however ophthalmic prescription business remain innovative medicine division outlook expect net sale be broadly line level include impact continue genericization gleevec glivec unite state europe management have earlier estimate impact generic competition sale be approximately novartis ag price ep surprise novartis ag price ep surprise novartis ag quotepipeline updatenovartis pipeline candidate progress have be encourage oncology portfolio continue gain traction significant boost fda approve breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah have be launch unite state breast cancer drug kisqali be approve europe first line option hr advanced metastatic breast cancer combination inhibitor drug be already approve unite state company also receive approval rydapt europe treatment newly diagnosed flt mutate acute myeloid leukemia type systemic mastocytosis meanwhile fda accept novartis regulatory application amg erenumab filing prevention migraine patient experience more migraine day month fda also accept supplemental new drug application tasigna grant priority review snda seek addition attempt treatment free remission drug label other hand tafinlar mekinist receive breakthrough therapy designation adjuvant melanoma sandoz propose biosimilar roche rituxan be accept regulatory review fda propose biosimilar version abbvie inc abbv free report humira adalimumab match reference drug term efficacy safety week clinical study biosimilar be currently review eu treatment several immunological disease takenovartis third quarter result beat earning sale estimate strong performance cosentyx entresto generic division sandoz also combat pricing pressure strongly buoy biosimilar launch rixathin erelzi first half novartis announce be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company believe alcon division have revive well now hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
55,AMGN,thank encourage industry trend hope favorable policy environment healthcare be top perform sector year notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far read healthcare etf hit new week high bullish trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive value style score growth momentum style score respectively look disappointing pfizer be schedule report earning oct open bell pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result oct market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision cent past day be report quarter merck have strong momentum style score value growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning oct market close read keep portfolio healthy biotech etfs amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see negative earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report oct open bell abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning oct market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision nickel past month be report quarter have solid value style score growth momentum style score respectively look ugly see healthcare etfs here gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning oct open bell have zack rank earning esp stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision couple cent be report quarter have solid growth style score unfavorable value momentum style score respectively bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum earning surprise well card healthcare sector be expect witness earning growth third quarter have strong zack rank top suggest further upside healthcare etfs particular etfs have zack etf rank read top rank healthcare etfs long term investor want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
56,AMGN,third quarter report cycle be full swing corporate earning have be reassure so far quarter expect momentum continue go ahead oct member accounting index total market capitalization have report result accord earning preview total earning index member be year quarter improvement revenue growth revenue be impressive ahead previous quarter growth significantly higher quarter average beat ratio be earning revenue more half company have beaten ep revenue estimate report total earning company third quarter be expect grow year year higher revenue meanwhile broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning only big name biotech pharma sector have report thus far johnson johnson jnj free report swiss base novartis ag nvs free report result be better expect company raise sale profit outlook year well novartis also beat estimate revenue earning quarter let take look pharma biotech company be set report third quarter result oct amgen inc amgn free report amgen be schedule release earning market close have deliver positive earning surprise last quarter amgen beat expectation last quarters average positive surprise quarter amgen have earning esp zack rank hold do not conclusively show amgenis likely beat estimate quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter higher demand amgen new drug be expect offset lower sale mature brand company key drug neulasta be face competition newer cancer therapy threat biosimilar also lurk several company be look launch generic version drug read more card amgen earning season glaxosmithkline plc gsk free report london base glaxo be schedule announceresult open bell tomorrow glaxo have beaten estimate last quarters meet same result average positive surprise last report quarter glaxo deliver positive surprise company have earning esp zack rank indicate be poise deliver beat time see complete list today zack rank strong buy stock here glaxo hiv product be expect drive sale pharmaceutical segment quarter moreover newly launch respiratory drug be expect offset decline sale seretide advair avodart meanwhile slowdown consumer segment due market condition impact divesture be expect continue read more glaxo earning deliver beat yet again vertex pharmaceutical incorporate vrtx free report company specially focus cystic fibrosis cf report result tomorrow market close last quarter vertex deliver positive earning surprise company come average positive earning surprise trail quarters company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg cent share approval label expansion cf drug kalydeco unite state august have broaden patient population drive sale drug moreover re imbursement agreement ireland italy orkambi be also positive read more be beat card vertex earning today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
57,AMGN,biotech major amgen inc amgn free report report third quarter result oct market close amgen deliver positive earning surprise last quarter amgen share be so far year compare favorably increase register industry period amgen performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be let see thing be shape company quarter factor playamgen newer product prolium xgeva kyproli blincyto continue perform well backed higher demand thus make lower sale mature brand enbrel epogen neulasta neupogen due competitive pressure neulasta demand be be hurt due competition pd other new cancer sale be also be hurt biosimilar competition unite state mainly zarxio sandoz biosimilar version neupogen be launch september neulasta neupogen sale be expect be hurt competitive dynamic third fourth quarters zack consensus estimate neulasta neupogen be respectively third quarter however management mentioned call new biosimilar competition be expect year suggest neulasta epogen not start face biosimilar competition year contrary previous expectation company mylan biocon novartis nvs free report coherus look launch generic version neulasta company look launch generic version epogen have receive complete response letter fda respective application delay launch bottom line continue be drive company overall cost cut effort share buyback company restructure plan likely make leaner more cost efficient investor focus remain performance company pcsk inhibitor repatha uptake repatha gain fda approval august have not be very encourage so far due pricing re imbursement issue payer restriction however second quarter repatha revenue improve sequentially drive higher demand management say presentation outcome study datum fourier have positive impact repatha share trend remain be see positive trend continue third quarter earning whispersour proven model do not conclusively show amgen be likely beat earning quarter be stock need have positive earning zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report ourearning esp filter zack rank amgen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision amgen inc price ep surprise amgen inc price ep surprise amgen inc quotestock consider stock biom genetic sector have positive esp favorable zack rank be celgene corporation celg free report earning esp zack rank company be schedule release result oct also schedule release result oct alexion pharmaceutical inc alxn free report have earning esp zack rank see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
58,AMGN,issue update research report allergan plc agn free report sep allergan boast dominant growth franchise several area be strengthen product portfolio strategic acquisition so far accretive acquisition lifecell zeltiq allergan have expand medical aesthetic business regenerative medicine body sculpting respectively allergan sell generic business aug anda distribution business teva pharmaceutical teva free report oct follow closure teva deal allergan now focus brand segment be used proceed buy back share pay debt pursue additional deal key product botox linzess new product such viberzi vraylar be support sale growth allergan fact second quarter conference call allergan raise previously issue earning sale guidance follow strong first half performance solid outlook rest year allergan also boast strong brand pipeline meaningful datum read out next few month company have more project mid late stage development include key phase iii program year allergan be extend pipeline adjacent category nash parkinson disease gene therapy many promising phase ii iii program development allergan have product launch plan biosimilar also represent significant opportunity allergan amgen inc amgn free report have collaboration agreement worldwide development biosimilar version roche rhhby free report cancer drug avastin herceptin rituxan biosimilar version avastin be market trade name mvasi receive fda approval month make first cancer biosimilar get fda nod however remain optimistic company growth prospect be face generic competition legacy brand namenda asacol hd well patent challenge other product brand portfolio meanwhile new competition key growth driver restasis linzess be investor concern shire dry eye disease drug xiidra launch last year pose strong competition restasis meanwhile synergy trulance plecanatide be launch second quarter cic competition linzess make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
59,AMGN,be second half year time analyze first half turn be pharma biotech stock term fda decision regulatory body approve novel drug first half be less year period figure however several fda decision line second half higher number drug be approve rest year key fda approval first half include amgen amgn free report novartis first cgrp antibody aimovig erenumab prevention migraine jnj free report next generation oral androgen receptor ar inhibitor erleada apalutamide pre metastatic prostate cancer crpc vertex pharmaceutical vrtx free report third medicine treat underlie cause cf symdeko be combination tezacaftor ivacaftor biomarin pharmaceutical palynziq treat pku drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst let take look few important regulatory event schedule month july fda decision indivior schizophrenia injection rbp jul fda be expect give decision indivior plc invvy free report rbp have be develop treatment schizophrenia rbp be once monthly injectable risperidone give used atrigel delivery system indivior be zack rank hold stock see complete list today zack rank strong buy stock here progenic pharmaceutical azedra review progenic pharmaceutical pgnx free report new drug application nda look get pipeline candidate azedra approve treatment patient suffering malignant rare neuroendocrine tumor paraganglioma be review fda be expect give decision jul month delay previous fda action date march azedra be add progenic portfolio acquisition molecular insight pharmaceutical decision insys therapeutic pain candidate jul fda be also expect give decision insys therapeutic insy free report buprenorphine sublingual spray moderate severe acute pain be important remember fda advisory committee vote approval company have file new drug application nda september last year base positive datum pivotal study candidate fda accept nda review december assign pdufa date jul be quite possible unfavorable vote committee influence fda decision delay approval drug fda panel back new indication glaxo nucala end month fda panel be expect give opinion glaxo gsk free report label expansion filing eosinophilic asthma drug nucala mepolizumab new indication chronic obstructive pulmonary disease copd latest filing glaxo be look get nucala approve add maintenance treatment copd eosinophilic phenotype nucala be presently approve treat severe eosinophilic asthma eosinophilic granulomatosis polyangiitis egpa glaxo hadfiled supplemental biologic license application sbla label expansion nucala include use copd november last year fda take recommendation panel advisory committee account review application be not bound follow same today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
60,AMGN,fda approve novel drug last year have give approval drug so far include august key approval year include gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other drug have blockbuster potential recent landmark approval be novartis kymriah make first gene therapy unite state mark begin new era treatment cancer other serious life threaten disease drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month september fda follow advisory panel vote mylan herceptin biosimilar mylan nv myl free report hear fda soon approval status biosimilar version roche blockbuster drug herceptin trastuzumab company partner biocon ltd get favorable vote fda oncologic drug advisory committee odac july biosimilar herceptin be approve wide range indication include breast cancer metastatic adjuvant setting earlier year mylan have enter global settlement agreement roche genentech hoffmann la roche ltd herceptin trastuzumab mylan get global license exclude japan brazil mexico trastuzumab product mylan well be first launch biosimilar version herceptin unite state approval boost investor sentiment company have lose year date versus decline industry fda advisory panel discuss glaxo pfizer ptc therapeutic few fda advisory panel meeting be schedule month fda vaccine related biological product committee vrbpac be meeting sep discuss safety effectiveness glaxosmithkline plc gsk free report shingrix glaxo be look get live recombinant vaccine approve prevention herpes zoster shingle person be year old shingle common potentially serious condition cause last pain other complication such scarring visual impairment then sep fda odac be meeting discuss supplemental new drug application snda submit pfizer pfe free report cancer drug sutent pfizer be look expand sutent label adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney fda be expect render final decision regard label expansion jan sutent bring sale first half later month sep fda peripheral central nervous system drug advisory committee discuss ptc therapeutic ptct free report new drug application nda translarna ataluren treatment patient due nonsense mutation gene translarna be already approve outside unite state fda be expect give response regard approval status drug oct fda grant approval amgen allergan avastin biosimilar amgen amgn free report allergan be also expect decision fda biosimilar version roche cancer drug avastin bevacizumab company get favorable vote fda advisory panel odac recently chance gain approval fda action date sep look good share amgen have gain year date significantly outperform industry rally merck bristol myer seek label expansionmerck mrk free report be look expand label pd therapy keytruda use treatment recurrent advanced gastric junction adenocarcinoma keytruda be priority review indication response expect sep keytruda bring sale first half be key product merck portfolio be be evaluate wide range indication merck have gain year date versus growth industry bristol myer squibb company bmy free report be also look expand label pd inhibitor opdivo opdivo be priority review use patient hepatocellular carcinoma hcc prior treatment nexavar sorafenib fda be expect give response sep opdivo prioritize brand bristol myer portfolio bring sale first half bristol myer have gain year date versus growth industry fda approve plivensia johnson johnson investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor be fda review response expect sep however early august plivensia fail get support fda arthritis advisory committee safety concern be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person unite state fda be not require do so usually follow advice advisory panel consider safety concern raise panel quite likely agency ask additional information grant approval share have gain year date outperform industry rally neos therapeutic be also await decision month nt amphetamine xr liquid suspension product candidate attention deficit hyperactive disorder adhd approval sep allow company go ahead plan launch product jan zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
61,AMGN,amgen inc amgn free report announce european commission have approve marketing application pediatric formulation granule capsule open mimpara treatment secondary shpt approval drug label have be expand include use child age year end stage renal disease esrd maintenance dialysis therapy standard care therapy adequately control secondary hpt remind investor june european medicine agency ema committee medicinal product human use chmp have render positive opinion recommend marketing approval mimpara expand label amgen share have rally year so far better industry register increase approval be base datum study assess use mimpara pediatric secondary hpt patient conduct amgen mimpara be already approve market eu oral therapy treat secondary hpt adult patient esrd maintenance dialysis therapy mitigate hypercalcemia adult patient parathyroid carcinoma unite state drug be market trade name sensipar sensipar mimpara generate sale second quarter year year label expansion be expect boost international sale drug remind investor sensipar be set face generic competition march next year many company be seek market drug generic version regard formulation patent secondary be often progressive patient suffering chronic kidney disease ckd affect ckd patient hemodialysis meanwhile very few treatment option be available treat condition investor also note amgen market shpt medicine parsabiv approve unite state earlier february eu back november parsabiv be approve treat shpt adult patient ckd hemodialysis first therapy year be approve condition drug have be administer intravenously thrice week end dialysis session amgen currently carry zack rank hold see complete list today zack rank strong buy stock here stock considerbetter rank biotech stock include alexion pharmaceutical inc alxn free report ligand pharmaceutical incorporate lgnd free report regeneron pharmaceutical inc regn free report zack rank strong buy share alexion have increase year date estimate have rise almost past day regeneron share have surge year so far estimate have rise have go past day share ligand have rise so far year estimate have rise respectively past day confidential zacksbeyond analyst blog see zack best recommendation be not available public executive vp steve reitmeister know key trade be be trigger expert have hottest hand click see now
62,AMGN,immunogen inc imgn free report announce strategic collaboration option agreement jazz pharmaceutical plc jazz free report development early stage hematology related antibody drug conjugate adc program also program be designate term agreement program include imgn cd target adc be phase study treatment acute myeloid leukemia aml imgn also be evaluate preclinical study treat hematological malignancy include aml imgn be expect enter clinic end consequently immunogen share rise almost follow news share have also outperformed industry year date stock have sky-rocket industry decline same time frame agreement immunogen take care development adc program prior potential opt jazz follow opt jazz be responsible further development well potential regulatory submission deal jazz make upfront payment immunogen additionally also pay development funding year support adc program program jazz exercise opt right time prior pivotal study time prior biologic license application bla program jazz elect opt immunogen be eligible receive milestone payment base certain pre decide believe deal jazz enable advance speed development early stage novel adc asset deal also provide immunogen sufficient funding support program give right co commercialize asset other hand jazz believe collaboration help expand oncology portfolio potential addition multiple innovative antibody drug conjugate immunogen be focuse development target cancer therapeutic used proprietary adc technology immunogen adc technology be also used roche rhhby free report market product kadcyla other development stage candidate own pipeline development program partner amgen amgn free report bayer ag biotest cytomx eli lilly novartis sanofi takeda immunogen inc price immunogen inc price immunogen inc quotezack rankimmunogen currently carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
63,AMGN,amgen inc amgn free report announce new analysis phase iii cardiovascular outcome study fourier pcsk inhibitor repatha analysis large cohort patient establish atherosclerotic cardiovascular disease show be strong progressive relationship lower achieve level ldl bad cholesterol lower risk cardiovascular event rate analysis suggest use intensive ldl therapy such repatha high risk cardiovascular patient safely reduce risk cardiovascular event heart attack stroke cardiovascular death year so far amgen share be better increase register industry result be present european society cardiology esc congress hold spain also publish lancet remind investor datum present fourier march year have reveal treatment repatha lead significant reduction myocardial infarction stroke uptake drug gain fda approval aug have not be very encourage so far due pricing re imbursement issue payer restriction fourier datum hold key commercial success repatha broaden use drug datum study look good be not very clear payer be willing improve access repatha base datum encouragingly second quarter conference call management say repatha hold share pcsk segment europe share trend improve sequentially market quarter meanwhile new brand share repatha be second quarter management say presentation outcome study datum have positive impact repatha share trend amgen file regulatory application eu include fourier datum repatha label jun last month amgen announce fda have grant priority review application seek approval include fourier datum label decision agency be expect dec sanofi sny free report partner regeneron pharmaceutical inc regn free report also face similar issue pcsk inhibitor praluent amgen currently carry zack rank hold see complete list today zack rank strong buy stock here better rank pharma biotech stock be gilead science inc gild free report zack rank buy share gilead be so far year estimate have inched almost respectively last day zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
64,AMGN,biogen inc biib free report announce biosimilar version abbvie inc abbv free report top selling blockbuster drug humira have be approve european commission biosimilar be market trade name imraldi imraldi sb be used whole range indication include rheumatoid arthritis axial ankylose spondylitis plaque psoriasis psoriatic arthritis crohn disease ulcerative colitis polyarticular juvenile idiopathic arthritis active enthesitis related arthritis hidradenitis suppurativa infectious uveitis remind investor biosimilar be grant positive opinion committee medicinal product human use chmp june year biogen have joint venture samsung biologic biosimilar samsung bioepis joint venture company already marketsa couple biosimilar eu flixabi biosimilar reference merck co inc mrk free report remicade benepali biosimilar reference amgen pfizer enbrel make imraldi third tnf biosimilar biogen receive marketing authorization eu benepali be do quite well generate sale first half flixabi record sale same period note earlier year amgen inc amgn free report gain eu approval amgevita biosimilar version humira biogen share have rise year so far industry record increase biogen carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
65,AMGN,sanofi inc sny free report perform quite well first half look well poise carry momentum second half earning share beat zack consensus estimate first quarter meet same second earning rise report basis first half constant currency rate cer year year basis first halfnet sale rise report basis cer jan sanofi swap merial animal health business boehringer ingelheim consumer healthcare chc business reflect exchange full consolidation sanofi european vaccine operation sale rise constant structure cer remind investor sanofi terminate sanofi pasteur msd joint venture merck co inc mrk free report europe december last year strong performance genzyme specialty care genzyme vaccine unit be make accelerate decline diabetes franchise support top line fact second quarter conference call sanofi raise previously issue profit outlookbacked better expect performance first half cost discipline tough payer environment hurt sale thediabetesunit sanofi expect business earning be broadly flat cer outlook compare favorably previous expectation flat cer so work sanofi favor second half continue strong performance genzyme unit especially multiple sclerosis drug aubagio lemtrada rare disease drug myozyme fabrazyme be positive vaccine unit be also expect perform well sale include emerge market rise cer genzyme unit cer vaccine unit first half meanwhile sanofi second quarter conference call sound quite optimistic sale prospect newly launch drug dupixent treat atopic dermatitis drug be launch march generate sale second quarter backed strong demand management waspleas drug uptake be optimistic sale prospect dupixent prove be important growth driver company other dupixent other new drug kevzara launch june soliqua once daily titratable fix ratio combination lantus lyxumia launch january also bring higher sale back half year however management expect diabetes franchise sale decline faster second half due impact formulary exclusion cvs health corporation cvs free report unitedhealth group difficult comparison last year diabetes sale decline first half sanofi diabetes franchise be significant pressure key product lantus face increase competitive pressure payor level biosimilar competition several european market japan cardiovascular franchise also remain be see sale trend sanofi pcsk therapy praluent improve second half uptake pcsk inhibitor praluent amgen inc amgn free report repatha have be slower expect due significant payer utilization management restriction limit market access europe praluent uptake remain limit guideline support broader use treatment be issue phase iii cardiovascular outcome study datum be also generic competition continue hurt sale many key drug sanofi portfolio include blockbuster drug plavix challenge believe new drug approval solid pipeline aggressive saving pave way growth second half do number say so far year sanofi share price have rise better increase industry strong quarterly result back back product approval year have lead uptick estimate well sanofi earning estimate go moved past day sanofi earning performance have also be pretty impressive company report positive surprise consistently average earning beat last quarters be sanofi carry zack rank hold seethe complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
66,AMGN,alexion pharmaceutical alxn free report get boost eu approve key revenue driver soliris additional indication meanwhile biogen biib free report be news investigation be launch rise price multiple sclerosis ms drug investigation have be launch rep elijah cumming rep peter welch letter be send company include biogen request information pricing strategy ms drug recap week most important storieseu label expansion alexion soliris alexion flagship product soliris gain eu approval treatment patient refractory generalized myasthenia gravis gmg make first only complement base therapy approve eu ultra rare subset gmg alexion launch soliris indication initially germany be evaluate additional eu launch gmg indication represent incremental growth opportunity soliris enable company enter neurology therapeutic area soliris be currently review japan response expect early next year gmg indication eu grant approval look soliris gain approval well decision be expect oct accord information provide company person suffer myasthenia gravis mg alexion target population be approximately total mg patient population result late stage study regain conduct company indicate refractory gmg patient respond treatment soliris soliris be alexion key growth driver drug bring sale first half company expect soliris revenue assume identification steady number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus globe also read alexion soliris label expansion approve europe alexion be zack rank strong buy stock see complete list today zack rank stock here biogen other face ms drug price probe biogen hold strong position ms market have be ask submit information ms drug avonex tysabri tecfidera plegridy zinbryta co promote abbvie accord letter drug have see least double digit price increase approval price drug have increase almost moreover zinbryta be introduce price annum price biogen other ms drug be hike match zinbryta price biogen have respond letter aug also read biogen other multiple sclerosis drug stock focus here pipeline setback ultragenyx ultragenyx pharmaceutical rare free report company focuse develop treatment rare ultra rare disease suffer pipeline setback candidate fail late stage study aceneuramic acid extend release ace fail meet primary well key secondary endpoint phase iii study patient gne myopathy gnem ultragenyx have decide discontinue development ace ultragenyx currently have investigational treatment fda review vestronidase alpha mps decision expect nov be look file fda approval burosumab link shortly fda nod ironwood gout drug ironwood pharmaceutical irwd free report once daily gout treatment gain fda approval duzallo have be approve treatment hyperuricemia associate gout patient have not achieve target serum uric acid level medically appropriate daily dose allopurinol alone make duzallo first fda approve fix dose combination treatment available single pill address cause hyperuricemia gout production excretion serum uric acid ironwood expect launch product fourth quarter ironwood expect duzallo drive sale gout franchise be expect deliver total annual peak sale more note duzallo label include box warning acute renal failure also read ironwood pharma combination gout drug get fda approval start roll nda submission mdd drug alk free report have start roll submission new drug application nda investigational major depressive disorder mdd drug alk roll nda submission once daily oral medicine novel mechanism action adjunctive treatment mdd be slate complete year end also read initiate roll submission depression drug alk have fast track designation have lose value year date versus growth industry biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index inched slightly last trading session major biotech stock alexion be celgene lose last month vertex vrtx free report be biogen slip see last biotech stock roundup here regeneron drop rsv antibody gilead hiv drug get priority review next biotech world watch usual regulatory pipeline update amgen amgn free report be present new datum pcsk inhibitor repatha european society cardiology esc congress surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
67,AMGN,second quarter earning season be draw close stock have report result aug zack sector record earning growth total earning increase year period revenue growth beat earning estimate top revenue expectation medical sector be sector consistently record earning growth last few quarters sector record earning growth revenue growth have record earning growth back revenue growth so far look beat ratio show earning beat revenue beat biotech stock specifically fared pretty well most key player top earning revenue expectation quite few company raise outlook year well biotech stock have have strong run so far nasdaq biotechnology index soar year date ytd be sharp contrast last year performance index be be several reason sector dismal performance last year foremost be drug pricing controversy drug pricing remain headline risk year well investor now seem be more comfortable drug pricing scenario be willing look fundamental sector fda have also approve more drug so far year do whole last year drug be approve have gain approval so far drug approve year represent blockbuster potential second half be expect be catalyst rich quite few company datum expect wide range therapeutic area far merger acquisition be concern do not expect much activity area give watch stance adopt most company regard drug pricing situation tax reform deterrent be high valuation company remain wary bidding war lead price deal however licensing deal continue especially orphan rare disease area well highly seek therapeutic area immune oncology choiceshere be look biotech stock deliver positive earning surprise second quarter be witness upward revision earning estimate company be zack rank strong buy zack rank buy stock see complete list today zack rank stock here alexion pharmaceutical inc alxn free report new haven ct base alexion deliver beat raise quarter flagship product soliris eculizumab continue perform well alexion be work expand soliris label have key catalyst come decision fda expect oct regard approvability soliris refractory generalized myasthenia gravis gmg alexion get boost week soliris gain eu approval indication make first only complement base therapy approve ultra rare subset gmg gmg indication represent incremental growth opportunity soliris alexion have rough share fall look set recover lose ground share increase so far outperform rally industry belong effort company new management team turn thing be impressive alexion be redefine strategy focus key expertise area company continue grow rare disease business include grow soliris strensiq kanuma increase productivity alexion focus internal research effort complement expertise development effort core therapeutic area hematology nephrology neurology metabolic disorder company have also decide prioritize certain pipeline candidate be discontinue preclinical program mrna therapy well other preclinical program do not fall complement franchise alexion zack rank stock have see zack consensus estimate current year earning be revise upward last day regeneron pharmaceutical inc regn free report tarrytown ny base regeneron key area focus include eye disease heart disease allergic inflammatory disease pain cancer infectious disease rare disease eye drug eylea company key growth driver continue perform well regeneron have be work diversify portfolio gain fda approval drug year dupixent moderate severe atopic dermatitis kevzara moderately severely active rheumatoid arthritis drug have blockbuster potential company also have strong pipeline have eventful second half year come key mid late stage pipeline catalyst line top line phase iii datum dupixent asthma be due later quarter positive datum allow company go ahead filing fourth quarter dupixent also gain eu approval eczema indication third quarter regeneron be evaluate dupixent pediatric atopic dermatitis set important datum readout schedule second half year be company pd antibody regn cutaneous squamous cell carcinoma cscc second most common skin cancer basal cell carcinoma second deadliest skin cancer melanoma positive datum allow company file fda approval first quarter meanwhile eylea be be evaluate combination nesvacumab top line datum phase ii study wet age related macular degeneration diabetic macular edema be expect fourth quarter year regeneron have see zack consensus estimate current year earning be revise upward last day regeneron zack rank stock have gain year date substantially outperform rally industry belong gilead science inc gild free report foster city base gilead be well know presence hepatitis virus hcv hiv market gilead top estimate second quarter hcv business do better expect company say hcv patient start first month be better originally expect moreover launch educational campaign oct encourage testing baby boomer have lead increase hcv antibody screening baby boomer turn have lead increase diagnosis company hiv franchise also continue do well company be progress pipeline include treatment evaluation cancer nonalcoholic steatohepatitis nash inflammatory disease gilead raise outlook year gilead have see zack consensus estimate current year earning be revise almost upward last day gilead be zack rank stock ligand pharmaceutical incorporate lgnd free report san diego base ligand business model be base develop acquire royalty revenue generate asset couple lean corporate cost structure company be focuse development licensing asset ligand captisol formulation technology have allow enter several licensing deal generate royalty company partner include big name amgen amgn free report novartis nvs free report other ligand also have licensing deal base omniab technology ligand have see zack consensus estimate current year earning be revise almost upward last day ligand zack rank stock have gain year date substantially outperform rally industry belong zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
68,AMGN,aug issue update report ligand pharmaceutical incorporate lgnd free report ligand captisol formulation technology platform have allow enter partnership several lead drug company novartis ag nvs free report merck co inc mrk free report amgen inc amgn free report provide fund form milestone royalty payment royalty depend sale key partner asset novartis kyproli amgen promacta ligand receive royalty milestone payment several fda approve product used captisol technology latest product approval include spectrum evomela lundbeck carnexiv melinta therapeutic baxdela apart several other candidate be late stage development be expect bring royalty company once commercialize july company announce have enter commercial license supply agreement amgen grant right use captisol formulation cd cd bite bispecific antibody amg agreement term ligand be entitle potential milestone payment royalty revenue future sale amg regard company internal pipeline various candidate be be develop indication diabetes most advanced candidate be lgd presently undergo phase ii study treatment type ii diabetes datum trial be await second half potential bring future licensing opportunity nonetheless ligand entry medical device segment acquisition multiple program own cormatrix be also encourage however ligand obtain captisol single supplier hovione major global supplier active pharmaceutical ingredient drug product intermediate locate portugal interruption captisol supply hit company result zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
69,AMGN,issue update research report amgen inc amgn free report aug lead biotech beat estimate earning sale second quarter result be announce jul amgen slightly tighten sale guidance raise earning outlook backed strong performance first half amgen newer drug prolium xgeva kyproli vectibix nplate sensipar be perform well backed strong demand amgen be also progress pipeline include biosimilar drug important pipeline candidate include aimovig erenumab prevention migraine review cnp bace inhibitor alzheimer disease phase iii omecamtiv mecarbil heart failure phase iii amgen have biosimilar pipeline company have collaborate allergan plc agn free report worldwide development oncology antibody biosimilar medicine roche herceptin avastin rituxan however company have challenge store give presence biosimilar competition slowdown sale mature product volume growth new product not be enough offset lose sale due decline mature brand enbrel epogen neulasta neupogen due competitive pressure neulasta sale be be hurt competition pd other new cancer therapy neupogen sale be go due biosimilar competition zarxio zarxio be sandoz novartis ag nvs free report generic arm biosimilar version neupogen be launch sep company expect neulasta neupogen sale continue be hurt competitive dynamic rest meanwhile neulasta epogen start face biosimilar competition next year also softness enbrel sale due stiff competitive pressure be key cause concern pricing pressure stiff competition be hurt sale enbrel main driver amgen revenue year meanwhile uptake amgen pcsk inhibitor repatha gain fda approval aug have not be very encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical also face similar issue pcsk inhibitor praluent second quarter however company do notice improve share trend drug follow presentation outcome study fourier datum march year datum show significant reduction myocardial infarction stroke company file regulatory application eu include fourier datum repatha label jun fda decision expect dec lastly amgen have have share pipeline setback latest be complete response letter crl receive fda evenity romosozumab osteoporosis postmenopausal woman increase risk fracture july follow heart related safety issue emerge otherwise successful arch result fda ask safety efficacy datum pivotal phase iii study arch bridge be include original application be file only basis pivotal frame study lead delay drug approval amgen inc price consensus amgen inc price consensus amgen inc quotezack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
70,AMGN,ligand pharmaceutical incorporate lgnd free report report second quarter earning cent share include tax impact stock base compensation expense significantly year figure cent earning also beat zack consensus estimate cent share lower cost higher revenue boost earning quarter ligand stock have outperformed industry year date company share have rally compare industry increase total revenue quarter surge year year back higher royalty revenue revenue also surpass zack consensus estimate quarterly revenue be report quarter approximately year year higher royalty sale novartis ag nvs free report promacta amgen inc amgn free report kyproli well spectrum pharmaceutical sppi free report evomela drive upside ligand license platform technology such captisol omniab partner use proprietary program material sale also soar owing favorable timing captisol purchase clinical commercial use license milestone revenue be thus register massive rise compare year period increase be courtesy favorable timing milestone license fee earn research development expense marginally decrease general administrative expense reduce year year other updatesin july company announce have enter commercial license supply agreement amgen grant right use captisol formulation cd cd bite specific antibody amg deal term ligand be entitle potential milestone payment royalty revenue future sale amg also june ligand announce have enter worldwide omniab platform license agreement surface oncology license surface be able use omnirat omnimouse omniflic platform fully human mono specific antibody company be entitle receive annual platform access payment development regulatory milestone payment tiered royalty product incorporating omniab antibody surface be responsible cost related program april ligand announce commercial license supply agreement marinus pharmaceutical inc grant latter right use company captisol formulation intravenous iv ganaxolone license agreement replace prior research contract allow marinus evaluate ganaxolone iv captisol preclinical phase clinical study raise revenue earning outlook company now expect earning approximately share compare expect previously company anticipate revenue be compare estimate previously core revenue be project comprise royalty approximately material sale approximately contract payment least old guidance company be expect receive additional contract revenue approximately ligand pharmaceutical incorporate price consensus ep pharmaceutical incorporate price consensus ep surprise ligand pharmaceutical incorporate quotezack rankligand currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
71,AMGN,earning season be fly start almost company have surpass expectation performance have be quite impressive biotech company major player beating market estimate president donald trump failure implement healthcare bill be positive biotech space read biotech etfs continue surge higher week major biotech player announce quarterly result amgen inc amgn free report gilead science gild free report biogen inc biib free report alexion pharmaceutical alxn free report beat earning revenue estimate read forget big tech biotech etfs be soar higher earning focusamgen report second quarter adjust earning share july beating zack consensus estimate increase more share year quarter moreover also beat consensus estimate revenue front company report revenue surpass consensus estimate increase year quarter company update full year gaap ep guidance range also update revenue guidance range company share lose market close july update guidance fall short analyst expectation gilead science report second quarter adjust earning share july beating zack consensus estimate decrease more share year quarter moreover also beat consensus estimate revenue front company report revenue surpass consensus estimate decrease more year quarter company update full year revenue guidance range company share gain market close july owing ep revenue beat biogen inc report second quarter adjust earning share july beating zack consensus estimate decrease more share year quarter company report revenue surpass consensus estimate increase roughly year quarter company update full year gaap ep guidance range also increase revenue guidance company share gain more pre market trading due better expect result close lower july alexion pharmaceutical inc report second quarter adjust earning share july beating zack consensus estimate increase roughly share year quarter company report revenue surpass consensus estimate increase roughly year quarter company update full year gaap ep guidance range increase revenue guidance company share be market close july primarily due better expect result now discuss few etfs high exposure company discuss ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech industry have aum charge fee basis point year fund have exposure biogen gilead amgen alexion july fund have return last year year date july currently have zack etf rank buy high risk outlook read kite pharma be revolutionize fight cancer vaneck vector biotech etf bbh free report fund have aum charge fee basis point year fund have exposure amgen gilead biogen alexion july fund have return last year year date july currently have zack etf rank high risk outlook read reason biotech etfs be soar ultra nasdaq biotechnology etf bib free report fund have aum charge fee basis point year fund have exposure biogen gilead amgen alexion july fund have return last year year date july want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
72,AMGN,sanofi sny free report report second quarter earning cent american depositary share be line zack consensus estimate earning rise report basis constant currency rate cer second quarter net sale rise report basis cer almost sale however miss zack consensus estimate sale benefit favorable exchange rate movement jan french drug maker swap merial animal health business boehringer ingelheim consumer healthcare chc business reflect exchange full consolidation sanofi european vaccine operation sale rise constant structure cer sale decline cer strong performance multiple sclerosis drug vaccine not make weak diabetes performance sale rise emerge market europe rest world japan south korea canada australia new puerto rico market growth rate mentioned be year year basis cer segmental sale include emerge market increase drive growth multiple sclerosis consumer healthcare franchise offset decline diabetes generic sale sanofi report global business unit gbus sanofi genzyme specialty care diabetes cardiovascular general medicine emerge market consumer healthcare sanofi pasteur vaccine sanofi genzyme specialty care gbu sale include emerge market increase drive mainly strong uptake multiple sclerosis drug aubagio lemtrada meanwhile sale rare disease drug myozyme lumizyme improve fabrazyme sale be cerdelga sale come however cerezyme sale decline quarter due difficult year comparison oncology sale rise drive mainly higher sale jevtana thymoglobulin jevtana sale be thymoglobulin record sale taxotere sale decline due generic competition japan eloxatin sale be flat sanofi regeneron pharmaceutical inc regn free report rheumatoid arthritis ra drug kevzara sarilumab be launch june approve canada feb eu jun kevzara record sale second quarter meanwhile dupixent launch march treat atopic dermatitis generate sale second quarter management be pleased drug uptake say drug have be prescribe physician dupixent be review eu receive positive recommendation european medicine agency panel earlier month drug generate total immunology sale second quarter diabetes cardiovascular gbu include emerge market decline diabetes franchise include emerge market decline due lower sale key drug lantus sale diabetes drug decline due tough payer environment sale diabetes drug emerge market be europe decline lantus sale decline quarter lantus sale decline due lower average net price cvs unite health formulary exclusion europe sale decline due biosimilar competition patient switch toujeo toujeo generate sale sequentially report quarter management warn diabetes franchise sale decline faster second half due exclusion cvs unite health formulary plan difficult comparison last year soliqua once daily titratable fix ratio combination lantus lyxumia launch jan generate sale second quarter compare previous quarter cardiovascular franchise sanofi pcsk therapy praluent garner worldwide sale report quarter sequentially incidentally amgen inc amgn free report report earlier week also report sequential increase sale pcsk inhibitor repatha uptake drug have not be very encourage so far due pricing re imbursement issue payer restriction general medicine emerge market gbu sale come sale establish product be strong performance emerge market be offset generic competition plavix japan plavix lose exclusivity japan lower sale europe sale generic decline sale decline europe well emerge market consumer healthcare gbu sale be however sale be flat exclude acquisition boehringer ingelheim consumer healthcare business lower sale europe due early cough cold season first quarter be partially offset higher sale drive pain allergy portfolio higher sale emerge market due sale recovery russia second quarter consolidated sanofi pasteur vaccine sale increase due strong performance pediatric combination menactra vaccine sale reflect termination sanofi pasteur msd joint venture merck co inc mrk free report europe dec cost risesel general administrative expense sg increase cer quarter reflect launch cost dupixent kevzara xyzal expense be cer reflect higher pipeline development cost oncology isatixumab pd sotagliflozin outlooksanofi raise previously issue financial outlook sanofi expect business earning be broadly flat cer outlook compare favorably previous expectation flat cer anticipate positive currency impact range business earning takesanofi second quarter result be not great report line earning miss sale expectation slight margin however share rise more pre market trading response raise earning forecast optimism surround dupixent launch fact so far year sanofi share price have rise better increase industry be encourage strong performance ms drug aubagio lemtrada be also optimistic sale prospect dupixent prove be important growth driver company however headwind include bleak outlook diabetes franchise generic competition many drug slower expect uptake new product praluent sanofi currently carry zack rank buy see complete list today zack rank strong buy stock here sanofi price consensus ep surprise sanofi price consensus ep surprise sanofi quotemore stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
73,AMGN,medical group have plenty great stock investor always be look company be outperform peer be amgen amgn free report stock right now take look stock year date performance comparison medical peer be able answer question amgen be individual stock medical sector collectively company sit zack sector rank zack sector rank consider different sector group average zack rank individual stock group be measure sector be list best worst zack rank be successful stock pick model emphasize earning estimate estimate revision system highlight number different stock be poise outperform broader market next month amgn be currently sporting zack rank buy past quarter zack consensus estimate amgn full year earning have moved higher mean analyst sentiment be stronger stock earning outlook be improve latest available datum show amgn have return start calendar year same time medical stock have gain average show amgen be outperform peer so far year look more specifically amgn belong medical biomedical genetic industry include individual stock currently sit zack industry rank stock group have lose so far year so amgn be perform better group term year date return go forward investor interested medical stock continue pay close attention amgn look continue solid performance
74,AMGN,biotech sector be focus regular pipeline update key story include bigwig gilead science gild free report get approval hiv drug biktarvy europe puma biotechnology pbyi free report soar positive chmp recommendation merrimack mack free report plunge failure phase ii study pancreatic cancer recap important storiesgilead biktarvy get ec approval gilead announce european commission have grant marketing authorization hiv combination therapy biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf biktarvy be approve once daily single tablet regimen str treatment hiv infection adult present past evidence viral resistance integrase class emtricitabine tenofovir approval be support positive datum ongoing phase iii study namely study treatment nave hiv infected adult study virologically suppress adult approval bic ftc taf become gilead third ftc taf base str approve european union year bic ftc taf meet primary objective week study regimen be earlier approve fda february approval europe further strengthen company hiv franchise read more gilead biktarvy get ec nod hiv infection merrimack plunge study failure share merrimack plunge company report disappointing result phase ii study front line metastatic pancreatic cancer phase ii trial carrie evaluate addition mm standard care treatment patient previously untreated metastatic pancreatic cancer high serum level free insulin growth factor igf primary endpoint study be progression free survival secondary endpoint include objective response rate disease control rate duration response overall survival safety merrimack report study do not meet primary secondary efficacy endpoint patient receive mm combination nab paclitaxel gemzar compare nab paclitaxel gemzar alone subsequently merrimack have terminate development mm sale onivyde company be back be development stage company be banking pipeline candidate boost growth prospect hence failure carrie study come huge disappointment investor give limit number candidate pipeline consequently company now plan focus other candidate pipeline mm mm read more merrimack crash phase ii pancreatic cancer study fail amgen present encourage datum repatha amgen amgn free report announce encourage datum phase iii study banting show pcsk inhibitor repatha significantly reduce bad cholesterol patient type ii diabetes have already undergo moderate high intensity statin therapy study evaluate monthly subcutaneous administration mg dose repatha period week patient type ii diabetes mixed dyslipidemia be optimized background statin therapy result study show addition repatha background statin therapy significantly reduce low density lipoprotein cholesterol ldl high density lipoprotein cholesterol hdl datum banting study also reveal patient repatha arm achieve ldl level less mg dl be recommend level american college clinical endocrinologist patient type ii diabetes compare patient placebo arm week read more amgen repatha reduce bad cholestrol type ii diabetes amgen carry zack rank buy see complete list today zack rank strong buy stock here puma biotechnology soar positive chmp opinion share puma biotechnology soar company announce committee medicinal product human use chmp european medicine agency ema have adopt positive trend vote recommend approval marketing authorisation application maa breast cancer drug nerlynx neratinib maa be seek approval drug extend adjuvant treatment early stage positive hormone receptor positive breast cancer news boost investor sentiment chmp have adopt negative opinion maa february positive opinion chmp indicate imminent tentative approval drug be approve fda july extend adjuvant treatment adult patient early stage overexpressed amplify breast cancer follow adjuvant trastuzumab base therapy incyte announce positive result jakafi gvhd incyte incy free report announce phase ii trial reach evaluate lead drug jakafi combination corticosteroid treatment patient steroid refractory acute graft versus host disease gvhd meet primary endpoint datum study show jakafi demonstrated overall response rate orr day moreover number patient show response point time study be propel positive datum reach study incyte now plan file supplemental new drug application snda fda label expansion jakafi treatment steroid refractory acute gvhd third quarter potential label expansion gvhd further boost sale read more incyte announce positive result jakafi gvhd biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock alexion gain past month celgene have lose amgen have gain see last biotech stock roundup here biotech stock roundup srpt sldb soar positive datum anik ziop crash next biotech stay tune regulatory update pipeline development news hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
75,AMGN,merck co inc mrk free report announce fda have accept supplemental biologic license application sbla keytruda pd therapy review company be seek approval blockbuster drug adjuvant therapy treatment patient resect high risk stage iii melanoma decision be expect feb year so far merck share have outperformed industry share have rise period industry decline sbla include datum pivotal eortc keynote study demonstrated keytruda achieve significant increase recurrence free survival rfs surgery compare placebo patient population recurrence free survival be achieve patient treat keytruda year compare placebo drug also reduce risk disease recurrence death placebo merck have claim keytruda be first pd therapy achieve rfs benefit stage iiia iiib iiic melanoma patient drug have achieve rfs benefit patient irrespective braf mutation remind investor drug be already approve type cancer indication several setting include first line melanoma recently approve cervical cancer large cell lymphoma keytruda garner sale first quarter sequentially year year sale drug be particularly boost strong momentum first line lung cancer indication be only approve pd therapy monotherapy combination eli lilly lly free report cancer drug alimta pemetrexed carboplatin merck be focuse further develop successful drug other indication keytruda be be evaluate more study include excess combination study more type cancer company have collaborate several company include amgen amgn free report incyte glaxo pfizer pfe free report separately evaluation keytruda combination other regimen merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
76,AMGN,amgen amgn free report announce new datum phase iii study banting show pcsk inhibitor repatha significantly reduce bad cholesterol patient type ii diabetes already receive moderate high intensity statin therapy datum be present annual scientific session american diabetes association weekend accord datum banting study addition repatha background statin therapy significantly reduce low density lipoprotein cholesterol ldl high density lipoprotein cholesterol hdl notably ldl be reduce week baseline patient population so far year amgen share have gain compare favorably industry decrease banting study evaluate monthly subcutaneous administration mg dose repatha period week patient type ii diabetes mixed dyslipidemia be optimized background statin therapy encourage datum study show patient type ii diabetes be already treat maximum tolerable dose statin therapy further reduce ldl hdl add repatha datum banting study also reveal patient repatha arm achieve ldl level less mg dl be recommend level american college clinical endocrinologist patient type ii diabetes compare patient placebo arm week addition repatha too reduce various lipid parameter include hdl compare placebo high hdl level cause cardiovascular event type ii diabetes patient combination ldl increase risk further remind investor repatha label be expand europe last month include prevention heart attack stroke adult establish cardiovascular disease encourage datum banting study further brighten prospect drug reduce cardiovascular event presumably larger patient population pcsk inhibitor available market be sanofi sny free report partner regeneron pharmaceutical inc regn free report praluent currently drug have record lower expect sale due higher pricing re imbursement issue payer restriction amgen inc price amgen inc price amgen inc quotezack rank stock consideramgen currently carry zack rank hold better rank stock pharma sector be aeglea biotherapeutic inc agle free report carry zack rank buy see complete list today zack rank strong buy stock here aeglea loss estimate narrow last day company deliver positive earning surprise trail quarters average beat share price have increase so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
77,AMGN,roche holding rhhby free report announce phase iii study impower immuno oncology drug tecentriq meet co primary endpoint overall survival os progression free survival pfs first interim analysis indication extensive stage small cell lung cancer es sclc study enrolled person be randomise equally receive tecentriq combination carboplatin etoposide arm placebo combination carboplatin etoposide arm control arm result study show initial first line treatment combination tecentriq chemotherapy carboplatin etoposide enabled patient es sclc live significantly longer compare chemotherapy alone combination also reduce risk disease worsening death pfs compare chemotherapy alone impower meet os pfs co primary endpoint study protocol present roche have ongoing phase iii lung cancer study be evaluate tecentriq alone combination other drug be fourth phase iii study evaluate tecentriq combination study come datum fifth demonstrate positive result note tecentriq be already approve unite state european union patient previously treat metastatic nsclc patient locally advanced metastatic urothelial cancer muc be not eligible cisplatin chemotherapy have have disease progression follow platinum contain therapy roche plan submit datum regulatory body company impower be first phase iii study immunotherapy base combination show improvement os pfs initial treatment extensive stage small cell lung cancer es sclc increase likelihood potential approval label expansion drug boost sale meanwhile fda have accept priority review bristol myer squibb company bmy free report supplemental biologic license application opdivo indication sclc disease have progressed more prior line therapy fda action date be aug hence competition be stiff sclc market roche roche stock have lose so far year industry decline approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
78,AMGN,merck co inc mrk free report share have perform well year so far contrast industry performance merck belong zack large cap pharmaceutical industry be stock group comprise largest drugmaker world zack large cap pharmaceutical industry have underperform well zack medical sector stock industry have collectively decline zack composite zack medical sector have rise year date respectively however merck share have rise year so far industry decline also earning estimate rise rise past day rally significant part merck outperformance year be drive strong performance positive regulatory update related pd inhibitor keytruda very short span time keytruda have become merck largest product be already approve use different setting involve different tumor type year have already gain approval new indication include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer label expansion approval drive sale keytruda future quarters treatment generate sale first quarter sequentially year year upside be drive global launch indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo recently conclude annual meeting american society clinical oncology pd inhibitor steal limelight encourage datum multiple clinical study datum presentation merck garner most attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study keytruda be also be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen other year merck partner astrazeneca azn free report gain approval europe japan parp inhibitor lynparza advanced ovarian cancer unite state metastatic breast cancer merck also announce positive datum several late stage study mainly evaluate keytruda further line extension merck also sign deal japan eisai co ltd jointly develop commercialize latter tyrosine kinase inhibitor lenvima monotherapy well combination keytruda several type cancer also agree buy viralytic limit australian pharmaceutical company develop oncolytic immunotherapy range cancer strengthen oncology portfolio conclusionmerck carry zack rank hold have share challenge form generic competition several drug pricing pressure rise competitive pressure diabetes franchise product isentress hiv zepatier hcv zostavax vaccine nonetheless go forward new product keytruda lynparza bridion continue contribute meaningfully top line merck animal health unit be also strong remain core growth driver company meanwhile merck also continue focus cost cut initiative drive bottom line see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
79,AMGN,biotech major amgen inc amgn free report announce have receive european commission ec approval include overall survival os datum tower study label bite antibody blincyto blincyto be approve treatment patient philadelphia chromosome negative ph relapse refractory cell precursor acute lymphoblastic leukemia tower study be conduct support conversion blincyto accelerate approval full approval study evaluate efficacy blincyto versus standard care soc chemotherapy treatment ph relapse refractory cell precursor adult result late stage study show median overall survival patient blincyto be month compare month standard care soc chemotherapy blincyto label unite state already include os datum tower study follow approval receive fda july last year fact inclusion os datum have be instrumental drive sale drug higher past quarters blincyto sale surge year period first quarter reflect rise inclusion os datum european label drug further boost sale remind investor pfizer inc pfe free report besponsa be approve treatment relapse refractory cell precursor june last year eu increase competition blincyto amgen share have gain so far year decrease register industry amgen currently carry zack rank hold better rank stock same sector include crispr therapeutic ag crsp free report genomic health inc ghdx free report sporting zack rank strong buy see complete list today zack rank stock here crispr therapeutic loss share estimate narrow last day stock have sky-rocket year date genomic health earning estimate surge almost past day stock have soar so far year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
80,AMGN,biotech sector be focus regular pipeline update sarepta therapeutic inc srpt free report solid bioscience sldb free report gain positive datum therapeutic inc anik free report ziopharm oncology inc ziop free report decline dismal result recap important storiessarepta solid bioscience surge go have be good duchenne muscular dystrophy dmd market share sarepta surge significantly company report impressive preliminary result phase iia gene therapy trial assess aavrh mhck micro individual dmd biopsy perform end day show robust micro expression muscle measure method observed patient patient enrolled also show significant decrease serum creatine kinase ck level mean reduction ck day read more sarepta stock soar encourage gene therapy result earlier solid bioscience share surge too company announce fda have lift clinical hold phase ii trial ignite dmd experimental candidate sgt notably sgt solid bioscience lead candidate be microdystrophin gene transfer be be evaluate treatment dmd clinical hold be lift fda acknowledge solid bioscience have satisfactorily address issue raise read more solid surge fda lift clinical hold dmd drug alexion submit bla alxn alexion pharmaceutical inc alxn free report announce company have submit biologic license application bla fda approval experimental long act complement inhibitor alxn treatment patient paroxysmal nocturnal hemoglobinurium pnh submission be rare disease used priority review voucher bla be entitle month review fda instead standard month review alexion lead drug soliris be already approve pnh tentative approval alxn give significant boost company alxn have earlier achieve inferiority soliris complement inhibitor treatment naive patient pnh base co primary endpoint transfusion avoidance normalization ldh level phase iii study alxn be administer intravenously week alexion carry zack rank hold see complete list today zack rank stock here plunge disappointing datum share therapeutic have drop market trading company report disappointing result phase iii trial cingal be be conduct support registration unite state trial compare cingal combination cross link triamcinolone hexacetonide alone cross link treat patient osteoarthritis knee primary endpoint be comparison pain reduction treat cingal compare only week however result do not show statistical significance even cingal achieve greater pain reduction numerically time point study cingal be third generation visco supplement orthovisc monovisc product treat pain associate osteoarthritis knee ziopharm oncology plunge fda place clinical hold car therapy share ziopharm oncology decline fda place clinical hold phase trial evaluate cd specific car therapy manufacture point care fda have request additional information relative chemistry manufacturing control support investigational new drug ind application trial therapy be be evaluate investigational treatment patient relapse refractory cd leukemias lymphomas amgen get european nod addition datum blincyto amgen amgn free report announce european commission ec have grant full marketing authorization blincyto blinatumomab base encourage overall survival os datum phase iii study tower adult patient philadelphia chromosome negative ph relapse refractory cell precursor acute lymphoblastic leukemia result show blincyto demonstrated superior improvement median os standard care soc chemotherapy median os be month blincyto versus month soc biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock regeneron gain past month celgene have lose amgen have gain see last biotech stock roundup here biotech stock roundup axon soar amgen drug get fda ec nod next biotech stay tune regulatory update pipeline development news today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
81,AMGN,teva pharmaceutical industry ltd teva free report announce discontinue phase iii study evaluate key pipeline candidate fremanezumab treatment chronic cluster headache decision be base datum pre specify futility analysis study show study be unlikely meet primary endpoint mean change baseline monthly average number cluster headache attack week period enforce phase iii clinical development program comprise chronic cluster headache study episodic cluster headache analysis long term safety study notably evaluation patient chronic cluster headache long term safety study also be stop however study episodic cluster headache not be affected carry plan fremanezumab calcitonin gene related peptide cgrp candidate be currently review unite state europe preventive treatment migraine adult quarterly monthly injection however company announce fda have postpone action date june september share company slip include hour trading jun however stock have rally so far year compare industry increase teva be focuse develop fremanezumab migraine indication cluster headache post traumatic headache disorder see inc aldr free report share price rise friday follow news teva decision suspend cluster headache study note be also develop cgrp candidate eptinezumab preventive treatment migraine candidate be be evaluate pivotal study biologic license application expect be file fda first quarter meanwhile several other company be develop treatment treat migraine multus dollar segment high unmet need fda approve amgen amgn free report partner novartis nvs free report cgrp drug aimovig treat episodic migraine other cgrp candidate development include eli lilly galcanezumab allergan atogepant galcanezumab be review unite state preventive treatment migraine lilly be also develop candidate cluster headache teva pharmaceutical industry ltd price teva pharmaceutical industry ltd price teva pharmaceutical industry ltd quote teva currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
82,AMGN,roche rhhby free report announce encourage datum final analysis cll study evaluate gazyva base treatment previously untreated chronic lymphocytic leukaemia cll phase iii multicenter open label randomize arm study be conduct evaluate safety efficacy profile gazyva combination chlorambucil compare mabthera combination chlorambucil chlorambucil alone nearly patient previously untreated cll comorbidity final result follow almost year show clinically meaningful improvement gazyva chlorambucil multiple endpoint include progression free survival pfs overall survival os compare head head rituxan chlorambucil long term datum confirm gazyva efficacy extend life patient suffering cll compare mabthera rituxan gazyva base treatment reduce risk death compare mabthera rituxan base treatment gazyva be approve combination chlorambucil patient previously untreated cll roche be leader oncology market wide portfolio drug breast cancer cll other additionally roche announce new datum multiple sclerosis ms drug ocrevus be present congress european academy neurology ean jun lisbon portugal datum new exploratory analysis extend control period phase iii study oratorio primary progressive multiple sclerosis ppms patient show ocrevus significantly delay time need wheelchair year measure length time person reach expand disability status scale greater edss used week confirm disability progression cdp patient treat ocrevus show reduction risk progress wheelchair compare placebo treat group analysis also show placebo treat patient population study oratorio have similar disability progression rate untreated real world ppms population extrapolate median time wheelchair edss placebo treat person oratorio study be year longer term efficacy safety datum be consistent drug favourable benefit risk profile ppms relapse ms rm addition new global study floodlight open be now enrolling patient unite state study used proprietary floodlight mobile technology collect monitor anonymize patient datum help gain better understand ms disease progression study be observational open access study aim enroll person globally include person relapse progressive form ms year roche be initiate new phase iiib study ocrevus ms market hold immense potential competition be stiff like biogen inc biib free report approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar roche stock have lose last month compare industry decline novartis nvs free report have already launch biosimilar version rituxan europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
83,AMGN,roche rhhby free report announce fda have approve label expansion oncology drug avastin bevacizumab fda approve avastin combination chemotherapy carboplatin paclitaxel follow avastin single agent treatment woman advanced stage iii iv ovarian cancer follow initial surgical resection approval be base datum phase iii gog study study show woman receive avastin combination chemotherapy continue use avastin alone have median progression free survival pfs month compare month woman receive chemotherapy alone year date share company have decrease compare industry decline approval avastin be now approve distinct used different type cancer unite state avastin be approve europe treatment advanced stage breast cancer colorectal cancer small cell lung cancer kidney cancer ovarian cancer cervical cancer be available unite state treatment colorectal cancer small cell lung cancer kidney cancer cervical cancer recurrent platinum resistant platinum sensitive ovarian cancer recurrent glioblastoma avastin be lead drug roche portfolio however sale avastin fall first quarter due increase use cancer immunotherapy medicine lung cancer stiff competition biosimilar loom large avastin amgen amgn free report obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer entry biosimilar key drug adversely impact sale roche hold ag price roche hold ag price roche hold ag quotezack rankroche have zack rank hold better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report illumina sport zack rank strong buy aeglea carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
84,AMGN,merck mrk free report have receive fda accelerate approval label expansion blockbuster pd therapy keytruda include advanced cervical cancer second line set company need evaluate drug confirmatory study indication gain continue approval eligible patient treatment cervical cancer be select base fda approve test pd expression tumor combine positive score cp approval come bit earlier expect date jun fda have grant priority review label expansion regulatory application march keytruda be most successful immuno oncology drug date approval several cancer indication include lucrative first line lung cancer be first pd therapy approve advanced cervical cancer first indication keytruda gynecologic cancer well year so far merck share have outperformed industry share have rise period industry decline latest fda approval be base datum single cohort multus cohort phase ii study keynote evaluate drug recurrent metastatic cervical cancer datum subset patient population express pd cp show keytruda achieve objective response rate moreover patient achieve complete response patient demonstrated partial response drug generate response cervical cancer patient pd expression tumor have cp merck be evaluate drug wide range cancer indication treatment setting more clinical study recently conclude annual meeting american society clinical oncology pd inhibitor steal limelight encourage datum multiple clinical study datum presentation garner attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study moreover merck have collaborate several pharma company include amgen amgn free report glaxo gsk free report pfizer pfe free report incyte evaluate keytruda combination other regimen drug generate worldwide sale almost first quarter year period line extension approval cervical cancer potential approval other indication review positive momentum drug be expect continue merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
85,AMGN,biotech sector be focus last week regular pipeline update collaboration licensing deal biotech bigwig amgen amgn free report drug win fda ec approval axovant axon free report soar licensing deal oxford biomedica meanwhile regeneron regn free report collaborate zoetis new veterinary treatment recap important story amgen get fda nod addition datum kyproli amgen announce fda have approve supplemental new drug application snda add positive overall survival os datum phase iii trial aspire myeloma drug kyproli datum add label show kyproli revlimid dexamethasone krd significantly reduce risk death extend overall survival month versus revlimid dexamethasone alone rd patient relapse refractory multiple myeloma addition european commission ec approve label expansion prolium denosumab treatment bone loss associate long term systemic glucocorticoid therapy adult patient increase risk fracture be third indication prolium have receive ec approval read more amgen get fda nod add aspire datum kyproli label amgen prolium get label expansion approval europe regeneron collaborate zoetis regeneron announce year collaboration agreement zoetis latter use monoclonal antibody therapeutic animal new veterinary treatment term regeneron have grant zoetis license proprietary velocimmune antibody technology latter use develop monoclonal antibody modify species specific use companion livestock animal exchange regeneron receive license fee approval sale milestone payment royalty potential veterinary treatment axovant science soar gene therapy deal share axovant science gain company announce have license exclusive worldwide right develop commercialize axo lentipd oxford parkinson disease axo lentipd formerly oxb be experimental gene therapy be develop parkinson disease deliver gene encode critical set enzyme require dopamine synthesis brain axovant plan initiate phase ii dose escalation study axo lentipd patient advanced parkinson disease end term agreement axovant make initial payment cash obtain right axo lenti pd well predecessor product prosavin be apply credit process development work clinical supply oxford biomedica provide axovant addition oxford biomedica also be entitle receive additional development regulatory commercial milestone payment potentially excess tiered royalty net sale axo lenti pd approve meanwhile axovant receive equity financing roivant science support clinical development axo lenti pd additional business development company also get new chief technology officer fraser read more axovant gain licensing deal oxford biomedica axovant currently sport zack rank strong buy see complete list today zack rank stock here biogen acquire asset thrombosis biogen biib free report enter exclusive option agreement tms co ltd acquire tms backup compound upfront payment agreement also include additional payment biogen exercise option potential development milestone well tiered royalty tms plasminogen activator enable restore blood flow follow acute stroke extend treatment window versus current standard care candidate be currently be evaluate double blind placebo controlled phase ii study japan safety efficacy single iv administration tms approximately patient ais hour stroke onset first patient be dose february acquisition be line biogen effort broaden neurology portfolio alexion team complement pharma alexion pharmaceutical inc alxn free report announce partnership complement pharma co develop preclinical complement inhibitor cp disorder cp be humanize monoclonal antibody preclinical stage bound circulation inhibit function body prevent mac formation periphery central nervous system alexion complement pharma collaborate development program cp complement pharma be responsible conduct preclinical phase study well manufacturing cp exchange alexion provide complement pharma milestone dependent payment phase ib development alexion be look develop pipeline reduce dependence key drug soliris pipeline development read more alexion complement pharma tie treat neuro disorder biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex gain past month celgene have lose vertex have gain see last biotech stock roundup here biotech stock roundup regeneron celgene amgen impress asco next biotech stay tune regulatory update pipeline development news hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
86,AMGN,allergan agn free report calcitonin gene related peptide cgrp candidate atogepant meet primary endpoint phase ii part phase iib iii study cgp md study be evaluate oral dosage candidate acute treatment episodic migraine meanwhile company have cgrp candidate ubrogepant pipeline demonstrated positive result phase iii study evaluate treatment single migraine attack positive datum readout cgp md study boost company cgrp pipeline company be currently discussion regulatory authority follow advance atogepant phase iii stage development allergan share have increase year so far industry rise cgp md study evaluate dose atogepant once daily mg mg mg twice daily mg mg prevention episodic migraine week atogepant achieve reduction statistical significance monthly migraine probable migraine mpm headache day baseline dose allergan present additional detail upcoming scientific meeting moreover potential approval candidate boost company migraine product line include botox treatment chronic migraine oral administration also help ubrogepant atogepant gain advantage other injectable drug approve meanwhile migraine space be attract lot interest due high unmet need several company be develop treatment disease amgen amgn free report partner novartis nvs free report receive approval commercialize cgrp drug aimovig treat episodic migraine other cgrp candidate development include eli lilly lly free report galcanezumab teva pharmaceutical fremanezumab eptinezumab galcanezumab fremanezumab be review unite state migarine be multus dollar market approximately person unite state suffering patient have episodic chronic migraine allergan plc price allergan plc price allergan plc quotezack rankallergan currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
87,AMGN,biotech major amgen inc amgn free report gain fda approval include positive overall survival datum multiple myeloma late stage aspire study kyproli label final datum phase iii aspire study present july last year show triple combination regimen kyproli significantly improve overall survival os patient relapse refractory multiple myeloma overall survival datum study show patient relapse refractory multiple myeloma live month longer treat kyproli celgene celg free report revlimid lenalidomide dexamethasone krd compare treat revlimid dexamethasone rd median os month krd versus median os month rd datum also show krd reduce risk death compare rd kyproli proteasome inhibitor be already approve use combination revlimid dexamethasone patient relapse multiple myeloma overall survival datum help drive usage boost sale amgen share have gain so far year decrease register industry similar application be also review eu april committee medicinal product human use chmp european medicine agency ema grant positive opinion recommend inclusion os datum aspire study label kyproli early amgen gain fda approval include overall survival datum head head endeavor study label approval include os result aspire study kyproli label now include os datum phase iii study drive sale drug future quarters kyproli have become key revenue driver amgen drug record sale first quarter represent growth year year drive increase demand robust uptake outside market kyproli represent significant commercial potential sale be likely be drive launch additional country expansion additional indication longer duration treatment amgen also have collaboration jnj free report study combination kyproli darzalex multiple clinical study treatment multiple myeloma amgen currently carry zack rank hold better rank biotech stock be biomarin pharmaceutical inc bmrn free report zack rank buy see complete list today zack rank strong buy stock here biomarin earning share estimate increase last day average earning surprise trail quarters be company share have rise year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
88,AMGN,amgen amgn free report announce european commission ec have approve label expansion blockbuster drug prolium drug be now approve treatment bone loss associate long term systemic glucocorticoid therapy adult patient increase risk fracture be also call glucocorticoid induced osteoporosis be third approve indication prolium europe approval be backed increase bone mineral density bmd achieve drug phase iii study similar line extension application receive approval unite state last month prolium be presently market europe treatment man postmenopausal woman osteoporosis high risk fracture well increase bone mass man prostate cancer receive hormone ablation amgen share have increase year so far industry decline phase iii study evaluate prolium improvement bmd patient receive glucocorticoid treatment compare allergan agn free report actonel risedronate study comprise patient group patient sustain glucocorticoid treatment glucocorticoid continue arm second patient initiate glucocorticoid therapy glucocorticoid initiate arm arm prolium demonstrated greater improvement lumbar spine bmd patient year year compare actonel study primary endpoint glucocorticoid induced osteoporosis be most common form secondary osteoporosis press release patient receive glucocorticoid treatment long term have show vertebral fracture proportion eligible patient be small line extension be likely boost sale drug further prolium be major revenue source amgen be witness growth market share unite state internationally competition generic other drug approve osteoporosis first quarter drug generate sale almost half dollar year year drug face competition generic other brand drug include eli lilly lly free report evista alendronate merck mrk free report fosamax raloxifene novartis zometa zoledronate amgen inc price amgen inc price amgen inc quotezack rankamgen currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
89,AMGN,be approve therapy completely cure autoimmune inflammatory disease development new treatment technology be ongoing meanwhile be difficult control autoimmune disease majority patient newest class medication treat disease be janus kinase jak inhibitor be provide patient better treatment option class therapy have generate significant interest due better efficacy compare tumor necrosis factor tnf inhibitor therapy autoimmune diseasesin patient autoimmune disease body immune system mistakenly attack healthy cell scientist be yet find reason abnormality however incidence autoimmune disease be rise be multiple type autoimmune disease include rheumatoid arthritis ra psoriasis multiple sclerosis ms inflammatory bowel disease ibd etc several company be dedicate bring better drug treatment disease symptom include fatigue muscle ach swell redness affected body part most common first line treatment autoimmune disease be disease modify rheumatic drug dmard especially methotrexate apart methotrexate be several class dmard include tnf inhibitor therapy approve disease be perform well abbvie abbv free report humira amgen amgn free report enbrel be blockbuster tnf inhibitor drug other however treatment have serious safety issue include increase risk tuberculosis lymphoma other jak pharma company be develop jak inhibitor work block particular signal body immune response cytokine instead suppress immune system do dmard patient treat jak inhibitor clinical study have show faster better response disease however safety concern still loom large segment be attractive company be only jak inhibitor presently approve treatment autoimmune disease especially ra however several company be develop candidate be likely increase competition go forward segment be news recently eli lilly lly free report olumiant jak inhibitor receive approval unite state abbvie abbv free report announce top line datum late stage study evaluate jak inhibitor candidate upadacitinib pharma biotech company grow interest jak inhibitor let take look pharma biotech company be look change way autoimmune disease be treat pfizer pfe free report xeljanz tofacitinib be first approve jak inhibitor unite state treatment ra have be available market drug be also approve psoriatic arthritis generate sale first quarter year year regulatory application seek line extension drug ulcerative colitis be approve late last month unite state regulatory application seek approval indication be review europe company currently carry zack rank hold see complete list today zack rank strong buy stock here eli lilly jak inhibitor olumiant baricitinib be second drug receive approval treat ra unite state drug be approve early month however be launch certain european country note fda reject company new drug application seek approval olumiant april cite safety concern lilly develop commercialize drug partnership incyte corporation drug generate sale first quarter sequentially lilly be currently evaluate drug autoimmune indication atopic dermatitis eczema late stage study company currently carry zack rank buy abbvie be company be focuse develop jak inhibitor base treatment company jak inhibitor upadacitinib show promising result late stage study evaluate candidate ra patient be also be develop atopic dermatitis late stage study enjoy breakthrough therapy status unite state late stage study be evaluate candidate crohn disease company currently carry zack rank galapago nv glpg free report be develop jak inhibitor candidate filgotinib collaboration gilead science inc gild free report separate late stage study be evaluate candidate ra crohn disease ulcerative colitis moreover several mid stage study be evaluate candidate multiple autoimmune indication include ankylose spondylitis psoriatic arthritis cutaneous lupus erythematosus other datum mid stagei study evaluate filgotinib psoriatic arthritis show significant improvement patient company currently carry zack rank prospect jak inhibitor several blockbuster dmard near patent expiration new class drug hold potential replace exist treatment boost prospect company have drug candidate pipeline commercial portfolio however jak inhibitor also have several side effect delay approval note lower dose lilly olumiant be approve box warning state risk serious infection malignancy thrombosis hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
90,AMGN,roche holding rhhby free report announce fda have approve rituxan rituximab treatment adult moderate severe pemphigus vulgaris pv company rituxan be first biologic therapy approve fda pv remind investor fda have grant priority review breakthrough therapy designation orphan drug designation rituxan treatment pv be autoimmune blister disease affect skin mucous membrane pf affect person unite state result approval rituxan be now approve treat autoimmune disease rheumatoid arthritis ra granulomatosis polyangiitis gpa microscopic polyangiitis mpa pv approval be base datum ritux trial compare ritux regimen eu approve rituximab product short term corticosteroid cs cs alone first line treatment patient newly diagnosed moderate severe pemphigus result study show pv patient treat ritux regimen meet endpoint compare pv patient treat cs alone note roche subsidiary genentech biogen biib free report have collaboration agreement rituxan unite state roche market mabthera brand name rituxan outside unite state rest world japan rituxan be co market chugai zenyaku kogyo co ltd approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar sale mabthera rituxan be first quarter sale europe be adversely impact market entry biosimilar roche stock have lose last month compare industry decline novartis nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
91,AMGN,investor biotech sector be glue last week highly await annual meeting american society clinical oncology asco overshadowed usual regulatory other update space meeting hold chicago jun jun provide company platform showcase datum scientist physician investment community other focus be mainly asco datum company biogen biib free report vertex vrtx free report remain limelight pipeline update recap important story biogen eisai report encourage datum elenbecestat biogen partner eisai announce encourage result alzheimer candidate elenbecestat bace inhibitor phase ii study study study be multicenter randomize double blind placebo controlled parallel group month study patient mild cognitive impairment mci due alzheimer disease mild moderate dementia due alzheimer disease confirm amyloid pathology pet positron emission tomography screening patient be randomize treatment arm receive elenbecestat mg placebo daily more half patient elenbecestat mg mg arm be switch mg arm month more datum show elenbecestat be generally safe well tolerate result demonstrated statistically significant difference amyloid beta a level brain measure amyloid pet suggest delay clinical symptom decline exploratory endpoint eisai biogen be jointly develop elenbecestat march company be currently conduct global phase iii study mission ad early alzheimer disease biogen currently carry zack rank hold see complete list today zack rank strong buy stock here vertex crispr sickle cell disease candidate put hold vertex pharmaceutical incorporate crispr therapeutic announce fda have place clinical hold investigational new drug application ind ctx treatment sickle cell disease pending resolution certain question raise fda company have submit ind fda april support plan initiation phase ii trial unite state adult patient sickle cell disease ctx be experimental gene edit autologous hematopoietic stem cell therapy be also be evaluate patient suffering thalassemia sickle cell disease fda clinical hold company plan initiate phase ii trial ctx europe adult patient transfusion dependent thalassemia crispr vertex equally share research development cost profit worldwide ctx read more vertex crispr sickle disease candidate put hold fda sarepta get negative chmp opinion exondys sarepta therapeutic inc srpt free report announce committee medicinal product human use chmp european medicine agency ema have adopt negative opinion duchenne muscular dystrophy dmd candidate exondys eteplirsen negative opinion be expect follow oral explanation trend vote consequently sarepta request re examination opinion result assignment new rapporteur co rapporteur additionally sarepta request scientific advisory group sag dmd be call turn allow neuromuscular specialist provide expert guidance insight other thing validity external control used importance certain functional endpoint re examination be complete end finally look asco result celgene celg free report have multiple presentation oncology drug revlimid pomalyst other experimental therapy american society clinical oncology asco annual meeting chicago il result transcend study experimental cd direct car cell therapy candidate lisocabtagene maraleucel liso cel jcar patient relapse refractory aggressive cell hodgkin lymphoma nhl be encourage read more celgene present datum car therapy revlimid pomalyst regeneron regn free report partner sanofi also announce datum trial evaluate cemiplimab advanced cutaneous squamous cell carcinoma asco datum study show patient treat cemiplimab experience robust tumor effect cemiplimab treat patient show response rate median observed time response month datum cut date gilead gild free report kite also announce result ongoing phase study asco show clinical response be observed investigational cell receptor tcr cell therapy target human papillomavirus type hpv solid tumor cancer cause hpv meanwhile gilead have also collaborate hookipa biotech ag obtain exclusive right hookipa therat vaxwave arenavirus vector base immunization technology major chronic infectious disease indication hepatitis virus hbv human virus hiv gilead partner galapago nv also announce phase ii study equator pipeline candidate filgotinib achieve primary endpoint improvement sign symptom psoriatic arthritis week amgen amgn free report also announce result phase iii trial asco show kyproli administer once weekly mg dexamethasone achieve superior progression free survival pfs overall response rate orr compare twice weekly kyprolisat mg dexamethasone twice weekly kd patient relapse refractory multiple myeloma separately share amgen be fda approve biosimilar blockbuster drug neulasta biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock gilead gain past month celgene have lose alexion have gain see last biotech stock roundup here biotech stock roundup gild epclusa china approval bmrn palynziq fda nod next biotech stay tune regulatory update pipeline development news today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
92,AMGN,mylan myl free report partner biocon announce fda have approve fulphila biosimilar amgen amgn free report neulasta news come significant boost mylan give potential market fulphilium accord neulasta generate sale month end mar biosimilar have be approve reduce duration febrile neutropenia fever other sign infection low count neutrophil type white blood cell patient treat chemotherapy certain type cancer notably be first fda approve biosimilar neulasta company plan launch biosimilar come week approval broaden mylan biosimilar portfolio fda approval be base comprehensive package analytical nonclinical clinical datum confirm biosimilar be highly similar brand drug datum demonstrated be clinically meaningful difference biosimilar product neulasta term safety purity potency company have earlier win fda approval ogivri biosimilar herceptin biosimilar be also approve additional country mylan biocon be collaborate develop biologic insulin product mylan own right product unite state canada japan australia new european union european free trade association country biocon have co exclusive right mylan product rest world march mylan biocon announce co develop biosimilar insulin glargine semglee have obtain approval european commission ec follow positive recommendation committee medicinal product human use chmp european medicine agency note mylan have widest portfolio generic biosimilar company have portfolio bioismilar insulin analog product mylan stock have gain last month compare industry decline share be trading news mylan effort develop biosimilar portfolio be impressive mylan also have partnership momenta pharmaceutical mnta free report development biosimilar company plan initiate patient clinical trial propose biosimilar regeneron pharmaceutical regn free report eylea first half trial be randomize double blind active control multicenter study patient diabetic macular edema compare safety efficacy immunogenicity reference drug eylea vascular endothelial growth factor vegf inhibitor have be approve treatment neovascular wet age related macular degeneration macular edema follow retinal vein occlusion diabetic macular edema diabetic retinopathy patient diabetic macular edema volatility unite state market be expect continue yet new approval position mylan better year ahead help combat decline epipen sale zack rankmylan carry zack rank hold see complete list today zack rank stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
93,AMGN,merck co inc mrk free report be steal limelight annual meeting american society clinical oncology asco chicago present practice change lung cancer datum pd inhibitor keytruda drug giant present encourage datum study evaluate drug advanced melanoma small cell lung cancer sclc patient share merck be monday response positive news year so far merck share have outperformed industry share have rise period industry decline year follow datum present pivotal advanced melanoma study show treatment keytruda lead long term survival benefit new analysis year datum phase iii keynote study show advanced melanoma patient remain progression free month complete year treatment keytruda year datum melanoma cohort phase ib keynote study demonstrated significant survival benefit advanced melanoma patient year os rate secondary endpoint study be patient previously untreated metastatic melanoma patient interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd overall population sclc patient overall response rate orr primary endpoint be patient tumor expressed pd orr be keytruda be be evaluate combination chemotherapy first line treatment patient extensive stage small cell lung cancer phase iii study keynote earlier asco merck present datum pivotal lung cancer trial keynote study evaluate keytruda monotherapy newly diagnosed lung cancer patient keynote study evaluate keytruda combination chemotherapy difficult treat squamous small cell lung cancer nsclc study show treatment keytruda lead improve survival further cement merck position lung cancer market be most lucrative oncology sector meanwhile keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc keytruda hold dominant position lung cancer be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo fact keytruda sale be gain particularly strong momentum first line lung cancer indication meanwhile keytruda be be evaluate several lung cancer study multiple setting stage disease monotherapy well combination therapy keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
94,AMGN,amgen inc amgn free report partner ucb sa announce fda have issue complete response letter crl biologic license application bla evenity romosozumab amgen be look get evenity approve treatment postmenopausal woman osteoporosis original bla include datum pivotal frame study however fda now require safety efficacy datum other pivotal phase iii study arch bridge be include application agency have ask resubmission bla be consider extension current review remind investor amgen have present datum arch fracture study romosozumab compare merck co inc mrk free report fosamax alendronate postmenopausal woman osteoporosis datum study show evenity romosozumab lead statistically significant superior fracture risk reduction fosamax alendronate be current standard care osteoporosis however cardiovascular side effect be observed study company then say safety datum arch datum now be consider regulatory review agree fda follow heart related safety issue emerge otherwise successful arch result amgen warn do not expect evenity be approve year crl thus do not come surprise so far year amgen share be better increase register zack categorize biom genetic industry frame study evaluate effectiveness evenity reduce risk new vertebral fracture month also compare effectiveness month evenity administration follow month xgeva placebo follow xgeva administration bridge study evaluate evenity older man osteoporosis history fragility fracture vertebral fracture study evaluate effectiveness evenity increase bone mineral density bmd lumbar spine effect bmd femoral neck total hip company be work fda be process re submit bla request datum separate press release amgen announce submission supplemental new drug application snda fda variation marketing application european medicine agency ema myeloma drug kyproli submission regulatory application be do expand drug label include overall survival os datum phase iii endeavor study remind investor kyproli twice weekly be already approve use combination dexamethasone celgene corporation celg free report revlimid lenalidomide dexamethasone base primary analysis progression free survival pfs datum aspire study submission include datum pivotal endeavor study compare kyproli velcade combination dexamethasone patient relapse refractory multiple myeloma datum demonstrated kyproli reduce risk death compare velcade increase median os month month vs month kyproli be first only therapy achieve superior os head head comparison current standard care velcade last week amgen announce os datum aspire study overall survival datum study show patient relapse refractory multiple myeloma live month longer treat kyproli revlimid dexamethasone krd compare treat revlimid dexamethasone rd median os month krd versus median os month rd kyproli be also be evaluate couple other study potential label expansion amgen be evaluate weekly dose regimen kyproli phase iii study arrow relapse refractory multiple myeloma patient datum be expect be amgen inc price consensus amgen inc price consensus amgen inc quotezack rankamgen currently have zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
95,AMGN,swiss pharmaceutical company novartis ag nvs free report be schedule report second quarter result jul look novartis share price movement year date show stock have outperformed zack classify large cap pharma industry share have rally compare industry gain last report quarter novartis deliver positive earning surprise company have post average positive earning surprise trail quarters let see thing be shape announcement factor impact quarternovartis operate segment innovative medicine pharmaceutical alcon sandoz generic new product cosentyx entresto boost top line cosentyx have be strong company have grab market share rival abbvie abbv free report humira amgen amgn free report enbrel cosentyx achieve blockbuster status record sale novartis have broaden oncology portfolio acquisition fda recent approval kisqali use combination inhibitor first line treatment postmenopausal woman hormone receptor positive human epidermal growth factor receptor negative hr advanced metastatic breast cancer further boost company oncology portfolio meanwhile fda have also recently approve label expansion zykadia first line treatment patient metastatic small cell lung cancer additionally novartis generic arm sandoz be make effort strengthen biosimilar portfolio company plan launch biosimilar major oncology immunology biologic key geography company be however face significant pricing pressure due delay launch glatopa mg be expect impact second quarter result also exclusivity key drug novartis portfolio be hurt company top line company blockbuster drug diovan be face stiff generic competition eu japan gleevec lose exclusivity feb eu dec thereby lead generic competition exforge be also face generic competition eu furthermore oncology drug be face new competition form immuno oncology therapy negative impact generic competition be expect impact sale company ophthalmologic division alcon continue face challenge due lower surgical equipment sale stiff competition face intraocular lens slowdown demand equipment purchase continue act dampener do not expect improve trend division sale be report quarter earning whispersour proven model do not conclusively show novartis beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp novartis be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank novartis currently carry zack rank rank be favorable company esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision novartis ag price ep surprise novartis ag price ep surprise novartis ag quotestock considerhere be stock healthcare sector want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
96,AMGN,amgen inc amgn free report partner ucb announce re submission biologic license application bla fda evenity romosozumab amgen be look get evenity approve treatment osteoporosis postmenopausal woman man increase risk fracture unite state evenity treat osteoporosis increase bone mineral density bmd also reduce risk fracture year date share amgen have increase industry decline remind investor first bla seek approval evenity same indication unite state be issue complete response letter crl fda july last year crl be issue due cardiovascular side effect observed arch study bla include datum only frame study fda then request resubmission application additional datum arch bridge study require second bla now include datum arch bridge study arch study evenity show statistically significant superior fracture risk reduction postmenopausal woman compare current standard care osteoporosis merck co inc mrk free report fosamax fda review potential evenity increase bmd well reduce risk fracture also cardiovascular safety signal arch study marketing application evenity be currently review europe japan amgen inc price amgen inc price amgen inc quote zack rank stock consideramgen have zack rank hold better rank stock same space be eisai co esaly free report chemocentryx inc ccxi free report lundbeck hluyy free report carry zack rank strong buy see complete list today zack rank stock here eisai earning estimate have moved past day past day stock have rally so far year chemocentryx loss share estimate have narrow cent past day company deliver positive earning surprise trail quarters average beat stock have rally so far year lundbeck earning share estimate have increase past day stock have rally so far year medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
97,AMGN,investor amgen inc amgn free report need pay close attention stock base move option market lately be jul put have highest imply volatility equity option today be imply volatility imply volatility show much movement market be expect future option high level imply volatility suggest investor underlie stock be expect big move direction other also mean be event come soon cause big rally huge sell however imply volatility be only piece puzzle putt together option trading strategy do analyst think clearly option trader be pricing big move amgen share be fundamental picture company currently amgen be zack rank buy medical biomedical genetic industry rank bottom zack industry rank last day zack consensus estimate current quarter have increase share give way analyst feel amgen right now huge imply volatility mean trade develop oftentimes option trader look option high level imply volatility sell premium be strategy many seasoned trader use capture decay expiration hope trader be underlie stock do not move much originally expect look trade option week very own dave bartosiak give top option trade check recent live analysis option trade nflx earning report completely free see here bartosiak trading netflix nflx earning option check embed video more detail
98,AMGN,expect johnson johnson jnj free report healthcare bellwether beat expectation report second quarter result jul market open last report quarter company deliver positive earning surprise performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson stock have depreciate year so far compare unfavorably decline record industry factor considerj sale improve first quarter be pharmaceutical segment continue positive momentum see second half consumer segment sale improve positive sale trend be expect continue second quarter fact be quite confident pharma segment continue perform better market year impact biosimilar sale key arthritis drug remicade sale consumer medical device segment be expect improve believe new product segment successful label expansion cancer drug imbruvica darzalex contribution recent acquisition continue drive top line growth core product stelara zytiga simponi simponi aria invega sustenna be expect contribute growth however past quarters revenue pulmonary arterial hypertension pah product add june acquisition actelion decline sequentially due lower sale tracleer outside unite state due generic competition be less likely pah revenue improve second competition be expect hurt sale remicade outside unite state please note market remicade partnership merck mrk free report however do not expect biosimilar entrant zytiga prezista risperdal consta invega sustenna unite state however full year guidance include impact generic procrit tracleer well remicade biosimilar regard newly launch tremfya say first quarter conference call uptake product have be strong drug record sale first quarter be expect be higher be report quarter expect discuss initial sale number erleada newly approve prostate cancerdrug second quarter conference call medical device segment sale be expect rise consistently vision care cardiovascular unit diabetes care unit however continue remain weakin consumer segment beauty counter product be expect do well domestic baby care product sale likely remain weak recent acquisition well new product be likely provide support however higher investment new product launch continue hurt profit earning whispersour proven model show be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp be zack consensus estimate stand share uncover best stock buy sell re report earning esp filter zack rank have zack rank combination zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other large drug biotech stock also have right combination element beat earning time amgen inc amgn free report earning esp zack rank company be schedule release result jul see complete list today zack rank stock here abbvie inc abbv free report have earning esp zack rank company be slate release result jul hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
99,AMGN,merck co inc mrk free report announce fda have grant priority review supplemental new drug application sbla pd inhibitor keytruda latest filing merck be look get keytruda approve treatment advanced hepatocellular carcinoma hcc form liver cancer patient previously treat systemic therapy sorafenib fda be expect give verdict nov sbla be base positive datum phase ii study keynote outcome demonstrated treatment keytruda monotherapy lead overall response rate orr patient advanced hcc datum also show complete response rate partial response rate result treatment keytruda datum be recently produce american society clinical oncology asco cancer symposium san francisco notably keytruda be already market several cancer indication include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer drug be first pd therapy gain fda approval be now already approve use different setting involve different tumor type have already secure fda nod new indication include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer drug be also be study more type cancer more trial include excess combination study merck be collaborate several company amgen amgn free report incyte glaxosmithkline gsk free report pfizer pfe free report separately evaluation keytruda combination other regimen keytruda be key top line driver merck logged sale first quarter sequentially year year sale continue be drive launch new indication globally company be carry keytruda development program be progress well several regulatory decision new indication unite state well europe expect label expansion approve widen patient population base further drive sale higher share merck have increase year date versus industry decline merck currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
100,AMGN,amgen inc amgn free report be look interesting pick technical perspective company be see favorable trend move average crossover front recently day move average amgn break day simple move average suggest short term bullish trend have already start take place stock have moved higher past week company currently have zack rank buy suggest now definitely be time candidate more bullishness especially be case investor consider have be happen amgn earning estimate revision front lately estimate have go lower past month compare higher consensus estimate have also moved higher too so give move estimate positive technical factor investor want watch candidate closely more gain future see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
101,AMGN,biogen inc biib free report be star performer friday trading session stock rally much close little lower rise day trade massive gain biotech firm come encourage phase clinical study datum alzheimer treatment final analysis month patient phase clinical study ban early alzheimer disease demonstrated statistically significant slow cognitive decline reduction amyloid beta accumulate brain company press release amyloid beta protein fragment be find brain patient suffering disease believe cause alzheimer be most common form dementia affect person worldwide accord alzheimer association currently be treatment disease way stop progression however food drug administration have approve medication treat symptom related memory loss language other thought process see healthcare etfs here such result mark important milestone company quest tackle alzheimer disease fact analyst welcome news first trial study drug be disappointing result risk environment many investor pull capital high growth high beta sector other large cap biotech stock also gain gilead gild free report celgene celg free report amgen amgn free report suggest investor be pin hope fast grow company see trading come day etf trading stock world also send biotech etfs space green day particular ishare nasdaq biotechnology etf ibb free report steal show climb follow more gain first trust amex biotechnology index fbt free report invesco dynamic biotechnology genome etf pbe free report vaneck vector biotech etf bbh free report fund provide exposure firm tracking nasdaq biotechnology index biogen take top spot ibb be most popular fund be biotech space aum expense ratio come ibb have zack etf rank hold high risk outlook read small cap biotech etfs be soar fund follow nyse arca biotechnology index measure performance company biotechnology industry be primarily involved use biological process develop product provide service hold security basket biogen occupy fifth position share charge bps annual fee have accumulate asset base have zack etf rank buy high risk outlook read sector etfs crushed year bull run fund provide exposure firm tracking dynamic biotech genome intellidex index biogen take top spot asset etf have manage asset base charge expense ratio have zack etf rank high risk outlook read pharma biotech etfs soar trump drug plan fund offer exposure large biotechnology corporation tracking mvis list biotech index here biogen be fifth firm accounting share bbh have amassed asset base charge bps fee year have zack etf rank strong buy high risk outlook lie ahead uptrend sector be likely continue year tax reform rise positive regulatory backdrop read top rank sector etfs buy new tax legislation have entice large pharmaceutical company bring offshore cash back home reduce tax rate instead prior repatriate money lead increase merger acquisition activity share buyback dividend additionally slower growth mature drug have also compel prominent biotechs acquire smaller one even hefty premium promising pipeline further trump most await plan lower drug price have add strength be not enough sector cyclical nature be advantage current market be ruffle trade war fear china unite state well geopolitical tension want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
102,AMGN,several major biotech stock rally friday biogen biib free report report positive result phase study ban therapy seek reduce toxic amyloid protein associate cognitive decline alzheimer disease share biogen be more afternoon trading hour thursday japan eisai co esaly free report partner ban development see gain nearly momentum be enough lift rest biotech space evidence ishare nasdaq biotechnology index fund ibb free report add biotech giant biogen celgene celg free report amgen amgn free report gilead gild free report have underperform broader nasdaq index past year industry likely need positive news spark optimistic trading speaking street real money column atlantic equity analyst steve chesney say investor finally be notice value effort company be believe innovation company biogen come report positive clinical result disease alzehimer imply probability success rest industry pipeline move little bit higher chesney tell street celgene share add touch intraday month high meanwhile amgen moved higher gilead gain more biogen latest test include patient early alzheimer disease company share positive result group period month nevertheless trial be still only phase challenge phase additional regulatory hurdle be still loom still biogen hope commercialize ban timely manner new product likely inspire positive analyst sentiment lift growth prospect come year past month zack consensus estimate biogen earning have drop share share mark year year growth early estimate have company earning peg share represent increase year project total biib be currently sporting zack rank hold medical biomedical genetic industry be sit bottom zack industry rank want more market analysis author make sure follow ryan_mcqueeney twitter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
103,AMGN,be pretty low key week biotech sector not too many major update key news gilead gild free report car therapy win chmp positive opinion keryx kerx free report plunge merger news recap important story gilead car therapy get positive chmp opinion gilead announce european medicine agency ema committee medicinal product human use chmp have issue positive opinion company marketing authorization application maa car therapy axicabtagene ciloleucel treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl more line systemic therapy axicabtagene ciloleucel chimeric antigen receptor cell car therapy modify patient own cell recognize attack cancer cell agency have grant prime status axicabtagene ciloleucel tentative approval be card ema generally take chmp recommendation account review maa note axicabtagene ciloleucel be approve fda october yescarta approval europe boost growth prospect therapy give market potential information provide company be estimate patient dlbcl be refractory have relapse more line therapy be eligible car therapy europe read more gilead car therapy get positive chmp opinion amgen announce result remicade biosimilar migraine drug amgen inc amgn free report announce result phase iii study evaluate efficacy safety biosimilar candidate abp brand drug remicade result confirm abp be inferior compare remicade base primary endpoint be assessment acr week acr american college rheumatology criterium be used measure effectiveness various arthritis medicine clinical study acr score mean person ra have improve remicade be approve treatment moderate severe rheumatoid arthritis chronic severe plaque psoriasis moderate severe crohn disease moderate severe ulcerative colitis psoriatic arthritis ankylose spondylitis note amgen have broad portfolio biosimilar be approve unite state be approve european union addition amgen announce encourage result open label extension ole study migraine drug aimovig result year study chronic migraine patient reinforce establish safety efficacy profile aimovig long term use moreover year interim analysis ongoing year study episodic migraine patient also reinforce long term safety tolerability aimovig amgen carry zack rank buy see complete list today zack rank strong buy stock here celgene report positive datum celgene corporation celg free report partner acceleron pharma xlrn free report announce positive top line result phase iii multus center study medalist evaluate efficacy safety versus placebo patient very low low intermediate risk myelodysplastic syndrome mds chronic anemia refractory intolerant ineligible treatment erythropoietin stimulating agent esa ring sideroblast positive require frequent red blood cell rbc transfusion study show achieve highly statistically significant improvement primary endpoint red blood cell rbc transfusion independence least consecutive week first week compare placebo candidate also meet key secondary endpoint demonstrate highly statistically significant improvement rbc transfusion independence least consecutive week first week study also achieve modify hematologic improvement erythroid iwg mhi meaningful secondary endpoint regulatory submission be plan unite state europe first half read more celgene meet primary endpoint study keryx plunge merger deal akebia share keryx inc plunge follow announcement definitive merger agreement akebia therapeutic inc akba free report company have agree combine stock merger form new fully integrate company focuse chronic kidney disease ckd call akebia therapeutic deal be expect close end keryx already have fda approve drug auryxia kitty akebia have late stage candidate pipeline however investor be not much impressed merger news share company fall read more keryx inks merger deal akebia share fall cara therapeutic rally positive result share cara therapeutic inc cara free report soar company announce positive top line datum adaptive phase ii iii trial intravenous iv cr patient undergo abdominal surgery iv form cr achieve statistical significance study primary endpoint pain relief hour auc period post surgery combine surgery mcg kg dose addition treatment same also result statistically significant reduction secondary endpoint incidence nausea vomit hour post surgery mcg dose respectively datum demonstrate overall benefit cr provide pain relief surgery type hour post surgery reduce post operative nausea vomit significant medical need post operative set brand name drug be korsuva company have earlier inked licensing deal fresenius medical care renal pharma ltd license worldwide right commercialize korsuva cr difelikefalin injection treatment chronic kidney disease biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex have gain past month celgene have lose vertex have gain see last biotech stock roundup here biotech stock roundup pbyi soar mack crash gild biktarvy get ec nod next biotech stay tune regulatory update pipeline development news today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
104,AMGN,abbvie inc abbv free report share have outperformed large cap pharma industry past month stock have return timeframe industry decline abbvie outperformance be backed decent quarterly result optimistic outlook stronger underlie business performance rest year positive pipeline news flow regulatory update be repute name pharmaceutical sector abbvie come existence jan abbott laboratory free report divest pharmaceutical divisionhere be reason invest stock favorable rank earning surprise record abbvie have zack rank buy see complete list today zack rank strong buy stock here have be consistently beating earning expectation earning surpass expectation last quarters average positive surprise company be expect record earning sale growth respectively meanwhile estimate increase respectively past day valuation look reasonable outperformance abbvie valuation look fairly reasonable currently abbvie currently have forward month price earning ratio be lowest level past year compare highest level median level past year be apparently upside left space also look inexpensive compare industry current well median ratio industry be respectively price earning forward month chart key drug humira go strong abbvie flagship product humira be approve several inflammatory indication rheumatoid arthritis humira continue witness strong demand trend launch drug new mechanism action competition indirect biosimilar currently approve indication humira sale have increase consistently backed robust demand trend product continue see strong growth dermatology market company expect humira sale approach biosimilar version humira be already approve fda settlement amgen amgn free report samsung bioepis biosimilar entry unite state be set thus delay direct biosimilar competition country strong oncology portfolio abbvie work rigorously expand accelerate presence oncology key drug oncology portfolio be imbruvica be currently approve quite few indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease several study imbruvica be ongoing evaluate drug alone combination different patient segment abbvie expect imbruvica peak sale more revenue abbvie have develop imbruvica partnership jnj free report abbvie be also study cancer drug venclyxto venclexta expand label address broader relapse refractory chronic lymphocytic leukemia cll patient population expand earlier line therapy broaden other hematologic malignancy multiple myeloma acute myeloid leukemia june regulatory application seek approval combination venclexta roche rhhby rituxan relapse refractory cll be approve unite state label expansion include broader patient population boost venclexta commercial potential meanwhile acquisition drugmaker stemcentrx add key late stage candidate rovalpituzumab tesirine rova abbvie portfolio rova be currently registrational study first second line small cell lung cancer sclc phase arm basket study rova neuroendocrine tumor be also ongoing promising pipeline abbvie have deep pipeline consist several interesting late stage candidate promising candidate include elagolix endometriosis risankizumab inflammatory disease depatux glioblastoma multiforme abbv early alzheimer disease progressive supranuclear palsy psp upadacitinib inflammatory disease company expect move tumor candidate clinical development several pivotal datum readout regulatory milestone be expect second half year include fda decision risankizumab elagolix regulatory application mavyret perform expectation abbvie week pan genotypic ribavirin free once daily hepatitis hcv treatment mavyret gain approval unite state eu canada japan mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor mavyret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history mavyret perform expectation first year launch record sale almost positive sale trend continue drug record sale first quarter less year market mavyret already command share unite state conclusion abbvie face share challenge form slower sale hcv drug potential biosimilar competition humira regular pipeline setback rise competition however believe abbvie be well position overcome headwind today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
105,AMGN,novartis nvs free report present positive result third phase iii trial breast cancer drug kisqali ribociclib advanced metastatic breast cancer annual meeting american society clinical oncology asco chicago phase iii trial monaleesa show kisqali faslodex significantly prolong progression free survival pfs compare faslodex alone postmenopausal woman hormone receptor positive human epidermal growth factor receptor negative hr advanced breast cancer median pfs be not reach subgroup patient take kisqali fulvestrant first line set however be estimate remain progression free median follow month moreover result monaleesa show consistent treatment benefit premenopausal woman hr advanced breast cancer regardless prior chemotherapy treatment advanced set remind investor kisqali be approve fda mar european commission august initial endocrine base therapy postmenopausal woman hr locally advanced metastatic breast cancer combination inhibitor novartis be currently discussion fda submit supplemental new drug application snda seek approval kisqali faslodex treatment postmenopausal woman hr advanced breast cancer company also present datum long term treatment free remission tfr study enestop enestfreedom patient philadelphia chromosome positive ph chronic myeloid leukemia cml chronic phase cp result open label phase ii trial enestop enestfreedom show sustain tfr patient treat front line second line tasigna nilotinib therapy week trial evaluate potential maintain molecular response mr stopping therapy eligible adult patient ph cml cp datum show durability safety tfr tasigna nearly patient lose tfr regain major molecular response restart therapy novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali continue boost sale approval kymriah acute lymphoblastic leukemia be major boost give potential car therapy space fda recently expand kymriah label boost sale last week novartis complete divestiture stake consumer healthcare joint venture glaxosmithkline plc gsk free report company also announce generic arm sandoz obtain positive opinion committee medicinal product human use chmp european medicine agency marketing authorization propose biosimilar abbvie abbv blockbuster drug humira generic division be seek approval propose biosimilar use indication brand drug include rheumatology dermatology tentative approval further boost generic division have be struggle competitive pricing last month sandoz obtain approval zessly biosimilar version remicade europe zessly approval sandoz now have approve biosimilar portfolio zessly be third biosimilar have be approve ec last month sandoz chmp have also recommend approval aimovig erenumab prevention migraine adult have least migraine day month drug be recently approve fda novartis amgen amgn free report be co commercialize drug unite state amgen have exclusive right drug japan novartis have exclusive right commercialize rest world novartis share have decline last month compare industry decline approval new drug bode well novartis company be face loss patent protection key drug zack ranknovartis carry zack rank hold see see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
106,AMGN,eli lilly company lly free report partner incyte corporation incy free report announce fda have approve mg dose olumiant baricitinib treat moderately severely active rheumatoid arthritis ra once daily oral jak inhibitor be approve monotherapy combination methotrexate treat adult patient inadequate response tumor necrosis factor tnf inhibitor therapy approval unite state be not much surprise consider fda advisory committee have recommend approval lower dose drug april however mg dose drug be not approve moreover drug label include box warning state risk serious infection malignancy thrombosis company expect launch drug end second quarter be available price lower lead tnf inhibitor approve ra include abbvie abbv free report humira amgen amgn free report enbrel other remind investor fda have issue complete response letter april new drug application seek approval olumiant request additional information determine most appropriate dose olumiant be already approve europe japan generate sale first quarter approval further boost sale drug lilly share price have increase year date compare industry decline approval be base datum ra beacon study evaluate olumiant combination disease modify rheumatic drug versus placebo datum show patient treat olumiant achieve improvement sign symptom ra compare placebo company conduct long term safety study olumiant ra patient part approval follow approval unite state incyte be now eligible receive milestone payment lilly expect record full second quarter olumiant be also be evaluate late stage study treatment atopic dermatitis eli lilly company price eli lilly company price eli lilly company quotelilly currently carry zack rank buy see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
107,AMGN,merck co inc mrk free report pd inhibitor keytruda rule annual meeting american society clinical oncology asco chicago drug giant present additional datum pivotal lung cancer study drug merck present additional datum pivotal keynote study patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent april merck have say such patient keytruda lead significant survival benefit compare platinum base chemotherapy latest release company say patient tps percent median overall survival os be month keytruda arm versus month chemotherapy arm pd tps percent patient population median os be month patient tps percent be month versus month month respectively chemotherapy alone also merck say risk progression death progression free survival pfs secondary endpoint be pd tps percent population time interim analysis be not statistically significant notably keytruda monotherapy be already market first line treatment patient metastatic nsclc tumor express pd protein level percent greater tps percent base datum keynote study os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market later year merck file regulatory application get os datum study include label keytruda merck also announce datum second interim analysis pivotallung cancer study keytruda phase iii keynote study evaluate keytruda combination carboplatin paclitaxel nab paclitaxel chemotherapy first line treatment metastatic squamous nsclc datum study show combination keytruda chemotherapy lead significant improvement os pfs regardless pd expression risk death os be reduce compare chemotherapy alone median os be month keytruda combination group versus month chemotherapy arm pfs improvement be nearly half patient keytruda combination group compare chemotherapy alone median pfs be month keytruda combination group versus month chemotherapy arm regulatory application include datum study be submit fda same time company have present datum first interim analysis keynote study say study meet pre specify secondary endpoint overall response rate orr early cohort participant asco company say orr be keytruda arm compare chemotherapy alonemetastatic squamous nsclc be difficult treat population account lung cancer case keytruda combination be approve treat difficult treat population lung cancer sale drug improve further year so far merck share have outperformed industry share have rise period industry decline keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further bolster demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo meanwhile keytruda be be evaluate several lung cancer study multiple setting stage disease monotherapy well combination therapy asco merck also present datum several combination study tyrosinekinase inhibitor lenvimaplus keytruda asco study evaluate lenvima keytruda combination different tumor type unresectable hepatocellular carcinoma hcc squamous cell carcinoma head neck scchn advanced renal cell carcinoma rcc advanced endometrial carcinoma ec demonstrated encourage orr well safety profile cancer combination remind investor march merck form deal japan eisai co develop commercialize lenvima monotherapy well combination keytruda several type cancer asco merck also present interim datum mid stage study keynote evaluate keytruda monotherapy first line treatment advanced clear cell rcc datum show keytruda arm orr primary endpoint be meanwhile sub group patient tumor expressed pd orr be keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
108,AMGN,teva pharmaceutical industry ltd teva free report confirm fda have extend action date biologic license application bla fremanezumab action date fremanezumab be now set september be previously set mid june be additional datum request fda fremanezumab be investigational therapy currently review fda quarterly monthly injection preventive treatment migraine adult be also review european union share teva increase year date industry decline remind investor fda accept review company bla fremanezumab december grant fast track designation candidate however january teva partner celltrion receive warning letter fda facility south korea follow inspection fill finish side facility thus delay approval drug facility manufacture active pharmaceutical ingredient apis fremanezumab teva thus state first quarter earning call do not expect receive fda approval bla fremanezumab mid june date company be constructive dialogue fda close collaboration partner celltrion recently note amgen amgn free report partner novartis nvs free report have receive fda approval pipeline candidate aimovig erenumab prevention migraine drug be first fda approve treatment specifically develop treat migraine block calcitonin gene related peptide cgrp receptor pharma giant eli lilly lly free report have cgrp candidate galcanezumab be review unite state decision galcanezumab be expect third quarter year teva carry zack rank hold see complete list today zack rank strong buy stock hereteva pharmaceutical industry ltd price teva pharmaceutical industry ltd price teva pharmaceutical industry ltd quotewall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
109,AMGN,revival ever volatile biotech sector have not live expectation so far performance biotech bigwig have be affected slowdown progress key drug competitive pressure have also adversely impact top line issue drug pricing competition remain headwind ace investor know biotech sector be lucrative market investment moreover be widely expect sector rebound second half year new drug approval have boost investor sentiment certain extent first half moreover approval drug boost respective company top line few be struggle decline sale legacy drug believe new drug approval label expansion exist high profile drug pipeline progress grow demand drug especially rare treat disease age population increase health care spending be factor positively impact performance owing competitive pressure quite few company have re-sort cost cut initiative turn propel bottom line somewhat meanwhile merger acquisition have picked pace sector slowdown mature product have force company eye lucrative acquisition bolster pipeline additionally increase activity be also be propel implementation new tax law have slash corporate tax rate new tax reform be also lure corporate bring back huge cash hold overseas time tax rate expect many more such deal latter half well industry lag shareholder returnseven macroeconomic condition look better price performance so far have not be impressive mentioned decline sale legacy drug pipeline setback have adversely impact price performance key biotech player turn have pull average industry zack biomedical genetic industry be stock group broader zack medical sector have underperform sector belong year date basis stock industry have collectively decline zack composite zack medical sector have rise decline year date respectively magnitude decline bigger company have more offset gain record small biotechnology company year date price performance biotech stock trading cheapgiven industry so far year valuation look cheap now valuation be tricky business biotech company take several year drug get regulatory approval so regular price multiple ratio do not provide fair picture biotech company more importantly company spend lot hence be more complex account such high expense uncertain future revenue stream be always uncertainty regard trial result fda decision get good sense industry relative valuation look price book ratio industry currently have price book ttm ratio be highest level past year well past year compare highest level median level past year believe investor dip enter market space also look inexpensive compare medical market large current well median price book ttm ratio medical sector be respectively price book trail month ttm compare zack composite too space look inexpensive current ratio median level same period be zack biomedical genetic industry respective ratio price book trail month ttm addition used price book ratio be standard multiple value company price free cash flow be good metric evaluate smaller biotech company do not have approve drug portfolio be more less dependent collaboration funding give high level be good metric judge biotech company even used price free cash flow adjust metric space look inexpensive compare medical market large current price free cash flow adjust ratio medical market be medical biomedical genetic industry be price free cash flow earning outlook look negativewhile ratio analysis show be solid value oriented path ahead not really consider current price level good entry point be convince reason predict rebound term reliable measure help investor understand industry prospect be earning outlook member company empirical research show company earning outlook significantly influence performance stock get good sense company earning outlook compare consensus earning expectation current financial year last year report number effective measure be magnitude direction recent change earning estimate trend earning estimate revision have not be favorable pipeline setback have lead many company slash outlook price consensus zack biomedical genetic industrylooking aggregate earning estimate revision appear analyst have start lose confidence group earning potential consensus ep estimate current fiscal year have be revise downward current fiscal year ep estimate revision zack industry rank indicate prospect group zack industry rank be basically average zack rank member stock zack biomedical genetic industry currently carry zack industry rank place bottom more zack industry research show top zack rank industry outperform bottom factor more proprietary heat map show industry rank have deteriorate considerably past week small biotechs promise long term growthwhile term outlook be not encourage long term year ep growth estimate zack biotech industry appear promising group mean estimate long term ep growth rate reach trough start quarter have revive thereafter reach current level also compare favorably zack composite highest level past year mean estimate long term ep growth rate important indication solid long term prospect smaller biotech company be improvement free cash flow yield image show consistence performance group free cash flow yield free cash flow yield zack biomedical genetic industry grow demand drug particularly target personalize therapy increase incidence chronic disease technological advancement evolve treatment regimen age population increase health care spending be factor keep sector track long term faster drug approval process propose removal outdated regulation push cost slowdown innovation also provide benefit bottom linethe biomedical genetic industry be continuously evolve largely volatile such scenario biotech company be expect adopt innovative business model invest new technology increase investment personalize medicine seek external partner collabora tor complementary strength sector be stumble challenge pose drug pricing issue pricing re imbursement pressure increase competition slowdown legacy product sale loss patent exclusivity key drug pipeline related setback however pipeline success innovative important therapeutic area cost cut share buyback new product launch increase activity appropriate utilization cash bring sector back track year industry currently have quite few stock sport zack rank strong buy buy here list few such stock have also be witness positive earning estimate revision amgen inc amgn free report be lead biotech company world consensus ep estimate base company have moved higher current year last day zack rank stock have rally so far year see complete list today zack rank stock here price consensus amgnani pharmaceutical inc anip free report have be see positive revision earning estimate last day analyst have revise estimate upward current year further zack rank stock have gain so far year price consensus anipillumina inc ilmn free report have be see positive revision earning estimate last day analyst have revise estimate upward current year further zack rank stock have surge year price consensus ilmn today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
110,AMGN,merck co inc mrk free report gain priority review yet supplemental biologic license application sbla pd inhibitor keytruda latest application merck be look get keytruda approve combination chemotherapy first line treatment metastatic squamous small cell lung cancer nsclc be difficult treat lung cancer patient population fda grant priority review sbla decision schedule oct sbla filing be base datum keynote study recently conclude annual meeting american society clinical oncology datum presentation pivotal lung cancer study result merck emerge winner annual key cancer event datum study show combination keytruda chemotherapy lead significant improvement overall survival os progression free survival regardless pd expression pd be protein present surface cell risk death os be reduce compare chemotherapy alone pfs improvement say reduction risk progression death be nearly half patient keytruda combination group compare chemotherapy alone datum be term practice change cnbc change way doctor look prescribe drug cancer patient further cement merck position lung cancer market be most lucrative oncology sector year so far merck share have rise industry decline short span time keytruda have become merck largest product be already approve use different setting involve different tumor type year have already gain approval new indication include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer label expansion approval drive sale keytruda future quarters treatment generate sale first quarter sequentially year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda be also be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte incy free report glaxo pfizer separately evaluation keytruda combination other regimen merck have zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
111,AMGN,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put amgen inc amgn free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front amgen have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend amgen current pe level put midpoint past year moreover current level be fairly high stock suggest be good entry point further stock pe also compare favorably industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point amgen have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead amgen stock term too ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now amgen have ratio be higher average come right now nonetheless see chart current level be well high stock particular past few year broad value outlookin aggregate amgen currently have zack value style score putt top stock cover look make amgen solid choice value investor other key metric make pretty clear too example cf ratio great indicator value come be far better industry average clearly amgn be solid choice value front multiple angle stock overall amgen be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give amgn zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be mostly trend higher current quarter have not see estimate revision past day full year estimate have see upward downward revision same time period result current quarter consensus estimate have rise past month full year estimate have inched see consensus estimate trend recent price action stock chart amgen inc price consensus amgen inc price consensus amgen inc somewhat favorable trend be stock have zack rank buy be look outperformance company term bottom lineamgen be inspire choice value investor be hard beat incredible lineup statistic front strong zack rank also indicate robust growth potential future however company prospect be constrain due adverse broader factor have sluggish industry rank bottom more industry fact past year industry have clearly underperform broader market see so value investor want broader factor turn name first once happen stock be compelling pick today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
112,AMGN,have be pretty hum first half biotech sector nasdaq biotechnology index nbi have lose so far performance biotech bigwig have be affected slowdown growth key drug competitive pressure continue impact sale nevertheless new drug approval boost investor sentiment key approval so far year include gilead science gild free report hiv regimen biktarvy vertex pharmaceutical symdeko tezacaftor ivacaftor ivacaftor treatment cystic fibrosis cf amgen aimoviq treatment migraine biomarin palynziq treatment other approval drug boost respective company top line few be struggle decline sale legacy drug increase amerger acquisition picked pace sector slowdown mature product have force company celgene celg free report eye lucrative acquisition bolster pipeline celgene acquire juno therapeutic gain traction promising car space february company acquire impact biomedicine add late stage candidate fedratinib highly selective jak kinase inhibitor pipeline alexion acquire sweden base wilson therapeutic add late stage candidate wtx pipeline be currently phase iii treatment wilson disease rare genetic disorder most recently akebia therapeutic inc keryx inc announce merger agreement company combine stock merger expect many more such deal latter half well lie ahead medical biom genetic sub industry carry zack industry rank place bottom zack industry issue drug pricing threat biosimilar loom large healthcare sector large expect better performance second half new drug approval label expansion exist high profile drug pipeline progress grow demand drug especially rare treat disease age population increase health care spending be factor positively impact performance choiceshere list few biotech stock backed zack rank strong buy buy increase share price look fairly place good run second half amgen inc amgn free report be lead biotech company world amgen newer drug prolium xgeva blincyto vectibix kyproli be perform well recent approval migraine candidate aimovig be huge boost biosimilar portfolio look solid too approve product amjevita mvasi deep pipeline amgen key drug be face biosimilar competition expect newer drug offset decline company have already undertake restructure plan lower cost aid bottom line amgen share have gain so far year decrease register industry amgen carry zack rank see complete list today zack rank stock here athersys inc athx free report be primarily focuse regenerative medicine company patented proprietary allogeneic stem cell product multistem cell therapy be lead platform product be currently advanced stage clinical development treat neurological condition cardiovascular disease inflammatory immune disorder certain pulmonary condition other condition current standard care be limit inadequate many patient particularly critical care segment stem cell therapy have gain lot investor attention late company such candidate be spotlight athersys carry zack rank share company have gain year so far industry decline celsion corporation clsn free report be company prospect look good company be focuse develop portfolio innovative cancer treatment include direct chemotherapy immunotherapy rna dna base therapy pipeline progress have be encourage so far thermodox company lead program be proprietary heat activate liposomal encapsulation doxorubicin be currently phase iii development treatment primary liver cancer other candidate pipeline include gen dna base immunotherapy localize treatment ovarian brain cancer celsion have platform technology development novel nucleic acid base immunotherapy other cancer dna rna therapy immunotherapy hold lot potential now company impressive pipeline progress be big positive investor celsion carry zack rank share company have return year so far industry decline aeglea biotherapeutic inc agle free report be clinical stage biotechnology company focus innovative human enzyme therapeutic patient suffering rare genetic disease cancer lead experimental therapy pegzilarginase be be evaluate treatment deficiency monotherapy arginine dependent cancer combination immune checkpoint inhibitor keytruda small cell lung cancer company be also develop pipeline additional product candidate target key amino acid other metabolite include homocysteine oxidized form homocystine target rare genetic disease well cysteine oxidized form cystine methionine cancer indication aeglea carry zack rank share company have return year so far industry decline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
113,AMGN,mylan myl free report india base lupin limit have enter partnership commercialize biosimilar amgen amgn free report blockbuster drug enbrel partnership agreement mylan commercialize lupin propose biosimilar europe australia new latin america africa most market asia note enbrel be approve treat certain autoimmune disease include rheumatoid arthritis psoriatic arthritis plaque psoriasis ankylose spondylitis accord brand sale approximately month end dec lupin successfully complete phase iii trial feb company have file product european medicine agency plan file product other jurisdiction assume approval biosimilar have great market potential give sale agreement lupin receive front payment company be entitle commercial milestone together equal share net profit product mylan have widest portfolio generic biosimilar addition biosimilar enbrel further boost company portfolio mylan biosimilar portfolio get boost recent fda approval fulphila biosimilar neulasta company have earlier win fda approval ogivri biosimilar roche rhhby free report herceptin other hand agreement mylan bode well lupin give former significant expertise global infrastructure mylan stock have lose year so far compare industry gain stock take hit earlier month company announce fda not approve abbreviated new drug application generic version glaxosmithkline gsk free report asthma drug advair diskus yet again mylan have receive major boost fda approval generic version copaxone mg company have more submission plan however generic business unite state continue experience pricing pressure volatility market be expect continue yet new approval position mylan better year ahead help combat decline epipen sale be also face supply constraint issue zack rankmylan carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
114,AMGN,amgen inc amgn free report announce positive top line result late stage study evaluate safety efficacy abp biosimilar version jnj free report merck mrk free report remicade compare reference product treatment moderate severe rheumatoid arthritis ra abp be tnf monoclonal antibody datum phase iii study show abp be inferior compare remicade base primary endpoint be assessment acr week acr american college rheumatology criterium be used measure effectiveness various arthritis medicine clinical study acr score mean person ra have improve datum show be clinically meaningful difference abp remicade amgen share have gain so far year decrease register industry amgen have biosimilar product portfolio amgen biosimilar version abbvie abbv free report ra drug humira amjevita be approve fda september eu march same indication humira amjevita be first biosimilar version humira be approve fda well amgen first biosimilar medicine be approve amgen begin selling amjevita most country eu year unite state january amgen have collaborate allergan worldwide development oncology antibody biosimilar medicine biosimilar version roche avastin mvasi be already approve unite state eu biosimilar version herceptin kanjinti be review unite state eu biosimilar version rituxan abp be late stage development several amgen own drug be face biosimilar competition biosimilar be already have negative impact key product neupogen neulasta eu unite state neupogen be already face biosimilar competition other key drug neulasta epogen start face biosimilar competition year entry additional biosimilar unite state have negative impact company top line sensipar also lose patent exclusivity march generic be launch soon amgen currently carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
115,AMGN,be time buy large cap stock stock screener criterium tracey top stock pick takeaway large cap stock amgn cma cvx hpq pcarpodcast zack comwelcome episode value investor podcastevery week tracey ryniec editor zack value investor portfolio service share top value investing tip stock pick last couple year large cap stock dominate headline dow nasdaq perform small cap index tide have recently turn small cap index russell be easily perform large cap have weaken trade tariff worry know mean value large cap now be buy opportunity screening large cap value stockstracey do basic screen find cheap large cap stock screen stock market cap forward be not always best metric find value screen be good enough basic indicator get cheap stock then add zack rank screening only zack rank strong buy buy stock have rank mean earning estimate be rise thing buy cheap stock whole new ballgame get cheap stock be also grow earning screen return stock isn too shabby tracey narrow favorite name cheap large cap stock buy now amgen amgn free report be mega cap biotechnology company have be favor now have forward reward investor patience dividend yield analyst be bullish earning rise comerica cma free report be texas base regional bank market cap april raise dividend now yield earning be expect pop low have peg ratio mean be value growth stock rare combination chevron cvx free report be largest oil company unite state market cap earning be expect jump thank increase price oil yet share trade forward just also get juicy dividend be not cut oil price plunge year hp inc hpq free report be bore technology company make notebook desktop printer look fundamental see attractive earning be expect rise fiscal analyst estimate be rise also really cheap forward just paccar pcar free report be global manufacturer light medium heavy duty truck brand kenworth peterbilt daf have market cap report record quarter first quarter order canada class truck be more double year prompt paccar raise full year industry sale range trading just earning be expect jump wall street have be ignore value stock couple year tide be turn suddenly cheap large cap stock be hold own case even beating return major index be buy big cap weakness find answer more week podcast wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
116,AMGN,investor interested stock medical biomedical genetic sector have probably already hear amgen amgn free report illumina ilmn free report stock offer value investor better bang buck right now ll need take closer look have find best way great value opportunity be pair strong zack rank great grade value category style score system zack rank be proven strategy target company positive earning estimate revision trend style score work grade company base specific trait amgen illumina be sporting zack rank buy right now system place emphasis company have see positive earning estimate revision so investor feel comfortable know stock have improve earning outlook be just piece puzzle value investor value investor also try analyze wide range traditional figure metric help determine company be undervalue current share price level style score value grade factor variety key fundamental metric include popular ratio ratio earning yield cash flow share number other key stat be commonly used value investor amgn currently have forward ratio ilmn have forward also note amgn have peg ratio popular figure be similar widely used ratio peg ratio also consider company expect ep growth rate ilmn currently have peg ratio notable valuation metric amgn be ratio be method compare stock market value book value be defined total asset total liability comparison ilmn have metric several other help amgn earn value grade ilmn have be give value grade amgn ilmn be impressive stock solid earning outlook base valuation figure feel amgn be superior value option right now
117,AMGN,novartis nvs free report announce generic arm sandoz obtain approval zessly biosimilar version johnson johnson jnj free report remicade europe zessly be approve use indication brand drug include rheumatoid arthritis adult crohn disease pediatric crohn disease adult ulcerative colitis pediatric ulcerative colitis ankylose spondylitis psoriatic arthritis plaque psoriasis approval european commission be base review comprehensive development program include analytical preclinical clinical datum confirm zessly match remicade term safety efficacy quality approval be card chmp have give positive opinion same march approval strengthen sandoz already strong biosimilar portfolio market biosimilar omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state rixathon biosimilar rituximab approve europe treat blood cancer immunological disease also approve eu riximyo duplicate marketing authorization erelzi biosimilar approve europe treat multiple inflammatory disease zessly approval sandoz now have approve biosimilar portfolio zessly be third biosimilar have be approve ec last month sandoz fda also approve biosimilar erelzi however launch be pending unite state due ongoing litigation amgen amgn free report note sandoz acquire biosimilar infliximab pfizer pfe free report february eu country norway iceland liechtenstein form european economic area novartis share have decline year compare industry fall however sandoz continue face pricing pressure sale be project decline upcoming quarters zack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
118,AMGN,month have go last earning report amgen inc amgn free report share have add time frame recent positive trend continue lead next earning release be amgn due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver amgen first quarter earning sale beatamgen report first quarter earning share beat zack consensus estimate earning increase year year drive higher product sale seasonally low expense lower tax rate lower share count total revenue quarter marginally surpass zack consensus estimate top line also register increase year year quarter detailtotal product revenue increase year quarter ex increase demand newer product prolium kyproli xgeva repatha blincyto be partially offset lower sale mature brand enbrel aranesp epogen neulasta neupogen due competitive pressure revenue amgen erythropoiesis stimulating agent esa aranesp decline prior year quarter due lower demand primarily due increase competitive pressure revenue other esa epogen decline due lower selling price owing newly negotiate contract davita inc neulasta revenue decline year period due lower demand unfavorable comparison last year first quarter increase competition pd other new cancer therapy be hurt demand neulasta however neulasta onpro kit body injector continue perform well command market share unite state neulasta sale amgen be optimistic see more global utilization onpro neupogen record decline sale due biosimilar competition unite state enbrel deliver revenue decline year quarter due lower selling price increase competition hurt demand unfavorable comparison last year first quarter benefit favorable change accounting estimate also hurt enbrel sale prolium revenue come year quarter due higher demand osteoporosis drug witness continue growth new patient start strong repeat injection rate drive year year growth xgeva deliver revenue year quarter mainly due higher demand sensipar mimpara revenue rise mainly ride higher demand inventory build probably due shift reimbursement medicare part part begin vectibix revenue come drive higher demand kyproli record sale year year drive increase demand robust uptake outside market europe majority sale come triplet regimen kyproli continue take market share velcade blincyto sale surge year period reflect rise demandrepatha generate revenue compare previous quarter drive volume growth call company say access repatha high risk cardiovascular patient have improve past few month outcome datum include repatha label other revenue decline due lower milestone payment receive first quarter parsabiv launch several market include unite state record sale quarter call company say unite state parsabiv have witness solid uptake midsize dialysis provider operate margin decreaseadjust operate margin decline basis point bps due higher operate cost sg spend increase higher investment support growth product well pre launch preparation aimovig bio similar product expense be almost flat compare year figure adjust tax rate be quarter point decrease first quarter amgen repurchase share worth first quarter plan repurchase stock second quarter guidanceamgen raise lower end sale earning guidance better expect first quarter earning revise tax outlook lead increase earning guidance company now expect revenue range compare previous prediction adjust earning be now anticipate range compare previous projection guidance assume approval launch migraine candidate aimovig amgevita also management seem quite confident repatha become important growth driver company inclusion outcome datum label nonetheless other continue competitive dynamic enbrel possible generic competition sensipar new competition neulasta aranesp be new challenge be account revenue guidance operate margin be expect be operate margin be expect be lower remain quarters due timing expense operate expense percent product sale be seasonally low first quarter ratio be expect be higher remain quarters year normalize level adjust tax rate be now estimate approximately lower past range reflect impact latest tax reform hope achieve improve cash position follow new tax law amgen plan invest approximately year capital expenditure have estimate be move then turn fresh estimate have trend downward past month have be revision higher current quarter compare lower amgen inc price consensus amgen inc price consensus amgen inc quotevgm scoresat time amgn have nice growth score be lag bit momentum front charting somewhat similar path stock be allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be equally suitable value growth investor momentum investor outlookestimate have be trend downward stock magnitude revision look promising notably amgn have zack rank hold expect line return stock next few month
119,AMGN,merck mrk free report announce pivotal study keynote evaluate keytruda chemotherapy combination first line metastatic squamous small cell lung cancer nsclc meet dual primary endpoint overall survival os progression free survival pfs drug combination chemotherapy demonstrated significantly longer os pfs versus chemotherapy alone merck supplemental biologic license application sbla seek continue approval keytruda combine eli lilly lly free report alimta platinum chemotherapy treat metastatic squamous nsclc be review unite state sbla be file base encourage datum phase iii study keynote company plan share datum keynote study fda expand sbla include patient squamous histology company present detailed datum keynote study upcoming annual meeting american society clinical oncology next month share merck be market trading news be announce year so far merck share have outperformed industry share have rise period industry decline notably keytruda be already approve monotherapy first line treatment patient metastatic nsclc tumor express pd protein level greater keytruda also have accelerate approval treat first line patient metastatic nsclc combination alimta chemotherapy merck remain focuse develop keytruda monotherapy combination therapy treatment lung cancer various mutation histology first line set bid further reinforce position segment lung cancer be attractive market be largest cause death cancer patient moreover keytruda be only immune oncology drug be approve treatment lung cancer first line set remind investor bristol myer bmy free report be also develop immune oncology drug opdivo first line lung cancer however keytruda early entry positive datum readout several phase iii study expand first line lung cancer patient bode well company top line note keytruda be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer meanwhile keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
120,AMGN,biotech space remain key area investor focus label expansion few prominent drug pipeline update few other amgen obtain fda approval prolium repatha exelixis also obtain approval lead drug cabometyx first line treatment kidney cancer europe recap important storieslabel expansion amgen drug be rain approval amgen amgn free report fda approve label expansion prolium treatment glucocorticoid induced osteoporosis giop man woman high risk fracture defined history osteoporotic fracture multiple risk factor fracture patient have fail be intolerant other available osteoporosis therapy notably be fifth indication proloa man woman high risk fracture receive systemic glucocorticoid therapy approval be base positive datum phase iii study show patient glucocorticoid therapy receive prolium have greater gain bone mineral density bmd compare receive active comparator risedronate last week amgen obtain approval label expansion repatha adult establish atherosclerotic cardiovascular disease myocardial infarction stroke peripheral arterial disease reduce cardiovascular risk lower low density lipoprotein cholesterol ldl level europe amgen partner novartis also obtain fda approval migraine drug aimovig erenumab read more amgen label expansion application prolium get fda nod amgen repatha gain eu nod include outcome datum amgen be zack rank hold stock see complete list today zack rank strong buy stock here exelixis get eu approval cabometyx exelixis exel free report announce partner ipsen have obtain approval european commission ec kidney cancer drug cabometyx cabozantinib mg mg mg first line treatment adult intermediate poor risk advanced renal cell carcinoma rcc european union approval broaden geographic reach drug market potential be significant first line treatment kidney cancer approval also trigger milestone payment exelixis ipsen approximately be recognize collaboration revenue first quarter payment be make ipsen next day read more exelixis cabometyx get eu nod first line kidney cancer regeneron announce datum dupixent regeneron regn free report partner sanofi sny free report announce pivotal phase iii trial evaluate dupixent treatment moderate severe atopic dermatitis adolescent age meet primary key secondary endpoint result show dupixent monotherapy significantly improve measure overall disease severity skin clear itch certain health related quality life measure new england journal medicine nejm also publish detailed result phase iii trial quest venture dupixent treatment moderate severe asthma result show dupixent significantly reduce risk severe asthma attack exacerbation improve lung function reduce dependence oral corticosteroid ocs drug also demonstrated significant improvement key primary secondary endpoint overall population quest venture study patient more severe type inflammatory asthma experience greatest benefit read more sanofi eczema drug dupixent succeed adolescent study company also announce datum evaluate cemiplimab potential treatment advanced small cell lung cancer nsclc phase be share american society clinical oncology asco annual meeting lexicon sanofi drug accept fda lexicon pharmaceutical inc lxrx free report partner sanofi announce fda have accept new drug application nda diabetes drug zynquista sotagliflozin zynquista be investigational oral dual inhibitor sglt sglt protein influence intestine kidney absorb eliminate sugar glucose result improve glucose control additional clinical benefit fda action date be expect be mar prescription drug user fee act pdufa earlier sanofi also submit regulatory application european medicine agency nabriva therapeutic announce positive datum lefamulin nabriva therapeutic plc nbrv free report announce positive top line result phase iii trial leap lefamulin evaluation pneumonia lefamulin trial evaluate safety efficacy day oral lefamulin compare day oral moxifloxacin adult patient moderate community acquire bacterial pneumonia cabp lefamulin meet fda primary endpoint inferiority compare moxifloxacin early clinical response ecr assessed hour follow initiation therapy intent treat itt patient population company plan file new drug application fda fourth quarter however stock fall investor be wary rate treatment emergent adverse event observed lefamulin arm biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock gilead gain past month celgene lose alexion gain see last biotech stock roundup here biotech stock roundup alxn vrtx post solid result gild disappoint next biotech stay tune regulatory update pipeline development news hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
121,AMGN,share allergan plc agn free report have decline report first quarter result apr fact so far year allergan share price have decline compare industry decline allergan first quarter result be strong beat expectation earning revenue earning rise year year drive higher revenue lower operate cost revenue increase organic basis exclude impact foreign exchange not only allergan raise earning sale guidance range also year allergan announce successful study result late stage study cgrp acute migraine candidate ubrogepant line extension study vraylar bipolar depression meanwhile infective drug avycaz gain fda nod third indication unite state gain eu approval mvasi allergan partner amgen amgn free report biosimilar version roche rhhby free report cancer drug avastin such strong quarterly performance positive regulatory update share pharma company continue decline year believe be allergan be face loss exclusivity several key product continue be concern analyst first generic version alzheimer treatment namenda xr estrace cream be launch first quarter blockbuster dry eye drug restasis allergan second best selling drug be expect be launch second quarter generic version delzicol be also expect be launch early second quarter allergan estimate product face loss exclusivity be worth sale product be expect decline significantly introduction generic first quarter conference call allergan management address disconnect business performance stock value allergan ceo brent saunder say be conduct strategic review business unlock shareholder value management discuss several strategic option include incremental aggressive share buyback divestiture certain asset concentrate more key therapeutic area splitting company make smaller bolt acquisition allergan have hire multiple financial advisor help evaluate different option regard activity allergan say large merger be unlikely make product pipeline acquisition strengthen key area therapeutic focus however saunder also say splitting company be not quite likely be outcome strategic review prove time consume complicate costly need see management optimism surround strategic option get reflect share price go forward allergan currently carry zack rank hold better rank drug biotech stock be ligand pharmaceutical lgnd free report zack rank strong buy see complete list today zack rank stock here ligand earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share have rally year date hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
122,AMGN,amgen inc amgn free report announce fda have approve supplemental biologic license application sbla seek label expansion prolium treatment glucocorticoid induced osteoporosis giop man woman high risk fracture have fail be intolerant other available osteoporosis therapy be fifth approve indication prolium approval be backed increase bone mineral density bmd achieve drug phase iii study drug be presently market unite state treatment postmenopausal woman osteoporosis high risk fracture well increase bone mass man osteoporosis high risk fracture share amgen be market trading follow news company share have rally year so far industry decline phase iii study evaluate prolium treatment giop patient man woman high risk fracture have fail be intolerant other available osteoporosis therapy compare allergan agn free report actonel risedronate study comprise patient group patient have receive glucocorticoid treatment less month prior study enrollment glucocorticoid initiate arm second patient have receive glucocorticoid treatment least month glucocorticoid continue arm arm glucocorticoid treatment be continue least month datum study show prolium increase lumbar spine bmd compare actonel glucocorticoid initiate arm lumbar spine bmd patient treat prolium glucocorticoid continue arm increase compare actonel glucocorticoid induced osteoporosis be most common form secondary osteoporosis serious condition be presently treat glucocorticoid treatment increase fracture risk first month treatment prolium now cater expand patient population drive sale higher prolium be key revenue generator amgen be witness market share gain unite state internationally competition generic other drug approve osteoporosis drug generate sale year year prolium face competition several drug especially generic version eli lilly lly free report evista alendronate merck mrk free report fosamax raloxifene novartis zometa zoledronate amgen inc price amgen inc price amgen inc quotezack rank amgen currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
123,AMGN,roche rhhby free report announce full result phase iii study haven evaluate haemophilium drug hemlibra emicizumab randomize multicenter open label phase iii study evaluate efficacy safety pharmacokinetic hemlibra prophylaxis versus prophylaxis episodic demand factor viii treatment patient hemophilia factor viii inhibitor trial result show hemlibra reduce treat bleed compare prophylaxis haven study haemophilium factor viii inhibitor moreover subset patient include study previously receive factor viii prophylaxis be standard care hemlibra reduce bleed compare prior therapy almost patient treat hemlibra week patient treat hemlibra week experience treat bleed compare none patient treat prophylaxis additionally result phase iii study haven show hemlibra administer week provide clinically meaningful control bleed person factor viii inhibitor remind investor fda grant breakthrough therapy designation hemlibra april patient hemophilia factor viii inhibitor base datum haven study drug be already approve fda routine prophylaxis prevent reduce frequency bleed episode adult child haemophilium factor viii inhibitor hemlibra be also approve european commission february routine prophylaxis bleed episode person haemophilium factor viii inhibitor roche hematology portfolio include approve drug mabthera rituxan gazyva gazyvaro tecentriq venclexta note roche be develop venclexta collaboration abbvie abbv free report company be jointly commercialize drug unite state abbvie be commercialize drug outside unite state well approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar roche stock have lose last month compare industry gain novartis nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
124,AMGN,paypal holding inc pypl free report share jump news company acquire european technology company izettle share amgen inc amgn free report rise news company winning food drug administration approval migration prevention drug aimovig trade desk inc ttd free report share increase report first quarter earning share surpass zack consensus estimate shareshare cbs corporation cbs free report surge news company board be voting issue special dividend reduce voting power redstone family
125,AMGN,migraine be serious neurological disease have significant effect patient daily life patient suffer debilitating pain physical impairment fear next attack be estimate patient frequent migraine attack lose more half life disease last week amgen amgn free report partner novartis nvs free report announce fda approval drug aimovig erenumab prevention migraine aimovig be first fda approve drug specifically develop treatment migraine block calcitonin gene related peptide cgrp receptor approval be base positive datum several mid late stage study drug achieve significant reduction monthly migraine day use acute migraine medication compare placebo datum study moreover aimovig show time higher probability reduce migraine day half compare placebo patient episodic migraine patient fail prior treatment approval aimovig investor focus have shift cgrp drug candidate treatment migraine eli lilly lly free report teva pharmaceutical industry limit teva free report respective cgrp candidate galcanezumab fremanezumab be review unite state inc aldr free report be also develop cgrp candidate eptinezumab treat migraine first quarter regulatory filing state be approximately person live serious neurological disease unite state alone include episodic chronic migraine migraine be rank top cause year live disability worldwide however traditional preventive therapy have tolerability limitation several side effect represent huge unmet need new cgrp therapy aimovig other review candidate cnbc article regulatory filing migraine market be worth next few year amgen have price aimovig once monthly mg single use prefil sureclick autoinjector annually price certainly pinch patient thus acceptance drug remain be see however insurance coverage aimovig copay program significantly bring cost moreover potential approval galcanezumab fremanezumab come month increase competition put downward pressure pricing look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
126,AMGN,week astrazeneca azn free report novartis nvs free report eli lilly lly free report announce regulatory pipeline update line extension market drug astrazeneca asthma drug fasenra fail meet primary endpoint late stage study evaluate expand indication chronic obstructive pulmonary disease copd lilly migraine candidate galcanezumab meet same late stage study evaluate indication prevention episodic cluster headache novartis multiple sclerosis ms drug gilenya gain fda approval use adolescent cgrp antibody aimovig also gain fda approval prevention migraine zoetis zts free report lilly announce acquisition deal recap week most important storieslilly buy small cancer biotech lilly have agree buy early phase oncology asset ak aurka pharma expand oncology pipeline lilly make upfront payment acquire share aurka pharma be lilly second cancer acquisition less week last week lilly have announce cash deal tobuy immuno oncology biotech armo bioscience read more eli lilly buy aurka pharma expand cancer pipeline development migraine candidate galcanezumab meet primary endpoint late stage study evaluate indication prevention episodic cluster headache galcanezumab be already review unite state migraine prevention decision expect third quarter year however separate phase iii study evaluate galcanezumab patient chronic cluster headache do not meet primary endpoint read more eli lilly cluster headache candidate succeed phase iii zoetis buy abaxis zoetis announce definitive agreement buy california base abaxis be lead global provider veterinary point care diagnostic instrument approximately share cash deal be aim enhance zoetis presence animal health diagnostic market diagnostic category be fast grow portion animal health industry have grow compound annual growth rate approximately last year read more zoetis inks deal acquire abaxis novartis aimovig get fda nod novartis partner amgen amgn free report gain fda approval cgrp antibody aimovig prevention migraine fda approval aimovig be now first only fda approve treatment migraine work block calcitonin gene related peptide receptor cgrp play critical role migraine attack meanwhile lilly teva pharmaceutical industry ltd teva free report be also await fda approval cgrp migraine candidate galcanezumab fremanezumab year novartis ms drug gilenya gain fda approval treatment child adolescent age relapse form multiple sclerosis approval expand patient population boost sale gilenya drug record sale first quarter represent year year growth rate constant currency basis read more novartis multiple sclerosis drug get fda nod adolescent astrazeneca fasenra fail meet endpoint phase iii copd study astrazeneca respiratory biologic medicine fasenra benralizumab fail meet primary endpoint late stage study evaluate new indication severe copd fasenra be already approve unite state eu japan add maintenance treatment patient severe eosinophilic asthma top line result pivotal phase iii galathea study show treatment fasenra do not result statistically significant reduction exacerbation compare placebo patient moderate very severe copd read more astrazeneca asthma drug fasenra fail copd study astrazeneca announce weak first quarter result miss zack consensus estimate earning sale due lower sale cholesterol drug crestor maintain previously issue outlook pfizer biosimilar retacrit get fda nod pfizer pfe free report retacrit be biosimilar version anemia drug amgen epogen jnj free report procrit gain fda approval indication reference product include treatment anemia due chronic kidney disease ckd pfizer already market biosimilar europe last year fda advisory committee have recommend approval retacrit read more pfizer get fda nod amgen anemia drug biosimilar fda name drugmaker block approval generic fda issue list company week say be used certain gaming tactic delay generic competition market drug fda say company be prevent generic player obtain necessary sample brand product be require secure approval generic drug inability secure such sample slow approval process list include big name shire novartis mylan astrazeneca teva biomarin gilead bayer other fda decision publish such list be part broader effort congress encourage approval low cost generic drug nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week decline bristol myer rise most past month glaxo gsk free report have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup lly buy cancer biotech azn roche announce update next pharma world watch fda decision many pipeline drug line extension market product month more stock news be bigger iphoneit become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
127,AMGN,amgen amgn free report partner novartis nvs free report announce fda have approve pipeline candidate aimovig erenumab prevention migraine drug be first fda approve treatment specifically develop treat migraine block calcitonin gene related peptide cgrp receptor aimovig be available pre filled self administer autoinjector sureclick once monthly mg dosage aimovig be review eu amgen share be hour trading follow announcement year date amgen share have increase compare industry decline aimovig approval be backed positive datum several mid late stage study drug significantly reduce monthly migraine day use acute migraine medication versus placebo study datum phase iiib liberty study episodic migraine patient fail prior treatment show aimovig have time higher probability reduce migraine day half compare placebo new treatment option specifically develop treat migraine be make way suggest potential demand aimovig amgen have price drug once monthly mg single use prefil sureclick autoinjector annually expect drug boost amgen top line go forward remind investor eli lilly lly free report teva pharmaceutical industry limit teva free report also have cgrp candidate galcanezumab fremanezumab respectively be review unite state decision galcanezumab be expect third quarter yeara fda decision fremanezumab be expect june however earlier month teva inform do not expect get fda approval fremanezumab pdufa date june be teva manufacturing partner fremanezumab celltrion make api receive warning letter fda year delay approval drug however teva expect fremanezumab be approve launch end year amgen inc price amgen inc price amgen inc quoteamgen currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
128,AMGN,dow snap record streak win traverse turbulent week trade war related concern continue weigh investor president trump express doubt success upcoming negotiation china additionally spike year treasury yield also spook market spark fresh inflationary concern such fear be also stoke encourage retail sale number last week dow increase last friday mark seventh straight session gain be blue chip index longest winning streak nov notably healthcare stock be initially follow news president trump unveil new healthcare plan however broad market re-cover later announcement be not follow stringent measure low inflation datum weak dollar also boost investor confidence equity index gain last week be blue chip index largest weekly gain march energy tech stock be major driver stock market oil price first rally last wednesday wake unite state decision exit iran nuclear deal increase fuel rally energy stock once again meanwhile apple inc aapl free report share jump celebrity investor warren buffett berkshire hathaway brk free report announce have buy share apple first quarter consequently share apple rise time high dow index gain monday increase eighth consecutive session marked blue chip index longest winning streak sep stock gain first trading day week trade fear subside president donald trump tweet sunday be consider relax stringent sanction have be impose chinese tech giant zte corp last month index lose tuesday yield year treasury note hit year high turn occur retail sale increase consecutive month raise inflationary fear moreover commerce secretary wilbur ross ambassador china terry branstad comment trade tension unite state china be far index gain wednesday reverse previous day broad base decline particular retail stock gain strong sale datum april macy inc free report first quarter earning report moreover russell benchmark index small cap stock hit time high overall most stock close green investor appear ignore concern regard rise yield government bond geopolitical tension index lose thursday president trump comment trade talk unite state china not be successful trump state be successful tend doubt ahead second round trade talk country meanwhile decline technology share negate gain make energy stock component move index home depot inc hd free report post fiscal first quarter adjust earning share escalate record year quarter figure also beat zack consensus estimate home depot have zack rank hold net sale grow year quarter however top line lag zack consensus estimate include impact adoption asu pertain revenue recognition home depot expect sale growth nearly fiscal accompany increase comp further company estimate earning share fiscal be nearly read home depot earning beat estimate sale lag walmart inc wmt free report first quarter fiscal earning share come ahead zack consensus estimate surge year year include time item earning slump cent share walmart have zack rank total revenue advanced surpass zack consensus estimate nearly currency neutral basis total revenue advanced consolidated operate income slip approximately operate income margin contract basis point constant currency basis operate income decline roughly read walmart earning sale jump online sale cisco system csco free report deliver third quarter fiscal gaap earning cent share come ahead zack consensus estimate penny further figure rise year quarter revenue increase year year marginally surpass zack consensus estimate fourth quarter fiscal revenue be expect grow year year basis zack consensus estimate revenue be peg represent year year growth gaap earning be anticipate cent cent share zack consensus estimate earning be cent translate year year growth stock have zack rank buy see complete list today zack rank strong buy stock here pfizer inc pfe free report announce fda have grant approval retacrit biosimilar version blockbuster drug amgen inc amgn free report epogen johnson johnson jnj free report procrit zack rank pfizer already market biosimilar europe retracrit be indicated treatment anemia due chronic kidney disease anemia due hiv infected patient anemia due effect concomitant chemotherapy anemia post chemotherapy drug be also approve reduction allogeneic red blood cell rbc transfusion patient undergo elective cardiac nonvascular surgery retacrit become first biosimilar erythropoiesis stimulating agent approve unite state procrit generate sale epogen sale be sale number suggest bright prospect retacrit be lower cost alternative treatment option patient used procrit epogen read pfizer get fda nod amgen anemia drug biosimilar general electric company ge free report power service business recently enter agreement saudi cement upgrade latter ge gas turbine hofuf plant base kingdom saudi arabia general electric have zack rank deal ge power upgrade turbine install advanced gas path agp solution enable saudi cement boost power output efficiency notably deal mark first installation ge power agp technology solution boost power generation productivity cement industry globally currently enable saudi cement boost power output total turbine read general electric upgrade saudi cement ge gas turbine jpmorgan chase co jpm free report want set joint venture brokerage china company be seek approval security regulator country jpmorgan have zack rank gao li spokeswoman china security regulatory commission recently state morgan broke hong kong ltd unit jpmorgan submit application acquire stake chinese security venture li also inform application be efficiently review regulator move bank come china pledge open financial market foreign investor april chinese authority release guideline give permission foreign company own maximum local security joint venture read jpmorgan seek china approval joint venture performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlookmarket have endure volatile week marked trade inflation related concern even encourage economic report such strong retail sale number have only serve fuel inflationary fear gain have only come investor have choose ignore concern next week feature crucial economic datum housing durable order encourage news front help propel stock higher day ahead more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
129,AMGN,biotech major amgen inc amgn free report gain approval european commission ec regulatory application seek approval include datum cardiovascular outcome study fourier european label pcsk inhibitor repatha label expansion application repatha get approval prevent heart attack stroke coronary lower ldl bad cholesterol level adult establish atherosclerotic cardiovascular disease europe amgen share have decline so far year be still better decrease register industry fourier outcome datum be already include label repatha follow fda approval december last year datum phase iiifourier study present last year reveal significant reduction myocardial infarction stroke treatment repatha compare current best therapy alone repatha significantly reduce risk hard mace heart attack stroke cardiovascular death compare standard treatment statin therapy individual component risk heart attack stroke coronary be reduce respectively uptake repatha gain fda approval august have not be encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical inc regn free report also face similar issue pcsk inhibitor praluent priority amgen right now be improve patient access repatha outcome datum fourier be key commercial success repatha broaden use drug cardiovascular indication approve be include repatha label patient access repatha be expect improve fact first quarter repatha generate revenue compare previous quarter drive volume growth call management say access repatha high risk cardiovascular patient have improve past few month fourier outcome datum include repatha label datum now also approve be include european label repatha expect sale increase further patient access medicine improve amgen say be work european payer remove prescribe barrier improve repatha affordability expand access drug amgen currently carry zack rank hold better rank biotech stock be ligand pharmaceutical incorporate lgnd free report zack rank buy see complete list today zack rank strong buy stock here ligand earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share have rally year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
130,AMGN,pfizer inc pfe free report announce fda have grant approval retacrit biosimilar version blockbuster drug amgen inc amgn free report epogen johnson johnson jnj free report procrit pfizer already market biosimilar europeretracrit be indicated treatment anemia due chronic kidney disease anemia due hiv infected patient anemia due effect concomitant chemotherapy anemia post chemotherapy drug be also approve reduction allogeneic red blood cell rbc transfusion patient undergo elective noncardiac nonvascular surgery retacrit become first biosimilar erythropoiesis stimulating agent approve unite state procrit generate sale epogen sale be sale number suggest bright prospect retacrit be lower cost alternative treatment option patient used procrit epogen however procrit already face biosimilar competition drug novartis nvs free report binocrit europe pfizer share have decline so far year compare favorably fall record industry approval be support comprehensive datum package demonstrated high level similarity retacrit epogen procrit last year fda sadvisory committee have recommend approval retacritpfizer have enter collaboration switzerland base pharma retacrit certain channel retacrit be third approve biosimilar pfizer commercial portfolio include inflectra biosimilar version remicade company be also develop different biosimilar candidate several mid late stage study trump administration continue rally exorbitantly high drug price fda have be actively approve generic biosimilar expensive brand drug bid bring price competition see several such approval expect trend continue year pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
131,AMGN,eli lilly company lly free report pipeline candidate galcanezumab meet primary well secondary endpoint late stage study evaluate prevention episodic cluster headache study show treatment galcanezumab mg once monthly lead statistically significant difference reduction weekly cluster headache attack compare placebo week month treatment period primary endpoint meanwhile week statistically significantly greater percentage patient galcanezumab arm achieve least reduction weekly cluster headache attack secondary endpoint compare placebo safety tolerability be consistent previous study evaluate galcanezumab migraine prevention lilly say work regulatory authority determine best path forward candidate however separate phase iii study evaluate galcanezumab patient chronic cluster headache do not meet primary endpoint accord lilly press release chronic cluster headache represent cluster headache case episodic cluster headache account cluster headache market galcanezumab be already review unite state migraine prevention decision expect third quarter year galcanezumab used calcitonin gene related peptide cgrp antibody prevention migraine amgen amgn free report partner novartis nvs free report aimvog erenumab teva pharmaceutical industry limit teva free report fremanezumab have be develop chronic episodic migraine prevention used cgrp mechanism be also review unite state fda decision fremanezumab be expect june however earlier month teva inform do not expect get fda approval fremanezumab pdufa date june be teva manufacturing partner fremanezumab celltrion make api receive warning letter fda year delay approval drug however teva expect fremanezumab be approve launch end year meanwhile fda action date amgen cgrp antibody aimovig prevention migraine be amgen look confident gain fda approval make first medicine cgrp class get approval year date lilly share have decline compare industry decline lilly currently carry zack rank buy see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
132,AMGN,radius health inc rdus free report report loss share first quarter narrower zack consensus estimate loss wider year period loss increase general administrative expense lead wider anticipate net loss year year company report sale tymlos abaloparatide surpass zack consensus estimate quarter detailtymlos sale increase fourth quarter radius health receive fda approval tymlos april treatment postmenopausal woman osteoporosis high risk fracture company begin shipment drug wholesaler end tymlos continue gain traction approximately cover life coverage commercial plan tymlos market share reach approximately new anabolic patient start anabolic therapy nbrx total anabolic osteoporosis market base patient month therapy trx pmot first quarter research development expense report quarter be year year general administrative expense report quarter increase due increase incompensation travel related expense increase selling general administrative expense pipeline company be develop formulation abaloparatide sc abaloparatide transdermal radius health suffer setback committee medicinal product human use european medicine agency ema adopt negative opinion radius health marketing authorization application abaloparatide sc march consequently april radius health submit request re examination chmp opinion radius health initiate phase iii study atom abaloparatide treatment osteoporosis male abaloparatide sc treatment osteoporosis man successful form basis supplemental nda seek expand drug label randomize double blind placebo controlled trial enroll approximately man osteoporosis high risk fracture study include primary endpoint change lumbar spine bone mineral density month versus placebo specialize high resolution imaging bone structure subset study participant estimate male osteoporosis be estimate account approximately total treat osteoporotic patient population quarter radius health finalize development pathway abaloparatide patch regulatory alignment fda enter scale commercial supply agreement company meanwhile radius health conduct single randomize comparator controlled phase iii trial elacestrant third line monotherapy approximately patient positive negative advanced metastatic breast cancer feedback fda ema result be expect support application global marketing approval positive patient study be randomize receive elacestrant investigator choice approve hormonal agent primary endpoint study be progression free survival study be plan be initiate second half phase study evaluate safety maximum tolerate dose rad patient hormone receptor positive locally advanced metastatic breast cancer be currently enrolling radius health expect provide update rad development program end company narrower expect loss first quarter be encourage sale tymlos be pick radius health see increase total number physician prescribe tymlos first quarter compare fourth quarter tymlos share new prescription physician increase fourth quarter first quarter price drug be increase implement feb go forward radius health expect tymlos capture average anabolic osteoporosis market anabolic market unite state be expect increase volume radius health share have rally last month compare industry gain osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen amgn free report prolium zack rank stock considerradius health currently carry zack rank sell better rank stock healthcare sector be exelixis exel free report currently sport zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate increase cent cent past day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
133,AMGN,ligand pharmaceutical incorporate lgnd free report report first quarter adjust earning share significantly year figure cent bottom line also beat zack consensus estimate share company have outperformed industry year date stock have rally versus industry decrease total revenue quarter review surge year year moreover top line surpass zack consensus estimate quarterly revenue be report quarter approximately year year royalty comprise royalty sale novartis nvs free report promacta amgen amgn free report kyproli spectrum pharmaceutical sppi free report evomela new accounting standard asc adopt start year first quarter royalty be compare second quarter royalty due timing revenue recognition royalty second quarter be license fee milestone other revenue be compare year quarter mainly owing upfront payment receive licensing ligand glucagon receptor antagonist gra program other milestone receive material sale increase year quarter ride timing captisol purchase clinical commercial use research development expense decline backed lower spending gra program partner first quarter moreover general administrative expense rise year year pipeline other updatesligand license gra program lgd now name rvt roivant science term agreement ligand receive upfront license fee be entitle receive additional milestone payment tiered royalty range low double digit mid teen top tier apply annual net sale roivant be responsible cost related program ligand also announce worldwide license agreement venbio partner fer pharmaceutical glenmark pharmaceutical use omniab platform technology fully human antibody additionally ligand initiate internally funded program develop proof concept contrast agent reduce renal toxicity diagnostic imaging procedure development program leverage ligand captisol technology well intellectual property obtain acquisition verrow pharmaceutical cash earn out company make significant progress several lead partner asset melinta therapeutic launch newly approve intravenous baxdela unite state treatment adult patient acute bacterial skin skin structure infection cause designate susceptible bacterium partner make regulatory filing new european union argentina sage therapeutic file new drug application intravenous brexanolone treatment postpartum depression retrophin initiate phase iii study sparsentan treat focal segmental reaffirm previous guidance expect full year revenue be approximately include royalty nearly material sale roughly license fee milestone almost potential additional license fee milestone adjust earning be estimate share zack rank ligand be zack rank strong buy stock see complete list today zack rank stock here ligand pharmaceutical incorporate price consensus ep surprise ligand pharmaceutical incorporate price consensus ep surprise ligand pharmaceutical incorporate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
134,AMGN,radius health inc rdus free report be schedule report first quarter result radius health inc price consensus ep surprise radius health inc price consensus ep surprise radius health inc quote radius health have disappointing track record company have report wider expect loss trail trail quarters average negative earning surprise last report quarter increase general administrative expense lead wider anticipate net loss year year radius health share have lose year industry gain let see thing be shape quarter review factor playradius health develop therapeutic treatment osteoporosis oncology endocrine disease company lead drug tymlos be approve unite state april drug be approve treat postmenopausal woman osteoporosis high risk fracture defined history osteoporotic fracture multiple risk factor fracture drug also be used patient have fail be intolerant other available osteoporosis therapy company report sale tymlos abaloparatide fourth quarter hence expect investor focus uptake drug upcoming earning call osteoporosis market unite state have great potential approximately postmenopausal woman suffer osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly forteo amgen amgn prolium meanwhile company marketing authorisation application eladyno abaloparatide sc europe treatment postmenopausal woman osteoporosis be review however scientific committee european commission committee medicinal product human use chmp give negative trend vote benefit risk balance marketing authorization application maa abaloparatide sc oral explanation chmp therefore adopt negative opinion same company be plan get abaloparatide sc approve treatment osteoporosis postmenopausal woman increase risk fracture radius health plan seek re examination chmp opinion december chmp issue third day list outstanding issue inform company intend refer maa scientific advisory group additional advice company have earlier issue second day list outstanding issue delay get approval europe be disappointing give market potential meanwhile company present positive datum elacestrant breast cancer december fda also grant fast track designation elacestrant october february radius health obtain scientific advice ema regard potential single arm monotherapy phase ii trial elacestrant patient positive negative advanced metastatic breast cancer base feedback ema fda company conduct single randomize controlled phase ii trial elacestrant third line monotherapy approximately patient positive negative advanced metastatic breast cancer hence expect management throw more light pipeline progress earning whispersour proven model do not show radius health be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp radius health be currently peg be most accurate estimate be peg loss zack consensus estimate stand loss uncover best stock buy sell re report earning esp filter zack rank radius health have zack rank sell note caution stock zack rank strong sell go earning announcement stock considerhere be pharma company consider model show have right combination element deliver earning beat quarter gw pharmaceutical plc gwph free report be expect report quarterly result company have earning esp zack rank see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
135,AMGN,spectrum pharmaceutical inc sppi free report incur loss cent share first quarter narrower zack consensus estimate loss cent year quarter loss cent share however adjust loss come cent wider year loss cent quarterly revenue come year quarter top line also beat zack consensus estimate spectrum pharma share have underperform industry so far year stock have lose industry decline quarter detailtotal product sale come year year sale be generate market product fusilev folotyn zevalin marqibo beleodaq evomela evomela be face pricing pressure due generic entry license fee service revenue be prior year quarter adjust research development expense be year quarter adjust selling general administrative spending be due higher legal fee related termination former chief executive officer company be focuse development pipeline candidate poziotinib rolontis outlook company increase revenue guidance range previously company expect have enough liquid fund continue operation pipeline updatespectrum pharma be evaluate poziotinib separate phase ii study treatment lung cancer phase ii study breast cancer april company publish result analysis first patient lung cancer study be conduct md anderson candidate achieve objective response rate patient egfr exon insertion mutation company be plan evaluate poziotinib several solid tumor exon mutation february company announce successful completion phase iii advance study rolontis candidate demonstrated inferiority amgen inc amgn free report neulasta improve duration severe neutropenia patient breast cancer have complete enrolling patient additional phase iii study recover datum study be include biologic license application bla advance study datum be file fda company expect file bla rolontis fourth quarter spectrum pharmaceutical inc price consensus ep surprise spectrum pharmaceutical inc price consensus ep surprise spectrum pharmaceutical inc quotezack rank stock pharma carry zack rank hold couple better rank stock biotech sector be ligand pharmaceutical lgnd free report protagonist therapeutic ptgx free report stock sport zack rank strong buy see complete list today zack rank stock here ligand earning share estimate moved remain stable last day company deliver positive earning surprise trail quarters average beat company share have rally year date protagonist therapeutic loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
136,AMGN,biotech space remain key area investor focus several bigwig announce quarterly result alexion alxn free report report solid result gilead gild free report report dismal number other development week regeneron regn free report sanofi announce plan lower price praluent amgen amgn free report receive positive opinion prolium recap important story progress report company alexion gilead vertex vrtx free report other report first quarter result last trading session alexion vertex deliver solid result quarter gilead earning sale miss estimate wider expect decline hcv franchise follow result alexion raise guidance also report positive datum long act complement inhibitor alxn show patient pnh be effectively safely switch treatment soliris week treatment alxn week tentative approval bode well alexion read more alexion earning beat estimate guidance vertex first quarter result be drive stellar performance cf product read more vertex earning beat strong cf product sale gilead be zack rank buy stock see complete list today zack rank strong buy stock here amgen get positive opinion prolium amgen announce committee medicinal product human use chmp european medicine agency ema have adopt positive opinion marketing authorization prolium treatment bone loss associate long term systemic glucocorticoid therapy adult patient increase risk fracture chmp opinion now be review european commission meanwhile company supplemental biologic license application prolium expand indication be also review unite state prescription drug user fee act action date note drug be already approve unite state treatment postmenopausal woman osteoporosis high risk fracture addition chmp have adopt positive opinion recommend label variation kyproli carfilzomib include final overall survival datum phase iii trial aspire demonstrated addition kyproli lenalidomide dexamethasone krd reduce risk death versus lenalidomide dexamethasone alone rd extend os month patient relapse refractory multiple myeloma regeneron partner sanofi cut praluent price regeneron partner sanofi announce company lower net price pcsk inhibitor praluent alirocumab injection more affordable patient access express script consequently praluent become exclusive pcsk inhibitor therapy express script national formulary agreement effective jul provide praluent lower net price enable streamline patient access base physician attestation meanwhile fda have accept priority review company biologic license application cemiplimab treatment patient metastatic cutaneous squamous cell carcinoma cscc patient locally advanced cscc be not candidate surgery candidate be grant breakthrough therapy designation status fda september target action date be oct biogen negotiate agreement neurimmune biogen biib free report neurimmune announce former have exercise option further reduce previously negotiate royalty rate payable potential future sale alzheimer disease candidate aducanumab candidate be currently phase iii result biogen make time payment neurimmune exchange reduction original royalty rate potential commercial sale aducanumab company have earlier announce reduction royalty rate reduce royalty rate potential commercial sale aducanumab be high single digit low teen biogen license worldwide right aducanumab neurimmune biomedical genetic industry yr return medical biomedical genetic industry yr return nasdaq biotechnology index gain last trading session major biotech stock alexion gain last month regeneron lose vertex gain see last biotech stock roundup here biotech stock roundup prta amgn revise view biib miss sale next biotech stay tune more earning regulatory update look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
137,AMGN,pfizer inc pfe free report report first quarter adjust earning share cent beat zack consensus estimate cent earning rise year year lower tax rate share count due aggressive share repurchase quarter make weaker sale performance higher cost pharma heavyweight record revenue miss zack consensus estimate revenue however rise year quarter report basis due positive impact currency change currency movement benefit pfizer first quarter revenue however operational basis exclude impact currency revenue decline year year international revenue rise operational basis revenue decline segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report basis operational basis year period ibrance eliquis do well quarter ih segment revenue be hurt lower sale enbrel lyrica prevnar prevenar meanwhile unfavorable customer buy pattern somewhat hurt sale ibrance xeljanz certain other product ibrance revenue rise quarter xeljanz sale rise lyrica sale decline eliquis alliance revenue direct sale rise chantix sale rise quarter revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare previous quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada global prevnar prevenar revenue decline higher international sale make decline unite state prevnar revenue tank unite state due lower government purchase last year pediatric indication continue decline revenue adult indication however prevenar revenue rise international market revenue consumer healthcare segment pfizer be consider selling rise global oncology revenue increase global vaccine revenue decline internal medicine decline inflammation immunology franchise decline additionally portfolio rare disease rise pfizer segment sale decline operationally revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state lyrica europe lower revenue legacy hospira product due product shortage viagra sale decline due generic competition begin december however business biosimilar emerge market do well quarter biosimilar revenue rise operationally emerge market revenue grow operationally pfizer launch inflectra biosimilar version johnson johnson jnj free report merck mrk free report blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market adjust selling informational administrative si expense decline operationally quarter adjust expense rise quarter pfizer buy back share worth include open market share repurchase accelerate share repurchase agreement execute march guidancerevenue be expect range adjust earning share be expect range mid point adjust ep be expect increase revenue be expect increase research development expense be likely be range si spending be project range adjust tax rate be expect be basis point less due expect advantage tax reform takepfizer first quarter result be mixed beat estimate earning miss same revenue meanwhile re affirm previously issue guidance share pfizer fall pre market trading lower expect sale quarter top line be hurt decline sale key drug lyrica prevnar prevenar enbrel also loss exclusivity product viagra continue supply shortage legacy hospira product hurt revenue year so far pfizer share have increase decrease industry pfizer face top line headwind form genericization key drug supply shortage legacy hospira product pricing pressure rise competition however believe new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance pfizer look well poise record profit growth pfizer also boast strong pipeline expect approximately drug approval next year include product have blockbuster potential pfizer carry zack rank buy see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
138,AMGN,latest earning preview earning season have already crossed half way mark be gain strength earning revenue growth track reach highest level year total earning member have already report result be same period last year higher revenue beating top line estimate beating revenue estimate proportion company beating earning revenue estimate be ongoing earning season seem have start solid note drug biotech sector major large cap player have report result bristol myer squibb bmy free report abbvie abbv free report beat zack consensus estimate earning well sale amgen inc amgn free report also surpass earning revenue expectation quarter higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor be expect keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue witness rise earning quarter review pharma biotech giant be schedule report earning result let see thing be shape company upcoming release pfizer inc pfe free report be slate releaseresult market open company deliver positive earning surprise last report quarter company performance have be impressive recent past earning surpass expectation trail quarters average beat accord zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp combination company zack rank earning esp make reasonably confident earning beat zack consensus estimate company earning quarter review be peg cent share innovative health segment new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner be expect drive top line essential health biosimilar emerge market be expect support sale bottom line be expect be drive cost saving share buyback read more pfizer earning beat estimate again pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotemerck co inc mrk free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise model do not conclusively show merck beat estimate quarter be stockha earning esp zack rank zack consensus estimate quarterly earning be peg cent share see complete list today zack rank strong buy stock here merck new product cancer drug keytruda lynparza bridion injection be likely drive top line however loss market exclusivity several drug softness diabetes januvia janumet franchise lower sale key product zostavax zepatier due competitive pressure hurt sale read more card merck earning season merck co inc price ep surprise merck co inc price ep surprise merck co inc quotegilead science inc gild free report be slate report result market close company deliver positive earning surprise trail quarters average beat last report quarter gilead deliver positive earning surprise model show gilead be likely beat estimate quarter combination gilead zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg share company strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue first quarter well franchise receive further boost fda approval once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection february hence sale get further boost read more be beat card gilead earning gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quoteincyte corporation incy free report be slate report result market open incyte track record have be impressive so far company deliver positive earning surprise trail quarters average beat last report quarter incyte deliver positive earning surprise model show incyte be likely beat estimate quarter combination incyte zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter incyte continue gain traction lead drug jakafi performance incyte jakafi performance be strong drive patient demand sale guidance be also impressive october fda approve label update drug include addition new patient report outcome datum comfort study well update warning related progressive multifocal pivotal reach trial evaluate jakafi patient steroid refractory acute graft versus host disease have complete enrollment result be expect first half assume successful result incyte expect submit snda seek approval jakafi indication jakafi sale be expect get boost update label read more jafaki help incyte beat earning estimate incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
139,AMGN,roche hold ag rhhby free report post strong sale number first quarter propel demand new drug biosimilar competition legacy drug sale come beating zack consensus estimate swiss pharma giant report sale chf first quarter year period company report result division pharmaceutical diagnostic growth rate mentioned be year year basis constant exchange rate sale pharmaceutical division increase drive strong growth ocrevus perjeta more offset lower sale mabthera rituxan tarceva avastin diagnostic division sale climb primarily back strong business result detailherceptin sale grow due increase demand unite state perjeta sale grow follow increase demand neoadjuvant metastatic setting sale also get boost fda approval perjeta use combination herceptin chemotherapy adjuvant surgery treatment positive early breast cancer high risk recurrence late sale kadcyla be drive increase demand international market strong ocrevus sale further boost top line drug used treat form multiple sclerosis continue gain traction unite state company also launch europe other country worldwide first quarter recently launch drug tecentriq alecensa lung cancer have also have encourage start immuno oncology drug tecentriq record growth sale alcenesa sale be witness solid demand unite state europe japan performance immunology franchise be drive increase sale actemra roactemra xolair gazyva gazyvaro sale be due growth unite state europe ophthalmology drug lucentis sale be growth be drive increase demand mg prefil syringe wet age related macular degeneration continue growth diabetic retinopathy however sale avastin fall due increase use cancer immunotherapy medicine lung cancer sale rituxan mabthera be also due entry biosimilar market however sale tarceva decline due grow use other therapeutic option sale xeloda continue be hit generic competition revenue diagnostic division climb back solid performance centralised point care solution unit be turn propel tissue diagnostic molecular diagnostic also perform impressively diabetes care sale increase outlook raisedroche sale expect grow low single digit compare earlier guidance be stable grow low single digit company expect core earning grow high single digit company intend further increase dividend local currency pipeline progressin january european medicine agency ema approve ocrevus treatment relapse primary progressive form multiple sclerosis february ema also grant approval hemlibra person haemophilium inhibitor factor viii march fda approve lucentis mg prefil syringe new method administer medicine treat form diabetic retinopathy april fda grant hemlibra breakthrough therapy designation routine prophylaxis prevent reduce frequency bleed episode patient hemophilia inhibitor factor viii quarter roche acquire flatiron health ignyta inc flatiron health enable accelerate development delivery breakthrough medicine oncology patient ignyta lead molecule entrectinib target tumor genetically defined gene rearrangement ro fusion nsclc ntrk fusion broad range solid tumor takeroche beat estimate first quarter drive contribution newly launch drug label expansion key drug perjeta tecentriq alecensa further drive growth ocrevus hemlibra have be successfully launch however sale avastin tarceva continue decline roche stock have lose last month compare industry gain approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rank stock considerroche carry zack rank hold better rank stock healthcare sector be ligand pharmaceutical inc lgnd free report zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have soar year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
140,AMGN,anthem inc antm free report share rise report first quarter adjust earning share surpass zack consensus estimate shareshare viacom inc viab free report increase report first quarter adjust earning share surpass zack consensus estimate shareford motor company free report share rise report first quarter earning share surpass zack consensus estimate shareshare amgen inc amgn free report increase report first quarter earning share surpass zack consensus estimate share
141,AMGN,biotech sector witness series event past week quite few company report quarterly result week announce pipeline update past week amgen revise annual guidance biogen report quarterly number sale miss estimate recap important story prothena plunge discontinuation study share prothena corp prta free report plunge company decide discontinue development lead pipeline candidate neod candidate antibody be be evaluate treatment al amyloidosis phase iib study pronto do not meet primary secondary endpoint hence company ask independent datum monitoring committee dmc phase iii vital study review futility analysis ongoing vital study thereafter dmc recommend discontinuation vital study futility hence company decide discontinue study development neod include vital study well open label extension study decision come major blow investor company have very limit number candidate pipeline neod be lead candidate prothena carry zack rank buy see complete list today zack rank strong buy stock here incyte lilly drug get fda advisory committee nod incyte corp incy free report eli lilly company lly free report announce fda arthritis advisory committee have recommend approval mg dose baricitinib once daily oral medication treatment moderately severely active rheumatoid arthritis adult patient have have inadequate response intolerance methotrexate however advisory committee do not recommend approval mg dose baricitinib propose indication base adequacy safety benefit risk profile fda be generally not require follow advisory committee recommendation consider same review nda baricitinib fda have earlier issue complete response letter same drug be approve olumiant europe amgen revise annual guidance amgen inc amgn free report revise guidance concurrent first quarter result company beat sale earning first quarter drive strong performance newly recently launch drug company now expect revenue be compare earlier estimate earning share be now project come compare earlier estimate biogen miss sale biogen biib free report miss revenue estimate first quarter spinraza sale be drab company lead multiple sclerosis franchise also see sale decline biotech have be struggle nevertheless earning beat estimate share re-cover end positive note end session earlier company also extend collaboration ionis pharmaceutical ion free report new year agreement develop novel antisense drug candidate broad range neurological disease agreement biogen pay ionis cash include purchase share ionis common stock price share read more biogen earning beat sale miss share calithera kidney cancer candidate get fast track status share calithera bioscience inc cala free report gain company announce fda have grant fast track designation lead candidate cb candidate be be develop combination exelixis exel cabozantinib treatment metastatic kidney cancer calithera cb selective potent inhibitor glutaminase be be evaluate phase ii study cantata combination cabometyx clear cell renal cell carcinoma patient previously treat least vascular endothelial growth factor tyrosine kinase inhibitor combination opdivo yervoy read more calithera kidney cancer candidate get fast track status biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock alexion lose last month regeneron lose vertex gain see last biotech stock roundup here biotech stock roundup alk cldx alxn acquire wilson therapeutic next biotech world stay tune quite be schedule report result later week early next week investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
142,AMGN,amgen inc amgn free report report first quarter earning share beat zack consensus estimate bottom line also increase compare year figure total revenue quarter marginally surpass zack consensus estimate top line also register increase year year share amgen dip almost apr hour trading however stock have decline so far year compare favorably decrease industry quarter detailtotal product revenue increase year quarter ex drive double digit unit growth company new recently launch product include repatha kyproli prolium xgeva revenue amgen erythropoiesis stimulating agent esa aranesp decline prior year quarter due lower demand primarily base increase competition revenue other esa epogen drop lower selling price due newly negotiate contract davita inc neulasta revenue decline year period lower demand be offset partially favorable change net selling price inventory increase competition pd other new cancer therapy be hurt demand neulasta however neulasta onpro kit body injector continue perform well command market share unite state neulasta sale notably neulasta epogen start face biosimilar competition unite state year hurt sale further neupogen record decline sale due biosimilar competition unite state zarxio sandoz novartis nvs free report generic arm biosimilar version neupogen be launch unite state september be affect sale enbrel deliver revenue year quarter lower selling price stiffer competition hit demand prolium revenue come year quarter backed higher demand osteoporosis drug witness consistent growth new patient start strong repeat injection rate drive year year growth meanwhile xgeva deliver revenue year quarter mainly owing higher demand earlier year amgen gain fda approval expand label xgeva include prevention ofskeletal related event sre inpatient multiple myeloma now xgeva be only accept prevention sre solid tumor patient bone metastase approval expand patient population have drive sale xgeva quarter additionally month xgeva gain eu nod well give indication sensipar mimpara revenue increase mainly ride higher demand vectibix revenue come drive higher demand kyproli record sale year year drive increase demand robust uptake outside market amgen regulatory application unite state include overall survival datum endeavor study label kyproli be grant fda approval january study demonstrated combination kyproli dexamethasone lead superior overall survival compare takeda velcade dexamethasone blincyto sale surge year period reflect rise demand notably last month amgen announce fda have grant accelerate approval new indication blincyto include treatment patient minimal residual disease mrd positive cell precursor acute lymphoblastic leukemia amgen pcsk inhibitor repatha generate revenue compare fourth quarter uptake drug gain fda approval august have not be very encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical regn free report also face similar issue pcsk inhibitor praluent december amgen gain fda approval include new indication risk reduction major cardiovascular event datum repatha label base datum phase iii cardiovascular outcome study fourier cardiovascular indication approve be include repatha label amgen be hopeful patient access repatha willimprove last month amgen announce chmp ema have give positive recommendation regulatory application seek approval include fourier datum european label repatha operate marginsadjusted operate margin decline basis point bps due higher operate cost sg spend increase higher investment support new product launch expense slip compare year figureamgen repurchase share worth plan buy back incremental share second quarter guidance company now expect revenue range compare previous prediction zack consensus estimate metric current year stand adjust earning be now anticipate range compare previous projection consensus mark metric current year be peg share adjust tax rate be now estimate approximately lower past range reflect impact latest tax reform hope achieve improve cash position follow tax law amgen plan invest approximately year capital expenditure amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quote zack rankamgen carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
143,AMGN,biomarin pharmaceutical inc bmrn free report report first quarter result apr market close biomarin deliver negative earning surprise last quarter biomarin earning track record have be decent company beating estimate past quarters deliver average positive surprise biomarin share have decline year so far compare favorably decrease register industry period let see thing be shape company quarter factor playkey orphan disease drug vimizim kuvan drive biomarin top line past few quarters be likely maintain trend quarter too robust patient growth penetration propel drug sale also naglazyme vimzin revenue vary quarterly basis primarily due inconsistent order pattern country fourth quarter conference call company have say be cautiously optimistic sale brazil be steady uneven buy pattern be observed quarter quarter nevertheless drug continue witness steady patient growth expect trend continue quarter expect management discuss pipeline be progress conference call brineura treatment child cln disease form batten disease be approve unite state eu last year brineura generate sale call company say focus initial stage launch be disease awareness early diagnosis company mentioned new site readiness take longer expect suggest slower revenue ramp investor call also expect management comment launch preparation pegvaliase pegvaliase develop treat pku be review unite state fda expect give decision regard pegvaliase launch call management have inform initial sale ramp pegvaliase be slow due education disease awareness lower dose patient induction titration phase also company mentioned expect price pegvaliase modest premium kuvan net annual treatment cost update be expect upcoming call earning whispersour proven model do not conclusively show biomarin be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be zack consensus estimate be cent most accurate estimate be peg lower cent uncover best stock buy sell re report earning esp filter zack rank biomarin zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerbiotech stock have positive esp favorable zack rank include alexion pharmaceutical inc alxn free report schedule release result apr have earning esp zack rank see complete list today zack rank stock here amgen inc amgn free report have earning esp zack rank company be schedule release result apr celgene corporation celg free report have earning esp zack rank company be schedule release result make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
144,AMGN,expect vertex pharmaceutical inc vrtx free report beat expectation report first quarter result apr market close vertex share have increase so far year industry have record decrease vertex track record have be impressive so far company deliver positive earning surprise last quarters average positive earning surprise last quarters be last report quarter vertex come positive surprise let see thing be shape quarter factor playvertex cystic fibrosis cf drug kalydeco orkambi perform consistently sale rise almost expect positive trend continue soon be report quarter however company announce last quarter earning call first quarter revenue be unfavorably impact higher gross net revenue adjustment buildup channel inventory fourth quarter january vertex announce extension marketing application orkambi be approve europe approval orkambi marketing label eu now include use child cf age year have copy del mutation expand patient population expand patient population be expect boost sale drug zack consensus estimate orkambi sale first quarter be kalydeco receive approval line extension include patient year older certain residual mutation cftr gene drug generate significant sale last year due rapid uptake expand patient population expect trend continue zack consensus estimate first quarter kalydeco sale be peg millionin boost vertex cf franchise fda approve vertex third cf drug symdeko be combination tezacaftor ivacaftor february drug be review europe however expect new drug contribute minimally first quarter sale expect company provide update symdeko plan initial uptake company remain focuse development triple combination regimen quarter vertex advanced vx vx phase iii development also phase iii study be initiate evaluate vx combination tezacaftor kalydeco ivacaftor cf patient investor focus call be triple combination cf regimen be crucial long term growth vertex company be also likely provide full year revenue guidance include symdeko sale call however operate expense be likely be higher side due initiation pivotal study launch symdeko likely positive surprise proven model indicate vertex be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent zack consensus estimate cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank vertex have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quoteother stock considerhere be biotech stock also want consider model show have right combination element post earning beat quarter celgene corporation celg free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here amgen inc amgn free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
145,AMGN,first quarter earning season start solid note show sign yet report cycle emerge strong latest earning preview member accounting index have already release financial figure apr total earning index participant jump year quarter drive improve revenue beat ratio be bottom line top line further good news be ongoing earning phase seem have also begin encouragingly drug biotech sector major large cap player johnson johnson jnj free report kick season strongly beating zack consensus estimate earning well sale first quarter large cap player have report earning performance last week be novartis nvs free report also surpass earning revenue expectation quarter remind investor drug biotech sector face severe volatility last couple month due broader market pressure mainly drive china trade war sector be still likely improve year progress expect surge new product sale sync rise demand apart successful innovation product line expansion strong clinical study result more frequent fda approval consistently sturdy performance key product grow demand drug especially address rare treat disease agee populace increase healthcare expenditure be factor keep sector well place also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning period discussion pharma biotech giant be schedule report earning number apr let see thing be shape company upcoming release eli lilly company lly free report eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quote lilly be slate release first quarter earning market open company deliver positive surprise last quarter moreover company performance have be impressive recent past earning surpass expectation trail quarters average positive surprise however proven model do not conclusively show lilly be likely beat earning quarter company favorable zack rank buy increase predictive power esp earning espof leave surprise prediction inconclusive company require positive esp be confident probable surprise zack consensus estimate quarterly earning be peg share lilly strong uptake new product trulicity taltz basaglar cyramza jardiance lartruvo compensate sale decline establish product namely zyprexa alimta ciali strattera effient expect uptrend find reflection result soon be report quarter read more lilly lly free report report earning card biogen inc biib free report biogen inc price ep surprise biogen inc price ep surprise biogen inc quote biogen be also slate release first quarterearning market open company track record have also be impressive so far deliver positive surprise trail quarters average beat however biogen come negative surprise fourth quarter moreover proven model do not conclusively show biogen be likely beat earning quarter company favorable zack rank hold increase predictive power esp earning esp leave surprise prediction inconclusive zack consensus estimate be peg share see complete list today zack rank strong buy stock here sale biogen multiple sclerosis drug improve patient growth major european market well growth strong emerge market drive international tecfidera sale inventory build quarter benefit sale expect momentum continue impending result soon be report quarter read more store biogen biib free report earning season amgen inc amgn free report amgen inc price ep surprise amgen inc price ep surprise amgen inc quote amgen be schedule release first quarter earning market close company deliver negative surprise previous quarter amgen earning performance have be quite robust metric beating expectation last quarters miss same remain average beat proven model show amgen be likely beat earning quarter combination amgen zack rank increase predictive power esp positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg share uncover best stock buy sell re report earning esp filter amgen latest product prolium kyproli xgeva blincyto be likely perform well backed higher demand upside make weak sale stiff competition mature brand such enbrel aranesp epogen neulasta neupogen be report quarter read more amgen amgn free report report earning be beat card today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
146,AMGN,healthcare space have be tough journey year popular etf health care select sector spdr fund xlv free report have shed so farwhile vanguard health care etf vht free report fidelity msci health care index etf fhlc free report have gain least meanwhile ishare healthcare etf iyh free report have add mixed trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read healthy earning unitedhealth etfs watch let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate higher chance beating estimate quarter stock have see positive earning estimate revision cent be report quarter deliver average positive earning surprise past quarters have vgm score pfizer be schedule report earning open bell merck be expect report result market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness positive earning estimate revision cent past day be report quarter merck have vgm score amgen carry zack rank have earning esp indicate reasonable chance beating estimate time earning surprise track past quarters be strong average positive surprise addition amgen witness positive earning estimate revision cent past day quarter be report stock have solid vgm score amgen report earning apr market close read small cap biotech etfs be soar abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see solid earning estimate revision cent past month be report quarter stock have solid vgm score company be schedule report apr open bell gilead be expect release earning market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision penny past month be report quarter have vgm score bristol myer likely report earning apr open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have vgm score sum earning surprise well card healthcare sector be expect witness earning growth first quarter suggest upside healthcare etfs particular etfs have zack etf rank see healthcare etfs here want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
147,AMGN,expect biotech major amgen inc amgn free report beat expectation report first quarter result apr market close amgen deliver negative earning surprise last quarter amgen share have decline past year still compare favorably decrease register industry period amgen performance have be modest company deliver positive surprise trail quarters average earning beat last quarters be amgen inc price ep surprise amgen inc price ep surprise amgen inc quotelet see thing be shape company quarter factor first quarter usually generate lowest product sale amgen amgen newer product prolium kyproli xgeva blincyto be likely perform well backed higher demand make lower sale mature brand enbrel aranesp epogen neulasta neupogen due competitive pressure early amgen gain fda approval include overall survival datum label kyproli blincyto reflect first quarter sale drug january xgeva gain fda approval prevention skeletal related event patient multiple myeloma label extension boost sale drug neulasta demand be be hurt competition pd other new cancer sale be also be hurt biosimilar competition unite state mainly zarxio sandoz biosimilar version neupogenwe expect neulasta neupogen first quarter sale be hurt competitive dynamic neulasta epogen be expect start face biosimilar competition unite state year also sensipar sale be likely decline sharply soon be report quarter drug lose patent exclusivity march enbrel sale be expect be hurt increase pricing competitive pressure enbrel be main driver amgen revenue fourth quarter conference call amgen say sale enbrel first quarter be expect be lowest represent approximately full year sale also repatha sale first quarter be expect be relatively flat sequentially hurt insurance verification patient pocket cost also investor be keen know sale repatha have improve inclusion fourier outcome datum label amgen partner allergan agn free report biosimilar version roche cancer drug avastin mvasi be approve eu january boost first quarter sale drug investor focus call be management comment preparation potential launch migraine candidate aimovig fda be expect give decision aimovig biologic license application bla mid meanwhile higher investment support product launch be likely result higher sg cost be report quarter earning whispersour proven model show amgen be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank amgen have zack rank combination amgen zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerbiotech stock have positive esp favorable zack rank include alexion pharmaceutical inc alxn free report schedule release result apr have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report have earning esp zack rank company be schedule release result wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
148,AMGN,biogen inc biib free report well know name multiple sclerosis ms market report first quarter result apr market open last quarter company deliver negative earning surprise biogen share have decline year underperform industry decline same time frame biogen earning performance have be decent so far have deliver positive surprise last quarters average earning beat last quarters be biogen inc price ep surprise biogen inc price ep surprise biogen inc quotelet see thing be shape considerin fourth quarter biogen witness higher sale multiple sclerosis drug patient growth major european market strong emerge market growth drive international tecfidera sale inventory build quarter benefit sale however call biogen mentioned seasonality absence inventory build benefit fourth quarter result hurt performance ms franchise first quarter continue competitive pressure especially roche rhhby free report newly launch ms drug ocrevus hurt performance biogen ms franchise particularly sale tysabri zack consensus estimate sale tecfidera first quarter be peg tysabri global market sale be fourth quarter conference call biogen say ocrevus launch have witness decrease number patient start increase discontinuation tysabri unite state negative trend continue quarter combine number patient used avonex plegridy be expect decline patient transition other oral ms therapy well due higher discount allowance zinbryta be unlikely have make significant contribution revenue quarter march biogen partner abbvie announce decision withdraw zinbryta market less year approval due grow safety concern limit commercial adoption drug due restrictive label company decide discontinue marketing drug ground complex evolve benefit risk profile zinbryta update be expect first quarter conference call biogen newly launch drug spinraza approve spinal muscular atrophy be likely see strong demand trend particularly international market fourth quarter conference call biogen management have say significant portion spinraza revenue growth be expect come outside unite state biogen biosimilar product flixabi biosimilar reference remicade benepali biosimilar reference enbrel be also generate significant revenue trend continue quarter well fourth quarter call company have also say operate expense be expect be sequentially lower first quarter however earning growth be expect be higher second fourth quarters yearearning whispersour proven model do not conclusively show biogen be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank biogen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerbiotech stock have positive esp favorable zack rank include alexion pharmaceutical inc alxn free report schedule release result apr have earning esp zack rank see complete list today zack rank stock here amgen inc amgn free report have earning esp zack rank company be schedule release result apr wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
149,AMGN,johnson johnson jnj free report kick pharma earning season strong note beating zack consensus estimate earning sale first quarter performance be drive continue positive momentum second half improvement consumer segment sale do perform earning share beat zack consensus estimate quarterly revenue be also beat consensus mark buoy strong performance company up previously issue sale outlook read more top earning estimate raise sale guidance pharmaceutical segment sale grow year year first quarter due strong sale domestic international market favorable currency impact sale market rise quarter international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well oncology sale increase quarter constitute almost quarter pharmaceutical sale core product xarelto stelara zytiga simponi simponi aria invega sustenna also contribute growth imbruvica sale rise drug be market partnership abbvie inc abbv free report edurant sale rise prezista sale increase however concerta sale continue decline due generic competition sale risperdal consta also fall sale invokana invokamet decline due higher manage care discounting blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report fall pharma segment achieve clinical milestone quarter include fda approval prostate cancer drug erleada treatment man metastatic castration resistant prostate cancer line extension already market prostate cancer drug zytiga combination prednisone first line set certainly boost sale now expect revenue range higher expect previously overall expect pharmaceutical segment remain strong consumer medical device segment continue improve expect other company merck amgen inc amgn free report pfizer lilly follow suit novartis report encourage resultsnovartis ag nvs free report also report week swiss pharma giant beat earning revenue estimate drive strong performance key drug cosentyx entresto novartis report core earning share beating zack consensus estimate record year quarter revenue increase beating zack consensus estimate read more novartis beat earning revenue estimate sale innovative medicine division grow drive volume growth cosentyx entresto however entry generic gleevec unite state europe impact sale unfavorably cosentyx sale increase drive strong growth indication expand access entresto sale increase drive increase uptake oncology franchise exclude gleevec grow drive promacta revolade tafinlar mekinist jakavi recent launch however sale sandoz division be due price erosion unite state however year so far share have lose novartis share be decrease witness industry other pharma bigwig report solid result too pfizerpfizer top line be expect be favorably impact new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner soon be report quarter moreover line extension xeljanz sutent bosulif receive fourth quarter be also expect bring more sale however loss exclusivity associate generic competition pristiq unite state lyrica europe product shortage legacy hospira likely affect sale negatively blockbuster drug enbrel sale continue decline quarter due biosimilar competition company sale be expect increase low single digit level zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale currently stand represent year year growth pfizer carry zack rank buy merckmerck blockbuster drug keytruda lynparza bridion injection be expect boost revenue first quarter keytruda sale be gain momentum approval launch keytruda new indication especially first line lung cancer however rise competitive pricing pressure be expect hurt sale zostavax zepatier januvia isentress animal health franchise sale be likely remain strong first quarter merck carry zack rank see complete list today zack rank strong buy stock here zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale be represent year year increase eli lilly lly sale lilly diabetes drug trulicity jardiance be expect grow drive market share gain other new drug such cyramza taltz lartruvo be also expect boost top line due continue strong demand verzenio be also expect generate higher sale first quarter however patent expiry country cymbalta strattera effient axiron zyprexa evista competitive pressure mainly immuno oncology agent alimta hurt sale drug expect strong uptake new product offset decline sale establish product quarter too zack consensus estimate sale earning be peg respectively zack consensus estimate sale stand represent rise year year lilly carry zack rank bristol myer squibb company bmy several label expansion bristol myer blockbuster cancer drug opdivo drive company sale last year be expect do so year well moreover cardiovascular drug eliquis also demonstrated strong performance expect trend continue quarter label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact however genericization plavix avapro avalide baraclude unite state due loss exclusivity be significantly hurt company top line company also face stiff competition immuno oncology space hiv business continue face competitive pressure zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale be peg represent rise year year bristol myer carry zack rank new product majority company be do well be expect offset decline sale legacy drug due loss exclusivity moreover most company boast deep promising pipeline also new tax law boost prospect strategic merger acquisition licensing deal collaboration smaller company strengthen company product portfolio wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
150,AMGN,roche hold ag rhhby free report member genentech announce fda have grant breakthrough therapy designation hemophilia drug hemlibra emicizumab kxwh designation be grant hemlibra treatment person hemophilia factor viii inhibitor designation aim expedite development review drug intend treat serious life threaten condition provide patient access soon possible designation be base datum phase iii haven study person year older hemophilia inhibitor study hemlibra prophylaxis dose subcutaneously week week show statistically significant clinically meaningful reduction treat bleed compare prophylaxis study meet primary endpoint well key secondary endpoint hemlibra significantly reduce bleed roche stock have lose year compare industry gain note fda approve hemlibra routine prophylaxis event reduce frequency bleed episode adult child haemophilium factor viii inhibitor november hemlibra be review fda priority review grant breakthrough therapy designation september january eu committee medicinal product human use chmp adopt positive opinion hemlibra emicizumab routine prophylaxis bleed episode patient suffering hemophilia factor viii inhibitor chmp have recommend drug use age group marketing authorisation application be be review accelerate assessment potential approval further boost roche hematology portfolio include approve drug mabthera rituxan gazyva gazyvaro tecentriq venclexta note roche be develop venclexta collaboration abbvie abbv free report company be jointly commercialize drug unite state abbvie be commercialize drug outside unite state approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer roche hold ag price roche hold ag price roche hold ag quotezack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
151,AMGN,amgen inc amgn free report have announce full result phase iiib study cgrp receptor antibody aimovig erenumab once again demonstrate significant reduction migraine frequency company be look get aimovig mg approve treatment episodic migraine patient previous experience preventive treatment failure due lack efficacy intolerable side effect phase iii liberty study randomize patient aforementioned indication receive aimovig mg placebo week datum study demonstrated reduction episodic migraine least half aimovig treat patient multiple treatment failure compare patient treat placebo moreover aimovig patient complete double blind phase liberty trial adverse event be find lead discontinuation treatment aimovig group outcome study be present annual meeting american academy neurology los angele share amgen increase more apr follow news release stock have gain so far year industry decline remind investor january year company announce aimovig meet primary endpoint libarty study significantly more patient aimovig dosage experience least reduction baseline monthly migraine day compare placebo study meet secondary endpoint well notably amgen be develop aimovig collaboration novartis ag nvs free report company be focuse develop commercialize treatment migraine alzheimer disease approve amgen novartis co commercialize aimovig unite state however amgen retain right japan novartis have right europe canada rest world importantly candidate be review unite state same indication response expect notably candidate be first investigational therapy target cgrp pathway have receive regulatory filing acceptance fda give indication company person unite state be affected migraine approximately be preventive therapy likely discontinue treatment year thus approval drug address hugely unmet need patient suffering disease country however several company namely teva pharmaceutical teva free report eli lilly lly free report other be develop migraine treatment target cgrp amgen inc price amgen inc price amgen inc quote zack rankamgen carry zack rank hold see complete list today zack rank strong buy stock here hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
152,AMGN,novartis ag nvs free report be schedule report first quarter result apr swiss pharmaceutical company stock have rally last month compare industry gain novartis have excellent track record last quarter novartis deliver positive earning surprise company post average positive earning surprise trail quarters let see thing be shape announcement factor playconcurrent result novartis provide guidance novartis expect net sale grow low mid single digit novartis operate segment innovative medicine pharmaceutical alcon sandoz generic innovative medicine be project grow mid single digit revenue sandoz be expect be broadly line decline slightly alcon sale be estimate grow low mid single digit innovative medicine division record sale combat generic pricing pressure novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali growth product cosentyx entresto promacta revolade jakavi tafinlar mekinist gilenya continue drive top line psoriasis cosentyx achieve multus blockbuster drug status back strong growth approve indication entresto sale benefit continue access improvement expansion sale force unite state approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space additionally novartis generic arm sandoz be make effort strengthen biosimilar portfolio launch rixathon biosimilar version roche rhhby free report rituxan rituximab erelzi biosimilar amgen amgn free report enbrel eu have boost company portfolio however sale division be project decline due continue industry wide pricing pressure unite state meanwhile loss exclusivity key drug novartis portfolio continue hurt company top line company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february eu december thereby lead generic competition exforge be also face generic competition unite state eu further oncology drug be face new competition form immuno oncology therapy ophthalmology division alcon be struggle consequently novartis take few step revive business turnaround have be encourage management believe create standalone company capital market exit create additional shareholder value decision be expect first half depend alcon performance future earning whispersour proven model do not conclusively show novartis beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp novartis be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank novartis currently carry zack rank rank be favorable company esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision novartis ag price consensus ep surprise novartis ag price consensus ep surprise novartis ag quote stock considerhere be stock healthcare sector want consider model show have right combination element post earning beat quarter pfizer inc pfe free report have earning esp zack rank company be schedule release first quarter result see complete list today zack rank stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
153,AMGN,mylan myl free report be partner fujifilm kyowa kirin biologic co ltd commercialize biosimilar abbvie abbv free report blockbuster arthritis drug humira adalimumab adalimumab be develop fujifilm kyowa kirin biologic mylan intend seek approval commercialize product europe european medicine agency ema accept marketing authorization application review propose biosimilar humira company expect receive ema decision second half agreement mylan have exclusive license commercialize biosimilar europe receive upfront fee fujifilm kyowa kirin company also be responsible sale activity product european country other hand fujifilm kyowa kirin biologic be eligible receive subsequent milestone payment sale royalty year share mylan increase compare industry fall humira be tnf inhibitor aim treat multiple chronic inflammatory condition be approve europe treatment rheumatoid arthritis juvenile idiopathic arthritis psoriatic arthritis ankylose spondylitis crohn disease ulcerative colitis plaque psoriasis hidradenitis suppurativa uveitis note few day biogen inc biib free report partner samsung bioepis announce resolution ongoing patent dispute abbvie regard biogen biosimilar version imraldi abbvie humira eu settlement agreement biogen samsung bioepis plan launch imraldi europe oct also unite state samsung bioepis enter settlement agreement abbvie allow former bring humira biosimilar market jan notably imraldi be second biosimilar version humira be launch eu biotechnology company amgen amgn free report be also expect launch biosimilar version humira eu come october year amjevita settlement abbvie notably amjevita be approve eu last march approve unite state september unite state settlement abbvie amjevita be likely be launch jan mylan price mylan price mylan quote zack rankmylan carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
154,AMGN,expect johnson johnson jnj free report healthcare bellwether beat expectation report first quarter result april market open last quarter company deliver positive earning surprise performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be stock have depreciate year so far compare unfavorably decline record industry factor considerj sale growth accelerate second half backed higher sale pharmaceutical segment improve performance medical device expect pharmaceutical segment remain strong consumer medical device segment likely continue improve believe new product segment label expansion drug imbruvica xarelto stelara darzalex meaningful contribution swiss biotech actelion buy june last year support top line zack consensus estimate sale pharmaceutical segment be however fourth quarter revenue pulmonary arterial hypertension pah product add actelion acquistion decline sequentially be be see pah revenue improve meanwhile biosimilar competition be expect continue hurt sale key arthritis drug remicade outside unite state however do not expect biosimilar entrant zytiga prezista risperdal consta invega sustenna unite state year regard newly launch tremfya note conference call uptake product have be decent drug record sale be expect be higher be report quarter meanwhile expect discuss plan erleada newly approve prostate cancer drug conference call also discuss initial sale uptake juluca first dual treatment hiv develop partnership glaxosmithkline gsk free report receive fda approval november last year juluca be review eu medical device segment sale be expect continue rise vision care cardiovascular unit diabetes care unit continue remain weak zack consensus estimate sale medical device segment be consumer segment global consumer category slowdown many company market continue hurt sale however recent acquisition well new product likely provide support zack consensus estimate sale consumer segment be meanwhile higher investment new product launch continue thwart profit earning whispersour proven model show be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be uncover best stock buy sell re report earning esp filter zack rank have zack rank combination zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other large drug biotech stock have right combination element beat earning time amgen inc amgn free report earning esp zack rank company be schedule release result apr see complete list today zack rank stock here abbvie inc abbv free report have earning esp zack rank company be slate release result apr today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
155,AMGN,merck co inc mrk free report announce datum phase iii study show treatment pd inhibitor keytruda monotherapy lead significantly improve overall survival os first line therapy certain lung cancer patient pivotal keynote study evaluate patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent such patient keytruda show significant survival benefit compare platinum base keytruda monotherapy be already market first line treatment patient metastatic nsclc tumor express pd protein level percent greater tps percent base datum keynote study os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market study continue evaluate progression free survival pfs secondary endpoint base recommendation independent datum monitoring committee dmc later year merck present datum keynote study medical meeting also file regulatory application get os datum study include label keytruda share merck be more apr news be announce market open year so far merck share have outperformed industry share have rise period industry decline meanwhile keytruda be be evaluate several lung cancer study multiple setting stage disease monotherapy well combination therapy keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further bolster demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda development program also significantly advanced several regulatory approval unite state europe japan new approval expand patient population drive sale last year positive momentum be expect sustain well meanwhile keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
156,AMGN,year world health day be celebrate apr world health organization have be organize event decade year be focuse make healthcare service accessible everyone theme universal health coverage everyone everywhere official int half world do not have access essential healthcare service moreover rise healthcare cost be push many person poverty organization want bring person healthcare coverage globally bid accomplish goal many philanthropic activity be carry several trust foundation globe give increase population incidence disease grow awareness healthcare coverage initiative drug sector be expect grow consequently company healthcare space be expect witness higher sale year come stock considerahead world health day suggest company investor add portfolio have choose stock carry zack rank strong buy buy vgm score stand value growth momentum have witness positive current year earning estimate revision past day market cap more see complete list today zack rank stock here plc gsk free report new product have be perform encouragingly meanwhile back back approval new product trelegy ellipta shingrix juluca have strengthen glaxo competitive position underperform broader industry glaxo share have picked year past couple month analyst have become bullish stock upward estimate revision earning glaxo earning estimate increase last day company hold zack rank have vgm score read more reason glaxo stock be great pick glaxosmithkline plc price glaxosmithkline plc price glaxosmithkline plc quoteamgen inc amgn free report newer drug prolium xgeva kyproli be perform well amgen be also progress pipeline expect approval launch migraine candidate aimovig year company restructure plan be make leaner more cost efficient amgen share have also outperformed industry year so far stock have be witness solid activity estimate revision front zack consensus estimate earning trend past day share zack consensus estimate increase same period company hold zack rank have vgm score amgen inc price amgen inc price amgen inc quotejohnson johnson jnj free report sale accelerate second half relatively softer first half backed higher sale pharmaceutical segment improve performance medical device new product segment label expansion drug imbruvica darzalex contribution recent acquisition mainly actelion be likely drive top line growth analyst have great expectation company year have be revise earning estimate upward past day earning estimate increase last day company hold zack rank have vgm score johnson johnson price johnson johnson price johnson johnson quotehorizon pharma public limit company hznp free report sale guidance be encourage company orphan rheumatology business unit have continue show strong growth moreover analyst have become increasingly bullish company past couple month upward estimate revision earning horizon pharma earning estimate increase last day company hold zack rank have vgm score read more be horizon pharma public great stock value investor right now horizon pharma public limit company price horizon pharma public limit company price horizon pharma public limit company quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
157,AMGN,novartis ag nvs free report announce result post analysis paradigm hf trial cardiovascular drug entresto result be publish jama cardiology result demonstrated treatment entresto significantly improve type physical social activity month heart failure patient reduce ejection fraction hfref versus previous standard care moreover improvement combine physical social activity patient treat entresto versus enalapril be equivalent difference year age notably improvement be visible month visit be sustain study year follow period hence positive result further prove entresto not only reduce risk death also have positive impact quality life heart failure patient remind investor entresto be indicated treatment symptomatic chronic heart failure hfref drug be approve europe unite state european society cardiology heart failure guideline heart failure guideline have give class recommendation drug use sacubitril valsartan patient hfref currently novartis be conduct multiple study entresto part fortihfy clinical program include large outcome study paragon hf be first phase iii trial entresto patient chronic heart failure preserve ejection fraction meanwhile novartis continue recruitment paradise mi phase iiib trial patient high risk heart failure acute myocardial infarction result expect drug be project key growth driver novartis cosentyx total entresto sale come entresto sale benefit continue access improvement expansion sale force unite state novartis share have gain year compare industry rally novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali approval kymriah acute lymphoblastic leukemia be major boost give potential car therapy space strong performance new drug cosentyx entresto propel growth go forward generic division sandoz also combat pricing pressure strongly buoy biosimilar launch rixathon biosimilar roche rhhby free report rituxan erelzi biosimilar amgen amgn free report enbrel company recently enter agreement glaxosmithkline gsk free report divest stake consumer healthcare joint venture latter proceed sale be used accord capital allocation priority include bolt acquisition zack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
158,AMGN,eli lilly company lly free report announce late stage study evaluate already approve cancer drug cyramza second line treatment liver cancer meet primary well secondary endpoint primary endpoint be overall survival os percentage patient be alive certain length time secondary endpoint be progression free survival pfs amount time patient live tumor grow larger phase iii reach study evaluate benefit cyramza single agent patient hepatocellular carcinoma hcc also know liver cancer be intolerant experience disease progression treatment bayer bayry free report amgen amgn free report nexavar also have elevated level alpha fetoprotein afp accord lilly press release approximately half advanced hcc patient have high afp marker poor prognosis result reach study show such patient derive survival benefit cyramza treatment follow first line treatment nexavar please note cyramza be already market single agent combination agent second line treatment advanced metastatic gastric cancer be also approve use combination agent second line treatment metastatic small cell lung cancer metastatic colorectal cancer lilly plan file regulatory application seek label expansion cyramza specify subgroup liver cancer patient population mid many cancer drug be be approve base progression free survival evidence benefit survival quality life however os datum once available sometimes show drug do not help person live longer fact cyramza offer overall survival benefit reach study probably impressed investor lead stock rise wednesday however year so far lilly share have decline compare unfavorably industry decrease cyramza generate revenue record year year increase meanwhile cyramza be be evaluate several study additional iii study cyramza advanced urothelial carcinoma first line egfr mutation positive nsclc be ongoing os datum urothelial carcinoma study be expect first half year pfs datum egfr mutation positive nsclc study be expect be release late december lilly announce top line datum phase iii study rainfall evaluate cyramza first line treatment patient advanced gastric cancer study meet primary endpoint pfs fail improve os lilly decide not seek regulatory approval first line set base datum study lilly carry zack rank buy see complete list today zack rank strong buy stock here large cap stock carry same zack rank lilly be glaxosmithkline gsk free report glaxo stock have return year so far earning estimate go respectively past day today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
159,AMGN,be week see edge therapeutic crash news discontinuation phase iii study amgen blincyto get fda nod label expansion ema accept regeneron sanofi application label expansion dupixent recap past week most important storiesedge therapeutic plummet failure late stage study edge therapeutic inc lose almost company announce disappointing result phase iii study newton lead pipeline candidate eg treatment adult aneurysmal subarachnoid hemorrhage asah newton study compare efficacy safety eg nimodipine microparticle standard care oral nimodipine adult patient asah pre specify interim analysis perform datum day visit first subject randomize treat study demonstrated low probability achieve statistically significant difference compare standard care study primary endpoint study be fully enrolled independent datum monitoring committee dmc recommend study be stop base conclusion have low probability meeting primary endpoint consequently edge therapeutic have decide discontinue newton study moreover company reduce size workforce order preserve cash resource be dec due failure late stage study be company lead candidate failure study put question prospect read more edge therapeutic lose edge failure late stage study plunge fda refusal file letter alk share plc alk free report plunge significantly company receive refusal file letter fda regard new drug application nda depressant alk alk be be evaluate adjunctive treatment major depressive disorder mdd patient inadequate response standard antidepressant therapy fda notified company agency be not able complete substantive review due lack sufficient evidence overall efficacy candidate propose indication fda have also ask company conduct additional well controlled clinical trial be able resubmit nda moreover fda have also request company conduct bioavailability study generate additional bridge datum alk reference list drug buprenorphine however plan appeal fda decision request type meeting fda determine next course action additional information require resubmission nda read more sink fda refuse depression drug review amgen get approval label expansion drug fda approve label expansion amgen inc amgn free report leukemia drug blincyto treatment adult child cell precursor acute lymphoblastic leukemia first second complete remission minimal residual disease mrd greater equal accelerate approval basis acclereat approval be base mrd response rate hematological relapse free survival addition european commission approve label expansion xvega include prevention skeletal related event adult advanced malignancy involve bone xgeva be already approve prevention skeletal related event patient bone metastase solid tumor latest approval european label xgeva be expand include patient multiple myeloma read more amgen xgeva get eu approval expand label amgen blincyto get fda nod minimum residual disease ema accept dupixent label expansion cemiplimab review regeneron pharmaceutical inc regn free report partner sanofi sny free report announce european medicine agency ema have accept company application additional indication dupixent company be seek agency approval dupixent use add maintenance treatment certain adult adolescent year age older inadequately controlled moderate severe asthma dupixent be already approve unite state european union treatment adult moderate severe atopic dermatitis ema have also accept marketing authorization application cemiplimab treatment patient metastatic cutaneous squamous cell carcinoma cscc patient locally advanced cscc be not eligible surgery read more ema accept regeneron sanofi application dupixent sanofi skin cancer candidate filing accept eu regeneron currently sport zack rank strong buy see complete list today zack rank stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock alexion lose last month celgene lose vertex gain see last biotech stock roundup here biotech stock roundup ptgx vrna amgn repatha get positive opinion next biotech world stay tune more regulatory pipeline update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
160,AMGN,share rigel pharmaceutical inc rigl free report crash company announce disappointing top line datum mid stage study lead candidate fostamatinib oral spleen tyrosine kinase syk inhibitor rigel stock have lose last month industry gain company be evaluate candidate proof concept phase ii study patient iga nephropathy igan orphan autoimmune disease kidney patient enrolled trial be require have diagnosis igan verify biopsy proteinurium greater mg day patient be randomize group placebo fostamatinib mg bid fostamatinib mg bid week study evaluate safety efficacy measure change proteinurium renal function however trial do not achieve statistical significance primary endpoint be mean change proteinurium compare fostamatinib dose group placebo control patient study mean change proteinurium spcr be mg placebo mg bid mg bid dose group respectively nevertheless initial datum show greater reduction proteinurium fostamatinib treat patient relative placebo patient find do not reach statistical significance pre specify subgroup analysis patient greater gram day proteinurium baseline patient greater gram day proteinurium have increase risk disease company also expect provide further analysis include histology datum later year result datum rigel now seek partner collaborate conduct follow clinical study igan funding concern partner be responsible subsequent fostamatinib ex territory rigel be also evaluate fostamatinib number other indication failure igan study be disappointing investor do have something look forward rigel nda fostamatinib patient chronic immune itp be currently review expect action date apr igan study fail rigel be now pin hope review tentative approval study boost investor sentiment give market potential chronic itp affect estimate adult patient unite state however not be easy company gain market share indication give presence novartis nvs free report promacta amgen amgn free report nplate rigel be also evaluate fostamatinib phase ii study autoimmune hemolytic anemia zack rank key pickrigel currently carry zack rank sell better rank stock same space be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
161,AMGN,biotech major amgen inc amgn free report announce european commission have approve regulatory application be look expand current indication xgeva prevention skeletal related event patient multiple myeloma now xgeva be approve prevention skeletal related event patient bone metastase solid tumor latest approval european label xgeva be expand include patient multiple myeloma eu approval be expect committee medicinal product human use chmp european medicine agency have give positive opinion recommend approval xgeva expand patient population february unite state fda have grant approval same january amgen share have decline so far year be still better decrease register industry eu approval be base safety efficacy datum pivotal phase iii study enrolled patient head head study compare xgeva novartis ag nvs free report zometa zoledronic acid meet primary endpoint inferiority drug delay time first study sre patient multiple myeloma bone complication patient multiple myeloma be quite damage now bisphosphonate be only treatment option available bone protection multiple myeloma patient however bisphosphonate cause renal toxicity lead renal impairment xgeva be not clear kidney offer better treatment option such patient xgeva be key revenue driver amgen generate revenue year year drive higher demand expect approval expand patient population eu help further boost sale drug zack rank stock consideramgen carry zack rank hold better rank biotech stock include ligand pharmaceutical incorporate lgnd free report regeneron pharmaceutical inc regn free report zack rank strong buy see complete list today zack rank stock here ligand stock have return year so far earning estimate go more respectively past day earning estimate regeneron moved north respectively past day hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
162,AMGN,amgen inc amgn free report announce fda have grant accelerate approval new indication leukemia drug blincyto fda approve latest supplemental biologic license application sbla blincyto label be expand include treatment patient minimal residual disease mrd positive cell precursor acute lymphoblastic leukemia approval blincyto become first fda approve drug treatment mrd patient however continue approval indication be subject clinical benefit datum confirmatory study drug be already approve treatment philadelphia chromosome negative ph relapse refractory cell precursor unite state europe amgen share be so far year compare industry loss period approval be base datum phase ii blast study evaluate blincyto mrd positive patient have achieve complete hematologic remission receive more cycle intensive chemotherapy datum show drug achieve complete mrd response detectable mrd patient median hematological relapse free survival rate drug be month note mrd refer detectable cancer cell patient have achieve complete remission conventional treatment method hence treatment mrd help achieve better possible clinical outcome patient delay stopping relapse destroy remain detectable trace leukemia blincyto have show impressive growth rate sale reach sale be expect improve further year due continue demand however impact expansion label include treatment mrd remain be see remind investor pfizer inc pfe free report besponsa have receive approval treatment relapse refractory cell precursor august unite state increase competition blincyto amgen inc price amgen inc price amgen inc quotezack rank stock consideramgen currently have zack rank hold better rank stock health care sector include horizon pharma public limit company hznp free report ligand pharmaceutical incorporate lgnd free report stock carry zack rank buy see complete list today zack rank strong buy stock here horizon pharma earning estimate increase last day company deliver positive earning surprise trail quarters average beat ligand earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share have increase so far year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
163,AMGN,be week see protagonist stock crash news discontinuation phase iib study amgen reptha get positive chmp opinion verona pharma stock rally positive top line datum copd study fda accept sbla bristol myer opdivo recap past week most important plummet study result share protagonist therapeutic ptgx free report plummet announcement discontinuation phase iib study propel ulcerative colitis uc candidate ptg company decide discontinue study plan interim analysis propel study independent datum monitoring committee determine study not be able achieve primary endpoint clinical remission interim analysis be do datum first patient have complete week treatment ptg total patient population study be company have notified stop further treatment patient currently study protagonist have also postpone decision initiate phase ii iii ptg patient chronic pouchitis await full review interim datum propel study read more protagonist therapeutic stall ulcerative colitis study amgen repatha get positive chmp opinion amgen amgn free report announce committee medicinal product human use chmp european medicine agency ema render positive opinion company regulatory application seek approval include datum cardiovascular outcome study fourier european label pcsk inhibitor repatha application seek new indication repatha label adult establish atherosclerotic cardiovascular disease myocardial infarction stroke peripheral arterial disease reduce cardiovascular risk lower ldl level concurrently chmp give positive opinion marketing authorization amgen allergan agn free report abp biosimilar roche oncology drug herceptin biosimilar have be recommend approval treatment same type cancer positive metastatic breast cancer positive early breast cancer positive metastatic adenocarcinoma stomach junction read more amgen repatha gain chmp nod include outcome datum verona pharma surge study result share verona pharma plc vrna free report surge follow positive top line datum phase iib study evaluate pipeline candidate rpl rpl first class inhaled dual inhibitor be be evaluate maintenance treatment chronic obstructive pulmonary disease copd study meet primary endpoint rpl demonstrated clinically statistically significant improvement lung function dose level additionally secondary endpoint be also meet support potential clinical benefit rpl treatment copd positive result study support progression rpl later stage development inhaled treatment copd patient verona pharma doesn have approve product portfolio successful development drug significantly boost result bristol myer opdivo sbla accept fda fda accept bristol myer squibb company bmy free report supplemental biologic license application sbla blockbuster drug opdivo combination yervoy treatment adult microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc have progressed follow treatment oxaliplatin irinotecan agency have also grant application priority review set action date jul combination be already approve variety oncology indication seattle genetic get breakthrough therapy designation enfortumab seattle genetic inc sgen free report partner astella pharma inc announce fda have grant breakthrough therapy designation antibody drug conjugate adc enfortumab vedotin treatment patient suffering locally advanced metastatic urothelial cancer be previously treat checkpoint inhibitor cpi candidate be be study pivotal clinical trial ev nct monotherapy patient set early phase clinical trial combination cpi therapy ev nct company be also evaluate enfortumab vedotin other solid tumor include ovarian small cell lung carcinoma pharma plunge positive trial pharmaceutical hold company ltd bhvn free report share plunge significantly company announce positive top line result phase iii trial bhv bhv migraine candidate rimegepant formerly know bhv rimegepant be oral cgrp receptor antagonist be be evaluate acute treatment migraine cgrp receptor antagonist represent novel class drug candidate treatment migraine result be statistically significant clinically meaningful multiple outcome measure candidate meet co primary efficacy endpoint superiority placebo hour post dose pain freedom freedom most bothersome symptom company be schedule submit nda rimegepant however investor be not much impressed datum compare rival allergan migraine candidate ubrogepant medical biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock biogen lose last month celgene lose vertex gain see last biotech stock roundup here biotech stock roundup alxn arna study datum prta team celgene next biotech world stay tune more regulatory pipeline update make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
164,AMGN,merck co mrk free report japanese partner eisai co ltd announce latter cancer drug lenvima have receive approval japan expand indication tyrosine kinase inhibitor lenvima have be approve japan first line treatment unresectable hepatocellular carcinoma hcc type liver cancer approval be base positive datum phase iii clinical study study reflect study show lenvima demonstrated statistically significant inferiority overall survival os month compare bayer ag bayry free report nexavar month study also show lenvima demonstrated highly statistically significant clinically meaningful improvement compare nexavar secondary endpoint progression free survival regulatory application seek approval lenvima hcc be also unite state eu follow approval japan eisai receive development milestone payment merck past year merck share have decline industry gain be first approval lenvima company strike global strategic collaboration last month jointly develop commercialize drug monotherapy well combination merck pd therapy keytruda several type cancer lenvima develop eisai be presently approve treatment thyroid cancer monotherapy second line treatment renal cell carcinoma rcc type kidney cancer combination novartis nvs free report afinitor everolimus also late stage study be already ongoing evaluate lenvima separate combination study keytruda afinitor rcc meanwhile keytruda lenvima combination enjoy breakthrough therapy designation fda rcc merck eisai plan jointly develop lenvima cancer type potential indication company share global development marketing cost well gross profit lenvima equally however eisai book lenvima worldwide product sale monotherapy combination meanwhile keytruda be be study more type cancer exceed study include excess combination study merck be collaborate company amgen inc amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen merck co inc price merck co inc price merck co inc quotezack rank merck carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
165,AMGN,biotech major amgen inc amgn free report announce committee medicinal product human use chmp european medicine agency ema have give positive recommendation regulatory application seek approval include datum cardiovascular outcome study fourier european label pcsk inhibitor repatha label expansion application amgen be look get repatha approve prevent heart attack stroke coronary adult establish atherosclerotic cardiovascular disease europe amgen share have decline so far year be still better decrease register industry fourier outcome datum be already include label repatha follow fda approval december last year datum phase iii fourier study present last year have reveal significant reduction myocardial infarction stroke treatment repatha compare current best therapy alone repatha significantly reduce risk hard mace heart attack stroke cardiovascular death compare standard treatment statin therapy individual component risk heart attack stroke coronary be reduce respectively uptake repatha gain fda approval august have not be encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical inc regn free report also face similar issue pcsk inhibitor praluent priority amgen right now be improve patient access repatha outcome datum fourier be key commercial success repatha broaden use drug cardiovascular indication approve be include repatha label patient access repatha be expect improve however analyst believe datum study look good be not very clear payer be willing improve access repatha base datum separate press release amgen partner allergan agn free report announce chmp have also give positive opinion recommend marketing authorization abp biosimilar version roche cancer drug herceptin amgen allergan be look get abp approve eu same cancer indication reference product include positive metastatic breast cancer positive early breast cancer positive metastatic adenocarcinoma stomach junction company application get biosimilar herceptin approve unite state be review decision fda expect meanwhile amgen allergan mvasi biosimilar version roche cancer drug avastin be approve unite state september last year eu early year amgen carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
166,AMGN,novartis ag nvs free report announce committee medicinal product human use chmp european medicine agency ema adopt positive opinion marketing authorization propose biosimilar johnson johnson jnj free report remicade infliximab chmp recommend approval biosimilar indication brand drug rheumatology dermatology note remicade be approve treat crohn disease adult child ulcerative colitis rheumatoid arthritis psoriatic arthritis ankylose spondylitis plaque psoriasis positive opinion be base comprehensive datum package be expect confirm biosimilarity infliximab original drug analytical preclinical clinical datum match quality efficacy safety earlier phase iii confirmatory study rheumatoid arthritis reflection meet primary endpoint demonstrate equivalent efficacy propose sandoz biosimilar infliximab reference medicine measure american college rheumatology acr response week novartis share have decline year compare industry fall novartis generic arm sandoz be leader biosimilar market product market biosimilar include omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state rixathon biosimilar rituximab approve europe treat blood cancer immunological disease also approve eu riximyo duplicate marketing authorization erelzi biosimilar approve europe treat multiple inflammatory disease fda also approve biosimilar erelzi however launch be pending unite state due ongoing litigation amgen amgn free report ema be due review chmp opinion note sandoz acquire biosimilar infliximab pfizer pfe free report february eu country norway iceland liechtenstein form eea term pfizer retain manufacturing right infliximab pf country outside eea meanwhile sandoz have quite number biosimilar pipeline tentative approval further boost company generic division company have also file approval biosimilar adalimumab pegfilgrastim eu apart froma strong generic portfolio novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space zack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
167,AMGN,share radius health rdus free report fall company suffer setback once again europe overall radius health share have lose last month industry gain scientific committee european commission committee medicinal product human use chmp render negative trend vote benefit risk balance marketing authorization application maa abaloparatide sc oral explanation chmp therefore adopt negative opinion same company be plan get abaloparatide sc approve treatment osteoporosis postmenopausal woman increase risk fracture radius health plan seek re examination chmp opinion december chmp issue third day list outstanding issue inform company intend refer maa scientific advisory group additional advice company have earlier issue second day list outstanding issue delay get approval europe be disappointing give market potential note abaloparatide injection be approve fda april brand name tymlos treatment postmenopausal woman osteoporosis high risk fracture multiple risk factor fracture patient have fail be intolerant other available osteoporosis therapy tymlos continue gain traction approximately cover life coverage commercial plan tymlos market share reach approximately new patient start anabolic therapy nbrx total prescription anabolic market osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fractur year tymlos be expect face significant competition eli lilly co lly free report forteo amgen amgn free report prolium radius health pipeline include abaloparatide patch potential use osteoporosis elacestrant rad treatment hormone receptor positive breast cancer rad steroidal selective androgen receptor modulator be be evaluate use hormone receptor positive breast cancer zack rank key pickradius health currently carry zack rank hold better rank stock health care sector be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
168,AMGN,roche hold ag rhhby free report announce fda have approve lucentis mg prefil syringe pfs new method administer medicine form diabetic retinopathy remind investor lucentis mg be first only fda approve medicine treat form diabetic retinopathy person diabetic macular edema dme be approve indication april pfs variation be expect be available second quarter diabetic retinopathy market have great potential be major cause blindness work adult affect nearly person unite state lucentis mg pfs be also approve fda october treatment neovascular wet age related macular degeneration amd macular edema follow retinal vein occlusion rvo myopic choroidal mcnv roche have collaboration agreement novartis nvs free report lucentis roche retain commercial right unite state novartis have exclusive commercial right rest world lucentis be lead drug roche ophthalmology franchise face stiff competition regeneron regn free report eylea year share roche have decline industry growth roche performance be strong drive contribution newly launch drug label expansion key drug perjeta tecentriq alecensa further drive growth ocrevus hemlibra have be successfully launch drug be expect bolster top line further roche dominate breast cancer space strong demand franchise drug recently announce ignyta acquisition further strengthen pipeline approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis have already launch biosimilar version rituxan mabthera europe amgen amgn free report also obtain fda approval biosimilar version avastin zack rankroche carry zack rank hold see complete list today zack rank strong buy stock here hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
169,AMGN,radius health inc rdus free report announce positive result phase iii study activextend endo endocrine society annual meeting expo chicago phase iii study active abaloparatide comparator trial vertebral endpoint trial be randomize double blind placebo controlled comparative multicenter month international study postmenopausal woman osteoporosis study evaluate efficacy safety abaloparatide sc mcg reduce risk vertebral nonvertebral fracture activextend be extension active trial trial enrolled patient complete month abaloparatide sc placebo active receive additional month open label alendronate patient complete month tymlos injection placebo active trial be transition receive additional month open label alendronate bisphosphonate bone mineral density bmd be measure lumbar spine total hip femoral neck begin active end activextend result show bmd response rate increase abaloparatide follow alendronate group placebo follow alendronate group active baseline month activextend additionally greater bmd response rate more be note abaloparatide follow alendronate group versus placebo follow alendronate group site combine month anatomic site bmd increase more be note respectively visit month abaloparatide follow alendronate patient experience bmd increase more site compare patient receive placebo follow alendronate result activextend responder analysis be consistent significant bmd response tymlos versus placebo observed active trial remind investor april fda approve tymlos abaloparatide sc treatment postmenopausal woman high risk osteoporosis fracture defined history osteoporotic fracture multiple risk factor fracture patient have fail be intolerant other available osteoporosis therapy radius health share have moved last month compare industry gain tymlos continue gain traction approximately cover life coverage commercial plan tymlos market share reach approximately new patient start anabolic therapy nbrx total prescription anabolic market osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fractur year tymlos be expect face significant competition eli lilly co lly free report forteo amgen amgn free report prolium company also suffer setback chmp issue third day list outstanding issue zack rank key pickradius health currently carry zack rank hold better rank stock health care sector be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
170,AMGN,merck co inc mrk free report announce supplemental biologic license application sbla pd therapy keytruda have be accept priority review fda latest application merck be look expand label keytruda treatment advanced cervical cancer disease progression chemotherapy fda grant priority review decision be expect jun be first time fda have accept filing pd therapy cervical cancer meanwhile be fourteenth regulatory submission keytruda accept fda sbla be base part datum phase ii keynote study year so far merck share have underperform industry merck share have decline period increase industry keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication be only pd approve first line set monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda development program also significantly advanced several regulatory approval unite state europe japan new approval expand patient population drive sale last year positive momentum be expect continue well meanwhile keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
171,AMGN,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put amgen inc amgn free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front amgen have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend amgen current pe level put midpoint past year number have increase rapidly past few month further stock pe also compare unfavorably broader industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point amgen have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead amgen stock term too ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now amgen have ratio be higher average come right now also see chart be well lows stock particular past few year broad value outlookin aggregate amgen currently have zack value style score putt top stock cover look make amgen solid choice value investor stock overall amgen be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give amgn zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be upbeat current quarter have see estimate go higher past day compare lower full year estimate have see same time period have have just small impact consensus estimate current quarter consensus estimate have rise past month full year estimate have increase see consensus estimate trend recent price action stock chart amgen inc price consensus amgen inc price consensus amgen inc stock have zack rank hold be look line performance company term bottom lineamgen be inspire choice value investor be hard beat incredible lineup statistic front however sluggish industry rank bottom more industry zack rank be hard get too excited company overall fact past year broader industry have clearly underperform market large see so value investor want estimate analyst sentiment turn name first once happen stock be compelling pick breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
172,AMGN,earning season pharma biotech sector be scatter few small biotech company yet report release so far provide clear picture sector performance overall sector perform reasonably well biotech pharma bigwig gilead gild free report celgene celg free report vertex vrtx free report beat earning revenue estimate meanwhile biogen biib free report announce mixed result earning beating estimate sale lag same however amgen amgn free report have rather weak quarter miss expectation earning sale also issue lower expect sale guidance drug biotech stock remain growth trajectory ramp new product sale successful innovation product line expansion favorable clinical study result frequent fda approval strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep drive sector faster drug approval process propose removal outdated regulation push cost slowdown innovation also prove beneficial year start expectation pick activity new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be expect spur merger activity year sanofi sny free report earlier year announce deal buy belgian biotech company ablynx haemophilium focuse biotech firm bioverativ banking positive trend impressive performance be perfect time cash bountiful prospect grow market here have picked biotech stock see positive estimate revision post earning release also flaunt zack rank strong buy buy see complete list today zack rank stock here earning estimate revision have greatest impact stock price stock rise estimate have significantly outperformed index year year hence investor safely bet stock have be see upward movement earning estimate company have also see steady rally share price post result ligand pharmaceutical incorporate lgnd free report san diego base biotechnology company ligand carry zack rank stock witness positive estimate revision last day company release fourth quarter earning feb have see zack consensus estimate earning rise company surpass earning revenue estimate fourth quarter mainly higher royalty revenue additionally share company have rally post earning release regeneron pharmaceutical inc regn free report tarrytown ny base company regeneron witness positive estimate revision last day company release fourth quarter earning feb zack rank stock have see zack consensus estimate earning rise respectively regeneron fourth quarter result be impressive earning sale beat estimate strong sale company key market drug eylea share company have rally release earning release horizon pharma plc hznp free report base dublin ireland horizon pharma carry zack rank company have see zack consensus estimate earning move last day company release fourth quarter earning feb share company have gain post earning announcement horizon pharma also beat earning sale estimate fourth quarter backed strong performance orphan unit company sale guidance be encourage well outlookwhile be strong year be expect be vital biotech sector company continue invest pipeline build global business drive new product growth zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
173,AMGN,regeneron pharmaceutical inc regn free report partner sanofi sny free report announce positive result odyssey outcome trial praluent late breaker session american college cardiology annual scientific session orlando fl study be evaluate long term clinical benefit praluent initiation patient post acute coronary syndrome trial meet primary endpoint result show praluent significantly reduce risk major adverse cardiovascular event mace patient recent acute coronary syndrome acs event such heart attack praluent reduce overall risk mace hr ci mace composite endpoint include patient experience heart attack ischemic stroke death coronary heart disease unstable angina require hospitalization result pre specify analysis also show patient baseline ldl level mg dl mmol experience more pronounce effect praluent reduce risk mace hr ci moreover new safety signal emerge trial injection site reaction experience more commonly praluent group compare patient maximally tolerate statin alone praluent placebo june regeneron sanofi announce phase iiib iv odyssey dm trial patient diabetes meet primary endpoint uptake drug hasn be encourage note cholesterol management market represent huge commercial potential remind investor regeneron receive major boost praluent become first pcsk inhibitor be approve july unite state drug be also approve eu september fda recently approve company new supplemental biologic license application sbla once monthly mg dose praluent alirocumab injection treatment adult high low density lipoprotein ldl cholesterol approval expand drug dose option meanwhile phase iii study evaluate praluent homozygous familial be initiate fourth quarter sbla use praluent apheresis be file fda have set target action date aug october court appeal federal circuit order new trial issue written description enablement vacated permanent injunction ongoing pcsk litigation regeneron stock have lose last month compare industry decline regeneron fourth quarter result be impressive earning sale beat estimate drive strong eylea sale potential label expansion eylea dupixent praluent further boost result however praluent be first pcsk drug get fda approval amgen amgn free report repatha be also approve unite state eu japan pose significant competition regeneron sanofi announce reduction net price praluent alignment new value assessment high risk patient institute clinical economic review company take precision medicine approach address burden cv disease focuse effort high risk patient most vulnerable future cv event such have suffer previous coronary event be unable reduce ldl cholesterol ldl mg dl maximally tolerate statin therapy zack rank stock sport zack rank strong buy see complete list today zack rank stock here top rank stock healthcare sector be ligand pharmaceutical lgnd free report carry zack rank buy ligand earning share estimate have moved respectively last day company deliver positive earning surprise trail quarters average beat hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
174,AMGN,merck co inc mrk free report announce oncology collaboration japan eisai co ltd jointly develop commercialize latter tyrosine kinase inhibitor lenvima monotherapy well combination merck pd therapy keytruda several type cancer deal merck pay eisai upfront amount lenvima develop eisai be presently approve treatment thyroid cancer monotherapy second line treatment renal cell carcinoma rcc type kidney cancer combination novartis nvs free report afinitor everolimus meanwhile lenvima monotherapy be review unite state eu japan hepatocellular carcinoma type liver cancer also late stage study be already ongoing evaluate lenvima separate combination study keytruda afinitor rcc meanwhile keytruda lenvima combination enjoy breakthrough therapy designation fda rcc merck eisai plan jointly develop lenvima cancer type potential indication company share global development marketing cost well gross profit lenvima equally however eisai book lenvima worldwide product sale monotherapy combination other upfront payment merck also pay certain option right well reimbursement cost other eisai be entitle regulatory sale milestone payment so far year merck share have underperform industry merck share have decline period compare decrease industry keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve first line set monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda development program also significantly advanced several regulatory approval unite state europe japan new approval expand patient population drive sale last year positive momentum be expect continue well meanwhile keytruda be be study more type cancer exceed study include excess combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen expect merck present datum several key keytruda study year include combination study incyte epacadostat first line metastatic melanoma also keytruda get approval relapse refractory primary mediastinal large cell lymphoma indication year fda action expect april merck carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
175,AMGN,spectrum pharmaceutical inc sppi free report incur loss cent share fourth quarter wider zack consensus estimate loss cent line year loss moreover adjust loss come cent wider year loss cent quarterly revenue come almost year quarter top line also miss zack consensus estimate share company be almost hour trading mar presumably due wider loss lower sale however spectrum pharma share have significantly outperformed industry past year stock have gain compare industry increase quarter detailtotal product sale come year year sale be generate market product fusilev folotyn zevalin marqibo beleodaq evomela evomela be face pricing pressure due generic entry license fee service revenue be prior year quarter adjust research development expense be year quarter adjust selling general administrative spending be company be focuse development pipeline candidate poziotinib rolontis resultstotal product sale come year year adjust research development expense be year period adjust selling general administrative spending be company report adjust loss cent period wider year loss cent company provide revenue guidance range company expect expense increase due higher investment related pipeline pipeline updatespectrum pharma be evaluate poziotinib separate phase ii study treatment lung cancer phase ii study breast cancer october company present result preliminary analysis lung cancer study candidate achieve objective response rate patient egfr exon insertion mutation phase iii study advance be conduct special protocol assessment spa agreement fda evaluate rolontis treatment chemotherapy induced neutropenia patient breast cancer last month company announce successful completion advance study rolontis candidate demonstrated inferiority amgen inc amgn free report neulasta improve duration severe neutropenia have complete enrolling patient additional phase iii study recover datum study be include biologic license application bla advance study datum be file fda company expect file bla rolontis fourth quarter spectrum pharmaceutical inc price consensus ep surprise spectrum pharmaceutical inc price consensus ep surprise spectrum pharmaceutical inc quote zack rank stock pharma carry zack rank hold couple better rank stock healthcare sector be ligand pharmaceutical incorporate lgnd free report regeneron pharmaceutical inc regn free report stock sport zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have soar year regeneron earning share estimate have be revise respectively last day company deliver positive surprise last quarters average beat breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
176,AMGN,president donald trump biggest tax overhaul decade have raise appeal buyback etfs be especially true massive tax cut repatriation policy have prompt company almost sector boost multus dollar share buyback program year notably approximately american corporate profit be sit overseas bank account half be cash new tax law encourage company bring cash back home much reduce rate read tax reform affect buyback dividend etfs company have announce worth share buyback begin year accord latest report senate democrat california base research firm trimtab state pace buyback have explode february record january largest share repurchase so far cisco csco free report have be forefront additional buyback plan be follow well fargo wfc free report pepsico pep free report abbvie abbv free report amgen amgn free report give optimism be expect be second busiest year buyback bull market begin company be track return record shareholder analyst morgan jpm free report expect company index buy back much share own stock year represent whopping jump repurchase last year additional buyback be result tax saving stronger earning be generate repatriation bonanza analyst goldman sachs gs free report project buyback rise year read top rank sector etfs stock top industry result investor take advantage ongoing boom share buyback follow etfs spdr buyback etf spyb free report fund focus top company highest buyback ratio last month follow buyback index charge investor bps annual fee sector look financial consumer discretionary take largest share allocation respectively information technology healthcare round next spot product have lower aum trade paltry volume share day average read buyback etf hit new week high powershare buyback achiever portfolio pkw free report etf track nasdaq buyback achiever index comprise company have repurchase more common stock trail month hold stock basket charge higher annual fee bps here also financial consumer discretionary be top sector least share closely follow consumer staple pkw be popular fund buyback space manage asset base nearly trading average daily volume share advisorshare wilshire buyback etf ttfs free report be actively manage fund seek generate long term capital appreciation investing stock liquidity fundamental characteristic be historically associate superior long term performance approach result basket security financial consumer discretionary top sector accounting asset be follow industrial information technology healthcare product have amassed asset base see low volume nearly share day fund charge bps annual fee ishare dividend buyback etf divb free report fund offer exposure broad basket company return capital shareholder pay dividend buy back stock information technology financial consumer discretionary health care industrial be top sector double digit exposure etf have newly debut space accumulate month trade paltry volume share day average charge bps annual fee read make ishare dividend buyback etf launch timely want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
177,AMGN,radius health inc rdus free report report loss share fourth quarter wider zack consensus estimate loss year quarter loss increase general administrative expense lead wider anticipate net loss year year radius health inc price consensus radius health inc price consensus radius health inc company report sale tymlos abaloparatide surpass zack consensus estimate quarter detailresearch development expense report quarter be year year due reduction expense associate elacestrant project development tymlos radius health receive fda approval tymlos april treatment postmenopausal woman osteoporosis high risk fracture begin shipment wholesaler end tymlos continue gain traction approximately cover life coverage commercial plan tymlos market share reach approximately new patient start anabolic therapy nbrx total prescription anabolic market general administrative expense report quarter jump primarily due personnel promotional consult expense related launch tymlos pipeline company be develop formulation abaloparatide sc abaloparatide transdermal labele supplement tymlos be submit fda fourth quarter positive month datum activextend study show continue significant risk reduction fracture patient be transition receive additional month bisphosphonate therapy january radius health meet fda discuss regulatory development path abaloparatide patch fda agree depend study result single randomize open label active controlled inferiority abaloparatide sc study patient postmenopausal osteoporosis high risk fracture be sufficient gain approval abaloparatide patch primary endpoint study be change lumbar spine bone mineral density month radius health expect initiate pivotal trial mid meanwhile radius health marketing authorisation application maa eladyno abaloparatide sc treatment postmenopausal woman osteoporosis europe be review committee medicinal product human use chmp european medicine agency ema company however suffer setback chmp issue second day list outstanding issue december chmp issue third day list outstanding issue inform company intend refer maa scientific advisory group additional advice company expect opinion chmp regard maa first half radius health fda have also agree design clinical trial man osteoporosis successful form basis snda seek expand use tymlos treat man osteoporosis high risk fracture study be expect be initiate first quarter company also plan initiate clinical trial man osteoporosis successful form basis snda seek expand label treat man osteoporosis high risk fracture study be expect be initiate first quarter meanwhile company present positive datum elacestrant breast cancer december fda also grant fast track designation elacestrant october february radius health obtain scientific advice ema regard potential single arm monotherapy phase ii trial elacestrant patient positive negative advanced metastatic breast cancer base feedback ema fda company conduct single randomize controlled phase ii trial elacestrant third line monotherapy approximately patient positive negative advanced metastatic breast cancer company wider expect loss fourth quarter be due escalate expense tymlos drug continue gain traction grab further market share radius health share have gain last month compare industry gain osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fractur year tymlos be expect face significant competition eli lilly co lly free report forteo amgen amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor company also setback chmp issue third day list outstanding issue zack rank key pickradius health currently carry zack rank hold better rank stock health care sector be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
178,AMGN,biotech sector have be attract lot investor attention lately sector be expect continue benefit increase activity new drug approval better innovation sector take beating last year owing drug price control trump plan tackle ever surge drug price get highlighted latest budget grow demand drug especially rare treat disease age population increase health care spending benefit industry economy backdropu market recently suffer sell owing fear rise rate enter correction territory decline more record high set january strong wage growth job datum introduce fear inflation make comeback lead investor bet aggressive rate hike consumer price increase year year january unchanged previous month economist forecast moreover president donald trump tax reform spending deal create further pressure price hence fed be expect hike interest rate multiple time year tame inflation jerome powell testimony be see indicative possibility fed raise rate more time gauge appropriate path monetary policy next few year fomc continue strike balance avoid over-heat economy bring pce personal consumption expenditure price inflation sustain basis financial time article cite statement powell such market be suffering anticipate rate hike cyclical nature biotech stock seem appeal investor moreover encourage industry trend positive earning be poise benefit etfs expose say sector read biotech crush market best etfs stock ytd let now discuss etfs focuse provide exposure sector spdr biotech etf xbi free report fund seek provide exposure biotech space track biotechnology select industry index have aum charge fee basis point year have holding bear less concentration risk less asset be allocate top holding fund top holding be bioverativ inc array biopharma inc arry free report juno therapeutic inc allocation respectively feb fund have return year year date xbi have zack etf rank buy high risk outlook ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech space track nasdaq biotechnology index have aum charge fee basis point year have holding bear concentration risk more asset be allocate top holding fund top holding be gilead science inc gild free report amgen inc amgn free report celgene corp celg free report allocation respectively feb fund have return year year date ibb have zack etf rank hold high risk outlook bottom lineibb be more popular xbi be evident higher aum however xbi be more appeal investor owing cheaper expense ratio better zack rank same time xbi have significantly outperformed ibb come performance xbi have return almost more ibb so far year year outperformed ibb more however investor note xbi be focuse provide exposure small cap stock space ibb be more incline large cap player want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
179,AMGN,biotech major amgen inc amgn free report announce committee medicinal product human use chmp european medicine agency ema have grant positive opinion update label neulasta include neulasta onpro kit innovative delivery system neulasta onpro kit combine pre filled syringe single dose neulasta single use body injector obi delivery system neulasta be used prevent chance infection patient myeloid cancer receive cancer therapy neulasta onpro kit be improve administration option patient provide opportunity administer recommend dose neulasta home day chemotherapy thereby save trip back doctor kit have be available unite state command market share unite state neulasta sale neulasta revenue decline year period due lower demand increase competition pd other new cancer therapy be hurt demand neulasta biosimilar be already hurt sale neulasta eu start face biosimilar competition unite state year many company be look get approval biosimilar version neulasta however biocon mylan myl free report coherus bioscience inc chrs free report novartis nvs free report generic arm sandoz have receive complete response letter fda application market generic version neulasta hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
180,AMGN,key highlight week include fda refusal file letter celgene corp celg free report ozanimod gilead science inc gild free report collaboration sangamo therapeutic inc used latter technology positive chmp opinion amgen inc amgn free report xgeva incyte corp incy free report beat revenue strong jakafi sale fourth quarter recap week most important storiesfda refuse ozanimod nda follow announcement receipt refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod share celgene be pre market trading candidate be be develop treatment patient relapse form multiple sclerosis however fda determine nonclinical clinical pharmacology section nda be inadequate allow complete review hence celgene request type meeting fda ascertain additional information need resubmission nda news come great disappointment investor celgene be take desperate attempt bolster portfolio reduce overdependence lead drug revlimid company recently obtain antitrust clearance impending juno acquisition celgene be zack rank hold stock see complete list today zack rank strong buy stock here gilead collaborate sangamo gilead kite have enter collaboration agreement sangamo therapeutic inc agreement kite use sangamo zfn technology modify gene develop next generation cell therapy autologous allogeneic use oncology lieu sangamo receive upfront payment potential milestone payment sangamo be also entitle receive tiered royalty sale potential future product result collaboration other hand kite be responsible development manufacturing product collaboration sangamo share sky-rocket high news collaboration investor have lot cheer give gilead expertise biotech field chmp positive amgen xgeva label expansion committee medicinal product human use chmp european medicine agency have give positive opinion expand current indication amgen xgeva include skeletal related event patient multiple myeloma give positive result phase iii study candidate get approval aforementioned indication study result show xgeva successfully meet primary endpoint demonstrate inferiority zoledronic acid delay time first study skeletal related event patient multiple myeloma fda already approve company supplemental biologic license application xgeva expand currently approve indication prevention skeletal related event patient bone metastase solid tumor include patient multiple myeloma january vertex initiate phase iii triple combination study cf vertex pharmaceutical inc vrtx free report leader cystic fibrosis cf market announce initiation phase iii study vx tezacaftor kalydeco investigational triple combination regimen patient suffering cf have del mutation minimal function mutation study be be conduct support submission nda unite state used datum week primary efficacy endpoint together safety datum week treatment earlier month fda approve symdeko treatment underlie cause cf patient age older have copy del mutation cystic fibrosis transmembrane conductance regulator gene have least mutation be responsive tezacaftor ivacaftor biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex gain last month regeneron lose amgen gain see last biotech stock roundup here biotech stock roundup abbvie result impress ablynx be acquire sanofi next biotech world stay tune more regulatory pipeline update approach last leg earning season wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
181,AMGN,rise last year large cap pharmaceutical industry have rise year so far have however underperform gain same time frame sector be strong start struggle little thereafter probably broader market correction also mention high drug price president donald trump state union address hurt investor sentiment however sector be largely expect rebound year progress be good year pharma biotech stock sector witness positive development lead much await recovery nyse arca pharmaceutical index gain sharp contrast decline witness be tough year pharma stock give furor rise drug price key reason sector improve performance be willingness investor look drug pricing controversy focus more fundamental instead drug pricing controversy remain headline risk investor appear more comfortable issue moreover significantly higher number fda approval restore investor confidence sector approval first gene cell therapy last year be major breakthrough sector come back believe new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep sector track faster drug approval process propose removal outdated regulation drive cost slow innovation also provide benefit possibility more merger acquisition be also high now tax reform be place big player be lookout company innovative pipeline technology have already be quite bit buzz year potential deal sanofi sny free report celgene celg free report have already announce deal meanwhile large cap pharma industry be top zack rank industry make sense look buy rank stock space investing stock large market cap be much more reliable investment fact control large portion give industry also company larger market cap have perform well look well poise earn higher profit here be look large cap pharma company sport favorable zack rank strong buy buy lundbeck hluyy free report denmark base lundbeck specialize psychiatric neurological disorder company key area focus include depression schizophrenia parkinson disease alzheimer disease accord lundbeck person world suffer psychiatric neurological disorder many receive inadequate treatment ytd lundbeck have outperformed large cap pharmaceutical industry share gain addition deliver revenue growth local currency lundbeck issue upbeat outlook estimate earning growth current year be meanwhile earning estimate be past day abbvie inc abbv free report abbvie beat estimate earning sale fourth quarter also raise earning expectation base continue strong operational performance abbvie key drug humira have be perform well base strong demand trend new competition abbvie share have outperformed industry past year support series positive news include promising datum several pivotal study regulatory nod include approval competitive hcv medicine mavyret approval imbruvica settlement humira patent dispute biotech major amgen amgn free report abbvie share be impressive year so far outperform industry estimate earning growth current year be meanwhile estimate be respectively past day pfizer inc pfe free report new york base pfizer be most well know name pharmaceutical sector not just medicine vaccine also consumer healthcare product pfizer report better expect fourth quarter result beat estimate earning well sale provide upbeat outlook believe pfizer snew product ibrance contribution acquisition cost cut share buyback help company earn profit future quarters pfizer share have rise year so far estimate earning growth current year be meanwhile estimate be respectively past day nordisk nvo free report year be eventful denmark base pharma giant gain regulatory approval key pipeline drug candidate include fast act insulin aspart fiasp once daily pre filled pen ozempic hemophilia treatment rebinyn meanwhile strong performance victoza be drive top line growth believe new product solid pipeline pave way growth year company past day earning estimate have rise respectively estimate earning growth current year be pfizer abbvie nordisk be zack rank buy stock lundbeck be zack rank strong buy stock see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
182,AMGN,radius health inc rdus free report be schedule report fourth quarter result mar radius health share have lose year compare industry slip radius health have disappointing track record company have report wider expect loss trail trail quarters average negative earning surprise let see thing be shape quarter radius health inc price consensus radius health inc price consensus radius health inc quote factor play radius health develop therapeutic treatment osteoporosis oncology endocrine disease company lead drug tymlos be approve unite state april drug be approve treat postmenopausal woman osteoporosis high risk fracture defined history osteoporotic fracture multiple risk factor fracture drug also be used patient have fail be intolerant other available osteoporosis therapy company report sale tymlos abaloparatide third quarter hence expect investor focus uptake drug upcoming earning call osteoporosis market unite state have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen amgn free report prolium meanwhile company marketing authorisation application eladyno abaloparatide sc europe treatment postmenopausal woman osteoporosis be review however december radius health announce committee medicinal product human use chmp issue third day list outstanding issue regulatory review abaloparatide sc chmp inform company refer marketing authorisation application scientific advisory group additional advice part ongoing risk benefit assessment hence chmp expect give opinion same first half july chmp provide second day list outstanding issue request additional datum analysis related safety efficacy abaloparatide sc ongoing regulatory review delay approval europe be disappointing give potential market hold meanwhile fda grant fast track designation pipeline candidate elacestrant experimental selective estrogen receptor regulator treatment woman advanced metastatic breast cancer elacestrant clinical development program be currently ongoing phase study patient advanced metastatic breast cancer have be heavily pre treat median prior line therapy have evaluable disease december radius health provide encourage datum phase clinical study elacestrant rad patient estrogen receptor positive breast cancer san antonio breast cancer symposium approximately patient be treat mg dose elacestrant phase dose escalation expansion cohort enrolled patient patient meet recist measurable disease criterium baseline be confirm partial response group elacestrant be well tolerate most common adverse event be low grade nausea dyspepsia vomit consequently radius health plan initiate phase ii study elacestrant monotherapy potentially pivotal study woman suffering advanced metastatic breast cancer early hence expect management throw light pipeline progress earning whispersour proven model do not conclusively show radius health be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp radius health be currently peg be most accurate estimate be peg loss zack consensus estimate stand loss uncover best stock buy sell re report earning esp filter zack rank radius health have zack rank rank be favorable company negative esp make surprise prediction difficult note caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be pharma company consider model show have right combination element deliver earning beat quarter gemphire therapeutic gemp free report be expect release fourth quarter result mar company have earning esp zack rank see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
183,AMGN,ligand pharmaceutical incorporate lgnd free report report fourth quarter adjust earning share significantly year figure cent bottom line also beat zack consensus estimate share company have outperformed industry year time stock have soar versus industry decrease total revenue quarter surge year year mainly back higher royalty revenue top line also surpass zack consensus estimate quarterly revenue be report quarter approximately year year higher royalty sale novartis nvs free report promacta amgen amgn free report kyproli spectrum pharmaceutical sppi free report evomela drive upside notably ligand license platform technology such captisol omniab partner use proprietary program material sale drop due unfavorable timing captisol purchase clinical commercial use license milestone revenue be register massive surge compare year period upside be attributable favorable timing milestone license fee earn research development expense rise moreover general administrative expense increase year year resultsfull year sale improve year year figure surpass zack consensus estimate moreover top line surpass previous guidance full year earning share compare favorably zack consensus estimate gain company have post earning year bottom line also surpass previous projection pipeline other updateslast month company enter worldwide omniab platform license agreement fer pharmaceutical other glenmark pharmaceutical pursuant deal company use ligand full omniab platform fully human mono multispecific antibody ligand be entitle receive annual platform access payment development regulatory milestone payment tiered royalty product incorporating omniab antibody meanwhile october ligand sign contract acquire crystal bioscience buyout crystal bioscience humab technology be part ligand omniab brand be call omnichicken addition omnichicken platform ligand omniab technology supplement third species fully humanize antibody discovery respect company internal pipeline various candidate be development indication diabetes most advanced candidate be lgd presently undergo phase ii trial treatment type ii diabetes company report positive top line datum same only last september expect revenue be approximately higher revenue year company anticipate additional license fee milestone payment adjust earning be estimate share much ahead earning ligand pharmaceutical incorporate price consensus ep surprise ligand pharmaceutical incorporate price consensus ep surprise ligand pharmaceutical incorporate quote zack rankligand carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
184,AMGN,novartis ag nvs free report end positive note courtesy strong performance psoriasis drug cosentyx cosentyx achieve multus blockbuster drug status back strong growth approve indication psoriasis ankylose spondylitis psoriatic arthritis drug have grab market share rival abbvie abbv free report humira amgen amgn free report enbrel drug have be evaluate more patient study have be prescribe more patient global basis indication novartis recently report new encourage datum cosentyx datum phase iii study scalp american academy dermatology aad annual meeting san diego randomize double blind placebo controlled phase iii study be be conduct evaluate efficacy safety cosentyx patient moderate severe scalp psoriasis eligible patient be equally randomize subcutaneous cosentyx mg placebo week then week week patient placebo group do not achieve least improvement baseline psoriasis scalp severity index pssi score week be re randomize cosentyx mg completion study primary endpoint be proportion patient achieve pssi response rate week majority patient scalp psoriasis cosentyx achieve clear skin pssi week improve quality life study show pssi response rate be achieve significantly higher proportion patient receive cosentyx vs placebo week vs further improvement take cosentyx week estimate scalp psoriasis affect person worldwide earlier month fda approve line extension cosentyx moderate severe scalp psoriasis fda approval come back positive efficacy safety outcome dedicate phase iii study scalp patient scalp psoriasis novartis share have gain year par industry gain label expansion drug be likely boost sale further zack rank key picknovartis carry zack rank hold better rank stock health care space be exelixis exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
185,AMGN,roche holding ag rhhby free report be set acquire privately hold healthcare technology service company flatiron health inc company sign definitive agreement roche acquire share flatiron health roche currently have exist equity stake roche pay acquisition transaction be expect close first half new york base flatiron health be market leader oncology specific electronic health record software well curator developer real world evidence cancer research roche flatiron health be best position provide technology datum analytic infrastructure need close deal flatiron health continue current business model network partnership overall objective roche have be active acquisition front december roche enter definitive merger agreement ignyta inc price share total value cash transaction roche have strong presence oncology market particular company dominate breast cancer space strong demand franchise drug apart strong breast cancer franchise roche oncology portfolio also boast drug avastin tarceva lung cancer roche stock have lose last month industry gain however remind investor competition amgen amgn free report novartis nvs free report biosimilar loom large roche key drug zack rank stock considerroche carry zack rank hold better rank stock health care space be exelixis exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
186,AMGN,abbvie abbv free report announce hike quarterly dividend authorization new share buyback program board abbvie stock rise more thursday response news dividend be increase cent share cent share cash dividend be payable shareholder record apr new quarterly dividend amount annual dividend share imply dividend yield please note be second dividend hike abbvie less month october last year abbvie announce hike quarterly dividend cent share cent share abbvie hike quarterly dividend fact inception abbvie have hike dividend fourth quarter conference call hold last month management hint shareholder return be likely go company cash position have improve follow recent tax reform fact abbvie have perform exceptionally well past year support series positive news stock have return past year compare favorably gain record industry abbvie meet primary endpoint several pivotal study key phase iii murano study venclexta roche rhhby free report rituxan relapse refractory chronic lymphocytic leukemia phase iii study evaluate oral jak selective inhibitor upadacitinib rheumatoid arthritis also phase iib study atopic dermatitis pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara humira moderate severe chronic plaque psoriasis meanwhile abbvie gain regulatory approval unite state europe japan competitive hcv medicine mavyret fda approval sixth indication cancer drug imbruvica fact mavyret launch have be stronger expect inform company fourth quarter conference call abbvie also settle patent dispute amgen amgn free report delay launch latter biosimilar version abbvie blockbuster arthritis drug humira unite state most country eu october agreement have remove major overhang abbvie share moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market several pivotal datum readout regulatory milestone expect bullish run stock continue importantly humira have be generate solid sale base strong demand trend drug trend expect continue year imbruvica abbvie second most important drug be also do consistently well have multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease factor bode well stock abbvie carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
187,AMGN,roche group rhhby free report member genentech announce fda accept supplemental biologic license application sbla grant priority review label expansion company leukemia drug rituxan rituximab company be seek get rituxan approve treatment pemphigus vulgaris be life threaten condition characterize progressive painful blister skin mucous membrane rituxan be already approve treat blood cancer include hodgkin lymphoma follicular lymphoma diffuse large cell lymphoma chronic lymphocytic leukemia well immunological disease rheumatoid arthritis priority review designation fda be generally grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease year share roche have decline industry growth sbla submission be base datum roche support randomize trial conduct france evaluate rituxan taper regimen low dose oral corticosteroid cs treatment compare standard dose cs alone first line treatment patient newly diagnosed moderate severe pemphigus study show rituxan provide considerable improvement pemphigus vulgaris remission rate successful taper cessation cs therapy however remind investor competition amgen amgn free report novartis nvs free report biosimilar loom large rituxan roche hold ag price roche hold ag price roche hold ag quotezack rank stock considerroche carry zack rank hold better rank stock health care space be exelixis exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat share price company surge year don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
188,AMGN,february issue update report immunogen inc imgn free report immunogen report fourth quarter result feb company post wider expect loss report quarter revenue miss estimate however loss be significantly narrower year figure sale show massive increase period top line improvement be mainly drive substantially higher license milestone fee related divestment company core cell asset imgn november debiopharm international fourth quarter conference call focus be mainly progress related company pipeline development share immunogen have significantly outperformed industry year time stock have soar industry decline immunogen have significantly progressed respect lead pipeline candidate mirvetuximab soravtansine candidate be evaluation phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer tumor express high medium level fr alpha notably combo therapy mirvetuximab soravtansine ovarian cancer be be evaluate phase ib ii forward ii study study consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda initial datum study demonstrated candidate have potential complement available therapy indication update datum program be expect first half notably mirvetuximab soravtansine enjoy orphan drug status unite state eu treatment ovarian cancer apart mirvetuximab soravtansine immunogen work develop couple other candidate include imgn imgn december immunogen release positive finding ongoing phase study evaluate imgn patient relapse refractory adult acute myeloid leukemia aml earlier january company initiate phase program analyze imgn treat hematological malignancy include aml immunogen have agreement several big healthcare company include amgen amgn free report bayer eli lilly novartis roche sanofi takeda contract turn allow other company use immunogen adc technology provide fund form license milestone fee royalty clinical material revenue research development support fee zack rankimmunogen carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
189,AMGN,earning season be fly start owing slew upbeat economic datum strong corporate performance president donald trump tax reform sign law however equity market have be suffering sell owing fear rise rate come performance biotech giant have be mixed bag biotech company beating market expectation few fail do so read follow etf move finally selloff set now discuss performance few biotech giant such amgen inc amgn free report gilead science gild free report biogen inc biib free report alexion pharmaceutical alxn free report earning focusamgen report fourth quarter adjust earning share miss zack consensus estimate unchanged year quarter company also miss zack consensus estimate revenue amgen report revenue miss zack consensus estimate decrease year quarter full year company report decrease revenue however gaap ep increase company expect gaap ep be range also expect revenue be range moreover amgen expect adjust tax rate be owing tax reform gilead science report fourth quarter adjust earning share surpass zack consensus estimate decrease share year quarter moreover company also beat zack consensus estimate revenue company report revenue surpass zack consensus estimate decrease more year quarter full year company report decrease revenue moreover gaap ep decrease period company expect full year revenue be range adjust expense adjust sg expense be project range respectively biogen inc report fourth quarter adjust earning share miss zack consensus estimate increase share year quarter company report revenue surpass zack consensus estimate increase roughly year quarter full year company report increase revenue moreover gaap ep increase biogen expect earning be range share company expect full year revenue be range alexion pharmaceutical inc report fourth quarter adjust earning share surpass zack consensus estimate increase roughly share year quarter company report revenue beat consensus estimate increase roughly year quarter full year company report increase revenue moreover gaap ep increase company expect full year revenue be range company expect gaap ep be range now discuss few etfs high exposure company discuss ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech industry have aum charge fee basis point year fund have exposure amgen biogen gilead alexion feb fund have return year have zack etf rank hold high risk outlook vaneck vector biotech etf bbh free report fund have aum charge fee basis point year fund have exposure amgen gilead biogen alexion feb fund have return year have zack etf rank high risk outlook proshare ultra nasdaq biotechnology etf bib free report fund have aum charge fee basis point year fund have exposure amgen biogen gilead alexion dec fund have return year want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
190,AMGN,novartis nvs free report announce fda have approve line extension il inhibitor drug cosentyx moderate severe scalp psoriasis fda approval come back positive efficacy safety outcome dedicate phase iii study scalp patient scalp psoriasis note drug be approve similar indication europe june be already approve treatment plaque psoriasis psoriatic arthritis psa ankylose spondylitis press release scalp psoriasis be difficult treat form psoriasis affect half approximately patient disease line extension drug be important achievement treatment scalp psoriasis topical agent phototherapy be challenge due presence hair other factor novartis share have return past year compare industry gain same period scalp study evaluate subcutaneous administration cosentyx mg week datum show significant improvement patient compare placebo cosentyx performance be impressive achieve multus blockbuster drug status back strong growth approve indication sale drug increase surpass mark drug have show superiority clinical study johnson johnson jnj free report stelara amgen amgn free report enbrel treat psoriasis novartis be also conduct head head clinical trial exceed surpass evaluate superiority cosentyx versus abbvie abbv free report humira psa propose biosimilar humira respectively superiority drug stelara enbrel have help gain market share potential superiority humira biosimilar line extension scalp psoriasis certainly boost prospect drug novartis ag price novartis ag price novartis ag quotezack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
191,AMGN,spectrum pharmaceutical inc sppi free report announce positive datum phase iii study advance evaluate lead pipeline candidate rolontis management chemotherapy induced neutropenia patient early stage breast cancer candidate demonstrated inferiority amgen inc amgn free report neulasta improve duration severe neutropenia share spectrum pharma have sky-rocket past year significantly outperform industry gain company be evaluate rolontis phase iii study advance recover early stage breast cancer patient advance study compare rolontis neulasta management chemotherapy induced neutropenia breast cancer patient receive docetaxel chemotherapy day completion enrollment recover study announce press release spectrum pharma be track file biologic license application seek approval rolontis management neutropenia fourth quarter apart rolontis company be develop qapzola treat muscle invasive bladder cancer poziotinib small cell lung cancer patient breast cancer october spectrum announce encourage preliminary datum poziotinib phase ii nsclc study patient have exon insertion mutation egfr however spectrum pharma product sale market product have be lacklusterin last month due intense competition keep investor focuse pipeline development spectrum pharmaceutical inc price spectrum pharmaceutical inc price spectrum pharmaceutical inc quotezack rank stock pharma carry zack rank hold couple better rank stock pharma sector include anthera pharmaceutical inc anth free report exelixis inc exel free report stock carry zack rank buy see complete list today zack rank strong buy stock here anthera loss estimate narrow last day company come positive earning surprise trail quarters average beat exelixis earning estimate increase cent cent last day company deliver positive earning surprise trail quarters average beat stock have return past year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
192,AMGN,roche holding ag rhhby free report announce positive result phase iii immotion study immunoncology drug tecentriq combination oncology drug avastin bevacizumab drug serve first line treatment option advanced metastatic renal cell carcinoma mrcc immotion multicenter randomize open label study be be conduct evaluate efficacy safety tecentriq avastin versus sunitinib person inoperable locally advanced metastatic renal cell carcinoma rcc have not receive prior systemic active experimental therapy study meet co primary endpoint investigator assessed progression free survival pfs patient disease expressed pd programme death ligand expression percent protein result show patient receive tecentriq avastin have reduce risk disease worsening death pfs compare person treat sutent median pfs mpfs vs month hr percent ci moreover pre defined analysis patient report outcome reveal combination tecentriq avastin markedly delay time worsening disease symptom interfere day day life compare sutent study be second phase iii study combination regimen monoclonal antibody tecentriq be approve various cancer bladder urinary tract cancer company be evaluate combination broad range cancer include advanced rcc datum co primary endpoint overall survival overall study population intention treat itt be encourage be still immature note exelixis exel free report cabometyx be also approve treat advanced rcc roche stock have gain past year compare industry gain roche performance be strong drive contribution newly launch drug label expansion key drug perjeta tecentriq alecensa drive growth further ocrevus hemlibra have be successfully launch however sale avastin tarceva continue decline approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis ag nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche carry zack rank hold see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
193,AMGN,biotech major amgen inc amgn free report report fourth quarter earning share miss zack consensus estimate earning be flat year year lower sale higher operate cost offset benefit lower tax rate include charge related tax reform fourth quarter loss share be earning share fourth quarter total revenue quarter miss zack consensus estimate revenue decline year year quarter detailtotal product revenue decline year quarter ex increase demand newer product prolium kyproli xgeva blincyto be not enough make lower sale amgen largest product enbrel aranesp epogen neulasta neupogen due competitive pressure revenue amgen erythropoiesis stimulating agent esa aranesp decline year quarter due lower demand unfavorable change currency rate revenue other esa epogen decline due lower selling price owing newly negotiate contract davita inc neulasta revenue be flat year period lower demand be offset change accounting estimate increase competition pd other new cancer therapy be hurt demand neulasta however neulasta onpro kit body injector continue perform well command market share unite state neulasta sale please note neulasta epogen start face biosimilar competition unite state year hurt sale further neupogen record decline sale due biosimilar competition unite state zarxio sandoz novartis nvs free report generic arm biosimilar version neupogen be launch unite state september be hurt sale enbrel deliver revenue year quarter due lower selling price increase competition hurt demand amgen launch enbrel autotouch autoinjector device november last year prolium revenue come year quarter due higher demand osteoporosis drug witness continue growth new patient start strong repeat injection rate drive year year growth meanwhile xgeva deliver revenue year quarter mainly due higher demand favorable change inventory level earlier year amgen gain fda approval expand label xgeva include prevention ofskeletal related event sre inpatient multiple myeloma now xgeva be only approve prevention sre solid tumor patient bone metastase approval expand patient population drive sale xgeva future quarters sensipar mimpara revenue be flat higher price increase be offset unfavorable inventory change vectibix revenue come drive higher demand kyproli record sale year year drive higher demand robust uptake outside market amgen regulatory application unite state include overall survival datum endeavor study label kyproli be grant approval fda earlier month also earlier week amgen announce committee medicinal product human use chmp have give positive opinion recommend addition endeavor kyproli label eu study demonstrated combination kyproli dexamethasone lead superior overall survival compare takeda velcade dexamethasone overall survival datum approve help drive usage boost sale kyproli blincyto sale surge year period reflect higher demand amgen pcsk inhibitor repatha generate revenue compare third quarter uptake drug gain fda approval august have not be very encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical also face similar issue pcsk inhibitor praluent priority amgen right now be improve patient access repatha december amgen gain fda approval include new indication risk reduction major cardiovascular event datum repatha label base datum phase iii cardiovascular outcome study fourier make repatha first pcsk inhibitor prevent heart attack stroke coronary adult establish cardiovascular disease cardiovascular indication approve be include repatha label patient access repatha be expect improve operate margin decreaseadjust operate margin decline basis point bps due higher operate cost expense related hurricane marium recovery effort expense decline quarter due lower late stage pipeline related cost lower payment licensing transaction sg spend increase due higher investment support new product launch partially offset impact october expiration enbrel residual royalty payment month amgen board director approve new share buyback plan bring total exist share repurchase authorization resultsfull year sale miss zack consensus estimate revenue be guidance range sale decline year year adjust earning be share also miss zack consensus estimate share earning be guidance range earning rise year year company expect total revenue range fall short zack consensus estimate adjust earning be now expect range zack consensus estimate be peg share adjust tax rate be expect be approximately much lower reflect impact tax reform expectation improve cash position follow tax reform amgen plan invest approximately next year capital expenditure approximately investment be make unite state include set new drug substance manufacturing plant country takeamgen have rather poor quarter miss expectation earning sale also issue lower expect sale guidance share lose market trading response however past year amgen share have return better increase register industry amgen newer product prolium xgeva vectibix nplate sensipar be perform well volume growth be not enough offset decline mature brand enbrel due competitive pressure however amgen be also progress pipeline expect approval launch migraine candidate aimovig year also amgevita amgen biosimilar version abbvie abbv free report blockbuster rheumatoid arthritis drug humira be expect be launch europe later year parsabiv specialty product kidney disease be launch unite state last month also management seem quite confident repatha become important growth driver company inclusion outcome datum label nonetheless other continue competitive dynamic enbrel possible generic competition sensipar new competition neulasta aranesp be new challenge amgen carry zack rank hold see complete list today zack rank strong buy stock here amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quotebreaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
194,AMGN,roche hold ag rhhby free report report sale chf fourth quarter year period roche stock have moved last month compare industry gain company report result division pharmaceutical diagnostic growth rate mentioned be year year basis constant exchange rate sale come chf earning share come chf chf sale pharmaceutical division increase drive strong growth tecentriq ocrevus alecensa perjeta diagnostic division sale climb primarily back strong business result detailherceptin sale improve due increase demand unite state brazil perjeta sale grow follow increase demand neoadjuvant metastatic setting sale kadcyla be drive increase demand international market meanwhile sale avastin decrease due increase use cancer immunotherapy medicine lung cancer sale rituxan mabthera be drive growth immunology segment growth gazyva gazyvaro be strong increase competition chronic lymphocytic leukemia recently launch drug tecentriq alecensa lung cancer be strong start tecentriq ocrevus alecensa contribute chf new sale performance immunology franchise be drive increase sale actemra roactemra strong uptake esbriet xolair increase use actemra roactemra subcutaneous formulation drive sale however sale tarceva decline due grow use other therapeutic option sale xeloda continue be hit generic competition sale tamiflu also decline revenue diagnostic division climb back solid performance centralised point care solution unit be turn propel tissue diagnostic molecular diagnostic also perform impressively however diabetes care sale decline sale continue be impact challenge market condition particularly north america outlookroche now expect sale remain stable grow low single digit company expect core earning grow high single digit company intend further increase dividend local currency pipeline company win fda approval new drug ocrevus treatment relapse primary progressive form multiple sclerosis hemlibra haemophlium factor viii inhibitor company continue expand label exist drug perjeta adjuvant surgery treatment positive early breast cancer high risk recurrence combination herceptin chemotherapy well full approval perjeta neoadjuvant use fourth quarter roche obtain fda approval label expansion few drug alecensa first line treatment alk positive small cell lung cancer nsclc zelboraf erdheim chester disease gazyva untreated advanced follicular lymphoma avastin glioblastoma adult patient cancer have progressed prior treatment alecensa be also approve monotherapy first line treatment adult patient anaplastic lymphoma kinase alk positive advanced nsclc europe january ema approve ocrevus treatment relapse primary progressive form multiple sclerosis hemlibra be grant positive opinion chmp meanwhile tecentriq combination avastin show positive study result lung cancer kidney cancer diagnostic front roche enter strategic long term partnership ge healthcare jointly develop co market digital clinical decision support solution takeroche performance be strong drive contribution newly launch drug label expansion key drug perjeta tecentriq alecensa further drive growth ocrevus hemlibra have be successfully launch however sale avastin tarceva continue decline approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis ag nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rank key pickroche carry zack rank hold better rank stock healthcare sector be exelixis exel free report zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
195,AMGN,acquisition once again remain focus week ablynx agree be acquire sanofi sny free report deal worth approximately seattle genetic sgen free report also announce intention acquire cascadian therapeutic meanwhile earning result be focus abbvie abbv free report report strong quarter provide upbeat outlook recap week most important storiesa look earning result company celgene celg free report abbvie biogen vertex vrtx free report report fourth quarter result last trading session celgene read more celgene earning sale beat solid revlimid vertex top earning well revenue estimate biogen top revenue miss earning read more biogen earning miss sale top view upbeat vertex also announce have select next generation corrector vx vx move late stage development part different triple combination regimen person cystic fibrosis cf last year vertex share be compare gain record industry belong abbvie share jump follow release better expect fourth quarter result upbeat outlook result be drive performance humira imbruvica mavyret read more abbvie soar result key takeaway earning call abbvie be zack rank buy stock see complete list today zack rank strong buy stock here ablynx be acquire sanofi belgium base biopharma company ablynx have agree be acquire french pharma giant sanofi price share cash approximately announcement come just few week nordisk have announce interest acquire ablynx deal value approximately ablynx have reject nordisk offer company board say proposal fundamentally undervalue ablynx growth prospect look ablynx pipeline show company well be position launch first product caplacizumab vwf acquire thrombotic purpura attp year caplacizumab be currently review eu regulatory application be file unite state first half estimate annual market opportunity attp life threaten blood clot disease be expect be company also have broad range partnership potential generate more milestone royalty other pipeline candidate also address significant market opportunity company have more program pipeline nanobody clinical development acquisition be expect close end second quarter read more sanofi buyout spree month buy ablynx bellicum fda clinical hold bellicum pharmaceutical share be almost follow company announcement fda have place clinical hold study be conduct bpx hold be place case encephalopathy be deem possibly connect bpx company say case be complex certain factor prior fail transplant prior history concurrent infection administration rimiducid combination other medication bellicum be now wait receive formal notice fda step need be take resumption study clinical hold not impact ongoing registration study europe seattle genetic boost pipeline cascadian acquisition seattle genetic announce be acquire cascadian therapeutic share cash acquisition slate close first quarter seattle be add tucatinib pipeline tucatinib be investigational oral small molecule tyrosine kinase inhibitor tki be highly selective growth factor receptor be overexpressed several cancer include breast colorectal ovarian gastric candidate be currently pivotal phase ii program metastatic breast cancer complement seattle exist pipeline biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock alexion decline gilead gild free report gain last month biogen be regeneron lose next biotech world watch amgen amgn free report fourth quarter result be market close today read more amgen benefit growth drug earning meanwhile fda be expect issue decision regard label expansion amag pharmaceutical feraheme february amag be look expand label current chronic kidney disease ckd indication include eligible adult patient iron deficiency anemia ida wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
196,AMGN,amgen amgn free report announce receive positive opinion committee medicinal product human use chmp european medicine agency recommend addition update overall survival os datum phase iii head head study label multiple myeloma drug kyproli carfilzomib phase iii endeavor study be conduct patient datum trial demonstrated combination kyproli dexamethasone kd lead superior overall survival compare takeda pharmaceutical velcade dexamethasone vd second line multiple myeloma set finding show combination therapy reduce risk death increase os month compare vd give patient population importantly january amgen announce fda have approve supplemental new drug application snda include os datum endeavor program kyproli label fda decision come much earlier expect initially expect april year note kd regimen be already approve unite state eu other country base primary analysis progression free survival endeavor study overall survival datum approve help drive usage kyproli boost sale remind investor kyproli be also approve unite state single agent treat patient multiple myeloma have receive least prior therapy include velcade agent significantly amgen collaborate johnson johnson jnj free report november study combination kyproli darzalex multiple clinical study address case multiple myeloma term agreement first study phase iii registrational trial evaluate combo therapy kyproli darzalex dexamethasone compare kyproli dexamethasone alone patient multiple myeloma have undergo prior line therapy have be initiate amgen share have outperformed industry year time stock have rally compare favorably industry increase incidentally kyproli become part amgen portfolio follow acquisition onyx register sale first month compare year figure drug label expansion immensely expand patient population well commercial potential company press release multiple myeloma be aggressive disease accounting approximately percent cancer moreover patient be annually diagnosed multiple myeloma europe almost case prove be fatal hence market opportunity combination therapy be huge eu cater unmet need patient additional option apprehend life threaten disease amgen inc price amgen inc price amgen inc quote zack rank key picksamgen carry zack rank hold better rank stock health care sector be xoma corporation xoma free report exelixis inc exel free report xoma sport zack rank strong buy exelixis carry zack rank buy see complete list today zack rank stock here xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month exelixis earning share estimate have be revise upward cent cent last day company pull positive surprise trail quarters average beat share price company have soar year time hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
197,AMGN,investor be always look stock be poise beat earning season amgen inc amgn free report be such company firm have earning come pretty soon event be shape quite nicely report be amgenis see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface amgn report fact most accurate estimate current quarter be currently share amgn compare broader zack consensus estimate share suggest analyst have very recently bump estimate amgn give stock zack earning esp head earning season amgen inc price ep surprise amgen inc price ep surprise amgen inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give amgn have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead amgen beat be card upcoming report hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
198,AMGN,pfizer inc pfe free report report fourth quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year drive higher international sale lower cost share count pharma heavyweight deliver revenue also beat zack consensus estimate revenue rise year quarter report basis operational basis revenue be flat year year sale detailcurrency movement benefit pfizer fourth quarter revenue february pfizer divest hospira infusion system business icu medical exclude currency headwind revenue prior year quarter sale rise operationally strong performance newer product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis somewhat offset lower sale enbrel viagra loss exclusivity product supply shortage legacy hospira product international revenue rise operational basis meanwhile revenue decline segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report basis operational basis year period pfizer ih revenue be drive persistently strong momentum eliquis globally xeljanz lyrica ibrance chantix champix primarily unite state ibrance revenue rise quarter drive strong revenue however ibrance sale be softer prior quarter time price adjustment hurt international sale xeljanz sale rise lyrica sale rise eliquis alliance revenue direct sale rise chantix sale rise quarter revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare third quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada total viagra ih sale decline due generic competition begin december global prevnar prevenar revenue rise higher international sale make decline unite state prevnar revenue tank unite state due continue decline revenue eligible adult patient population however prevenar revenue rise international market due favorable timing government purchase emerge market pediatric indication consumer healthcare revenue decline global oncology revenue increase global vaccine revenue rise internal medicine rise inflammation immunology franchise rise additionally portfolio rare disease decline pfizer be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision be expect year also be retain business pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state lyrica europe lower revenue legacy hospira product due product shortage divesture however business biosimilar emerge market do well quarter biosimilar revenue rise operationally emerge market revenue grow operationally pfizer launch inflectra biosimilar version johnson johnson jnj free report merck mrk free report blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market adjust selling informational administrative si expense decline operationally quarter adjust expense also decline resultsfull year sale be flat year year operational basis sale marginally beat zack consensus estimate be line guidance range adjust earning share full year exceed zack consensus estimate well guide range earning rise year year guidancerevenue be expect range zack consensus estimate be peg adjust earning share be expect range zack consensus estimate share mid point adjust ep be expect increase revenue be expect increase research development expense be expect range si spending be project range adjust tax rate be expect be takepfizer fourth quarter result be expectation beat estimate earning revenue meanwhile issue upbeat guidance also pfizer say plan invest approximately capital project unite state next year increase access foreign cash follow tax reform however initial gain share pfizer fall premarket trading believe lower sale unite state sequentially softer performance ibrance quarter hurt investor sentiment past year pfizer share have increase compare unfavorably increase industry top line headwind form genericization key drug supply shortage legacy hospira product pricing pressure rise competition pfizer achieve adjust earning growth new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance meanwhile pfizer look well poise record profit growth pfizer carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
199,AMGN,roche holding ag rhhby free report announce fda have grant breakthrough therapy designation experimental drug oral medicine balovaptan previously know rg vasopressin have receptor antagonist individual autism spectrum disorder asd designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient benefit patient current treatment option designation balovaptan be primarily base efficacy finding phase ii trial vanilla vasopressin antagonist improve social communication autism study adult asd meanwhile phase ii trial balovaptan child adolescent asd be ongoing other trial asd be also be plan note asd be approximately time more prevalent boy girl estimate boy girl suffer asd unite state world health organization estimate global prevalence asd be approximately person global burden disease roche have more dozen pipeline candidate neuroscience portfolio disease include multiple sclerosis alzheimer disease spinal muscular atrophy parkinson disease autism earlier month european commission grant marketing authorization multiple sclerosis drug ocrevus approval boost roche neuroscience portfolio roche stock have rally year compare industry gain approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis ag nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rank key pickroche carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
200,AMGN,meredith corporation mdp free report have credit solid history reward shareholder have be pay quarterly dividend last year management have recently approve quarterly dividend hike cent share annually mark company successive year dividend hike increase dividend be paid mar shareholder record feb notably hike reflect yield nearly stock close price jan annually new dividend represent hike cent share prior payout january de moine ia base company announce increase regular quarterly dividend cent share annually dividend hike be frequent company stable cash position healthy cash flow believe such hike not only enhance shareholder return raise market value stock well fact dividend increase company persuade investor buy hold scrip instead selling impressively zack rank hold company maintain shareholder friendly policy total shareholder return tsr strategy turn aids management enhance shareholder value share repurchase dividend strategic business investment drive growth implementation strategy more year company return average annual basis apart meredith company boee company ba free report aes corporation aes free report amgen amgn free report have raise respective dividend payout late boee raise quarterly dividend percent share payable mar aes corporation have approve quarterly dividend hike cent share be payable feb amgen hike quarterly dividend share payable mar stock news dividend hike share meredith gain last month stock have gain compare industry growth company be slate report second quarter fiscal result jan management have earlier state meredith second quarter earning be likely be range cent share report prior year quarter sharp decline earning projection quarter be primarily due benefit cent register year period backed robust political advertising revenue moreover advancement technology print medium be decline nevertheless company strategic initiative particularly digital space brand licensing activity solid portfolio television station reinforce position lead medium marketing company see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
201,AMGN,novartis ag nvs free report subsidiary advanced accelerator application obtain fda approval new drug application nda lutathera lutetium lu dotatate treatment somatostatin receptor positive neuroendocrine tumor gep net include foregut midgut hindgut neuroendocrine tumor adult remind investor last week novartis complete successful tender offer advanced accelerator application lutathera be first class drug first available fda approve peptide receptor radionuclide therapy form treatment comprise target molecule carry radioactive component approval be base encourage phase iii study result demonstrated reduction risk disease progression death lutathera best standard care arm octreotide lar mg week compare mg octreotide lar alone hazard ratio ci approval luthera expand novartis neuroendocrine tumor portfolio approval new drug boost novartis portfolio be face generic competition blockbuster drug gleevec last week novartis report encourage result fourth quarter result beat earning sale estimate strong performance cosentyx entresto psoriasis cosentyx achieve multus blockbuster drug status back strong growth approve indication entresto sale benefit continue access improvement expansion sale force unite state novartis stock have rally last month compare industry gain generic division sandoz also combat pricing pressure strongly buoy launch rixathon biosimilar version roche holding rhhby free report rituxan rituximab erelzi biosimilar amgen amgn free report enbrel eu propose biosimilar version abbvie abbv free report humira adalimumab have also be accept review fda meanwhile strategic decision alcon retain business separation capital market transaction such spin initial public offer have be postpone company believe alcon division have revive well now hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
202,AMGN,roche rhhby free report announce eu committee medicinal product human use chmp have adopt positive opinion hemlibra emicizumab routine prophylaxis bleed episode patient suffering hemophilia factor viii inhibitor chmp have recommend drug use age group marketing authorisation application be be review accelerate assessment final decision be expect european commission shortly chmp recommendation be base positive result pivotal clinical study person haemophilium inhibitor phase iii haven haven study note fda approve hemlibra routine prophylaxis event reduce frequency bleed episode adult child haemophilium factor viii inhibitor november hemlibra be review fda priority review grant breakthrough therapy designation fda person age year older haemophilium inhibitor september meanwhile hemlibra be be evaluate clinical development program include additional phase iii study haven haven result haven show statistically significant clinically meaningful reduction number treat bleed time adult adolescent year age older haemophilium inhibitor receive hemlibra prophylaxis week week compare receive prophylaxis interim result haven show clinically meaningful control bleed adult adolescent year age older haemophilium inhibitor receive hemlibra prophylaxis once week potential approval europe further boost roche hematology portfolio include approve drug mabthera rituxan gazyva gazyvaro tecentriq venclexta well encourage pipeline comprise candidate polatuzumab vedotin rg small molecule antagonist mdm idasanutlin rg note roche be develop venclexta collaboration abbvie abbv free report company be jointly commercialize unite state abbvie be commercialize drug outside unite state earlier month european commission grant marketing authorization multiple sclerosis ms drug ocrevus drug be approve active relapse form ms defined clinical imaging feature well early primary progressive ms term disease duration level disability imaging feature characteristic inflammatory activity roche stock have lose year compare industry gain approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis ag nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
203,AMGN,expect biotech major amgen inc amgn free report beat expectation report fourth quarter full year result feb market close amgen deliver positive earning surprise last quarter amgen share be past year compare favorably increase register industry period amgen performance have be pretty impressive company deliver positive surprise consistently average earning beat last quarters be amgen inc price ep surprise amgen inc price ep surprise amgen inc quotelet see thing be shape company quarter factor playamgen newer product prolium xgeva kyproli vectibix blincyto be expect deliver good backed higher demand however sale mature brand aranesp enbrel epogen neulasta neupogen be expect be lower due competitive pressure neulasta demand be be hurt competition pd other new cancer therapy neupogen sale be also be hurt biosimilar competition unite state mainly zarxio sandoz biosimilar version neupogenwe expect neulasta neupogen sale continue be hurt competitive dynamic fourth quarter meanwhile neulasta epogen be expect start face biosimilar competition unite state year enbrel sale be expect continue be hurt increase pricing competitive pressure enbrel be main driver amgen revenue company launch enbrel mini autotouch new auto injector device enbrel unite state november be likely provide support fourth quarter sale meanwhile operate expense be expect be higher fourth quarter prior quarter reflect typical pattern business well cost related recovery effort follow hurricane marium amgen expect record expense related hurricane marium recovery effort fourth quarter reduce earning share cent investor focus call be management comment initial impact inclusion cardiovascular outcome datum label pcsk inhibitor repatha december amgen gain fda approval include new indication risk reduction major cardiovascular event datum repatha label base datum phase iii cardiovascular outcome study fourier make repatha first pcsk inhibitor prevent heart attack stroke coronary adult establish cardiovascular disease cardiovascular indication approve be include repatha label amgen believe patient access repatha improve please note uptake repatha gain fda approval august have not be very encourage so far due pricing re imbursement issue payer restriction earning whispersour proven model show amgen be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank amgen have zack rank combination amgen zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considersome other stock biotech sector have positive esp favorable zack rank be alexion pharmaceutical inc alxn free report earning esp zack rank company be schedule release result feb emergent biosolution inc ebs free report earning esp zack rank company be expect result next month schedule release result feb incyte corporation incy free report have earning esp zack rank see complete list today zack rank stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
204,AMGN,novartis ag nvs free report enter licensing agreement spark therapeutic develop register commercialize luxturna voretigene neparvovec market outside unite state note luxturna be approve unite state dec time gene therapy restore functional vision child adult patient biallelic mutation rpe retinal pigment epithelial kda protein gene market authorization application be file european medicine agency july novartis make upfront payment well pay milestone royalty spark therapeutic meanwhile spark therapeutic retain exclusive right luxturna unite state retain responsibility obtain approval europe spark therapeutic also be responsible supply luxturna separate manufacturing supply agreement novartis remind investor fda approve novartis breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah have be launch unite state earlier week novartis report encourage result fourth quarter result beat earning sale estimate strong performance cosentyx entresto psoriasis cosentyx achieve multus blockbuster drug status back strong growth approve indication entresto sale benefit continue access improvement expansion sale force unite state generic division sandoz also combat pricing pressure strongly buoy launch rixathon biosimilar version roche holding inc rhhby free report rituxan rituximab erelzi biosimilar amgen inc amgn free report enbrel eu propose biosimilar version abbvie inc abbv free report humira adalimumab have also be accept review fda meanwhile strategic decision alcon retain business separation capital market transaction such spin initial public offer have be postpone company believe alcon division have revive well now hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
205,AMGN,novartis ag nvs free report report encourage result fourth quarter earning revenue beat estimate drive strong performance cosentyx entresto novartis ag price ep surprise novartis ag price ep surprise novartis ag quote fourth quarter core earning share beat zack consensus estimate be record year quarter revenue increase volume growth drive cosentyx entresto be partially offset negative impact generic competition pricing revenue also beat zack consensus estimate novartis stock have rally last month compare industry gain growth rate mentioned be year year basis constant exchange rate quarter detailnovartis operate segment innovative medicine pharmaceutical alcon ophthalmology unit sandoz generic innovative medicine division record sale generic competition impact sale segment primarily due entry generic gleevec unite state europe pricing too impact sale nevertheless growth product cosentyx entresto promacta revolade jakavi tafinlar mekinist gilenya boost sale psoriasis cosentyx achieve multus blockbuster drug status back strong growth approve indication entresto sale benefit continue access improvement expansion sale force unite state cosentyx generate sale entresto sale come oncology franchise exclude gleevec grow sale sandoz division be volume growth be offset price erosion unite state sale unite state decline due pricing pressure sale grow mainly drive zarxio unite state launch rixathon biosimilar version roche holding inc rhhby free report rituxan rituximab erelzi biosimilar amgen inc amgn free report enbrel eu sale alcon division be surgical sale increase drive broad recovery most market segment include strong growth vitreoretinal product vision care sale be fuel continue double digit growth daily total earlier novartis announce be mull strategic option lag eye care unit alcon include retain business separation capital market transaction such spin initial public offer company update strategic plan announce have potential grow sale market deliver profitability line industry company also make significant progress develop potential capital market solution include financial carve out tax legal entity structuring identify list incorporation location final decision be take depend alcon sale performance be not likely happen first half meanwhile novartis have moved ophthalmic otc product alcon division effective jan allow innovative medicine division focus pharmaceutical pipeline resultssale come beat zack consensus estimate earning share come beating zack consensus estimate share outlooknovartis expect net sale grow low mid single digit innovative medicine be project grow mid single digit revenue sandoz be expect be broadly line decline slightly alcon sale be estimate grow low mid single digit pipeline updatenovartis pipeline candidate progress have be encourage be good year novartis major approval oncology portfolio continue gain traction significant boost fda approve breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah have be launch unite state novartis be seek expand kymriah label novartis supplemental biologic license application kymriah suspension intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma be ineligible relapse autologous stem cell transplant have be accept fda priority review breast cancer drug kisqali be approve europe first line option hr advanced metastatic breast cancer combination inhibitor drug be already approve unite state company also receive approval rydapt europe treatment newly diagnosed flt mutate acute myeloid leukemia type systemic mastocytosis sandoz continue progress biosimilar pipeline propose biosimilar version abbvie inc abbv free report humira adalimumab have also be accept review fda biosimilar version humira be already review eu tasigna be approve europe treatment pediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp pediatric patient ph cml cp resistance intolerance prior therapy include imatinib takenovartis fourth quarter result beat earning sale estimate strong performance cosentyx entresto generic division sandoz also combat pricing pressure strongly buoy biosimilar launch rixathin erelzi meanwhile strategic decision alcon retain business separation capital market transaction such spin initial public offer have be postpone company believe alcon division have revive well now hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
206,AMGN,novartis ag nvs free report announce positive result phase iiib study liberty assessed efficacy safety erenumab amg mg patient episodic migraine have experience previous preventive treatment failure due lack efficacy intolerable side effect study meet primary endpoint significantly more patient take erenumab experience least reduction baseline monthly migraine day compare placebo trial meet secondary endpoint include reduction monthly migraine day lower day need acute rescue medication improvement score migraine physical function impact diary mpfid tool responder rate number patient experience least reduction monthly migraine day compare placebo safety datum be consistent previous study erenumab date show placebo safety profile novartis present full datum upcoming scientific meeting novartis stock have rally last month compare industry gain erenumab investigational fully human monoclonal antibody be design selectively block calcitonin gene related peptide cgrp receptor play critical role migraine activation candidate be be develop novartis collaboration amgen inc amgn free report candidate be first investigational therapy target cgrp pathway have receive food drug administration european medicine agency ema regulatory filing acceptance approval novartis amgen co commercialize erenumab unite state amgen have exclusive right drug japan novartis have exclusive right commercialize rest world novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie inc abbv free report humira amgen enbrel zack rank key picknovartis currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
207,AMGN,amgen amgn free report announce fully human monoclonal antibody aimovig erenumab meet primary secondary endpoint unique phase iiib study prevention patient episodic migraine have fail multiple prior preventive treatment notably aimovig be only investigational therapy design selectively block calcitonin gene related peptide cgrp receptor play significant role migraine activation aimovig be review unite state eu prevention episodic chronic migraine decision fda be expect moreover share company be year compare favorably industry increase phase iiib liberty study be design evaluate efficacy safety aimovig broad spectrum migraine patient range preventive treatment well have try fail such therapy result study demonstrated least patient achieve reduction monthly migraine day baseline last week compare placebo primary endpoint study datum trial also show consistent efficacy safety tolerability aimovig wider spectrum migraine patient include complicate case remind investor amgen develop aimovig collaboration novartis nvs free report company have now agree combine capability co commercialize candidate unite state incidentally amgen retain exclusive right japan novartis retain exist right rest world have exclusive right commercialize aimovig canada expand deal world health organization migraine be most debilitating illness approximately american daily activity be affected frequency severity migraine subject be undergo preventive therapy discontinue treatment year hence approval aimovig provide company much need access huge patient population unite state be need additional curative option apprehend disease however several company include teva pharmaceutical industry limit teva free report allergan agn free report other be also develop migraine treatment target cgrp amgen inc price amgen inc price amgen inc quote zack rankamgen carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
208,AMGN,have complete just week biotech sector be already see significant pickup merger acquisition deal year start celgene corporation celg free report announce intention acquire impact biomedicine soon thereafter nordisk nvo free report confirm be look acquire belgium base biopharma company ablynx nordisk have initially propose acquire ablynx share cash however company come back revise offer ablynx reject first proposal nordisk latest offer include upfront cash payment share contingent value right cvr worth share total equity valuation approximately offer too have be reject ablynx company board announce proposal fundamentally undervalue ablynx growth prospect last week celgene be once again news rumor be look acquire immuno oncology focuse juno therapeutic yesterday rumor be confirm company say be acquire juno approximately acquisition announcement be make yesterday french pharma giant sanofi sny free report say be buy biopharma company bioverativ celgene be look strengthen presence cancer space impact juno acquisition sanofi be look expand presence specialty care strengthen leadership rare disease bioverativ acquisition more deal follow announcement be make expectation be pretty high more such deal fact last week acorda therapeutic share be rumor biogen biib free report be interested acquire company factor grow biosimilar competition slowdown growth legacy product major pipeline setback loom patent expiry pricing challenge grow competition have force big player seek deal acquisition grow pipeline boost revenue stream tax reform expect lead increase cash repatriation seem set more announcement company pfizer amgen amgn free report biogen merck johnson johnson gilead be expect be lookout suitable deal year end third quarter gilead have acquire kite approximately have cash equivalent balance include overseas cash amgen cash balance be also sep be hold overseas meanwhile merck exit third quarter cash equivalent worth be hold overseas bristol myer squibb overseas cash holding be approximately end third quarter biogen overseas cash balance be approximately end third quarter cash be likely be used share buyback dividend payment company be also expect use fund acquisition deal most company be lookout asset technology be potentially address unmet need immuno oncology be currently very much demand company be also focuse rare disease orphan disease area valuation look high cancer focuse company especially one involved immuno oncology valuation appear be more reasonable specialty pharma company company be focuse central nervous system disease other such area many large cap player have expressed interest pursue deal have also point deal make sense financial perspective high valuation bidding war keep key player sideline company avexis bluebird biomarin puma biotechnology incyte exelixis exel free report be often consider acquisition target exelixis be zack rank strong buy stock see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
209,AMGN,healthcare be perform well start new year thank encourage industry trend favorable policy environment notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain nearly so far bullish trend be likely continue head earning season big name johnson johnson jnj free report pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read tax bill etf investor need know let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stocksjnj have zack rank earning esp indicate lower chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive momentum style score value growth style score johnson johnson be slate release earning jan open bell see healthcare etfs here pfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see positive earning estimate revision penny be report quarter deliver average negative earning surprise past quarters have impressive growth value momentum style score respectively pfizer be schedule report earning jan open bell merck be expect report result feb market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision couple cent past day be report quarter merck have value growth momentum style score respectively amgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day quarter be report stock have solid value style score growth momentum style score look dull amgen report earning feb market close read wave push biotech etfs higher abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter stock have solid value growth style score momentum style score be unimpressive company be schedule report jan open bell gilead be expect release earning feb market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision cent past month be report quarter have solid value style score growth momentum style score look ugly bristol myer likely report earning feb open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have solid momentum growth style score respectively unfavorable value style score sum earning surprise well card healthcare sector be expect witness earning growth fourth quarter suggest upside healthcare etfs particular etfs have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
210,AMGN,merck co inc mrk free report announce datum phase ii keynote study evaluate use pd therapy keytruda patient advanced hepatocellular carcinoma hcc form liver cancer be previously treat systemic therapy sorafenib datum show treatment keytruda monotherapy lead overall response rate orr datum also show complete response rate partial response rate treatment datum also include month overall survival os progression free survival pfs rate median pfs keytruda arm be month month pfs rate percent however datum show median os be not reach time analysis month os rate be datum be present present american society clinical oncology asco gi cancer symposium san francisco notably keytruda be already market several cancer indication include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer last week merck announce keytruda combination lilly lly free report alimta pemetrexed acisplatin carboplatin meet dual primary endpoint phase iii keynote study combination be evaluate first line treatment patient metastatic squamous nsclc study meet primary endpoint progression free survival pfs os co primary endpoint remind investor third quarter call merck have mentioned be include overall survival os co primary endpoint keynote study defer readout study be then estimate study complete february therefore year earlier expect positive read keynote study be big boost company share merck have lose past year compare unfavorably industry increase remind investor keytruda be key top line driver merck bring sale third quarter sequentially year year sale continue be drive launch new indication globally significantly keytruda sale unite state have gain particularly strong momentum new indication first line lung cancer meanwhile keytruda development program also significantly advanced regulatory approval new indication unite state additional disease europe keytruda be continuously grow expand new indication market globally be trial more type cancer study include excess combination study merck be collaborate separately several company namely amgen inc amgn free report incyte glaxo pfizer inc pfe free report evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotezack rankmerck carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
211,AMGN,novartis ag nvs free report be schedule report fourth quarter result jan swiss pharmaceutical company stock have rally last month compare industry gain novartis have excellent track record last quarter novartis deliver positive earning surprise company post average positive earning surprise trail quarters let see thing be shape announcement factor playconcurrent third quarter result novartis reiterate annual guidance net sale be expect be line level include impact continue genericization gleevec glivec unite state europe novartis operate segment innovative medicine pharmaceutical alcon sandoz generic novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space sale division be expect grow marginally new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie inc abbv free report humira amgen inc amgn free report enbrel cosentyx achieve blockbuster status record sale entresto be expect record revenue sale cosentyx be project reach additionally novartis generic arm sandoz be make effort strengthen biosimilar portfolio company plan launch biosimilar major oncology immunology biologic key geography company be however face significant pricing pressure impact fourth quarter result company now expect sale decline broadly line meanwhile loss exclusivity key drug novartis portfolio continue hurt company top line company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february eu december thereby lead generic competition exforge be also face generic competition unite state eu further oncology drug be face new competition form immuno oncology therapy negative impact generic competition be expect impact sale performance ophthalmology division alcon business be weak due competition face intraocular lens slowdown demand equipment purchase consequently novartis take few step revive business turnaround have be encourage management believe create standalone company capital market exit create additional shareholder value decision be expect first half depend alcon performance future earning whispersour proven model do not conclusively show novartis beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp novartis be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank novartis currently carry zack rank rank be favorable company esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be stock healthcare sector want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release fourth quarter result jan complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
212,AMGN,amgen inc amgn free report partner allergan agn free report announce european commission have grant marketing approval biosimilar version roche rhhby free report blockbuster cancer drug avastin bevacizumab mvasi drug be approve unite state september mvasi be approve eu treatment multiple type cancer note mvasi be first bevacizumab biosimilar be approve european union approval be line expectation consider committee medicinal product human use chmp european medicine agency ema have render positive opinion approval mvasi november approval be support comprehensive datum package demonstrated similarity mvasi bevacizumab amgen have collaborate allergan worldwide development oncology antibody biosimilar medicine other mvasi amgen allergan portfolio also include biosimilar version herceptin review unite state eu rituxan late stage study overall amgen have biosimilar pipeline include biosimilar version johnson johnson merck remicade alexion soliris amgen biosimilar version abbvie abbv free report blockbuster rheumatoid arthritis drug humira amjevita be approve fda september eu trade name amgevita march same indication humira amjevita be first biosimilar version humira be approve fda well amgen first biosimilar medicine be approve settlement agreement abbvie amgen begin selling amjevita most country eu year unite state january amgen biosimilar opportunity be likely translate annual revenue more amgen have also partner daiichi sankyo biosimilar japan past year amgen share have return compare increase register industry amgen carry zack rank hold see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
213,AMGN,couple quiet week cancer space witness activity fda action label expansion positive datum readout major drug several company meanwhile biosimilar blockbuster cancer drug receive approval europe new drug be also grant approval treatment leukemia amgen inc amgn free report multiple myeloma drug kyproli receive fda nod include overall survival os datum head head endeavor study label first car therapy receive approval novartis ag nvs free report kymriah get boost fda accept supplemental biologic license application sbla seek label expansion diffuse large cell lymphoma dlbcl moreover astrazeneca azn free report lynparza get fda nod label expansion metastatic breast cancer teva pharmaceutical also announce approval label expansion acute promyelocytic leukemia drug trisenox injection first line set combination tretinoin moreover amgen partner allergan agn free report announce approval mvasi biosimilar version roche rhhby free report blockbuster cancer drug avastin europe datum readout include encourage datum merck mrk free report keytruda confirmatory phase iii lung cancer study exelixis inc exel free report cabometyx phase iii hepatocellular carcinoma study apart biolinerx ltd blrx free report also announce encourage partial result phase iia combat study pancreatic cancer lead pipeline candidate bl partial datum study show bl monotherapy be safe well tolerate patient give indication let see news detail amgen kyproli get label update avastin biosimilar approve fda approve regulatory application include os datum endeavor study label kyproli fda decision come much earlier expect be initially expect april similar application be review europe read more amgen get fda nod add endeavor datum kyproli label amgen inc price amgen inc price amgen inc quotenovartis car therapy sbla accept fda novartis announce fda have accept grant priority review sbla seek label expansion car therapy kymriah potential approval expand drug access patient relapse refractory dlbcl be ineligible relapse autologous stem cell transplant read more novartis sbla car therapy kymriah accept fda novartis ag price novartis ag price novartis ag announce label expansion lynparza breast cancer astrazeneca parp inhibit ovarian cancer treatment lynparza be grant label expansion unite state include metastatic breast cancer indication lynparza become first parp inhibitor approve treat metastatic breast cancer expand label certainly boost drug prospect give advantage other parp inhibitor be only approve ovarian cancer read more astrazeneca lynparza label now include breast cancer astrazeneca plc price astrazeneca plc price astrazeneca plc quotemerck keytruda impressive phase iii lung cancer study merck share get boost jan follow announcement keytruda combination lilly alimta carboplatin achieve dual primary endpoint confirmatory phase iii keynote study study be evaluate combination treatment metastatic squamous small cell lung cancer nsclc first line set datum be report much earlier anticipate february combination be grant accelerate approval aforementioned indication read more merck strong confirmatory phase iii lung cancer study merck company inc price merck company inc price merck company inc quoteexelixis cabometyx positive phase iii carcinoma study exelixis partner ipsen announce datum pivotal phase iii celestial study cabometyx datum study evaluate drug advanced hepatocellular carcinoma show achieve significant os benefit patient have receive prior treatment median os achieve drug be month versus month placebo read more exelixis ipsen report positive result lead cancer drug exelixis inc price exelixis inc price exelixis inc quoteapart gilead announce week have enter collaboration agreement pfizer develop car therapy yesacrta combination latter utomilumab patient refractory large cell lymphoma make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
214,AMGN,share spectrum pharmaceutical inc sppi free report have be witness upside biotech company have more double past month surge significantly outperform rise industry period spectrum be focuse acquire develop commercialize product primarily field hematology oncology company market product be utilize treat several cancer indication include lymphoma leukemia myeloma however primary focus be development pipeline include poziotinib qapzola rolontis pipeline price performance last month be attribute strong pipeline company initiate phase iii study qapzola phase ii study poziotinib complete enrollment phase iii pivotal study rolontis spectrum pharmaceutical be develop qapzola treat muscle invasive bladder cancer rolontis management chemotherapy induced neutropenia breast cancer patient poziotinib small cell lung cancer patient nsclc breast cancer october spectrum announce encourage preliminary datum poziotinib phase ii nsclc study patient have exon insertion mutation egfr patient treat poziotinib have objective response stock witness rise follow news spectrum be evaluate candidate phase ii study nsclc patient exon insertion mutation egfr meanwhile phase iii study advance recover be evaluate company most advanced candidate rolontis study have similar design be evaluate rolontis versus amgen inc amgn free report neulasta management neutropeniain early stage breast cancer recover study be be conduct strengthen regulatory package biologic license application be expect be file fourth quarter top line datum advance study be expect first quarter however product sale have be lackluster last month keep investor focuse pipeline development meanwhile spectrum cash cash equivalent rise third quarter help company fund development candidate positive datum readout rolontis study expect quarter propel stock further spectrum pharmaceutical inc price spectrum pharmaceutical inc price spectrum pharmaceutical inc quotezack rank stock carry zack rank hold couple better rank stock pharma sector include inc agen free report plc alk free report stock carry zack rank buy see complete list today zack rank strong buy stock here loss estimate narrow last day company deliver positive earning surprise trail quarters average beat company share have return past year earning estimate remain flat cent increase cent cent last day company come positive earning surprise trail quarters average beat make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
215,AMGN,share nektar therapeutic nktr free report have increase massive year time substantially outperform industry gain let analyze factor lead massive rally nektar rapid progress robust pipeline year accompany several study initiation positive readout strategic collaboration have drive share price consistently company pegylation technology also facilitate development several approve product unite state eu partnership healthcare company namely astrazeneca azn free report movantik ucb cimzia amgen amgn free report neulasta other furthermore have robust pipeline early late stage candidate nektar have make significant progress lead candidate onzeald formerly know nktr be currently accelerate assessment eu treat adult advanced breast cancer well brain metastase response be anticipate first half meanwhile randomize phase iii confirmatory study attain begin onzeald late last year study compare onzeald single agent chemotherapy physician choice patient advanced breast cancer have brain metastase late positive result program be likely support regulatory filing unite state apart onzeald nektar be work develop other candidate september company announce initiation phase ii propel study evaluate efficacy safety immuno oncology candidate nktr combination roche tecentriq atezolizumab merck mrk free report keytruda pembrolizumab phase ii pivot study evaluate nktr potential combination treatment regimen bristol myer squibb opdivo be also underway tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication november company announce positive datum pivot study treat patient melanoma renal cell carcinoma small cell lung cancer also nektar enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio candidate nktr be be examine phase iii program treatment chronic pain july company report positive top line finding oral human abuse potential study analyse nktr assess opioid abuse potential compare oxycodone be plan submit new drug application candidate april march company initiate phase clinical study evaluate nktr treat wide range auto immune disease inflammatory disorder subsequently july nektar seal co development deal elly lilly company nktr pursuant agreement company own responsibility complete ongoing phase study candidate company share phase ii development cost lilly acquire lion share total expense year look extremely favorable stock several update line expect approval onzeald eu breast cancer submission nda nktr act catalyst further drive stock nektar therapeutic price nektar therapeutic price nektar therapeutic quotezack ranknektar carry zack rank sell see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
216,AMGN,investing sound large cap pharma stock seem judicious be fundamentally lucrative ensure steady stream cash inflow investor drug sector have good run bounce back drug pricing issue dampen performance importantly sector see considerable increase new drug approval last year fda approve novel drug last year more double tally large cap pharma industry witness impressive rally decline run be propel encourage quarterly result increase demand new product sale successful innovation product line expansion strong clinical study result continue strong performance legacy product also boost sector factor be expect play instrumental role well take large cap drug sector new high industry be already so far year notably large cap pharma industry carry zack industry rank place top zack industry back testing show top zack rank industry outperform bottom half factor more pass tax overhaul bill congress be cherry top slash corporate tax rate be likely further boost profit margin moreover cash repatriation window allow bill help company bring cash stash foreign location leave company extra cash hand lead strategic deal merger acquisition year be relatively fewer most drug company large market cap have see share price rise so far here present company johnson johnson jnj free report abbvie inc abbv free report zoetis inc zts free report nordisk nvo free report outperformed industry last year have potential repeat same performance johnson company stock be compare favorably gain record industry company have zack rank hold see complete list today zack rank strong buy stock here company share be boost approval drug tremfya plaque psoriasis juluca hiv several line extension major drug include xarelto simponi aria stelara imbruvicain trend be expect continue have several regulatory application label expansion key drug review potential approval line extension certainly boost company growth prospect meanwhile be several pivotal datum readout regulatory milestone line moreover pharma segment growth accelerate third quarter slow first half due number factor include competition key drug remicade concerta upside be expect continue stock company be company hold zack rank buy company report series positive news include promising datum several pivotal study regulatory approval unite state europe japan competitive hcv medicine mavyret fda approval sixth indication imbruvica settlement humira patent dispute amgen inc amgn free report abbvie also expect several pivotal datum readout regulatory milestone be expect further aid company datum readout pivotal phase iii trinity study rova third line later small cell lung cancer be important catalyst stock moreover fda decision be expect new drug application nda elagolix endometriosis be grant priority review october last year abbvie blockbuster drug humira have be perform well competitive pressure company expect drug performance continue boost topline imbruvica be also do consistently well multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease nordiskshare company increase company carry zack rank company be grant approval expand label diabetes drug victoza include treatment major adverse cardiovascular event adult type ii diabetes august moreover new diabetes drug fiasp receive approval september treat adult diabetes december fda approve ozempic semaglutide once daily pre filled pen improve glycaemic control type ii diabetes patient also receive approval rebinyn hemophilia unite state refixia treatment adolescent adult same indication europe company expect launch ozempic approval same europe certainly boost company revenue moreover company serve almost half insulin market quarter diabetes market grow diabetes market certainly boost topline company share rise company sport zack rank strong buy company have diversify portfolio livestock companion animal product company increase share dermatology product dog market companion animal business have be perform well launch apoquel cytopoint company acquire nexvet biopharma last year boost pipeline solution chronic pain management dog cat company also expand reach poultry diagnostic product major european market zoetis topline be expect benefit cytopoint be launch europe fourth quarter company expect cattle herd size increase drive growth strong product portfolio consistently successful pipeline development anticipate growth demand drug company likely attract investor attention year well zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
217,AMGN,amgen inc amgn free report announce fda have approve regulatory application include overall survival os datum head head endeavor study label multiple myeloma drug kyproli please note fda decision come much earlier expect be initially expect april amgen have submit supplemental new drug application snda fda july last year regulatory application eu seek approval include os datum endeavor study be also submit same month datum present endeavor study earlier have demonstrated combination kyproli dexamethasone lead superior overall survival compare takeda velcade dexamethasone second line multiple myeloma set kyproli dexamethasone arm reduce risk death increase os month compare combination velcade dexamethasone kyproli be already approve patient population overall survival datum help drive usage boost sale other ongoing study kyprolisinclude phase iii arrow study be evaluate weekly dose regimen kyproli relapse refractory multiple myeloma patient phase iii aspire study evaluate triple combination regimen kyproli celgene celg free report revlimid lenalidomide dexamethasone krd patient relapse multiple myeloma compare revlimid dexamethasone rd amgen have also form collaboration jnj free report study combination kyproli darzalex multiple clinical study treatment multiple myeloma kyproli generate sale third quarter record year year growth drive higher demand robust uptake outside market share amgen be more wednesday past year amgen share have return compare increase register industry amgen carry zack rank hold better rank biotech stock be vertex pharmaceutical incorporate vrtx free report zack rank strong buy see complete list today zack rank stock here vertex stock have return past year earning estimate have go almost past day zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
218,AMGN,acquisition once again remain focus week celgene celg free report rumore be talk juno regard possible deal recap week most important storiesjuno soar acquisition rumor juno share sky-rocket report celgene be interested acquire immuno oncology focuse company accord wall street journal report company be talk regard possible acquisition deal juno acquisition rumor turn be true be second acquisition announcement be make celgene year just last week company announce intention acquire impact biomedicine be develop fedratinib myelofibrosis polycythemia vera celgene be lot pressure strengthen pipeline revenue stream company have tough issue pipeline setback well weak performance otezla weigh stock however remain be see much celgene be willing shell juno juno market cap jan be juno share have be upward trend follow gilead kite acquisition announcement last year august juno be focuse development innovative cellular immunotherapy treatment cancer company have long be consider potential acquisition target last year juno share be compare gain record industry belong juno cell base cancer immunotherapy be base chimeric antigen receptor high affinity cell receptor technology company have several cell base candidate pipeline target variety cell malignancy well multiple solid tumor multiple myeloma juno suffer major setback development erstwhile lead pipeline candidate due safety issue include patient death company be now focuse liso cel next generation car cell product target cd juno expect file fda approval liso cel relapse refractory diffuse large cell lymphoma dlbcl second half immuno oncology space remain quite lucrative celgene have pay hefty premium finalize deal juno celgene already have collaboration deal place concert patent challenge update concert pharmaceutical cnce free report suffer major blow post grant review pgr petition challenge validity patent be reject patent trial appeal board ptab patent trademark office concert have file petition last year july challenge validity patent have be assign incyte pharmaceutical incy free report concern patent cover deuterate ruxolitinib analog concert ctp be deuterium modify version ruxolitinib incyte market ruxolitinib unite state name jakafi have patent cover ruxolitinib be unexpired concert seek marketing approval ctp setback concert say always challenge validity patent later federal court moreover company say decision do not affect plan develop ctp alopecia areata however company be now reassess plan develop ctp additional indication ctp be novel jak inhibitor currently phase ii development alopecia areata fda recently grant fast track status candidate indication read more concert pharmaceutical plunge patent petition setback vertex orkambi label expand eu vertex pharmaceutical vrtx free report gain eu approval use orkambi lumacaftor ivacaftor child cystic fibrosis cf year age group copy del mutation child europe category approval be line expectation consider company have get positive opinion european union committee medicinal product human use chmp indication november read more vertex cystic fibrosis drug pediatric use eu vertex be zack rank strong buy stock see complete list today zack rank stock here humira biosimilar bla accept fda fda have accept review biologic license application bla submit sandoz biosimilar version abbvie blockbuster drug humira adalimumab humira be approve wide range indication recent healthcare conference abbvie say global humira sale crossed approach company expect drug lose exclusivity international market fourth quarter believe sale erosion be manageable note sandoz be not first file biosimilar version humira fact company amgen amgn free report boehringer ingelheim have already gain approval humira biosimilar amgen enter global settlement license agreement abbvie expect launch humira biosimilar europe october unite state january meanwhile abbvie boehringer be engage patent litigation unite state eiger plunge pipeline setback eiger suffer major setback investigational treatment ubenimex pulmonary arterial hypertension pah fail meet primary endpoint mid stage study base disappointing update company have decide discontinue development ubenimex pah continue evaluate ubenimex lymphedema ubenimex be mid stage study indication datum expect second half year company share be news biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be slightly last trading session major biotech stock celgene decline gilead gild free report gain last month biogen be regeneron lose see last biotech stock roundup here celgene acquire impact morgan healthcare conference focus next biotech world watch usual regulatory pipeline update synergy pharmaceutical get know approval status trulance use adult patient irritable bowel syndrome constipation ib jan more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
219,AMGN,amgen inc amgn free report stock be compare favorably gain record industry last year share price surge be support series positive news include promising datum several pivotal study rapid progress pipeline line extension positive trend be likely continue year well backed stock rally few new product be approve last year fda approve mvasi amgen allergan agn free report biosimilar version roche rhhby free report cancer drug avastin parsabiv secondary shpt eu approve amgevita amgen biosimilar version humira amgen also gain approval several line extension fda approval include new indication risk reduction major cardiovascular event datum repatha overall survival tower study leukemia drug blincyto label approval arefined indication metastatic colorectal cancerdrug vectibix eu approval pediatric formulation secondary shpt line extension expand eligible patient population drug drive sale higher future quarters amgen make several datum presentation study evaluate line extension key market product repatha kyproli blockbuster potential other study pipeline candidate tezepelumab asthma evenity osteoporosis factor likely support stock several pivotal datum readout regulatory milestone expect bullish run stock be likely continue year amgen expect regulatory approval pipeline candidate aimovig erenumab prevention episodic chronic migraine evenity label expansion prolium kyproli month amgen already receive fda approval expand patient population xgeva multiple myeloma patient biosimilar portfolio amgen expect eu approval mvasi fda eu approval biosimilar version roche other cancer drug herceptin also amgen newer drug prolium xgeva vectibix nplate sensipar be perform well trend expect continue next year drive sale sale other newer product kyproli repatha blincyto be expect pick be approve forlabel expansion last year amgen restructure plan be make leaner more cost efficient lend support bottom line amgen face challenge give presenceof biosimilar competition slowdown sale mature drug mainly blockbuster drug enbrel positive be expect outweigh headwind amgen market enbrel partnership pfizer inc pfe free report amgen carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
220,AMGN,novartis ag nvs free report generic arm sandoz announce fda accept biologic license application bla propose biosimilar abbvie inc abbv free report humira biosimilar be submit pathway drug be already approve treatment number inflammatory disease include rheumatoid arthritis plaque psoriasis crohn disease ulcerative colitis datum package submit fda comprise analytical preclinical clinical datum be expect demonstrate sandoz propose biosimilar adalimumab match reference biologic term safety efficacy quality also include pharmacokinetic study healthy volunteer phase iii confirmatory safety efficacy study patient moderate severe chronic plaque type psoriasis novartis stock have rally past year compare industry gain biosimilar version humira be also review eu note sandoz hold lead position biosimilar space portfolio market biosimilar currently deep pipeline biosimilar version rituximab rixathon be approve european commission june be currently review unite state meanwhile sandoz witness strong growth outside unite state buoy launch rixathon erelzi biosimilar amgen inc amgn free report enbrel europe however pricing pressure intensified unite state company expect low single digit sale decline sandoz fourth quarter mainly due seasonal shipment phase continue pricing pressure unite state meanwhile novartis be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company believe alcon division have revive well now even separation capital market create value shareholder other hand novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space zack rank key picknovartis currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
221,AMGN,fourth quarter earning season be expect be strong earning growth likely pick continue accelerate dip precede quarter index be anticipate see earning growth revenue growth market be also record level scaling series high start year forecast compare favorably earning growth revenue growth revision trend have be favorable earning estimate hold better relative other comparable period earning estimate have moved percentage point start quarter additionally zack sector be likely be contributor earning growth suggest potential upside many corner market read etfs stock favorite sector earning give strong sentiment investor focus etfs large allocation stock have high chance surprising upcoming release result winning bet earning season find right etfs handpicking etfs portfolio stock be most likely beat earning be mean feat however proprietary methodology find earning esp stock calculate percentage difference most accurate estimate zack consensus estimate be solid build block uncover best stock buy sell re report earning esp filter bet etfs winning combination stock have positive earning esp favorable zack rank strong buy buy hold lead profit investor be especially true earning beat definitely draw investor attention propel stock price related etfs first run zack stock screener find stock positive earning esp favorable zack rank then narrow list select group stock higher positive earning esp accordingly choose etfs comprise few stock higher chance beating estimate particular industry see etf category here research show stock combination chance positive earning surprise be high result fund be excellent investor seek guarantee profit earning season vaneck vector biotech etf bbh free report fund offer exposure large biotechnology corporation tracking mvis list biotech index stock portfolio be expect beat earning quarter amgen amgn free report celgene celg free report illumina ilmn free report incyte incy be top holding have earning esp respectively firm have zack rank collectively account asset biomarin pharmaceutical bmrn free report account share basket also have zack rank earning esp bbh have amassed asset base charge bps fee year volume be moderate exchange share daily average have zack etf rank high risk outlook read value biotech etfs buy now powershare dynamic retail portfolio pmr free report fund follow dynamic retail intellidex index measure performance company engage operate general merchandise store such department store discount store warehouse club superstore specialty store include apparel electronic accessory footwear store home improvement home furnishing store total product hold security stock portfolio expect come earning beat suggest solid upside etf particular best buy bby dollar tree dltr home depot hd free report walgreen boot alliance wba be top holding account share have earning esp respectively fund have accumulate just asset base charge bps fee year average daily volume be paltry share etf carry zack etf rank medium risk outlook read holiday sale year high best consumer etfs stock powershare dynamic energy exploration production portfolio pxe free report product follow dynamic energy exploration production intellidex index thoroughly evaluate company base variety investment merit criterium include price momentum earning momentum quality management action value hold stock basket have higher chance beating estimate quarter firm continental resource clr conocophillip cop eog resource eog occidental petroleum corp oxy have earning esp respectively eog have zack rank rest have zack rank pxe be expensive choice energy space expense ratio fund have aum trade volume share day average have zack etf rank high risk outlook read energy etfs stock soar start ishare home construction etf itb free report fund provide pure play home construction stock tracking dow jone select home construction index asset basket be expect surprise quarter top firm dr horton dhi free report have zack rank esp dhi account nearly share basket other firm toll brother tol free report home depot hd free report lowes company low free report have earning esp respectively have zack rank product have amassed asset base trade robust volume more share day average charge bps annual fee have zack etf rank high risk outlook read top rank etfs stock crushed market want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
222,AMGN,rise demand immuno oncology drug combination merck co inc mrk free report pd therapy keytruda be fast become key top line driver pharma giant keytruda be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer have crossed mark sale third quarter keytruda become second largest product merck portfolio treatment fetch sale first month year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum indication first line lung cancer therapy be only pd approve first line set keytruda development program also significantly advanced regulatory approval secure new indication unite state europe japan key approval indication include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo first line lung cancer new approval expand patient population drive sale third quarter momentum be maintain fourth quarter well meanwhile keytruda be be study more type cancer study include excess combination trial merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen datum several program keytruda be present medical conference expect merck present datum several key keytruda study year include combination study incyte epacadostat first line metastatic melanoma also keytruda get approval relapse refractory primary mediastinal large cell lymphoma indication year fda action expect april conclusionmerck do witness setback regard keytruda pipeline program october company announce delay readout important lung cancer study postpone be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer turn raise investor concern delay readout give competitor chance gain traction lung cancer market also combination study keytruda multiple myeloma be put clinical hold follow report death keytruda group last july also merck top line have be lately hurt generic competition several drug pricing pressure believe keytruda have immense commercial potential couple other newer drug ease impact genericization rivalry immuno oncology market have rise follow fda approval newer oncology treatment pfizer bavencio avelumab merkel cell carcinoma mcc bladder cancer indication astrazeneca imfinzi durvalumab bladder cancer believe keytruda give drug tough run money be ample scope growth immuno oncology space merck carry zack rank hold see complete list today zack rank strong buy stock here share merck have decline year industry rally zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
223,AMGN,year have be better expect biotech sector nasdaq biotechnology index be drug pricing issue competition slowdown growth key drug be expect remain hangover well approval new drug strategic acquisition several big wig be likely boost investor sentiment thus needless say hold promise generate stellar return slowdown mature product compel bigwig gilead science gild free report undertake acquisition bolster pipeline gilead acquire erstwhile kite pharma add yescarta kitty company also inked agreement acquire cell design lab gilead currently carry zack rank hold see complete list today zack rank strong buy stock here recently celgene inc celg free report inked deal acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis polycythemia vera celgene be look new deal acquisition give lacklustre have suffer few pipeline setback weakness otezla sale celgene currently carry zack rank acquisition merger keep investor focuse space addition new drug approval label expansion exist drug boost top line prominent biotech company amgen inc amgn free report look poise growth several blockbuster drug portfolio amgen new drug prolium xgeva vectibix nplate sensipar be perform well company recently win fda approval supplemental biologic license application sbla xvega expand drug label treatment multiple myeloma amgen carry zack rank exelixis inc exel free report be biotech look poise growth recent fda approval label expansion lead drug cabometyx treatment previously untreated advanced renal cell carcinoma be expect drive growth drug have perform impressively approval exelixis currently carry zack rank alexion pharmaceutical inc alxn free report blockbuster drug soliris continue perform well fda approval drug generalized myasthenia gravis further boost sale new product strensiq be gain momentum company redefine strategy kanuma alexion carry zack rank investor also keep eye key upcoming pdufa date regeneron pharmaceutical inc regn free report be look expand label newly approve drug dupixent drug be already approve treatment adult moderate severe atopic dermatitis company be also evaluate drug treat asthma adult liberty asthma quest study sbla same be expect be file shortly regeneron be work expand lead ophthalmology drug eylea label additional indication fda have accept review company sbla label expansion eylea injection company be seek approval week dose interval eylea injection patient wet age related macular degeneration wet amd base physician assessment action date set fda be aug regeneron carry zack rank big biotech vertex pharmaceutical incorporate vrtx free report be take measure strengthen already dominant position cystic fibrosis market cf vertex have cf drug kalydeco orkambi portfolio blockbuster potential company have develop cf corrector tezacaftor vx combination ivacaftor regulatory application be review unite state pdufa date feb eu potential approval further bolster demand vertex currently carry zack rank medical biomedical genetic industry yr return medical biomedical genetic industry yr threat biosimilar loom large key drug most company expect investor remain focus dynamic sector eye new drug approval important datum read out wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
224,AMGN,astrazeneca plc azn free report announce european commission ec have grant approval asthma disease candidate benralizumab be approve add maintenance treatment severe eosinophilic asthma adult patient be market trade name fasenra approval fasenra be first respiratory biologic drug have week maintenance dose schedule drug be available fix dose subcutaneous injection prefil syringe remind investor fasenra receive approval same indication unite state november last year be also review share have gain past year compare favorably industry growth period ec approve fasenra base datum program include phase iii study sirocco calima zonda datum sirocco calima show fasenra achieve significant reduction exacerbation improvement lung function meanwhile datum zonda study show fasenra alone combination standard care glucocorticoid lead statistically significant clinically relevant reduction daily maintenance oral corticosteroid ocs compare placebo severe asthma patient disease be drive inflammation eosinophil type white blood cell have now have only limit treatment option mostly oral steroid fasenra distinctively target rapidly deplete eosinophil have show potential reduce oral steroid use such patient glaxosmithkline gsk free report nucala subcutaneous administration teva pharmaceutical industry teva free report cinqair intravenous infusion be presently market same indication administer once week asthma be chronic inflammatory disease breathlessness have significant unmet medical need affect individual worldwide patient have severe asthma become uncontrolled receive high dose standard care medicine require use chronic ocs benralizumab be also be evaluate treatment chronic obstructive pulmonary disease copd late stage study other severe asthma candidate astrazeneca portfolio be tralokinumab tezepelumab partnership amgen inc amgn free report astrazeneca respiratory portfolio account total product sale first month segment see decline sale period due competition other market condition however addition drug portfolio certainly boost performance astrazeneca plc price astrazeneca plc price astrazeneca plc carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
225,AMGN,novartis ag nvs free report initiate head head trial surpass psoriasis drug cosentyx drug be compare propose biosimilar treatment ankylose spondylitis trial be first head head clinical trial investigate superiority cosentyx slow spinal bone damage compare propose biosimilar adalimumab note surpass exceed be part larger rheumatology program cosentyx head head exceed trial cosentyx be be compare abbvie inc abbv free report humira psoriatic arthritis psa trial be currently recruit patient trial be first large double blind head head clinical trial versus humira psa investigate superiority cosentyx acr week primary endpoint novartis stock have rally year compare industry gain cosentyx be first target biologic specifically inhibit il cornerstone cytokine involved inflammation enthesis play major role psa drug be approve treatment active psa drug be approve treatment moderate severe plaque psoriasis uptake cosentyx have be strong company have grab market share rival humira amgen inc amgn free report enbrel cosentyx achieve blockbuster status record sale novartis expect sale cosentyx note novartis have strong oncology portfolio company breast cancer portfolio include drug afinitor kisqali tykerb approval new drug label expansion exist drug further enhance portfolio march novartis acquire certain oncology product pipeline compound glaxosmithkline plc gsk free report exchange company sell influenza vaccine business glaxo meanwhile sandoz generic arm novartis continue advance portfolio biosimilar generic zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
226,AMGN,humana inc hum free report recently announce have extend exist partnership tivity health inc tvty free report dec term alliance humana offer tivity health silversneaker fitness program individual medicare advantage group medicare advantage member be silversneaker tivity health silversneaker founder be overall wellness program offer medicare eligible group retiree member participate health plan offer variety option fitness level ability access exercise equipment class fun social activity thousand location nation apart humana lead health insurer unitedhealth group inc unh free report have also be provide tivity health silversneaker program member aids humana humana be associate silversneaker company have be successful significantly motivate medicare advantage member actively improve physical health extension alliance enable humana remain commit medicare advantage member order help achieve best health humana constant approach connect health lifestyle have lead include silversneaker key element many medicare advantage plan take care complete health physical benefit social enrichment pact silversneaker reflect company focus preventive healthcare benefit consumer company preventive healthcare save consumer serious sickness educate various health precautionary measure company other hand gain lower medical cost due healthier consumer reduce claim cost recent alliance pactshumana have always be engage build strategic partnership improve health medicare advantage member august company joined force biotechnology company amgen inc amgn free report improve health outcome efficiency prior july company partner oscar health offer commercial health insurance small business county nashville area share price last year share humana have gain underperform industry rally strategic initiative be likely favor stock go forward zack rank humana carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
227,AMGN,merck mrk free report japanese partner easai co ltd announce fda have grant breakthrough therapy designation btd combination regimen merck pd therapy keytruda easai multiple receptor tyrosine kinase inhibitor lenvima company be develop combination potential treatment advanced metastatic renal cell carcinoma rcc kidney cancer be btd keytruda second lenvima designation aim expedite development review drug intend treat serious life threaten condition provide patient access soon possible merck share have decrease past year underperform industry gain period fda grant btd combination regimen base datum rcc arm open label phase ib ii study study be currently evaluate keytruda lenvima cancer indication keytruda be merck blockbuster immunotherapy drug approve several cancer indication easai lenvima be approve single agent treat differentiate thyroid cancer combination novartis nvs free report chemo drug afinitor everolimus advanced rcc follow prior angiogenic therapy apart lenvima merck have collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotemerck carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
228,AMGN,amgen amgn free report partner ucb announce marketing authorization application maa seek approval evenity treat osteoporosis have be accept european medicine agency ema amgen be look get evenity approve treatment osteoporosis postmenopausal woman man increase risk fracture europe share company have increase past year outperform industry decline period maa include datum pivotal phase iii study frame arch bridge postmenopausal woman osteoporosis postmenopausal woman osteoporosisat high risk fracture man have osteoporosis evenity treat osteoporosis increase bone formation reduce bone resorption simultaneously increase bone mineral density bmd reduce risk fracture arch study evenity show statistically significant superior fracture risk reduction postmenopausal woman compare current standard care osteoporosis merck co inc mrk free report fosamax ema review potential evenity increase bmr well reduce risk fracture also cardiovascular safety signal arch study remind investor biologic license application bla seek approval evenity same indication unite state be issue complete response letter crl fda july crl be issue due cardiovascular side effect observed arch study bla include datum only frame study fda have request resubmission application additional datum arch bridge study separate press release amgen report mechelen belgium base biocartis group have sign development agreement amgen develop former idylla tm cdx biomarker test analyze novel oncology compound be used treatment certain solid tumor amgen inc price amgen inc price amgen inc quotezack rank stock consideramgen currently carry zack rank hold couple better rank stock pharma sector include celldex therapeutic inc cldx free report catabasis pharmaceutical inc catb free report stock carry zack rank buy see complete list today zack rank strong buy stock here celldex loss estimate remain stable cent cent last day company deliver positive earning surprise trail quarters average beat catabasis loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
229,AMGN,merck co inc mrk free report announce phase iii study evaluate pd therapy keytruda monotherapy treatment high risk melanoma meet primary endpoint recurrence free survival rfs keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer interim datum keynote study show treatment keytruda adjuvant therapy surgically resect high risk melanoma patient lead significantly improve rfs compare placebo other word keytruda show potential extend duration disease recur high risk melanoma patient study continue evaluate other key endpoint include overall survival result study be submit regulatory authority also be present future medical meeting merck be conduct study collaboration european organisation research treatment cancer eortc share merck have decline past year industry surge keytruda second largest product merck portfolio be key top line driver merck fact keytruda be continuously grow expand new indication market globally keytruda development program also significantly advanced several key regulatory approval further drive sale keytruda be be study more type cancer more study include combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo gsk free report pfizer inc pfe free report separately evaluation keytruda combination other regimen press release merck announce fda have accept new drug application nda investigational candidate doravirine nucleoside reverse transcriptase inhibitor nnrti treatment hiv infection merck be look get doravirine approve once daily single tablet combination other antiretroviral agent also once daily fix dose combination regimen contain doravirine lamivudine tc tenofovir disoproxil fumarate tdf dor tc tdf fda be expect give decision application oct merck carry zack rank hold see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
230,AMGN,turn be notable year pharma biotech industry fda give nod novel drug well several biological license application bla include path breaking cancer treatment kymriah yescarta number compare favorably not only just novel drug be approve earlier year well look chart show highest number approval record be novel drug be approve accord fda center drug evaluation research cder higher number new application be submit compare year average nov regulatory application be approve meet pdufa goal date quite few approval come ahead fda action date drug be approve first review cycle be approve priority review status nov approval action rate be many drug approve have also gain breakthrough therapy designation breakthrough therapy be approve last year nov inception breakthrough therapy designation have be grant cder total request nov major part breakthrough therapy request be cancer drug follow hematology antiviral landmark decision last year include approval couple gene base therapy cancer novartis nvs free report kymriah gilead science gild free report yescarta therapy have potential change way look cancer treatment other key approval include lilly lly free report verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron regn free report sanofi kevzara rheumatoid arthritis roche rhhby free report multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other many drug have blockbuster potential store fda intend continue work recruitment hire new drug program staff agency also work continue implementation new pdufa vi bsufa ii agreement other aspect fda reauthorization act fdara st century cure act st century cure act be expect encourage more innovation sector maybe surge new drug approval drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst key drug currently fda review decision expect come month include amgen amgn free report investigational migraine drug aimovig target action date dova pharmaceutical avatrombopag gw pharmaceutical gwph free report epidiolex cannabidiol cbd investigational treatment seizure associate lennox gastaut syndrome lgs dravet syndrome epidiolex be currently priority review rare difficult treat condition childhood onset epilepsy response fda expect jun dova avatrombopag be also priority review treatment patient chronic liver disease cld be schedule undergo procedure response regulatory body be expect amgen be zack rank hold stock see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
231,AMGN,amgen inc amgn free report announce fda have approve supplemental biologic license application sbla expand label key drug xgeva xgeva be currently approve prevention skeletal related event sre solid tumor patient bone metastase latest fda approval label xgeva be expand include patient multiple myeloma fda decision come earlier pdufa date feb similar regulatory application be also review eu past year amgen share have return contrast decrease register industry fda approval be base safety efficacy pivotal phase iii study enrolled patient head head study compare xgeva novartis ag nvs free report zometa zoledronic acid meet primary endpoint inferiority drug delay time first study sre patient multiple myeloma bone complication patient multiple myeloma be quite damage now bisphosphonate be only treatment option available bone protection multiple myeloma patient however bisphosphonate cause renal toxicity lead renal impairment xgeva be not clear kidney offer better treatment option such patient xgeva be key revenue driver amgen generate revenue first month year year expect approval expand patient population help further boost sale drug amgen carry zack rank hold better rank biotech stock be vertex pharmaceutical inc vrtx free report exelixis inc exel free report zack rank strong buy see complete list today zack rank stock here vertex stock have return past year earning estimate have go almost past day earning estimate exelixis have moved north past day stock price have increase past year medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
232,AMGN,alzheimer disease ad area be focus once again pfizer inc pfe free report say be drop plan develop treatment alzheimer parkinson disease accord news source pfizer expect decision result elimination position neuroscience discovery early development program expect additional detail be available company presentation annual jpmorgan healthcare conference today pfizer have have long association alzheimer disease research area company become part dementia discovery fund be form speed development new treatment neurological disease bring together major pharma company uk government alzheimer research uk fund be involved financing new early stage drug development project however alzheimer have always be highly challenge area not much progress be make investment lot fund resource fact pfizer have face major setback way back development effort alzheimer disease treatment company partner johnson johnson jnj free report decide discontinue development bapineuzumab iv follow late stage failure other company eli lilly company lly free report merck mrk free report have also stumble effort develop treatment alzheimer lilly decide november not seek approval investigational ad treatment solanezumab follow disappointing result late stage study candidate be be evaluate see slow progression memory problem associate amyloid protein form plaque brain person alzheimer meanwhile evaluation merck investigational alzheimer disease treatment verubecestat be halter phase ii iii study epoch february base interim analysis external datum monitoring committee edmc study fail study be ongoing result expect february biogen also suffer setback recently independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint phase ii study failure show early positive result come major disappointment biogen be develop candidate association eisai clinical stage company axovant science axon free report suffer major setback september investigational alzheimer disease candidate fail meet co primary efficacy endpoint late stage study company decide discontinue development mg dose treatment alzheimer disease last year company share be compare decline industry belong accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval road setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale company be currently work alzheimer disease treatment include biogen novartis nvs free report astrazeneca eisai amgen amgn free report biogen aducanumab be most important candidate company pipeline candidate currently couple late stage study biogen be also work elenbecestat bace inhibitor phase iii program candidate be be develop collaboration eisai lilly also have quite few alzheimer disease candidate pipeline include lanabecestat be be develop collaboration astrazeneca datum readout expect meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be also collaborate ac immune development alzheimer disease treatment company pfizer lilly merck be zack rank hold stock see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
233,AMGN,immunogen inc imgn free report announce have initiate phase study evaluate cd antibody drug conjugate adcs imgn treat patient hematological malignancy include acute myeloid leukemia aml blastic plasmacytoid dendritic cell neoplasm notably imgn used company indolino benzodiazepine cancer kill agent know ign be immunogen second ign adc move clinical development first be imgn cd target adc already evaluate phase study treatment aml remind investor fda have complete safety review investigational new drug ind application imgn october last year be file company mid september aforementioned indication ind application be support positive datum preclinical study demonstrated imgn promising activity aml cell spare normal bone marrow cell immunogen share have significantly outperformed industry year date stock have sky-rocket compare industry increase same time frame phase study follow dose regime imgn once week thereafter select dose be evaluate expansion cohort patient mentioned hematologic malignancy remind investor immunogen have earlier enter strategic collaboration option agreement jazz pharmaceutical plc jazz free report august development imgn collaboration also include imgn notably immunogen be focuse develop target cancer therapeutic used proprietary adc technology fact innovative technology company be also used roche rhhby free report market product kadcyla other development stage candidate pipeline additionally adc technology be used development program immunogen partner amgen amgn free report bayer ag biotest cytomx eli lilly novartis sanofi takeda immunogen inc price immunogen inc price immunogen inc quotezack rankimmunogen carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
234,AMGN,biosimilar space be focus key fda approval biosimilar contain version active substance already approve original biological drug development biosimilar be technically more challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same be highly lucrative acceleration approval biosimilar market have thus attract lot many player be witness rapid growth here go progress report merck co inc mrk free report launch reneflexis biosimilar version remicade infliximab unite state july approval april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold see complete list today zack rank strong buy stock here remicade have be see intense competition biosimilar space late note pfizer inc pfe free report supply inflectra biosimilar version remicade pfizer be strong player biosimilar market december pfizer get fda approval remicade biosimilar ixifi treatment rheumatoid arthritis crohn disease pediatric crohn disease ulcerative colitis ankylose spondylitis psoriatic arthritis plaque psoriasis company have portfolio market biosimilar medicine outside unite state include inflectra retacrit epoetin zeta nivestim filgrastim strong pipeline distinct biosimilar molecule various stage development pfizer currently carry zack rank generic leader mylan nv myl free report be also explore biosimilar market have potential grow early last december mylan partner biocon ltd announce fda approval ogivri trastuzumab dkst biosimilar version herceptin trastuzumab ogivri have be approve indication include label reference product herceptin include treatment overexpressing breast cancer metastatic stomach cancer ogivri be first fda approve biosimilar herceptin first biosimilar mylan biocon joint portfolio mylan currently carry zack rank meanwhile amgen inc amgn free report allergan plc agn free report win fda approval biosimilar version avastin september treatment multiple type cancer note mvasi be first biosimilar approve unite state treatment cancer amgen biosimilar version humir amjevita be already approve fda be launch unite state jan company resolve litigation abbvie inc abbv free report company have also submit bla fda abp biosimilar candidate herceptin july note company be collaborate oncology biosimilar include abp be second be submit fda approval company also submit marketing authorization application european medicine agency candidate note amgen have total biosimilar pipeline have be approve fda amgen currently carry zack rank boehringer ingelheim cyltezo adalimumab adbm biosimilar humira be also approve fda august medical generic drug industry yr return medical generic drug industry yr slew fda approval expect investor remain focuse space future zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
235,AMGN,year have turn be pretty impressive pharma biotech stock industry be hampered drug pricing issue bounce back make considerable headway courtesy slew fda approval regulatory body approve novel drug last year easily surpass total tally particularly large cap player industry rake stellar return last month nonetheless same space also post decline upbeat quarterly result rise demand new product sale successful innovation product line expansion strong clinical study result well continue strong performance legacy product propel large cap drug sector scale new high moreover tailwind be expect drive sector growth meanwhile jubilant republican have late pass tax overhaul bill first time year bill slash corporate tax rate such tax reduction be likely further boost profit margin company more cash left hand turn also be used striking strategic deal year be relatively fewer notably large cap pharma sub industry carry zack industry rank place top zack industry backtesting show top zack rank industry outperform bottom half factor more banking such positive trend investing sound large cap pharma stock year seem judicious have therefore identify large cap stock base favorable combination solid zack rank strong buy buy strong vgm score stock be backed sound fundamental ensure steady stream cash inflow back test result show only stock impressive vgm style score combine bullish zack rank offer best upside potential be select company poise continue winning streak year abbvie inc abbv free report illinois base company be lucrative option stock have zack rank buy vgm score share company have soar year time moreover stock earning sale be further estimate increase respectively positive trend be support series positive news past few month abbvie present promising datum several pivotal study gain key regulatory approval settle humira patent dispute amgen amgn free report several pivotal datum readout regulatory milestone expect bullish run stock be expect continue year nordisk nvo free report also recommend nordisk denmark base global healthcare company leader worldwide diabetes market share company have surge year time moreover stock earning sale be further estimate increase respectively currently stock vgm score carry zack rank see complete list today zack rank strong buy stock here nordisk have be news past few month base encourage progress diabetes pipeline december nordisk announce fda have approve semaglutide once daily pre filled pen improve glycaemic control type ii diabetes patient be market trade name ozempic company expect launch ozempic unite state begin meanwhile september fda have approve fiasp fast act insulin aspart treat adult diabetes august fda have approve label expansion company diabetes drug victoza now approve reduce risk major adverse cardiovascular event adult type ii diabetes company label expansion effort corresponding approval bode well growth roche hold ag rhhby free report investor count switzerland base roche hold vgm score company be zack rank player share have gain last month roche dominate breast cancer space strong demand franchise drug herceptin perjeta kadcyla company also have dominant position lung cancer market company be look label expansion drug namely actemra be approve treatment giant cell arteritis last be sixth fda approval actemra medicine be launch moreover recent fda approval hemlibra routine prophylaxis prevent reduce frequency bleed episode patient haemophilium be encourage also potential acquisition ignyta announce couple week earlier be likely strengthen roche pipeline integration add mid stage cancer candidate entrectinib portfolio continuous label expansion key drug regular approval robust pipeline be expect drive stock wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
236,AMGN,abbvie inc abbv free report share be expect be northbound carry momentum achieve last year stock be compare favorably gain record industry abbvie carry zack rank buy see complete list today zack rank strong buy stock here last year share price surge be support series positive news abbvie meet primary endpoint several pivotal study key phase iii murano study venclexta roche rhhby free report rituxan relapse refractory chronic lymphocytic leukemia phase iii study evaluate oral jak selective inhibitor upadacitinib rheumatoid arthritis also phase iib study atopic dermatitis pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara humira moderate severe chronic plaque psoriasis meanwhile abbvie gain regulatory approval unite state europe japan competitive hcv medicine mavyret fda approval sixth indication cancer drug imbruvica abbvie also settle patent dispute amgen amgn free report delay launch latter biosimilar version abbvie blockbuster arthritis drug humira unite state most country eu october agreement have remove major overhang abbvie share moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market factor likely support rally several pivotal datum readout regulatory milestone expect bullish run stock continue important catalyst stock be datum pivotal phase iii trinity study rova third line later small cell lung cancer sclc first half year important regulatory milestone be fda decision elagolixin second quarter please note new drug application nda elagolix endometriosis be grant priority review fda october last year importantly humira have be generate strong sale new competition abbvie raise long term target humira sale october base strong demand trend drug imbruvica abbvie second most important drug be also do consistently well have multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease factor bode well stock wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
237,AMGN,have be banner year stock market trend be likely continue next year tax reform act major drive factor stock couple strong corporate earning accelerate economic growth many part world christmas tree symbolize good tiding let build similar tree stock loving investor rake big gain start base most valuable portion tree technology sector seem be perfect fit here be place top broad zack sector industry classification semiconductor general be expect outperform be cyclical sector tend move higher market rally new area such autonomous car cloud compute gaming wearable vr headset drone virtual reality device internet thing iot artificial intelligence continue fuel exceptional growth intel intc have zack rank strong buy seem excellent pick stock see solid earning estimate revision cent next year past day fall industry have zack rank top see complete list today zack rank stock here stock form leave tree be westlake chemical corporation wlk free report basic material sector acco brand corporation acco industrial product sector sector be expect benefit trump pro growth policy especially big spending infrastructure thus carry sector rank top westlake chemical have zack rank be part industry rank top have see solid earning estimate revision next year past day expect growth rate other hand acco brand see positive earning estimate cent next year past day expect earning estimate have zack rank buy industry rank top look best stock be first see top stock portfolio here top layer have select energy sector be expect be largest contributor earning growth hollyfrontier corporation hfc seem intriguing pick sector have rank top stock see solid earning estimate revision cent next year past day expect earning growth rate have zack rank industry rank top very top be star stock zack rank xoma corporation xoma have soar nearly year so far room more upside next year zack consensus estimate have moved loss loss cent rise earning estimate indicate analyst optimistic view earning indicate higher chance outperformance additionally stock boast solid industry rank top now be do tree structure time decorate bell candy light chocolate concentrate area expect benefit most tax reform bell candy be company be poise benefit tax policy bring offshore cash home reduce tax top hoarder be tech sector apple aapl microsoft msft free report cisco csco free report alphabet googl free report oracle orcl free report hold money overseas accord moody drug maker amgen inc amgn gilead science gild pfizer pfe free report merck co mrk free report also stash huge cash offshore be likely gain tax repatriation policy stock have zack rank hold banking stock be fairy light tree light dual tailwind rise rate tax cut accord keefe bruyette wood tax cut add median bank earning ab bernstein see earning share jump large bank mid cap bank be several choice bank new york mellon corporation bk free report currently have zack rank industry rank top company be expect generate double digit earning growth next year small cap stock pay highest effective tax rate be sweet treat be biggest beneficiary corporate tax cut accord thompson reuter datum company russell pay median effective tax rate larger multinational pay mega cap stock dow jone industrial average pay additionally tend outperform rise rate environment give spread top rank stock double digit earning growth potential include upland software inc upld free report farmer merchant bancorp inc fmao free report geopark ltd gprk petm express inc pet free report stock double year voila tree be bring bountiful return investor jingle santa bell look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
238,AMGN,share nektar therapeutic nktr free report have sky-rocket almost year so far substantially outperform industry increase let analyze factor lead massive rally nektar rapid progress robust pipeline year include several study initiation positive readout strategic collaboration have drive share price consistently company pegylation technology have facilitate development several approve product unite state eu partnership healthcare company namely astrazeneca azn free report movantik ucb cimzia amgen amgn free report neulasta other notably randomize phase iii confirmatory study attain begin company lead candidate onzeald late last year trial compare onzeald single agent chemotherapy physician choice patient advanced breast cancer have brain metastase shortly positive result program support regulatory filing unite state apart onzeald nektar be work develop other candidate september company announce initiation phase ii propel study evaluate efficacy safety nktr combination roche tecentriq atezolizumab merck mrk free report keytruda pembrolizumab phase ii trial evaluate nktr potential combination treatment regimen bristol myer squibb opdivo be also underway candidate be be examine tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication november company announce positive datum study treat patient melanoma renal cell carcinoma small cell lung cancer significantly company enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio candidate nktr be be examine phase iii program treatment chronic pain july company report positive top line finding oral human abuse potential study analyse nktr assess opioid abuse potential compare oxycodone company be plan submit new drug application candidate april meanwhile march company initiate phase clinical study evaluate nktr treat wide range auto immune disease inflammatory disorder subsequently july nektar seal co development deal elly lilly company nktr pursuant agreement company own responsibility complete ongoing phase study candidate company share phase ii development cost lilly acquire lion share total expense successful development undertrial candidate boost company top line consider lucrative market be target nektar carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
239,AMGN,jubilant republican deliver tax bill president trump christmas promise republican tax plan get final approval house give corporate america massive permanent tax break turn encourage corporation invest more unite state result rise wage job stronger economy miner energy retailer tech bank pharma be expect enjoy biggest gain tax package health insurer hospital be poise lose needless say moneyed american trump also make most tax overhaul house give final approval tax house representative approve biggest overhaul tax code year send tax bill president signature house be compel vote again be discover bill have earlier pass violate necessary rule senate republican pass simple majority house nevertheless pass tax reform bill majority republican lead senate have earlier pass vote republican successfully counter opposition democrat pass bill slash corporate taxe provide temporary tax relief wealthy middle class american headline grab move be corporate tax rate be lower be implement next year instead be delay republican also repeal corporate alternative minimum tax income bring back overseas be taxed instead current immediate offset spending short live capital equipment be expect further save company congress joint committee taxation winner loser republican tax largest beneficiary tax bill include mining accommodation food service make use allowance short live equipment levy repatriate overseas profit boost major automaker general motor company gm free report ford motor accord ub meanwhile reduction effective rate be shot arm energy player pay second highest tax rate bloomberg intelligence retailer bill be beneficial multiple front tax relief wealthy middle class increase discretionary income boost demand consumer good big consumer product maker such coca cola company ko free report pepsico have large cash holding offshore be used innovation deal make note bloomberg intelligence analyst ken shea time low tax rate foreign profit also help multinational include large tech major bring fund hold overseas back unite state bring back massive overseas cash pile help tech company carry combination share buyback pay dividend activity let not forget tech behemoth apple inc aapl alphabet inc googl free report microsoft cisco system oracle hold money overseas avoid pay corporate tax rate earning thus be position gain immensely trump tax reduction plan bank also face high tax burden make big gainer tax rate go kbw estimate jpmorgan chase jpm free report well fargo co wfc free report bank america corp bac free report enjoy more hike profit corporate tax rate be cut read more wall street hit record high tax cut optimism gainer american biopharma company meanwhile make third top firm most cash abroad slash tax rate repatriate offshore cash thus benefit big drug maker amgen inc amgn free report offshore gilead science pfizer merck co accord recent credit suisse report report further add lower corporate tax rate enefit certain drug maker pay high effective tax rate have lower foreign income main company be effective tax rate unite therapeutic regeneron pharmaceutical however bill be mixed bag health care repeal obamacare individual mandate win help health insurer hospital provision require american have health insurance coverage less pay fine end such provision reduce number person buy insurance coverage hospital lesser number insure person mean fewer pay customer individual unitedhealth group incorporate unh free report drop effective tax rate boost profit much accord ana gupte analyst leerink partner health insurer have payed income tax third quarter wind big victory trumpthere be doubt pass bill be great victory trump politically personally have pledge provide such business friendly policy election year such promise have also help broader equity market gain traction major bourse hit series record high year further measure be likely help market sustain current bull run head addition legislative be beneficial trump family remember tax bill trim ultra rich individual tax bracket pass provision provide major windfall wealthy investor trump see complete list today zack rank strong buy stock here look best stock be first see top stock portfolio here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
240,AMGN,radius health inc rdus free report announce committee medicinal product human use chmp provide third day list outstanding issue regulatory review abaloparatide sc chmp inform company refer marketing authorisation application maa scientific advisory group additional advice part ongoing risk benefit assessment hence chmp expect issue opinion same first half july chmp issue second day list outstanding issue request additional datum analysis related safety efficacy abaloparatide sc ongoing regulatory review delay approval europe be disappointing give potential market radius health share price have decrease year so far compare industry gain note tymlos abaloparatide be approve fda april treatment postmenopausal woman osteoporosis high risk fracture defined history osteoporotic fracture multiple risk factor fracture patient have fail be intolerant other available osteoporosis therapy osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fractur year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor meanwhile radius health be also develop abaloparatide td short wear time transdermal patch december company initiate human replicative clinical evaluation compare optimized abaloparatide td patch subcutaneous formulation company post positive result trial september company be currently focuse complete manufacturing scale other require activity need initiate pivotal study evaluate abaloparatide sc transdermal patch program have potential allow physician treat osteoporosis rarely use injectable drug expand practice include use anabolic therapy zack rank key pickradius health currently carry zack rank hold better rank stock healthcare sector be therapeutic inc cort free report currently carry zack rank buy see complete list today zack rank stock strong buy here earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
241,AMGN,spectrum pharmaceutical inc sppi free report announce termination chief executive officer ceo rajesh shrotriya cause other leadership change company appoint present chief operate officer coo joseph turgeon new ceo immediate effect management turgeon also continue serve president company currently have be elect board director well meanwhile spectrum promote thomas riga present executive vice president chief commercial officer head business development post coo furthermore company have elect director stuart krassner chairman board director notably change be effective immediately share spectrum pharma have sky-rocket last month significantly outperform industry gain markedly turgeon riga have combine experience nearly year pharmaceutical industry turgeon have year pharma experience include year vice president sale amgen inc amgn free report riga have carry number executive role amgen eli lilly company lly free report privately hold dendreon year lackluster product sale have keep investor focuse pipeline development company stock have be surge begin year backed progress lead pipeline candidate company be currently develop poziotinib phase ii study small cell lung cancer patient qapzola phase iii study muscle invasive bladder cancer rolontis phase iii study treat chemotherapy induced neutropenia patient breast cancer company expect file biologic license application rolontis end candidate hold promise target multus dollar market however remain be see change leadership position impact company spectrum pharmaceutical inc price spectrum pharmaceutical inc price spectrum pharmaceutical inc quotezack rank stock pharma carry zack rank hold therapeutic incorporate cort free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
242,AMGN,merck mrk free report announce disappointing result pivotal phase iii keynote study evaluate pd therapy keytruda pembrolizumab second line treatment patient advanced gastric junction gej adenocarcinoma notably keytruda be already approve unite state monotherapy third line treatment advanced gastric gej additionally be approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer share merck have lose year so far compare unfavorably industry increase phase iii study fail meet primary endpoint overall survival os notably progression free survival pfs show statistical significance pd positive patient population however company say continue evaluate keytruda other phase iii study monotherapy well combination chemotherapy first line treatment patient gej remind investor keytruda be key top line driver merck bring sale third quarter sequentially year year sale continue be drive launch new indication globally significantly keytruda sale unite state have gain particularly strong momentum new indication first line lung cancer drug sale be primarily drive melanoma outside unite state meanwhile keytruda development program also significantly advanced year regulatory approval new indication unite state additional disease europe important approval include nod advanced bladder cancer unite state eu advanced microsatellite instability high cancer first sanction combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer keytruda be continuously grow expand new indication market globally be trial more type cancer study include excess combination study merck be collaborate separately several company namely amgen inc amgn free report incyte glaxo pfizer inc pfe free report evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotezack rankmerck carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
243,AMGN,pfizer inc pfe free report announce fda have approve label expansion janus kinase jak inhibitor xeljanz tofacitinib dose mg twice daily mg once daily extend release xr formulation latest approval xeljanz now be administer treat adult patient active psoriatic arthritis psa have inadequate response conventional synthetic disease modify antirheumatic drug csdmard tumor necrosis factor inhibitor respectively notably xeljanz mg twice daily be approve unite state second line treatment option patient moderate severely active rheumatoid arthritis ra have have inadequate response tolerate methotrexate mtx drug be approve europe china march ra significantly be first only jak inhibitor approve unite state moderate severe ra active psa share pfizer have gain so far year underperform industry rally supplemental new drug application snda xeljanz be file fda year aforementioned indication approval be base encourage datum phase iii opal oral psoriatic arthritis trial study broaden xeljanz opal broaden opal trial evaluate efficacy safety xeljanz adult patient psa program achieve primary efficacy endpoint statistically significant improvement twice daily xeljanz mg compare placebo month measurement american college rheumatology response change baseline health assessment questionnaire disability index score overall safety result study be find be consistent observed broader rheumatology development program xeljanz remind investor company be also look get drug label expand include treatment adult patient suffering moderate severe active ulcerative colitis response fda be expect march next year additionally pfizer be conduct phase iiib iv head head study compare xeljanz abbvie abbv free report humira february company announce top line result assessment outcome trial demonstrated inferiority combo therapy comprise xeljanz mtx compare other combo agent humira mtx thus meeting primary endpoint be encourage pfizer label expansion effort xeljanz sale surge year year first month drug label expansion boost further sale blockbuster drug approve treat psa ra include johnson johnson jnj free report remicade amgen inc amgn free report enbrel pfizer market outside unite state canada pfizer press release company announce have start phase iii study evaluate efficacy safety once daily janus kinase jak inhibitor pf treatment moderate severe atopic dermatitis initiation surface first trial jak atopic dermatitis efficacy safety global development program pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
244,AMGN,roche holding ag rhhby free report announce positive result pivotal phase iii study murano evaluate venclexta rituxan compare bendamustine rituxan br treatment relapse refractory chronic lymphocytic leukemia cll result study show fix duration treatment venclexta rituxan significantly reduce risk disease progression death compare br result be present american society hematology annual meeting primary endpoint study be investigator assessed progression free survival note roche be develop venclexta collaboration abbvie inc abbv free report company be jointly commercialize unite state abbvie be commercialize drug outside unite state company expect submit datum murano study fda remind investor fda grant accelerate approval venclexta april treatment cll deletion detected fda approve test have receive least prior therapy murano study be be conduct aim convert current accelerate approval venclexta full approval meanwhile venclexta have be grant breakthrough therapy designation fda combination rituxan person relapse refractory cll monotherapy relapse refractory cll deletion combination hypomethylating agent azacitidine decitabine untreated acute myeloid leukaemia aml ineligible intensive chemotherapy combination low dose cytarabine patient untreated aml ineligible intensive chemotherapy roche hematology portfolio have approve drug include mabthera rituxan gazyva gazyvaro tecentriq venclexta well encourage pipeline comprise candidate polatuzumab vedotin rg small molecule antagonist mdm idasanutlin rg company also obtain fda approval hemlibra emicizumab kxwh routine prophylaxis prevent reduce frequency bleed episode adult child haemophilium factor viii inhibitor so far year share company have moved compare industry gain approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be already face competition biosimilar novartis ag nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank sell see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
245,AMGN,roche hold ag rhhby free report announce positive result phase iii study immotion immuno oncology drug tecentriq study evaluate efficacy safety tecentriq avastin versus sutent renal cell carcinoma patient study meet co primary endpoint investigator assessed progression free survival pfs demonstrated combination tecentriq avastin provide statistically significant clinically meaningful reduction disease worsening death pfs patient pd protein compare sutent first line treatment patient suffering advanced metastatic renal cell carcinoma top line result co primary endpoint overall survival be not mature immotion be second successive positive phase iii study tecentriq include avastin combination component initial treatment study follow positive phase iii squamous small cell lung cancer nsclc impower study reveal tecentriq avastin chemotherapy have pfs advantage avastin chemotherapy note tecentriq be already approve european union unite state previously treat metastatic nsclc metastatic urothelial cancer so far year share company have moved compare industry gain addition roche announce positive result randomise phase ii go study compare polatuzumab vedotin combination bendamustine mabthera rituxan br br alone patient suffering relapse refractory diffuse large cell lymphoma be not candidate haematopoietic stem cell transplant study meet primary endpoint demonstrate addition polatuzumab vedotin br increase complete response rate end treatment measure positron emission tomography assessed independent review committee approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be already face competition biosimilar novartis ag nvs have already launch biosimilar version rituxan mabthera europe amgen amgn free report partner allergan agn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi be first cancer biosimilar approve unite state zack rank roche currently carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
246,AMGN,begin expectation be pretty high pharma biotech sector finally see lot merger acquisition however do not happen few high value deal be announce focus be mostly small bolt acquisition licensing deal agreement accord mergermarket global pharma medical biotech trend report global pharma medical biotechnology sector be range span deal so far year decline year period dip be mostly attributable pharma medical sector key deal announce year include gilead gild free report kite johnson johnson jnj free report actelion acquisition boost value transaction biotech sector biotech stock continue command hefty premium be concern key question now face sector be activity remain sluggish be surge deal tax reform work activity be expect increase upcoming quarters tax reform cash repatriation be expect lead boost area biotech remain highly seek sector company innovative technology pipeline remain demand disease area nonalcoholic steatohepatitis nash immuno oncology central nervous system disease see quite bit activity treatment orphan disease gene editing technology be also demand be several large drugmaker be lookout deal company be look replace sale blockbuster product be face loss patent exclusivity other be look build pipeline acquisition well licensing agreement expectation be high big player sanofi sny free report pfizer merck amgen amgn free report announce deal company gilead be also expect be lookout additional acquisition target major deterrent however be high valuation bidding war keep key player sideline backdrop here be look biotech stock find radar company lookout acquisition target incyte corporation incy free report wilmington base incyte be company be often consider attractive acquisition target thank flagship product jakafi promising pipeline jakafi jak jak inhibitor look well position growth jakafi revenue be expect range incyte be also work expand jakafi label additional indication include steroid refractory acute graft versus host disease gvhd datum expect first half essential thrombocythemia et rare blood cancer lead life threaten complication company have several catalyst line include potential approval baricitinib resubmission new drug application moderate severe rheumatoid arthritis expect january well advancement immuno oncology pipeline company immuno oncology pipeline include ido inhibitor epacadostat pi delta inhibitor incb jak inhibitor itacitinib incb other epacadostat be late stage development melanoma datum due first half have immense commercial potential epacadostat be be evaluate several other type cancer well juno therapeutic inc company juno share have be upward trend follow gilead kite acquisition announcement earlier year juno be focuse development innovative cellular immunotherapy treatment cancer company be consider potential acquisition target juno cell base cancer immunotherapy be base chimeric antigen receptor high affinity cell receptor technology company have several cell base candidate pipeline target variety cell malignancy well multiple solid tumor multiple myeloma company suffer major setback development erstwhile lead pipeline candidate due safety issue include patient death juno be now focuse jcar next generation car cell product target cd jcar be currently registrational study hodgkin lymphoma nhl company expect file approval second half juno share be year date compare gain record industry belong bluebird bio inc blue free report bluebird be clinical stage company work develop gene therapy serious genetic disease cell base immunotherapy cancer company pipeline include lenti currently phase ii iii study treatment cerebral lentiglobin currently study treatment transfusion dependent thalassemia severe sickle cell disease company lead oncology program bb bb be bcma car program be be develop collaboration celgene incyte juno bluebird be zack rank hold stock see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
247,AMGN,sanofi inc sny free report announce start new phase iii study evaluate investigational biologic isatuximab combination other cancer medicine treatment multiple myeloma rare blood cancer first study ikema compare combination isatuximab amgen amgn free report kyproli carfilzomib dexamethasone kyproli dexamethasone second study imroz evaluate combination isatuximab dexamethasone celgene celg free report multiple myeloma drug revlimid lenalidomide japanese firm takeda velcade bortezomib combination velcade revlimid dexamethasone ikema study include patient relapse refractory multiple myeloma have be previously be treat line therapy imroz evaluate cancer combination newly diagnosed multiple myeloma patient not eligible transplant primary endpoint be progression free survival studiesplease note isatuximab be already be evaluate monotherapy phase iii study relapse refractory multiple myeloma phase ii acute lymphoblastic leukemia sanofi share have rise so far year compare unfavorably gain record industry sanofi carry zack rank sell better rank large cap pharma stock be johnson johnson jnj free report carry zack rank buy see complete list today zack rank strong buy stock here share have rise year so far earning estimate have go past day wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
248,AMGN,roche hold ag rhhby free report member genentech announce fda have converted accelerate approval avastin receive previously treat glioblastoma most aggressive form brain cancer full approval full approval be base datum phase iii eortc study avastin base treatment increase time disease progression death compare chemotherapy alone study however do not meet primary endpoint be significant increase overall survival avastin base treatment however show patient be able completely stop intake corticosteroid treatment avastin arm compare control arm evidence study show avastin treatment delay disease progression reduce need corticosteroid lead conversion provisional approval full apart recent approval drug be already approve unite state various indication include first second line treatment metastatic colorectal cancer advanced nonsquamous small cell lung cancer nsclc metastatic kidney cancer advanced cervical cancer recurrent ovarian cancer so far year share company have increase compare industry gain however drug have be face competition have be witness decline sale september amgen amgn free report partner allergan agn free report announce fda approve biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi be first cancer biosimilar approve unite state be also first biosimilar avastin same country zack rank stock considerroche carry zack rank sell top rank health care stock same space be johnson johnson jnj free report sporting zack rank buy see complete list today zack rank strong buy stock here johnson johnson earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
249,AMGN,abbvie inc abbv free report partner janssen johnson johnson jnj free report pharmaceutical subsidiary announce combination study evaluate key cancer drug imbruvica waldenstrm wm rare form hodgkin lymphoma meet primary endpoint interim datum phase iii innovate study show combination imbruvica roche rhhby free report rituxan lead improve progression free survival pfs treatment naive previously treat patient wm compare rituxan alone base early positive result independent datum monitoring committee idmc recommend unblinded study abbvie plan discuss positive interim datum regulatory be already approve monotherapy treatment wm fact include wm imbruvica be presently approve distinct patient population include mantle cell lymphoma mcl small lymphocytic lymphoma sll chronic lymphocytic leukemia cll marginal zone lymphoma mzl chronic graft versus host disease gvhd imbruvica be add abbvie pipeline acquisition pharmacyclic have become key revenue driver abbvie abbvie expect record imbruvica global revenue more sale unite state expect cross first month imbruvica have record sale represent growth year year fact abbvie expect imbruvica peak sale more revenue present cll segment be largest revenue contributor imbruvica growth expansion hodgkin lymphoma nhl other indication be major growth driver future imbruvica have multus dollar potential abbvie be explore potential expand label solid tumor autoimmune disease imbruvica be phase iii study diffuse large cell lymphoma follicular lymphoma abbvie be position imbruvica pipeline molecule treatment feature several company sponsored study abbvie share have gain so far year compare favorably gain only record industry share price surge be support series positive news past few month abbvie present promising datum several pivotal study gain regulatory approval unite state europe japan competitive hcv medicine mavyret receive fda approval sixth indication imbruvicaand settle humira patent dispute amgen inc amgn free report abbvie carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
250,AMGN,week company amgen amgn free report revance therapeutic inc rvnc free report abbvie abbv free report be news amgen get fda approval inclusion cardiovascular outcome datum pcsk inhibitor abbvie revance provide datum pipeline candidate recap week most important storiesrevance soar rt datum revance share shot positive top line datum late stage study evaluate company next generation neuromodulator rt rt meet primary well secondary endpoint study be conduct reduction moderate severe glabellar line frown line wrinkle brow long term safety study be currently ongoing study schedule complete second half successful completion study allow revance file fda approval first half potentially launch product company believe fda approval make rt first neuromodulator long act duration month currently market neuromodulator have show duration month treat glabellar line rt approval well change neuromodulator treatment landscape be need only twice year accord information provide company treatment glabellar line be most popular aesthetic procedure injectable neuromodulator almost third global neuromodulator sale come area currently approve treatment include botox dysport amgen pcsk inhibitor label approve cardiovascular outcome datum amgen pcsk inhibitor repatha get bit boost fda grant approval company request add cardiovascular outcome datum drug label make repatha first pcsk inhibitor prevent heart attack stroke coronary adult establish cardiovascular disease repatha be also approve use adjunct diet alone combination other lipid lower therapy statin treatment adult primary hyperlipidemia reduce low density lipoprotein cholesterol ldl update label provide physician new treatment option prevent cardiovascular event dramatically lower ldl cholesterol repatha especially case patient be already maximally tolerate statin therapy need lower ldl cholesterol level further cardiovascular outcome datum help drive repatha sale be yet take expect factor strict utilization management criterium process employ insurer pharmacy benefit manager pbms impact sale however amgen have be work payer improve access appropriate patient repatha remain growth brand company read more amgen pcsk inhibitor get fda nod stroke prevention amgen be zack rank hold stock see complete list today zack rank strong buy stock here positive datum abbvie risankizumab imbruvica abbvie risankizumab meet primary endpoint fourth pivotal phase iii study conduct treatment patient moderate severe plaque psoriasis week treatment almost half risankizumab patient achieve complete skin clearance pasi compare patient placebo risankizumab be be develop collaboration boehringer ingelheim read more abbvie psoriasis candidate succeed phase iii study abbvie also present datum combination btk inhibitor imbruvica rituxan treatment newly previously treat patient waldenstrm wm primary endpoint progression free survival pfs be achieve late stage study imbruvica be approve different indication include chronic lymphocytic leukemia previously treat mantle cell lymphoma wm well chronic graft versus host disease abbvie expect imbruvica revenue priority review clovis snda clovis oncology clvs free report supplemental new drug application snda use parp inhibitor rubraca rucaparib have be grant priority review status fda company be look get rubraca approve use maintenance treatment woman recurrent ovarian cancer be platinum sensitive complete partial response platinum chemotherapy requirement diagnostic testing fda grant priority review response be apr clovis share be year date compare gain record industry belong galectin nash datum galectin therapeutic inc share fall datum phase iib study gr md candidate show statistically significant clinically meaningful result sub group alcoholic steatohepatitis nash cirrhosis patient fail achieve statistical significance total group patient positive week datum ultragenyx drug ultragenyx pharmaceutical inc rare free report partner kyowa kirin announce positive week datum late stage study burosumab krn adult link xlh company say further improvement disease symptom fracture heal be observed week treatment burosumab burosumab be currently priority review treatment pediatric adult patient xlh response fda expect apr biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline slightly last trading session major biotech stock amgen be vertex decline last month biogen biib free report be regeneron regn free report lose see last biotech stock roundup here regeneron eylea datum biogen ms deal next biotech world watch usual pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
251,AMGN,abbvie inc abbv free report announce fourth pivotal phase iii study evaluate investigational il inhibitor risankizumab treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint top line datum immhance study show significant portion patient treat risankizumab achieve high level skin clearance nearly half patient treat risankizumab achieve complete skin clearance versus placebo week treatment continuous treatment risankizumab week risankizumab patient maintain response year datum show patient achieve better disease improvement time continuous treatment risankizumab rather withdraw therapy initial response result study support regulatory filing candidate week result study be present international congress psoriasis gene clinic meeting london abbvie have license risankizumab boehringer ingelheim abbvie be responsible future development candidate remind investor october abbvie have announce pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara abbvie humira treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint top line datum present study show risankizumab achieve significantly greater response clear almost clear skin versus stelara humira placebo week treatment risankizumab be also be evaluate phase ii study other immunological disorder crohn disease psoriatic arthritis abbvie share have gain so far year compare favorably gain only record industry share price surge be support series positive news past few month abbvie present promising datum several pivotal study gain regulatory approval unite state europe japan competitive hcv medicine mavyret receive fda approval sixth indication imbrivicaand settle humira patent dispute amgen inc amgn free report abbvie carry zack rank hold see complete list today zack rank strong buy stock here better rank large cap pharma stock be lundbeck hluyy free report carry zack rank buy share lundbeck have rise so far year earning estimate have go past day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
252,AMGN,mylan myl free report india base partner biocon announce fda have approve biosimilar version roche rhhby free report herceptin trastuzumab biosimilar be available tradename ogivri include indication herceptin label include positive breast cancer metastatic stomach cancer mylan be also seek approval herceptin biosimilar europe company announce acceptance marketing authorization application maa biosimilar friday european medicine agency ema maa be look get approval biosimilar amgen inc amgn free report neutropenia drug neulasta however fda have issue complete response letter biologic license application seek approval biosimilar version neulasta unite state meanwhile amazon be explore option pharmaceutical segment report cnbc amazon first focus distribute generic be reportedly preliminary talk generic maker mylan sandoz novartis nvs free report generic arm mylan share be friday rumour amazon plan enter pharmacy segment meanwhile share company have decline so far year outperform industry fall period ogivri be first approve biosimilar herceptin unite state earlier march mylan receive global license trastuzumab product roche allow commercialize biosimilar worldwide mylan be already lead supplier cancer medication company supply network help ogivri reach patient quickly boost prospect potential approval europe provide further boost separate press release mylan announce fda have approve generic version blood thinner heparin mylan be focuse develop generic biosimilar popular drug biosimilar portfolio press release mylan currently have abbreviated new drug application review represent annual brand sale mylan price mylan price mylan quotemylan carry zack rank hold see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
253,AMGN,amgen inc amgn free report announce fda have approve regulatory application seek approval include datum cardiovascular outcome study fourier label pcsk inhibitor repatha label expansion repatha now be prescribe prevent heart attack stroke coronary patient establish cardiovascular disease year so far amgen share be better increase register industry datum phase iiifourier study present first quarter have reveal significant reduction myocardial infarction stroke treatment repatha compare current best therapy alone repatha significantly reduce risk hard mace heart attack stroke cardiovascular death compare standard treatment statin therapy individual component risk heart attack stroke coronary be nominally reduce respectively repatha however repatha do not show improvement cardiovascular death risk have raise investor concern then notably repatha gain fda approval august treatment patient incapable manage ldl cholesterol acceptable level be approve country include unite state japan canada overall member country european union give indication however uptake drug have not be very encourage so far due higher pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical inc regn free report also face similar issue pcsk inhibitor praluent fourier datum hold key commercial success repatha broaden use drug cardiovascular indication approve be include repatha label patient access drug improve amgen file regulatory application unite state eu include fourier datum repatha label june july fda have grant priority review regulatory application amgen currently carry zack rank hold see complete list today zack rank strong buy stock here better rank large cap pharma stock be johnson johnson jnj free report have zack rank buy share have rise year so far earning estimate have go past day zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
254,AMGN,abbvie inc abbv free report share have gain so far second half year compare favorably gain only record industry share price surge be support series positive news past few month abbvie present promising datum several pivotal study gain key regulatory approval settle humira patent dispute amgen resolution amgen lawsuitabbvie announce resolution patent dispute amgen inc amgn free report september have delay launch latter biosimilar version abbvie blockbuster arthritis drug humira unite state most country eu october agreement have remove major overhang abbvie share company be still face patent challenge boehringer ingelheim gain approval biosimilar version humira cyltezo august moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market key regulatory approvalsabbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada third quarter mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history august abbvie gain approval sixth indication imbruvica drug be approve chronic graft versus host disease gvhd serious potentially life threaten condition high unmet medical need cgvhd be first indication imbruvica outside cancer also imbruvica be first treatment specifically approve cgvhd positive datum studiesabbvie announce positive datum phase iii murano study venclexta roche rhhby free report rituxan relapse refractory cll last month datum show venclexta rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll label expansion indication expand patient population venclexta significantly boost commercial potential abbvie oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment ra highly statistically significant clinically meaningful result dose mg mg upadacitinib compare placebo upadacitinib also meet primary endpoint phase iib study treatment adult patient atopic dermatitis also know eczema company plan advance candidate phase iii study next year datum upadacitinib study be announce september october abbvie announce pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara humira treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint several pivotal datum readout regulatory milestone expect bullish run stock continue next year importantly humira have be generate strong sale new competition abbvie raise long term target humira sale october base strong demand trend drug imbruvica abbvie second most important drug be also do consistently well have multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease factor bode well stock abbvie carry zack rank hold seethe complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
255,AMGN,have be pretty good year pharma biotech stock fda decision be concern regulatory body have approve novel drug so far easily surpass last year total tally be quite few landmark approval year include approval couple gene base therapy cancer novartis nvs free report kymriah treatment certain pediatric young adult patient form acute lymphoblastic leukemia gilead science gild free report yescarta cell base gene therapy treatment adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment therapy have potential change way look cancer treatment other key approval year include lilly verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month december cardiovascular outcome datum be part amgen pcsk inhibitor label amgen amgn free report be look add cardiovascular outcome datum label pcsk inhibitor repatha fda grant priority review company regulatory application response be december cardiovascular disease be lead cause death world addition datum repatha label boost product sale sale pcsk inhibitor be once consider be worth multus dollar be yet ramp significantly repatha sale first month be amgen continue work payer improve patient access repatha fda allow addition cardiovascular outcome datum label company be position promote repatha ability reduce risk cardiovascular event heart attack stroke amgen share be year date substantially outperform gain record industry belong amgen be zack rank hold stock see complete list today zack rank strong buy stock here fda approve mylan herceptin biosimilar mylan myl free report partner biocon also get response fda biosimilar version roche blockbuster cancer drug herceptin trastuzumab month fda have previously extend target action date biosimilar order review clarificatory information provide company be expect give response december remind investor earlier year july fda oncologic drug advisory committee odac have vote favor approve biosimilar fda be not require do so usually follow recommendation advisory panel mylan share be year date compare decline record industry belong fda follow advisory panel recommendation nvo diabetes drug nordisk nvo free report key player diabetes market get know approval status latest diabetes product offer semaglutide month once weekly semaglutide be fda review improvement glycemic control adult type ii diabetes fda advisory panel voting favor approval chance gain approval look high nordisk share be year date substantially outperform gain record industry belong christmas cheer aclaris aclaris therapeutic acrs free report be focuse address significant unmet need medical aesthetic dermatology be seek fda approval lead pipeline candidate topical treatment seborrheic keratosis sk accord information provide company person unite state be affected sk common malignant skin tumor current treatment cryosurgery curettage excision be painful invasive timely approval make first fda approve medication treatment sk fda action date be december aclaris share be year date compare rally industry belong valeant eye drop ocular redness review valeant pharmaceutical international inc vrx free report new drug application nda luminesse brimonidine tartrate ophthalmic solution be fda review pdufa action date december topical vasoconstrictor formulation have be develop relieve redness eye due minor eye irritation approve eye drop be first counter otc product be develop brimonidine tartrate treatment ocular redness valeant share be year date compare rally industry belong hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
256,AMGN,be relatively slow week give thanksgiving break key development week include biogen biib free report deal alk free report regeneron regn free report disappointing datum eylea recap week most important storiesbiogen inks deal ms drug biogen key player multiple sclerosis ms market have sign worldwide development alk alk novel oral monomethyl fumarate mmf small drug molecule be currently late stage development treatment relapse form ms term deal receive cost incur related development alk upfront payment well royalty mid teen rate worldwide net sale also receive achievement certain milestone first payment be record collaboration biogen be basically look protect sale blockbuster oral ms drug tecfidera dimethyl fumarate new drug application nda alk be file regulatory pathway reference tecfidera alk have be associate differentiate gi tolerability profile be also head head study tecfidera evaluate gi profile read more biogen acquire worldwide license ms candidate share be agreement biogen be biogen share be year date compare gain record industry belong eylea combination fall short mid stage study regeneron provide disappointing update related plan expand label flagship eye drug eylea company say combination eylea nesvacumab antibody evaluate couple mid stage study do not show sufficient differentiation compare eylea alone justify advancement late stage development study be patient diabetic macular edema dme other be patient wet age related macular degeneration wet amd be not first time regeneron have face setback effort co formulate blockbuster drug last year company have announce mid stage study evaluate eylea combination rinucumab pdgfr beta antibody fail show improvement eylea alone patient neovascular age related macular degeneration wet amd next be datum late stage study evaluate eylea diabetic retinopathy grow patient population significant need result be first half read more regeneron stock fall mid stage eye disease study fail catalyst drug positive second phase iii study catalyst pharmaceutical cprx free report share be positive top line result second late stage study firdapse symptomatic treatment lambert eaton myasthenic syndrome lem rare autoimmune disorder company say remain track file fda approval first quarter firdapse have breakthrough designation unite state read more catalyst report positive phase iii datum firdapse catalyst be zack rank hold stock see complete list today zack rank strong buy stock here cytomx get milestone payment bristol myer cytomx therapeutic ctmx free report be receive milestone payment partner bristol myer squibb fda accept investigational new drug application ind ctla direct probody therapeutic company be collaborate discovery development novel therapy used cytomx proprietary probody platform bristol myer have option select oncology target oncology target include ctla bristol myer have select oncology target now biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen be regeneron decline reflect investor disappointment eylea pipeline setback last month biogen be regeneron lose see last biotech stock roundup here rare drug get fda nod acorda cytokinetic hit pipeline setback next biotech world watch usual pipeline regulatory update amgen amgn free report get response fda december regard supplemental biologic license application sbla inclusion risk reduction major cardiovascular event base datum large repatha cardiovascular outcome study repatha be amgen pcsk inhibitor investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
257,AMGN,share nektar therapeutic nktr free report have be almost year so far substantially outperform industry increase period let analyze factor lead massive rally nektar rapid progress robust pipeline year include several study initiation strategic collaboration have push share price consistently company pegylation technology have facilitate development several approve product unite state eu partnership healthcare company namely astrazeneca azn free report movantik ucb cimzia amgen amgn free report neulasta other notably randomize phase iii confirmatory study attain begin company lead candidate onzeald late last year trial compare onzeald single agent chemotherapy physician choice patient advanced breast cancer have brain metastase shortly positive result program support regulatory filing unite state apart onzeald nektar be work develop other candidate september company announce initiation phase ii propel study evaluate efficacy safety nktr combination roche tecentriq atezolizumab merck mrk free report keytruda pembrolizumab phase ii study evaluate nktr potential combination treatment regimen bristol myer squibb opdivo be also underway candidate be be examine tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication notably company enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio candidate nktr be be examine phase iii study treatment chronic pain july company report positive top line result oral human abuse potential hap study evaluate nktr assess opioid abuse potential compare oxycodone company be plan submit new drug application nda candidate april meanwhile march company initiate phase clinical study evaluate nktr treat wide range auto immune disease inflammatory disorder subsequently july nektar enter co development deal elly lilly company nktr pursuant agreement company be responsible complete ongoing phase study candidate company share phase ii development cost lilly capture lion share total cost successful development candidate boost company top line consider lucrative market be target nektar carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
258,AMGN,novartis ag nvs free report be currently go transitional stage company blockbuster drug diovan be face stiff generic competition unite state eu japan loss patent protection top selling drug continue hurt sale exforge be also face generic competition unite state eu oncology drug be face new competition immuno oncology therapy moreover certain patent extension cover afinitor gilenya expire negative impact generic competition impact sale ceo joseph jimenez step position vasant global head drug development chief medical officer replace effective feb nevertheless believe approval new drug label expansion exist drug boost company top line psoriasis drug cosentyx be approve treatment new indication ankylose spondylitis psoriatic arthritis psa uptake cosentyx have be strong company have grab market share rival abbvie inc abbv free report humira amgen inc amgn free report enbrel cosentyx achieve blockbuster status record sale novartis expect garner sale cosentyx entresto respectively other approval include farydak odomzo combination tafinlar mekinist novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu improve formulation exjade oncology portfolio receive further boost approval new drug recent fda approval kisqali use combination inhibitor first line treatment postmenopausal woman hormone receptor positive human epidermal growth factor receptor negative hr advanced metastatic breast cancer boost sale drug be also approve europe meanwhile fda also approve label expansion zykadia include first line treatment patient metastatic small cell lung cancer european commission ec have recently approve tasigna treatment pediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp pediatric patient ph cml cp resistance intolerance prior therapy include imatinib fda recently approve breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve approval provide major boost novartis approval open new frontier treatment cancer advance immune cellular therapy child young adult cell comprise approximately cancer diagnosis child year be most common form childhood cancer unite state kymriah have be launch unite state moreover sandoz hold lead position biosimilar space portfolio market biosimilar currently deep pipeline biosimilar version roche holding rhhby free report rituxan rituximab rixathon be approve european commission june be currently review unite state biosimilar version humira be also review eu novartis stock have rally year date compare industry gain first half novartis announce be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company believe alcon division have revive hence decision possible spin be take zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
259,AMGN,johnson johnson jnj free report announce submission regulatory application fda european medicine agency ema seek label expansion multiple myeloma mm drug darzalex first line set potential approval allow darzalex be used combination proteasome inhibitor mm drug velcade bortezomib melphalan prednisone treat mm treatment nave patient have autologous stem cell transplantation bone marrow approve be fifth indication drug be encourage effort expand darzalex label further drug generate sixth company total oncology sale first month note darzalex be first approve november monotherapy mm patient treat least prior line therapy follow approval past year combination therapy second third line setting share have outperformed industry so far year company share have gain compare industry gain have submit top line datum phase iii alcyone study support regulatory application geography datum study show darzalex combination therapy reduce risk disease progression death compare treatment bortezomib melphalan prednisone standard care alone present datum annual meeting american society hematology schedule be hold dec dec note license darzalex genmab subsidiary janssen hold worldwide right develop manufacture commercialize drug have pay milestone payment genmab national cancer institute new patient be likely be diagnosed mm cause death unite state alone darzalex compete other approve market treatment mm include celgene corporation celg free report revlimid amgen inc amgn free report kyproli bristol myer bmy free report emplicti johnson johnson price johnson johnson price johnson johnson quotej carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
260,AMGN,amgen inc amgn free report announce launch enbrel mini autotouch new auto injector device enbrel unite state enbrel mini single dose prefil cartridge used autotouch reusable autoinjector device provide additional administration option rheumatoid arthritis drug enbrel enbrel mini autotouch device be approve fda september amgen share have rally year so far better industry growth sale amgen largest product enbrel have be soft quite time now pricing pressure stiff competition be hurt sale enbrel main driver amgen revenue enbrel have record sale so far decline year year ra market be extremity crowd give presence treatment abbvie abbv free report humira pfizer pfe free report xeljanz other remain be see new device enbrel lead improvement sale however conference call amgen have say decline trend price market share continue europe biosimilar version enbrel be available unite state sandoz generic arm novartis nvs free report have receive fda approval biosimilar version enbrel erelzi notably erelzi be yet be launch unite state currently amgen have zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
261,AMGN,biotech industry turn year drug pricing issue cripple performance last year have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring sector track year however rise first month year january september medical biotech genetic industry have decline so far fourth quarter oct date macro industry specific factor result sudden downfall uncertain macro picturea big component sell be confusion pass tax reform reform aim bring corporate tax stimulate economic well employment growth propose tax reform approve leave more cash hand biotech company cash be invest merger acquisition have be relatively fewer year compare last go say significant uncertainty regard timely pass tax reform have cast shadow future biotech sector october president trump once again criticize high drug price come time investor have start expect trump action drug price not be onerous previously fear send health care stock lower tepid resultscome industry specific factor most big biotechs beat estimate earning sale however share most company decline post earning release various reason gilead gild free report top earning revenue estimate third quarter witness continue decline sale hcv drug harvoni sovaldi result competitive pricing pressure amgen amgn free report also beat expectation earning sale raise earning guidance however sale decline year year result share price decline post earning call sale pcsk inhibitor repatha be also disappointing celgene celg free report share plunge follow release third quarter result celgene earning top estimate revenue fall short moreover company lower outlook otezla sale well total revenue earning outlook biogen biib free report third quarter result be better expect share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza alexion alxn free report top earning estimate miss revenue third quarter vertex vrtx free report abbvie abbv free report be only outperformer conclusionwe believe biotech space be back track be more certainty regard timing tax reform be fundamental sector remain strong meanwhile earning season now stock start pick positive datum key clinical study drive sector share price biotechs be correlated success key study major biotech player need infusion new growth driver pipeline product portfolio internal development buy asset outside strategic deal sign biotechs also push stock higher look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
262,AMGN,astrazeneca plc azn free report announce fda have grant approval asthma disease candidate benralizumab benralizumab approve add maintenance treatment severe eosinophilic asthma patient age year older be market trade name fasenra share london unite kingdom base pharma giant be more tuesday so far year astrazeneca share have gain compare favorably industry growth fasenra be give fix dose subcutaneous injection prefil syringe once week make first respiratory biologic medicine be approve convenient week maintenance dose schedule glaxosmithkline gsk free report nucala subcutaneous administration teva pharmaceutical industry teva free report cinqair intravenous infusion be presently market same indication administer once fda approval fasenra be base positive datum pivotal study sirocco calima show significant reduction exacerbation improvement lung function treatment benralizumab meanwhile phase iii study zonda show add benralizumab standard care lead statistically significant clinically relevant reduction daily maintenance oral corticosteroid ocs use benralizumab dose regimen compare placebo severe asthma patient disease be drive inflammation eosinophil type white blood cell have now have only limit treatment option mostly oral steroid fasenra distinctively target rapidly deplete eosinophil have show potential reduce oral steroid use such patient fasenra be regulatory review eu japan many other country earlier week astrazeneca say committee medicinal product human use chmp european medicine agency ema have recommend marketing approval benralizumab asthma be chronic inflammatory disease breathlessness have significant unmet medical need be affect individual worldwide patient have severe asthma become uncontrolled receive high dose standard care medicine require use chronic ocs benralizumab be also be evaluate treatment chronic obstructive pulmonary disease copd late stage study other severe asthma candidate astrazeneca portfolio be tralokinumab tezepelumab partnership amgen inc amgn free report astrazeneca carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
263,AMGN,just handful biotech company left report third quarter result focus be back regulatory pipeline update major news week dynavax technology dvax free report finally gain fda approval hepatitis vaccine loxo oncology loxo free report be news collaboration agreement bayer recap week most important storiesloxo bayer deal worth loxo be focuse development highly selective medicine patient genetically defined cancer see share lose ground announcement collaboration agreement bayer be worth company be collaborate global development loxo highly selective trk inhibitor larotrectinib loxo patient trk fusion cancer agreement term include upfront payment loxo receive achievement certain regulatory commercial milestone additional milestone related loxo development cost be split equally company company co promote unite state loxo receive tiered double digit royalty net sale sale milestone totale ex territory larotrectinib be schedule be file fda approval late early loxo share be news investment community express disappointment sharing profit unite state well absence acquisition deal fda nod dynavax hepatitis vaccine turn be third time lucky dynavax company finally gain fda approval hepatitis vaccine heplisav regulatory action make heplisav first new hepatitis vaccine unite state more year only dose hepatitis vaccine adult hepatitis highly infectious potentially deadly virus affect wide range adult unite state infection rise give absence cure however hepatitis be prevent vaccination heplisav be first fda approve product dynavax company expect launch vaccine first quarter achillion slip secondary offer news achillion pharmaceutical inc achn free report be news shareholder johnson johnson innovation jjdc inc jjdc be selling whole equity positon achillion approximately share achillion not receive part proceed offer remind investor achillion have agreement johnson johnson janssen pharmaceutical hepatitis virus hcv treatment time announce hcv agreement achillion have also announce equity transaction jjdc invest achillion get approximately newly issue unregistered share achillion share be significantly company have announce termination hcv agreement september read more achillion hcv partnership terminate stock fall year date achillion share be compare industry rally zymework inks deal company zymework inc clinical stage company announce licensing agreement janssen biotech company development next generation bispecific antibody therapeutic deal janssen get worldwide royalty bearing license research develop commercialize bispecific antibody used zymework azymetric efect platform zymework be entitle upfront payment development milestone commercial milestone payment well tiered royalty potential sale janssen also have option add more bispecific program deal mean additional money zymework deal be boost zymework already have partnership agreement several other large company merck lilly celgene glaxo daiichi sankyo include deal zymework have potential earn milestone worth total agreement zymework be zack rank buy stock see complete list today zack strong buy rank stock here chmp positive amgen drug amgen amgn free report partner allergan get positive opinion european union committee medicinal product human use chmp abp biosimilar version roche blockbuster cancer drug avastin bevacizumab abp be already approve unite state trade name mvasi amgen also get positive opinion chmp effort expand use nplate pediatric patient chronic immune purpura read more amgen get positive chmp opinion expand nplate label chmp positive vertex orkambi label expansion vertex vrtx free report also get positive opinion chmp label expansion cystic fibrosis cf drug orkambi use child cf year age group copy del mutation approval age group expand target patient population patient decision be month orkambi be already approve age group unite state be expect bring revenue meanwhile company expect seek regulatory approval use orkambi child cf year age group have copy del mutation first quarter read more vertex get chmp recommendation orkambi label expansion biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock regeneron lose alexion be last month vertex be celgene be see last biotech stock roundup here regeneron deliver strong result cellectis clinical hold lift next biotech world clinical stage company ultragenyx pharmaceutical inc rare free report well gain fda approval first product week fda expect give response november approval status vestronidase alpha rhgus mps also know sly syndrome patient world be afflict disease be rarest form mps currently be approve treatment mps hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
264,AMGN,novartis ag nvs free report generic arm sandoz report datum clinical study study compare propose biosimilar adalimumab biosimilar rituximab reference drug abbvie inc abbv free report humira roche holding rhhby free report mabthera respectively study include innovative trial involve switch pharmacokinetic pk pharmacodynamic pd study phase iii confirmatory efficacy safety study meet primary endpoint proportion patient achieve improvement week study confirm be meaningful clinical difference efficacy safety immunogenicity patient continuously receive adalimumab continuously receive reference drug switch biosimilar adalimumab reference drug multiple occasion addition phase iii study evaluate rituximab retreatment patient rheumatoid arthritis ra have already receive reference rituximab treatment ra past study evaluate biosimilar reference drug term safety immunogenicity patient switch reference drug biosimilar rituximab continue treatment reference drug addition pk pd datum demonstrated equivalence phase pk study meet primary endpoint be demonstrated biosimilar adalimumab reference drug note sandoz hold lead position biosimilar space portfolio market biosimilar currently deep pipeline biosimilar version rituximab rixathon be approve european commission june be currently review unite state biosimilar version humira be also review eu meanwhile sandoz witness strong growth outside unite state buoy biosimilar launch rixathon erelzi biosimilar amgen inc amgn free report enbrel europe however pricing pressure intensified unite state company expect low single digit sale decline sandoz fourth quarter mainly due seasonal shipment phase continue pricing pressure unite state novartis stock have rally year date compare industry gain first half novartis announce be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company believe alcon division have revive hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
265,AMGN,amgen inc amgn free report announce committee medicinal product human use chmp european medicine agency ema have give positive opinion expand label nplate include pediatric population nplate be presently market treatment chronic immune purpura itp autoimmune disease characterize low platelet count adult amgen be look get nplate approve use pediatric patient year age older be refractory other treatment corticosteroid immunoglobulin positive opinion be base study demonstrate nplate reduce rate bleed child rare blood disorder amgen share have rally year so far better industry growth separate press release amgen partner allergan agn free report announce chmp have render positive opinion marketing application biosimilar version roche rhhby free report cancer drug avastin abp accord company be first bevacizumab biosimilar have be recommend approval avastin biosimlar be approve unite state september be market trade name mvasi remind investor amgen allergan have collaborate worldwide development oncology antibody biosimilar medicine include roche avastin herceptin ritixan fact amgen have biosimilar pipeline biosimilar version abbvie abbv free report rheumatoid arthritis drug humira amjevita be approve fda last year eu march year same indication however settlement abbvie amgen begin selling amjevita most country eu next year unite state january currently amgen have zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
266,AMGN,ligand pharmaceutical inc lgnd free report report third quarter adjust earning cent share significantly year figure cent bottom line also beat zack consensus estimate cent ligand share have outperformed industry year date stock have soar compare industry increase total revenue quarter surge year year mainly back higher royalty revenue top line also surpass zack consensus estimate quarterly revenue be report quarter approximately year year higher royalty sale novartis nvs free report promacta amgen amgn free report kyproli spectrum pharmaceutical sppi free report evomela drive upside ligand license platform technology such captisol omniab partner use proprietary program material sale also soar owing favorable timing captisol purchase clinical commercial use license milestone revenue be register massive rise compare year period increase be courtesy favorable timing milestone license fee earn research development expense marginally decrease however general administrative expense increase year year pipeline other updatesin september ligand pharmaceutical announce positive top line result phase ii study evaluate efficacy safety pipeline candidate lgd treatment patient type diabetes mellitus dm inadequately controlled metformin monotherapy study achieve statistical significance primary endpoint change baseline hemoglobin week treatment dose mg mg mg test july company announce have enter commercial license supply agreement amgen grant right use captisol formulation cd cd bite specific antibody amg term deal ligand be entitle potential milestone payment royalty revenue future sale amg raise earning revenue outlook company now expect revenue range compare previous expectation least contract payment adjust earning be now expect range share compare past projection ligand pharmaceutical price consensus ep surprise ligand pharmaceutical incorporate price consensus ep surprise ligand pharmaceutical incorporate quotezack rankligand carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
267,AMGN,radius health inc rdus free report post loss share third quarter wider loss share year quarter zack consensus estimate loss year year increase net loss be attributable increase general administrative expense radius health inc price ep surprise radius health inc price ep surprise radius health inc quoteradius health share price have decrease last month compare industry fall company report sale tymlos abaloparatide license revenue come however total revenue miss zack consensus estimate quarter detailresearch development expense report quarter be year year due decrease vasomotor project related spending decline abaloparatide sc project cost fall elacestrant rad oncology project cost general administrative expense report quarter jump increase be primarily result increase approximately professional fee support cost include cost associate increase headcount prepare tymlos unite state higher compensation expense include stock base compensation due increase headcount be also responsible increase cost pipeline fda approve tymlos abaloparatide injection treatment postmenopausal woman high risk osteoporosis fracture company be develop formulation abaloparatide sc abaloparatide transdermal radius health announce positive top line result complete month activextend clinical trial tymlos meet primary secondary endpoint company expect submit snda fda connection activextend result year end company also plan initiate clinical trial man osteoporosis successful form basis snda seek expand label treat man osteoporosis high risk fracture study be expect be initiate first quarter meanwhile radius health marketing authorisation application eladyno abaloparatide sc treatment postmenopausal woman osteoporosis europe be review committee medicinal product human use chmp european medicine agency company however suffer setback chmp issue second day list outstanding issue consequently radius health be work chmp address issue company expect response prior end company schedule meeting fda january align regulatory pathway pivotal study abaloparatide td meanwhile company discuss regulatory pathway elacestrant breast cancer meeting fda indicated depend study result demonstrate improvement available therapy plan single arm phase trial be consider pivotal study accelerate approval however confirmatory study be ongoing time nda submission radius health provide further study detail phase study be initiate expect early fda also grant fast track designation elacestrant october candidate be also be evaluate low dose estrogen receptor ligand potential relief frequency severity moderate severe hot flash postmenopausal woman vasomotor symptom update be provide end company wider expect loss third quarter be disappointing expense continue increase tymlos potential label expansion drug further boost performance osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fractur year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor company also setback chmp issue second day list outstanding issue zack rank key pickradius health currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report currently carry zack rank buy see complete list today zack rank stock strong buy here exelixis report strong result third quarter earning share estimate inched cent cent last day company have deliver positive earning surprise trail quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
268,AMGN,sanofi sny free report report third quarter earning american depositary share be line zack consensus estimate earning decline report basis however constant currency rate cer earning rise third quarter net sale rise report basis cer almost sale however miss zack consensus estimate unfavorable exchange rate movement hurt sale january french drug maker swap merial animal health business boehringer ingelheim consumer healthcare chc business reflect exchange full consolidation sanofi european vaccine operation sale decline constant structure cs cer sale decline cer unite state however sale rise emerge market europe rest world japan south korea canada australia new puerto rico growth rate mentioned be year year basis cer segmental sale include emerge market increase however cs cer pharmaceutical sale decline double digit growth multiple sclerosis drug vaccine franchise robust growth emerge market be offset decline diabetes establish product generic sale sanofi report global business unit gbus sanofi genzyme specialty care diabetes cardiovascular general medicine emerge market consumer healthcare sanofi pasteur vaccine sanofi genzyme specialty care gbu sale include emerge market increase drive strong launch dupixent higher sale multiple sclerosis ms drug sale ms drug aubagio rise sale lemtrada go however sale drug decline sequentially quarter meanwhile sale rare disease drug myozyme lumizyme improve fabrazyme sale be cerdelga sale come cerezyme sale rise oncology sale rise drive mainly higher sale jevtana thymoglobulin jevtana sale be thymoglobulin record sale taxotere sale rise eloxatine sale be sanofi regeneron pharmaceutical inc regn free report rheumatoid arthritis ra drug kevzara sarilumab be launch unite state june netherlands germany europe third quarter kevzara record sale third quarter compare previous quarter meanwhile dupixent dupilumab treat atopic dermatitis be launch unite state march dupixent generate sale third quarter compare previous quarter management be pleased drug uptake say unite state drug have be prescribe physician meanwhile dupixent be approve eu september be expect be launch germany end year kevzara dupixent generate total immunology sale third quarter diabetes cardiovascular gbu include emerge market decline diabetes franchise include emerge market decline due lower sale key drug lantus sale diabetes drug unite state decline due tough payer environment sale diabetes drug emerge market be europe decline lantus sale decline quarter lantus sale decline unite state due lower average net price exclusion cvs unite health formulary plan europe sale decline due biosimilar competition patient switch toujeo toujeo generate sale report quarter year year basis decline sequentially soliqua once daily titratable fix ratio combination lantus lyxumia be launch unite state january netherlands trade name suliqua recently soliqua suliqua generate sale quarter compare previous quarter management warn diabetes franchise sale decline accelerate rate fourth quarter due cvs unite health formulary exclusion plan difficult comparison last year consider recent market trend sanofi now expect global diabetes sale decline range cagr timeframe previously sanofi have guide sale decline range cardiovascular franchise sanofi pcsk therapy praluent garner worldwide sale report quarter flat sequentially incidentally amgen amgn free report report last week also do not report very significant sequential improvement sale pcsk inhibitor repatha uptake drug have not be very encourage so far due pricing re imbursement issue payer restriction general medicine emerge market gbu sale come sale establish product be strong performance emerge market be offset lower sale europe generic competition plavix japan renvela renagel unite state sale generic decline due lower sale europe consumer healthcare gbu sale be however sale be only exclude acquisition boehringer ingelheim consumer healthcare business due increase competition develop market third quarter consolidated sanofi pasteur vaccine sale increase due strong performance pediatric combination booster vaccine menactra vaccine sale reflect termination sanofi pasteur msd joint venture merck mrk free report europe december cost risesel general administrative expense sg increase cer quarter reflect launch cost dupixent kevzara expense be cer reflect higher pipeline development cost oncology isatixumab pd sotagliflozin outlooksanofi maintain previously issue financial outlook sanofi expect business earning be broadly flat cer anticipate negative currency impact range business earning compare unfavorably prior expectation positive currency impact takesanofi third quarter result mixed report line earning miss sale expectation strong performance multiple sclerosis vaccine franchise successful launch dupixent robust emerge market sale not make weak performance diabetes cardiovascular unit share sanofi be slightly more pre market trading so far year sanofi share price have rise slightly increase industry however greater previously expect headwind currency company maintain earning forecast be encourage be encourage strong performance ms drug aubagio lemtrada be also optimistic sale prospect dupixent prove be important growth driver company however headwind include bleak outlook diabetes franchise generic competition many drug slower expect uptake new product praluent sanofi price consensus ep surprise sanofi price consensus ep surprise sanofi quotesanofi currently carry zack rank sell see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
269,AMGN,major biotech company report earning result last trading day company amgen amgn free report vertex vrtx free report top expectation be mixed quarter company celgene celg free report alexion read more alexion top earning lag sale view biomarin read more biomarin loss narrow profit guidance raise recap week most important storiesa look earning result be earning week several key name report third quarter result amgen top expectation witness year year decline revenue company also announce not be develop oral cetp inhibitor amg be explore licensing opportunity candidate read more amgen earning top sale decline stock fall meanwhile celgene plunge follow release third quarter result celgene top earning estimate revenue fall short moreover company lower outlook otezla sale well total revenue earning outlook reflect impact discontinuation ged crohn disease market dynamic impact otezla opportunity risk associate late stage datum read out schedule read more celgene top earning sale miss update view vertex have strong presence cystic fibrosis cf market report strong quarter earning revenue surpass expectation company also raise guidance cf franchise sale read more vertex beat earning sale raise view vertex have gain year date outperform industry rally abbvie abbv free report top earning estimate revenue be line read more abbvie earning top revenue line view gilead surpass expectation company hepatitis virus hcv franchise remain immense pressure read more gilead weak hcv sale earning beat incyte epacadostat be study early lung cancer imfinzi incyte corporation incy free report report strong third quarter result also announce expansion clinical trial collaboration astrazeneca company say evaluate efficacy safety incyte investigational selective ido enzyme inhibitor epacadostat combination astrazeneca pd inhibitor imfinzi compare imfinzi alone company conduct late stage study patient locally advanced stage iii unresectable small cell lung cancer nsclc disease have not progressed follow platinum base chemotherapy concurrent radiation therapy crt study be co funded company be conduct astrazeneca patient enrolment schedule commence first half note incyte have clinical trial collaboration merck well bristol myer squibb epacadostat incyte be zack rank hold stock see complete list today zack strong buy rank stock here voyager sanofi exit parkinson disease program voyager therapeutic inc vygr free report share be sanofi exit company vy aadc program advanced parkinson disease deal sign february sanofi have exclusive option ex development commercial right vy aadc deal term include upfront payment well future potential development sale milestone payment tiered royalty product sale accord voyager sanofi decide exit deal option do not include right unite state voyager gain global right vy aadc program advanced parkinson disease company say remain track dose first patient second quarter gw finish roll drug submission epilepsy drug gw pharmaceutical plc gwph free report announce have complete roll submission new drug application nda unite state epidiolex cannabidiol adjunctive treatment seizure associate lennox gastaut syndrome lgs dravet syndrome lgs dravet syndrome be highly treatment resistant form childhood onset epilepsy gw have rare pediatric disease orphan drug designation indication unite state dravet syndrome indication have fast track status well fda timely approval allow company launch product biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene lose reflect sell follow release third quarter result alexion be last month vertex be celgene be see last biotech stock roundup here biogen top earning gilead car drug get fda nod next biotech world focus remain earning result several mid small cap biotech company more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
270,AMGN,pfizer inc pfe free report report third quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year drive slightly higher sale lower cost share count pharma heavyweight deliver revenue be line zack consensus estimate revenue rise year quarter report well operational basis sale detailcurrency movement hurt pfizer third quarter revenue slightly divestiture hospira infusion system business hurt sale quarter february pfizer divest hospira infusion system business icu medical inc icui free report exclude currency headwind revenue sale rise strong performance newer product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis offset lower sale enbrel viagra prevnar prevenar vaccine franchise loss exclusivity product international revenue rise operational basis meanwhile revenue be flat segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report operational basis year period pfizer ih revenue be drive persistently strong momentum ibrance eliquis globally growth lyrica xeljanz primarily unite state ibrance revenue rise quarter xeljanz rise lyrica sale rise eliquis alliance revenue direct sale rise revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare second quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada total viagra ih sale decline lower demand wholesaler destock ahead potential generic competition december hurt sale viagra global prevnar prevenar revenue decline prevnar revenue tank unite state due continue decline revenue eligible adult patient population however prevenar revenue rise international market due favorable timing government purchase emerge market consumer healthcare revenue rise global oncology revenue surge drive ibrance global vaccine revenue rise internal medicine rise inflammation immunology franchise rise additionally portfolio rare disease decline earlier month pfizer say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision be expect next year pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state vfend lyrica europe lower revenue legacy hospira product due product shortage divesture however business biosimilar emerge market do well quarter pfizer launch inflectra biosimilar version johnson johnson jnj free report merck blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market emerge market revenue grow operationally adjust selling informational administrative si expense decline operationally quarter adjust expense also decline guidance pfizer raise adjust earning guidance tighten revenue expectation year revenue be expect range compare expect previously zack consensus estimate be peg adjust earning share be expect range compare expect previously zack consensus estimate be peg share mid point adjust ep be expect increase previously research development expense be expect range previously si spending be project range previously takepfizer third quarter result be mixed beat earning estimate deliver line sale however company raise adjust earning guidance year share be pre market trading so far year pfizer share be compare unfavorably increase industry pfizer continue face headwind form genericization key drug lose alliance revenue pricing pressure rise competition be hurt top line nonetheless believe new product ibrance contribution acquisition cost cut effort share buyback help company achieve guidance pfizer also boast strong pipeline expect multiyear wave potential new product launch product line extension bavencio be be consider key long term growth driver pfizer bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march year advanced bladder cancer bavencio be also approve eu japan september mcc other leukemia treatment besponsa inotuzumab ozogamicin relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be also approvedby fda third quarter besponsa be also approve eu june pfizer carry zack rank hold see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
271,AMGN,earning season be fly start equity market scaling record high owing slew upbeat economic datum strong corporate performance president donald trump tax reform proposal however performance have be mixed bag biotech company beating market expectation few fail do so read fiscal deficit gdp etfs focus now discuss performance few biotech giant such amgen inc amgn free report gilead science gild free report biogen inc biib free report alexion pharmaceutical alxn free report read keep portfolio healthy biotech etfs earning focusamgen report third quarter adjust earning share oct surpass zack consensus estimate increase share year quarter company also beat zack consensus estimate revenue front amgen report revenue surpass zack consensus estimate decrease year quarter company update full year gaap ep guidance range previous guide range owing hurricane recovery cost also update revenue guidance range previous guide range company share lose hour trading oct revise guidance gilead science report third quarter adjust earning share oct miss zack consensus estimate decrease more share year quarter however company beat zack consensus estimate revenue front company report revenue surpass zack consensus estimate decrease more year quarter company update full year revenue guidance range previous guide range company share fall hour trading oct owing ep miss biogen inc report third quarter adjust earning share oct surpass zack consensus estimate increase share year quarter company report revenue surpass zack consensus estimate increase roughly year quarter company share decline market close oct due weaker expect sale sclerosis franchise alexion pharmaceutical inc report third quarter adjust earning share oct surpass zack consensus estimate increase roughly share year quarter company report revenue fail beat consensus estimate increase roughly year quarter company update full year gaap ep guidance range increase revenue guidance company share decline market close oct primarily due revenue miss now discuss few etfs high exposure company discuss ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech industry have aum charge fee basis point year fund have exposure amgen biogen gilead alexion oct fund have return year year date oct have zack etf rank hold high risk outlook vaneck vector biotech etf bbh free report fund have aum charge fee basis point year fund have exposure amgen gilead biogen alexion oct fund have return year year date oct have zack etf rank high risk outlook proshare ultra nasdaq biotechnology etf bib free report fund have aum charge fee basis point year fund have exposure amgen biogen gilead alexion sep fund have return last year year date oct want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
272,AMGN,abbvie inc abbv free report report mixed result third quarter company surpass earning estimate post line revenue period importantly company raise long term sale expectation blockbuster rheumatoid arthritis drug humira rise competition market response share nudge almost pre market trading year so far abbvie share have surge significantly outperform industry rally company report third quarter earning share beating zack consensus estimate bottom line grow year year company post revenue report quarter have meet zack consensus estimate revenue also increase year year exclude favorable impact foreign exchange rate fluctuation operational revenue climb quarter detailkey drug humira record sale growth operational basis revenue come sale unite state rally humira sale ex market be operational basis report basis growth major market category drive upside increase competition new class drug well indirect biosimilar competition international market third quarter net revenue imbruvica stand year year sale imbruvica be compare year figure abbvie record international profit sharing johnson johnson jnj free report other product deliver impressive performance include duodopa show revenue growth operational report basis product call creon witness increase revenue operational report basis hcv chronic hepatitis virus product record sale operational report basis respectively downside be attributable intense pricing competitive pressure hcv market adjust sg expense be expense escalate quarter adjust operate margin be sale report quarter abbvie announce hike quarterly dividend cent share cent share increase payment begin dividend payable february next year outlookabbvie raise adjust earning range compare expect previously earning guidance reflect year year growth mid point zack consensus estimate be currently peg share long term guidanceabbvie project adjust ep range show approximate rally mid point revise range outlook abbvie estimate humira generate global sale higher predict previously several company be work biosimilar version humira amgen amgn free report humira biosimilar receive fda approval september launch be delay due settlement patent dispute abbvie make humira free competition few more year also abbvie have robust intellectual property be expect generate positive sentiment investor zack rank key picksabbvie currently carry zack rank hold better rank stock health care sector be eli lilly company lly free report carry zack rank buy see complete list today zack rank strong buy stock here eli lilly earning share estimate increase last day company deliver positive earning surprise trail quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
273,AMGN,biomarin pharmaceutical inc bmrn free report report narrower expect loss third quarter miss estimate sale biotech also raise previously issue adjust net income guidance so far year biomarin share have underperform industry biomarin share be industry have witness increase loss narrower expectedthird quarter loss cent share be narrower zack consensus estimate loss cent well year loss cent time upfront payment receive sarepta therapeutic inc srpt free report primarily lead narrower loss quarter july biomarin enter license settlement agreement sarepta resolve exon skip patent litigation exclude time upfront payment contingent consideration gain adjust loss share be cent third quarter sale misstotal revenue come year quarter revenue however miss zack consensus estimate quarterly detailsproduct revenue be quarter year year kuvan revenue rise reflect patient growth north america continue growth ex north american territory acquire number patient kuvan therapy unite state increase third quarter naglazyme sale decline year year vimizim contribute total revenue year year however vimizim sale decline sequentially naglazyme vimzim revenue vary quarterly basis primarily due timing central government order country mainly brazil earlier month day biomarin have say slowdown federal purchasing order brazil have hurt naglazyme vimizim product revenue third quarter moreover time biomarin have say slowdown continue fourth quarter only be able meet lower end total product revenue guidance not include milestone payment sarepta however earning release biomarin say day brazilian ministry health have initiate purchasing process expect revenue be guidance biomarin receive aldurazyme royalty totale sanofi sny free report genzyme quarter brineura receive approval treatment child cln disease form batten disease unite state eu second quarter newest drug biomarin portfolio generate sale third quarter compare second quarter company say worldwide launch brineura be line expectation achieve sale unite state european country germany france italy argentina research development expense decline own lower spending brineura program discontinuance kyndrisa program last year selling general administrative sg expense increase primarily due increase expense related acquisition international kuvan right cost associate brineura launch higher stock compensation expense pipeline updateregard pegvaliase have be develop treat pku company plan submit marketing application europe first quarter slightly delay end guide previously unite state pegvaliase biologic license application bla be currently priority review last month biomarin announce fda be not look hold advisory panel meeting company bla pegvaliase earlier month company say fda be expect give decision first half meanwhile phase iii study high dose vg kg mid dose vg kg hemophilia candidate valoctocogene roxaparvovec formerly bmn be expect be initiate end year concurrent earning release biomarin announce fda have grant breakthrough therapy designation valoctocogene roxaparvovec base positive datum phase ii study earlier month biomarin also announce have select bmn small molecule drug next development candidate bmn be evaluate treatment friedreich ataxia fa rare autosomal recessive disorder disease modify therapy be currently approve investigational new drug ind application begin phase study be expect be submit second half next year outlook company tighten previously issue sale guidance however raise adjust earning guidance lower expectation operate cost biomarin expect total revenue range include milestone payment sarepta compare previously represent year year growth vimizim sale be expect range previously kuvan sale be project range previously naglazyme sale be project range previously expense related be expect sg expense be project range compare previously bottom line adjust basis be expect turn positive company raise adjust net income guidance meanwhile management be commit profitability improvement longer term call biomarin also say expect present market product pegvaliase drive top line compound rate cost rise lower level biomarin carry zack rank hold better rank stock biotech sector be amgen inc amgn free report zack rank buy see complete list today zack strong buy rank stock here amgen earning estimate have rise last day company deliver average quarter positive surprise share have rise so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
274,AMGN,radius health inc rdus free report be schedule report third quarter result nov radius share price have decrease year date compare industry decline radius health have disappointing track record so far company report wider expect loss trail quarters negative average surprise let see thing be shape quarter factor playradius focus development therapeutic treatment osteoporosis oncology endocrine disease company lead drug tymlos be approve unite state april drug be approve treat postmenopausal woman osteoporosis high risk fracture defined history osteoporotic fracture multiple risk factor fracture drug also be used patient have fail be intolerant other available osteoporosis therapy company report sale tymlos first week launch company be move ahead plan contract manage care organization access cover life commercial medicare part plan hence expect investor focus uptake drug upcoming earning call osteoporosis market unite state have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium meanwhile company marketing authorisation application eladyno abaloparatide sc europe treatment postmenopausal woman osteoporosis be review however company suffer setback committee medicinal product human use chmp european medicine agency issue second day list outstanding issue request additional datum analysis related safety efficacy abaloparatide sc consequently radius be work chmp address issue company expect response eladyno prior end radius health announce positive top line result complete month activextend clinical trial tymlos meet primary secondary endpoint company expect submit snda fda connection activextend result year end fda grant fast track designation pipeline candidate elacestrant experimental selective estrogen receptor regulator treatment woman advanced metastatic breast cancer elacestrant clinical development program be currently ongoing phase study patient advanced metastatic breast cancer have be heavily pre treat median prior line therapy have evaluable disease hence expect management throw light pipeline progress earning whispersour proven model do not conclusively show radius be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp radius health be currently peg be most accurate estimate zack consensus estimate be peg loss uncover best stock buy sell re report earning esp filter zack rank radius health have zack rank rank be favorable company esp make surprise prediction difficult note caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be pharma company consider model show have right combination element post earning beat quarter incyte corporation incy free report have earning esp zack rank company be expect release result oct see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
275,AMGN,biotech major amgen inc amgn free report report third quarter earning share beat zack consensus estimate earning increase year period backed lower operate cost offset year year sale decline include cost related discontinuation pipeline candidate amg oral cetp inhibitor report earning be share year year total revenue quarter slightly beat zack consensus estimate revenue decline year year unfavorable impact foreign exchange hurt sale quarter revenue decline ex sale grow exclude currency headwind quarter detailtotal product revenue decline include negative currency impact year quarter ex strong demand newer product prolium blincyto be not enough make lower sale mature brand enbrel epogen neulasta neupogen due competitive pressure revenue amgen erythropoiesis stimulating agent esa aranesp decline year quarter due lower demand revenue other esa epogen decline due lower selling price owing recently negotiate contract davita inc unfavorable change inventory also hurt epogen sale neulasta revenue decline year period dueto unfavorable shift timing purchase large customersand increase competition pd other new cancer therapy however neulasta onpro kit body injector continue perform well command market share unite state neulasta sale neupogen record decline sale due biosimilar competition unite state zarxio sandoz novartis nvs free report generic arm biosimilar version neupogen be launch unite state september be hurt sale enbrel deliver revenue year quarter due lower selling price increase competition hurt demand enbrel lose market share less point rheumatology dermatology segment prolium revenue come year quarter due higher demand osteoporosis drug witness market share gain unite state international market meanwhile xgeva deliver revenue year quarter mainly due unfavorable shift timing purchase large customer sensipar mimpara revenue increase due higher price increase vectibix revenue come drive higher demand kyproli record sale year year drive higher demand robust uptake outside market amgen regulatory application unite state eu include overall survival datum endeavor study label kyproli be review study demonstrated combination kyproli dexamethasone lead superior overall survival compare velcade dexamethasone overall survival datum approve help drive usage boost sale kyproli fda be expect give decision apr next year blincyto sale surge year period reflect higher demand july fda approve inclusion overall survival datum tower study label blincyto convert accelerate approval full approval addition datum have boost sale amgen pcsk inhibitor repatha generate revenue not very significant improvement second quarter change inventory accounting adjustment favourably affected second quarter sale be miss third quarter uptake drug gain fda approval august have not be very encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical regn free report also face similar issue pcsk inhibitor praluent priority amgen right now be improve patient access repatha amgen regulatory application include datum phase iii cardiovascular outcome study fourier repatha label be priority review decision fda expect dec remind investor datum fourier study present first quarter have reveal significant reduction myocardial infarction stroke datum be key commercial success repatha broaden use drug datum study look good be not very clear payer be willing improve access repatha base datum operate margin operate margin rise basis point bps due lower operate cost reflect continue benefit transformation process improvement effort expense decline quarter due lower late stage pipeline related cost lower upfront payment licensing transaction third quarter last year sg spend decline due october expiration enbrel residual royalty payment offset investment support new product launch amgen buy back share worth quarter month amgen board director approve new share buyback plan guidancewhile amgen slightly raise lower end previously issue sale outlook raise earning guidance back effective cost management company expect total revenue range compare expect previously adjust earning be now expect range compare share expect previously however company tighten report earning guidance range share account cost related hurricane recovery effort puerto rico manufacturing facility company do not expect negative impact product supply expense related hurricane marium be expect hurt earning share cent operate expense be expect be higher fourth quarter third amgen beat expectation earning sale raise earning guidance full year share lose more market trading due decline sale probably due disappointing sale repatha key new drug however so far year amgen share be better increase register industry amgen newer product prolium xgeva vectibix nplate sensipar be perform well volume growth not be enough offset decline mature brand enbrel due competitive pressure however amgen restructure plan make leaner more cost efficient amgen be also progress pipeline include biosimilar drug amgen currently carry zack rank hold see complete list today zack rank strong buy stock here amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
276,AMGN,third quarter report cycle be witness revenue acceleration positive revision trend result third company member be already revenue beat ratio company be slightly precede quarter be unusually high compare historically total earning member have report already be same period last year higher revenue beating ep estimate accord latest earning preview report company account index total market capitalization report total earning company be expect grow year year higher revenue biotech pharma bigwig eli lilly company lly free report biogen inc biib free report amgen inc amgn free report have report third quarter result week company beat expectation earning sale lilly also raise earning sale outlook amgen slightly raise lower end previously issue sale outlook raise earning guidance back effective cost management however share biogen amgen decline follow result announcement concern regard biogen multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza hurt investor sentiment amgen year year decline sale lead share price fall here have large pharma company be set report third quarter result oct let see thing be shape quarter abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning breaking even last quarters beating same other bring average surprise quarter abbvie have earning esp almost zack rank hold zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter company key drug humira be likely remain main growth driver backed higher demand quarter abbvie expect humira sale rise high teen range internationally same be estimate increase mid single digit range operational basis other drug duopa creon be also expect continue perform well soon be report quarter read more abbvie spring surprise earning season abbvie inc price consensus abbvie inc price consensus abbvie inc quotemerck co inc mrk free report merck be schedule release earning market open merckhad deliver positive earning surprise last quarter company earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be company also have earning esp almost zack rank zack consensus estimate be peg share see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection be likely drive top line quarter keytruda sale unite state be gain particularly back strong momentum new indication first line lung cancer read more merck keep earning streak alive previous article show merck be likely beat earning quarter however estimate change thereafter be not certain beat earning season merck company inc price consensus merck company inc price consensus merck company inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
